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EXECUTIVE SUMMARY 
Although the U.S. ranks highest in per capita health care spending, there is overwhelming 
evidence of gaps between well-founded standards of care and health care practice.  The Institute 
of Medicine reports, To Err is Human: Building a Safer Health System (1999) and Crossing the Quality 
Chasm: A New Health System for the 21st Century (2001), and other sentinel studies have focused 
national attention on improving the quality and safety of health care.  Stakeholders agree that the 
quality of care delivered in the U.S. is inadequate and that the organization and delivery of health 
care must be improved. 
Given the shortfalls in quality and continued escalation in costs, health care must be assessed 
continually to inform decision-making, and redesign delivery and incentives as needed, to yield 
appropriate, high quality care.  An integral component of care is laboratory medicine, which 
extends across research; screening, diagnosis, and treatment; and public health.  Appropriate use 
of laboratory testing is essential for achieving safe, effective, and efficient care to patients.   
Health care must be informed by data derived from scientific assessment of efficacy and 
effectiveness of procedures, and must adapt to ongoing changes in science, technology, and 
practice.9  Laboratory medicine is not only responding to these changes, but is contributing to 
them in an environment of demographic, social, and economic change.  
The Centers for Disease Control and Prevention (CDC) has commissioned this report to 
contribute to the groundwork for transforming laboratory medicine over the next decade.  CDC 
charged The Lewin Group, under subcontract to Battelle Memorial Institute, with drafting this 
document, Laboratory Medicine: A National Status Report.  The report examines in detail the key 
factors affecting the laboratory medicine sector, and is organized into chapters on the following 
main topics: 
 Value of laboratory medicine 
 Market profile of the laboratory medicine sector 
 Laboratory medicine workforce 
 Quality and the total testing process 
 Quality systems and performance measurement 
 Laboratory information systems  
 Federal regulatory oversight of laboratory medicine  
 Reimbursement for laboratory medicine 
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THE VALUE OF LABORATORY MEDICINE TO HEALTH CARE 
Laboratory testing has a major effect on clinical decisions, providing physicians, nurses, and other 
health care providers with information that aids in the prevention, diagnosis, treatment, and 
management of disease.  Despite this scope of influence, spending on laboratory services accounts 
for only 2.3% of U.S. health care expenditures and 2%of Medicare expenditures.   
 Laboratory tests provide objective data about patient health that enable screening for 
risk factors, accurate and early diagnosis, determination of disease severity and 
likelihood of recovery, selection and monitoring of treatment, and evaluation of 
potential adverse outcomes.   Some laboratory tests are vital to patient self 
management of chronic conditions.   
 Information provided by laboratory testing is critical for maintaining quality and safety, 
including the prevention of adverse reactions.  For managing medication, testing 
provides information for maintaining optimum drug levels, helps to detect and recover 
from medication errors, and enables use of genetic information to guide personalized 
prescribing.  Laboratories protect the blood supply from pathogens and accurately 
match patients and blood products.   
 Services provided by clinical laboratories are critical to public health at the individual and 
population levels by identifying nosocomial infections, antimicrobial resistance, infectious 
disease outbreaks, exposure to toxic substances, and chemical and biological threats.  
Laboratories also help to mitigate the effects of natural disasters by enabling rapid 
turnaround of tests used during triage and emergency care of individual patients as well 
as tests to confirm the presence of communicable diseases that threaten the population.  
 Laboratory medicine supports the practice of evidence-based medicine and is being 
incorporated into clinical practice guidelines, which assist practitioners and patients in 
making decisions about individuals’ health care in specific circumstances.   
 Laboratory testing is one of several important indicators for assessing quality of care, 
particularly for national priority health conditions such as diabetes, heart failure, and 
colon cancer.  Laboratory data can be used in support of value-based purchasing.  
 Greater attention by providers and payers to evidence-based medicine, practice 
guidelines, and quality indicators is contributing to more appropriate use of laboratory 
tests, diminishing both overuse and underuse of tests.     
 The evidence base for the cost-effectiveness of laboratory tests, and the broader therapeutic 
regimens and other interventions of which they are a part, is growing.  This evidence is 
helping to inform appropriateness of test selection and sequencing, technology acquisition 
decisions, formulary design (including for pharmacogenomic-mediated therapies), and 
screening and other population-based interventions.  It is also being considered in selected 
coverage and payment policies of some health plans and other third-party payers.       
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MARKET PROFILE OF THE LABORATORY MEDICINE SECTOR 
The revenue, spending, and test volume of the U.S. clinical laboratory testing market has grown 
steadily over the past decade.  Market expansion is attributed to changes in demographic factors 
and burden of disease; scientific, medical, and technological advances; and increased consumer 
awareness and self care.   
 Based on 2007 data from the Centers for Medicare and Medicaid (CMS) Online Survey, 
Certification, and Reporting (OSCAR) database, CDC estimates that approximately 6.8 
billion laboratory tests are performed annually in the U.S.  Other data from 2007 
evaluations indicate the following regarding the extent of the market for laboratory tests. 
• Laboratory testing revenues were a projected $52 billion in 2007. 
• Clinical pathology comprises 66% of all laboratory tests and $32 billion in 
revenue.  
• Anatomic pathology and cytology account for 23% of laboratory tests and $11 
billion in revenue. 
• Molecular and esoteric (e.g., low volume tests such as those for rare diseases) 
testing account for 8% of laboratory tests and $4 billion in revenue. 
• Drugs of abuse testing accounts for 3% of laboratory tests and $1.5 billion in 
revenue. 
 More than 4,000 laboratory tests are available for clinical use.  Of the 1,162 tests that are 
reimbursed by Medicare, about 500 are performed regularly.     
 The number of genetic tests is growing.  An estimated 1,430 diseases are now detectable 
using genetic testing; of these, an estimated 287 are tested only in research settings.   
 The number of Clinical Laboratory Improvement Amendment (CLIA)-certified 
laboratories has grown to exceed 200,000 in 2007.  Physician office laboratories represent 
54% of clinical laboratories in this sector, four out of five of which are certified to 
perform only waived and/or provider-performed microscopy tests (e.g., rapid 
streptococcal detection, wet mount examination).  
 Hospital-based laboratories account for the largest proportion of total testing volume 
(55%) and generate the highest proportion of total testing revenue (54%), projected at 
$28.4 billion for 2007.  From 1999 to 2006, the average annual growth rate of both test 
volume and revenue was approximately 6-7%.  In 2006, privately-owned laboratories 
generated revenues of $15.5 billion (32% of total laboratory testing revenue that year).  
 Consumer directed testing is a key area for market growth.  In 2004, 10-15% of hospital 
and commercial clinical laboratories offered some form of direct access testing.  
Laboratories should be prepared to assume a greater advisory role and provide other 
support to promote informed self care by consumers. 
 Publicly available information about the economic status and quality of the laboratory 
medicine sector remains limited.  The main current sources are CMS’ OSCAR database, 
ad hoc surveys, and commercial market reports used for investment purposes.  As a 
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group, these leave certain gaps in covering the laboratory market, including reliable 
estimates of market revenues, spending, test volume, and laboratory testing trends.   
LABORATORY MEDICINE WORKFORCE 
Comprising pathologists, doctoral-level laboratory scientists, technologists/scientists, and 
technicians, the laboratory medicine workforce has a vital role in the health care system, 
managing and applying evidence-based, scientific testing techniques to support patient care and 
protect against public health threats.  However, there is growing concern regarding shortages in 
the number of laboratory professionals entering the workforce.  The shortage could become 
pronounced with the forthcoming retirement of many laboratorians.  At the same time, the 
demand for laboratory services continues to increase.  Innovative technologies are changing the 
practice of laboratory medicine, educational requirements and staff qualifications. 
 In 2005, there were an estimated 19,339 pathologists in the U.S., including 80% in 
community practice.  Minorities are under-represented in the discipline of pathology, 
with 10% identified as Asian, 3% Hispanic, and 1% African American.  Slightly more 
than half of pathology residents are female. 
 An estimated 160,760 medical technologists/scientists (including cytotechnologists) 
and 144,710 technicians were employed in the U.S. in 2006. While nearly three-fourths 
of this workforce is female, it is more representative of the diverse ethnic makeup of 
the population, i.e., 12% Asian, 11% African American, and 7% Hispanic.  By type of 
region, 58% of technologists/scientists work in an urban setting, 24% in suburban, and 
18% in rural.     
 The number of technologist/scientist and technician education programs has declined 
by more than 50% since 1970, with the most dramatic decline in technologist/scientist 
programs, 71% of which closed between 1970 and 2007.  In contrast, the number of 
phlebotomy training programs increased six-fold from 1987 to 2003.     
 Current enrollment in specialized technologist/scientist and technician educational 
programs is lowest in blood banking and histotechnology.  Recent recruiting efforts 
appear to be effective, specifically those targeted at recruiting minorities and males.  
 The shortage of technologists/scientists and technicians is expected to worsen over the 
next decade with demographic changes and retirements.  Although personnel vacancies 
were highest in 2000 (11-22%), they remained steady from 2002 to 2005 at an annual rate 
of 4-7%.  Vacancies vary according to staff position, laboratory type and size, and 
geographic location.   
 Technological advances will change the qualifications required of the next generation of 
laboratory professionals.  The laboratory sector needs to clearly redefine staffing 
qualifications and workforce level requirements accordingly.    
QUALITY AND THE TOTAL TESTING PROCESS 
The total testing process (TTP) defines the preanalytic, analytic, and postanalytic phases of 
laboratory testing, and serves as the basis for designing and implementing interventions, 
restrictions, or limits that can reduce or remove the likelihood of errors.  Despite continued 
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improvements, many sources of error remain to be addressed.  Higher rates of error occur in the 
preanalytic phase of testing, but the distribution of errors can vary widely among institutions, 
settings, and types of tests.  Estimated error rates by phase of testing are in the ranges of 32-75% in 
the preanalytic phase, 13-32% in the analytic phase, and 9-31% in the postanalytic phase.  Some 
errors that occur in the analytic phase originate with errors in preanalytic processes. 
Chief issues affecting quality include poor communication and insufficient knowledge of tests that 
occur most often during test selection/ordering and interpretation of results.  Common errors in 
clinical and anatomic pathology involve patient and/or specimen misidentification, specimen 
collection errors, and specimen contamination.  Test turnaround time and notification of critical 
values are frequently cited for ratings of below-average to poor in customer satisfaction surveys.  
Medical and scientific advances, such as in genetic testing, will raise further quality challenges.   
 Lack of uniformity and standardization of clinical pathology test values among 
manufacturers hinders implementation of laboratory-based guidelines, which require 
method-dependent decision limits.  Heterogeneity of test values also makes it difficult 
for clinicians to work in an integrated health system using more than one testing 
method, or to address the needs of special patient populations. 
 Laboratorian consultations are standard practice and reimbursed for anatomic pathology, 
but this is not always the case in clinical and molecular pathology.  The primary barriers to 
interpretive consultations in clinical pathology reports are lack of reimbursement for such 
consultations and the shortage of subspecialty expertise.  Expanded consultation services 
to clinicians would contribute to improved patient care and outcomes.  
 Quality control (QC), performance evaluation, and test reproducibility standards to 
minimize diagnostic discrepancies and errors have been better defined and applied in 
clinical pathology than in anatomic pathology.  Such measures should be developed for 
anatomic pathology. 
 Standardization of data elements and report formats for all laboratory tests is necessary 
to improve physician comprehension and use of results as well as to integrate report 
data into clinical practice information technology applications.  Better use of graphical 
displays in results reports is especially important for new proteomic and genetic tests.     
 Effective technologies and strategies to reduce identification-related errors include use of 
barcoded labels for containers and slides, inpatient wristbands, and computerized 
physician/practitioner order entry (CPOE).  Automated analyzers and results verification 
have decreased cognitive-related errors in clinical pathology, while external, secondary 
consultation in anatomic pathology can help decrease errors for complex cases.  
 Point-of-care testing (POCT) has the potential to significantly enhance the quality of care, 
although additional research is needed to identify the best methods for integrating 
POCT into daily clinical processes and improving its accuracy as needed.  Operators of 
POCT devices must be trained appropriately in testing practices.   
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QUALITY SYSTEMS AND PERFORMANCE MEASUREMENT 
Achieving consistently high levels of quality in laboratory medicine calls for moving beyond 
stand-alone, analytic-focused, QC, quality assurance (QA), and proficiency testing (PT) activities.  
It requires more comprehensive quality management systems (QMS), such as those espoused in 
ISO 9001:2000 and ISO 15189:2003 standards.  Performance measurement is an important 
component of QMS and has been a core feature of quality improvement programs across many 
industries.  In laboratory medicine, the great bulk of effort on formal performance measurement 
and improvement to date has focused on the analytic phase, with insufficient attention to the pre- 
and postanalytic phases.   
 Continuous quality improvement, Toyota “lean” production, Six Sigma, and failure 
mode and effects analysis are strategic tools for implementing QMS that are realizing 
benefits among early adopters, from small physician office laboratories to large reference 
laboratories.  Use of continuous quality improvement and Six Sigma has contributed to 
financial savings and decreased turnaround time, lean production has improved test 
quality and reduced errors, and failure mode and effects analysis has decreased time to 
report critical laboratory values.   
 To date, QMS has been most broadly adopted in transfusion medicine to meet Food and 
Drug Administration (FDA) requirements.  However, adoption of QMS more broadly 
among laboratories should increase as CMS and accreditation organizations incorporate 
these standards into their requirements.  Obstacles to implementation of QMS that must 
be addressed include resistance to culture change, lack of leadership and staff 
commitment to QMS, and insufficient funding of QMS activities. 
 Aside from PT, CLIA provisions have emphasized structural policies, procedures, and 
documentation requirements as a condition for accreditation and certification.  Process 
measures to assess quality in the TTP remain relatively underdeveloped.  Existing ones 
have not been uniformly defined or assessed for generalizability, and are subject to wide 
variation in their implementation.   
 Substantial work is needed to standardize indicators for pre- and postanalytic process-
related performance measures.  Data collection, analysis, and reporting methods also 
need to be standardized.   
 Research on laboratory performance has been limited by its focus on the larger, hospital-
based laboratories.  Further research is needed examine the challenges faced by smaller 
laboratories and physician office laboratories when implementing process-related 
performance measurement and quality improvement programs.     
 A small body of evidence addresses the downstream clinical and economic impacts of 
particular tests.  The lack of substantive research on the impact of laboratory testing 
restrains the demonstration of the value of laboratory medicine.     
LABORATORY INFORMATION SYSTEMS  
Laboratory information systems (LIS) have evolved over the past 30 years from simple systems 
designed to generate accurate reports to complete systems that can link laboratory data “end to 
end” across the TTP.  Information technology and Web-based applications have enabled dramatic 
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improvements in laboratory data management, communications, services, education, and 
marketing.  Health care organizations have helped to advance the integration and reach of 
laboratories by linking the LIS with hospital information systems, pharmacy databases, etc.   
 The extent of LIS adoption and capabilities varies widely.  While integrated delivery 
systems and large laboratories rely on LISs for many aspects of laboratory testing, 
physician office laboratories and smaller laboratories primarily use the LIS to facilitate 
compliance with CLIA requirements (e.g., QC, PT, QA, patient test management).   
 Lack of harmonized data standards is the single greatest barrier to laboratories’ ability to 
integrate data within the laboratory as well as exchange data with external partners.  
Further progress in integrating laboratory data more fully with clinical practice 
applications cannot be realized unless laboratories, health care organizations, vendors, and 
others stakeholders resolve differences in data interchange and terminology standards.  
 Successful integration of enhanced data management features requires increased 
computing power and multidirectional, coordinated communication that links the LIS, 
preanalytic processing components, specimen transportation system, analyzers, and 
postanalytic archiving system. 
 The volume and complexity of data generated from genetic, proteomic, and 
pharmacogenetic testing, especially from high-throughput analyses and increased 
reliance on automation, requires that LISs be capable of storing and retrieving large 
quantities of data. 
 Enabling CPOE, decision support systems, and electronic health record applications with 
laboratory data in real time requires continued development of rule-based algorithms 
capable of generating and integrating accurate alerts, reminders, order sets, results reports, 
and a list of differential diagnoses based on patient signs, symptoms, and characteristics. 
 Digital pathology systems require further advances in high-power computation, data 
storage capacity, image formatting, and processing algorithms to facilitate the shift from 
single-field images to whole-tissue-processing.   
FEDERAL REGULATORY OVERSIGHT OF LABORATORY MEDICINE  
In the U.S. health care system, the purposes of regulation include one or more of the following:  
protect personal and public health, advance personal and public health, and ensure that the 
public has access to sufficient, accurate information for using regulated products and services to 
improve their health.  The purpose of oversight by designated agencies and organizations is to 
enforce and otherwise achieve adherence to the rules and standards comprising regulation.   
CLIA has served as the primary regulatory program governing U.S. clinical laboratory testing 
since its implementation in 1992.  The CLIA program is administered by CMS, which has primary 
oversight of the program, in cooperation with CDC and FDA.  Rapid technological advances, 
demographic shifts, lower tolerance for error, and higher expectations for personal data security 
pose challenges to certain aspects of the current regulatory framework for clinical laboratories.   
 Technological advances have made laboratory tests easier to use and less subject to user 
error, resulting in considerable growth in the number of waived tests from 9 tests in 1993 
to more than 1,600 test systems and 76 analytes in 2007.  However, a CMS study found that 
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some certificate of waiver facilities perform tests beyond the approved level of complexity.  
CMS has taken measures to support surveys at a percentage of these facilities. 
 For non-waived testing, available evidence on the long-term impact of PT on laboratory 
performance is limited, and findings of existing studies are confounded by limited 
comparable data from CMS and survey organizations and other methodological 
shortcomings.  Existing studies indicate generally improved performance in recent years, 
although some failure rates remain unacceptably high.   
 While laboratories’ flexibility to self-determine QC procedures is desirable, several 
factors may contribute to the inconsistencies in implementing this practice.  CMS, the 
Clinical and Laboratory and Standards Institute, and other stakeholders are developing 
evaluation protocols that will outline principles for validation and provide laboratories 
with scientific guidance on the development of QC procedures for specific testing 
technologies and environments.  
 CMS has taken several actions to improve the operation of the program, including 
aligning CLIA technical requirements for QA, QC, and PT with systems-based 
approaches to quality management; issuing guidance documents identifying effective 
survey processes; strengthening enforcement of regulatory obligations; and 
assembling a working group to assess program expansion opportunities pertaining 
to revenues, staffing levels, and data collection capabilities.   
 Only a small number of genetic tests are regulated as in vitro diagnostics subject to FDA 
premarket review for safety and efficacy (via the 510(k) or pre-market approval routes).  
Most genetic tests are developed in-house by laboratories and are regulated under CLIA 
general provisions.  This framework may be insufficient for the level of efficacy and 
protection sought for many tests by clinicians and patients, and creates incentives for 
genetic tests to be categorized as laboratory-developed tests and not be subject to the 
510(k) or premarket approval routes associated with FDA-regulated tests.  CMS is 
working with the Secretary’s Advisory Committee on Genetics, Health, and Society; 
CDC; CLIAC; FDA; and other experts to ensure the quality of genetic testing.   
 Recent guidance documents issued by FDA clarify its oversight of in vitro diagnostic 
multivariate index assays and analyte specific reagents (the active ingredients used in 
some laboratory-developed tests).  This guidance indicates a noteworthy assertion of 
oversight that exposes the small but growing area of highly complex genetic testing to 
greater scrutiny usually associated with premarket review processes.   
REIMBURSEMENT FOR LABORATORY MEDICINE 
Government and private sector third-party payment has enabled patients to access and benefit 
from health care products and services, including laboratory testing.  The design and updating of 
coverage, coding, and payment systems should strive to enable patient access to medically 
necessary care, support delivery of high-quality care, and sustain innovation of new technologies.  
Further, these systems should discourage inefficiency, fraud and abuse, and non-competitive 
practices.  Difficulty in acquiring coverage, appropriate coding, and adequate payment can pose 
significant hurdles in the use of laboratory testing and decreased incentives for laboratories and 
test manufacturers to engage in further test development.   
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Even though private sector insurance accounts for higher total revenues, the Medicare program 
exerts the strongest influence on laboratory services payment for all U.S. payers.  All public 
payers and approximately 67% of private payers use Medicare’s payment methodologies as the 
basis for their own and as tools for negotiating discounts with providers.  Suboptimal practices 
and other shortcomings in the Medicare reimbursement system for laboratory testing affect other 
public and private sector payers in the U.S. health system.  Redesign of the current Medicare 
payment system for laboratory services is needed in order to meet the growing scientific, 
technical, clinical, and economic challenges of the U.S. health care system. 
 The Medicare statute restricts payment for screening and other preventive technologies 
and services, unless otherwise specified by Congress.  Having to add these technologies 
and services to Medicare benefits on a case-by-case basis via the legislative route is 
cumbersome and impedes access to certain proven, beneficial tests.   
  Continued use of 56 different fee schedules across the U.S. is inefficient and unnecessarily 
complex.  For certain commonly ordered tests, the multiple schedules result in large 
regional variations, while for other tests, national limitation amounts results in inadequate 
Medicare payments.     
 There is a notable lack of reliable data on the relationships among historical costs on 
which the Medicare Clinical Laboratory Fee Schedule is based, current production 
costs, and the effects of economies of scale and other cost-reducing effects of 
technological changes.  
 Studies of data-derived methods for evaluating the appropriateness of payment rates 
and for designing potential new payment systems, e.g., based on resource-based relative 
value and microcosting (e.g., activity-based costing) have not been completed.  
 CMS is proceeding with a competitive bidding demonstration project for laboratory 
services, with the expectation of substantial savings.  Supporters of the demonstration 
believe that current prices on the fee schedule have no substantial relationship to actual 
costs.  However, the demonstration project model is highly exclusivea and could have 
significant detrimental effects on clinical laboratories that lose in the bidding process, as 
many depend on Medicare reimbursement for a sizable portion of their revenues.   
 Despite modest improvements in their transparency, the processes for establishing 
payment levels for new laboratory tests, including assignment of new and existing Current 
Procedural Terminology® codes to tests and related methods of cross-walking and gap-
filling, remain archaic and inadequate.   
 Federal government investigations of clinical laboratory-related fraud and abuse resulted 
in penalties amounting to more than $1.727 billion from 1992 to 2006.  Through a separate 
rulemaking, CMS will address contractual joint ventures that enable non-pathologist 
physicians and other entities to profit from self-referrals of pathology services.  
Approaching the close of the first decade of the 21st century, health care now accounts for one-sixth 
of the U.S. economy.  Laboratory medicine guides, and is often the pivotal determinant in, decisions 
                                                     
a Competitive bidding initiatives that rely on exclusive or selecting contracting allow only those laboratories 
submitting winning bids to participate; losing laboratories are barred from receiving any payment from contracts 
during the time of the procurement. 
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that influence the magnitude and allocation of resources in much of this burgeoning sector.  Any 
efforts to improve the quality of health care, let alone transform it, must engage the vibrant market 
of laboratory medicine and its workforce, systems for ensuring quality, systems for managing 
information, and scientific and technological advances.  Such efforts must also confront complex 
and, in certain ways, inadequate regulatory and payment systems that strain to cope with the 
extraordinary diversity and volume of this field.  Further, it will be incumbent upon those in 
laboratory medicine to demonstrate its value continually along the dimensions of access, informed 
decisions, patient and provider satisfaction, health care outcomes, and cost-effectiveness.   
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INTRODUCTION 
The history of laboratory medicine extends to the first recorded examination of human bodily 
fluids during the time of the ancient Greek physician Hippocrates around 300 BC.1  Two thousand 
years later, the first true clinical laboratory opened in 1896 at Johns Hopkins Hospital.2  Discovery 
of the disease-causing agents of epidemics such as tuberculosis, diphtheria, and cholera and the 
development of tests to detect their presence throughout the end of the 19th century propelled the 
laboratory to a position of importance by the early 20th century.3  The American Society of Clinical 
Pathologists was formed in 1922 as the first professional society supporting physicians 
specializing in pathology.  In 1926, all hospitals accredited by the American College of Surgeons 
were required to establish a clinical laboratory under the direction of a physician.   
Today, the clinical laboratory serves a vital role in the health care system, spanning research, clinical 
care, and public health surveillance.  More than 200,000 clinical laboratories provide testing and 
services in the U.S.  The Clinical Laboratory Improvement Amendments (CLIA) of 1988, 
consolidated regulation of all types of clinical laboratories under one statute and established 
standards for quality assurance, record maintenance, and proficiency testing for all laboratories.  
CLIA defines a clinical laboratory as: 
“…a facility for the biological, microbiological, serological, chemical, immunohematological, 
hematological, biophysical, cytological, pathological, or other examination of materials derived 
from the human body for the purpose of providing information for the diagnosis, prevention, or 
treatment of any disease or impairment of, or the assessment of the health of, human beings. These 
examinations also include procedures to determine, measure, or otherwise describe the presence or 
absence of various substances or organisms in the body.  Facilities only collecting or preparing 
specimens (or both) or only serving as a mailing service and not performing testing are not 
considered laboratories.”4 
While this definition describes components of laboratory medicine and the activities that take place 
within a clinical laboratory, it does not fully address the practice of laboratory medicine.  The 
practice of laboratory medicine implies a broader scope of influence beyond the activities in the 
laboratory, such as consultations with clinicians to assist with test ordering and results 
interpretation, performance measurement for quality improvement in the delivery of patient care, 
and, on a small yet growing scale, direct interactions with patients and the public.  During a 1986 
meeting of the Center for Disease Control and Prevention’s (CDC) Institute on Critical Issues in 
Health Laboratory Practice, the extralaboratory functions were incorporated into the concept of the 
total testing process—a framework defined by the activities of three distinct phases―preanalytic, 
analytic, and postanalytic―that align with clinical workflow outside and inside the laboratory.  In 
2003, CLIA provisions were revised to align regulatory requirements correspond with one total 
testing process.  Thus, for the purposes of this report, laboratory medicine is defined broadly as: 
Testing services and associated practices for the assessment, diagnosis, treatment, management, or 
prevention of health-related conditions utilized in making patient care decisions and improving 
public health. 
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CONTEXT OF THE REPORT 
Although the U.S. ranks highest in per capita health care spending, there is overwhelming 
evidence of gaps between well-founded standards of care and health care practice.5  The Institute 
of Medicine (IOM) reports To Err is Human: Building a Safer Health System (1999) and Crossing the 
Quality Chasm: A New Health System for the 21st Century (2001), as well as other sentinel studies, 
have focused national attention on improving the quality and safety of care delivery.5-8   
Stakeholders agree that the quality of care delivered in the U.S. in inadequate and that the 
organization and delivery of health care must be changed. 
Given the shortfalls in quality and continued escalation in costs, health care must be assessed 
continually to inform decision-making, and redesign delivery and incentives as needed, to yield 
appropriate, high quality care.  An integral component of care is laboratory medicine, which 
extends across research, clinical (i.e., screening, diagnosis, and treatment), and public health 
settings.  Laboratory services account for only 2.3% of total health care expenditures; however, 
they have a significant role in informing health care decisions and spending.  Appropriate use of 
laboratory testing is essential for achieving safe, effective, and efficient care to patients.     
SCOPE OF REPORT 
Health care must be informed by data derived from scientific assessment of efficacy and 
effectiveness of procedures, and must adapt to rapid changes in science, technology, and 
practice.9  Indeed, laboratory medicine is not only responding to these changes, but is contributing 
to them in an environment of demographic, social, and economic change.  Detailed, 
comprehensive information about the laboratory medicine sector, particularly in regard to best 
practices and the quality of services provided, is necessary to address current and forthcoming 
challenges to this important aspect of health care.   
CDC has commissioned this report, among others, to lay the groundwork for transforming 
laboratory medicine over the next decade.  The Lewin Group, under subcontract to Battelle 
Memorial Institute, was charged with drafting this document, Laboratory Medicine: A National 
Status Report.  The report provides a detailed overview of the key factors affecting the laboratory 
medicine sector.  It is intended that the report serve as a point of reference for measuring and 
improving quality in the future as well as for policy guidance to professional organizations, 
government agencies, and others who provide, use, regulate, and pay for laboratory services.  
Aside from an executive summary and this introduction, the report is organized as follows: 
 Chapter I describes the value of laboratory medicine in clinical care and the broader 
health care system.  The chapter addresses the roles of laboratory medicine in 
screening, diagnosis, and treatment; evidence-based medicine; clinical practice 
guidelines; assessing quality of care; contributing to cost-effective health care; and 
protection from threats to public health. 
 Chapter II provides detailed information on the magnitude and composition of the 
U.S. clinical laboratory testing market, including data by setting (hospitals, physician 
offices, independent laboratories, home), and by clinical discipline (clinical pathology, 
including molecular diagnostics; anatomic pathology).   
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 Chapter III provides an overview of the laboratory medicine workforce, including 
professional responsibilities, demographic characteristics, vacancy rates, and wages.  The 
chapter also addresses the status of educational programs and licensing and certification 
requirements at the federal and state levels. 
 Chapter IV describes the total testing process and the quality issues and errors most 
relevant to each phase of laboratory testing for clinical and anatomic pathology.  Also 
addressed are communication factors associated with the preanalytic and postanalytic 
phases.  A section of the chapter examines point-of-care testing and related matters of 
quality.    
 Chapter V describes the status and future of quality systems in laboratory medicine, 
including the shift away from analytic-focused quality control, quality assurance, and 
proficiency testing to more comprehensive, systematic approaches to quality 
management.  Also included is discussion of the current status of performance 
measurement in laboratory medicine. 
 Chapter IV addresses laboratory information systems and automation technology, 
including the extent to which they have been adopted into integrated delivery systems 
and physician office laboratories.  This includes discussion of emerging technologies 
(e.g., computerized physician order entry, electronic health records) and health care 
system integration requirements.  
 Chapter VII describes federal regulatory oversight of clinical laboratories by the 
Centers for Medicare and Medicaid Services (CMS)a and oversight of marketed tests by 
the Food and Drug Administration (FDA).  The chapter reports on the status of waived 
testing, the status of non-waived testing under CLIA (e.g., proficiency testing, quality 
control, personnel, and surveys), the respective roles of CMS and FDA in oversight of 
laboratory developed tests, and outstanding issues in genetic testing and transfusion 
medicine.  
 Chapter VIII describes public and private sector reimbursement systems for clinical 
laboratory services, with a focus on coverage decisions, coding and payment 
methodologies associated with prospective and fee-for-service systems, and new 
initiatives to reduce costs, such as competitive bidding.    
 
 
 
 
 
 
                                                     
a Formerly, CMS was the Health Care Financing Administration. 
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METHODS AND LIMITATIONS 
The process for development, organization, and management of the report content is 
summarized in this section.  Also briefly discussed are certain limitations of available data and 
information used in the report.  
METHODS 
Report Outline 
A kick-off meeting was held in October 2006 in Atlanta to review the purposes and scope of this 
report and other tasks associated with the broader contract.  CDC, Battelle, and invited experts 
provided background information on key aspects and issues in laboratory medicine to be 
considered for inclusion in the status report.  Drawing from the meeting, Lewin drafted an outline 
of the structure and content of the report.  The outline was circulated to the representatives of 
laboratory medicine stakeholder groups for review and comment.  Suggested modifications were 
considered and incorporated as appropriate.  As Lewin initiated the report, assembled information, 
and gained further insights from experts and other stakeholders, the scope of the report was refined 
further under the guidance of a Technical Experts Committee. 
Technical Experts Committee 
In January 2007, nine individuals agreed to serve on the multidisciplinary Technical Experts 
Committee.  The committee members were selected and approved by CDC on the basis of their 
experience, interest, and expertise in one or more of the main topic areas addressed by the 
report.  They functioned as advisors, providing guidance on the development of specific 
chapters to ensure that the report content was comprehensive, appropriate, and accurate.  
Members of the committee provided input on specific queries and document drafts via 
conference calls and electronic communications.  
Data Gathering 
In preparing this report, Lewin compiled, analyzed, and synthesized secondary data from 
multiple sources, including published and unpublished literature, government databases and 
reports, market research reports, Internet searches, and personal communications with industry 
experts and government officials.   
Literature searches 
For a broad environmental scan of the field, Lewin conducted searches of published and 
unpublished literature using bibliographic databases and web-based search engines.  In the peer-
reviewed journal literature, searches were conducted predominately in the MEDLINE/PubMed 
database.  This involved examination of qualitative and quantitative literature covering general and 
systematic reviews, guidelines, clinical trials, observational studies, and other analyses.  For specific 
sections of the report, searches also were conducted in the Cochrane Library, National Guideline 
Clearinghouse, and Blue Cross Blue Shield Technology Evaluation Center Assessments database.    
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Government database searches and reports 
The Online Survey, Certification, and Reporting (OSCAR) database of CMS provided information 
about laboratory certification, accreditation, and proficiency testing.  Queries of the OSCAR 
database produced the most recent estimates of test volume for waived and non-waived tests by 
laboratory setting and numbers of facilities performing waived and non-waived tests.  Searches of 
publicly available CMS databases, such as those for the Medicare Physician Fee Schedule, Clinical 
Laboratory Fee Schedule database, and Part B Extract Summary System Data File, provided 
information about payment rates.  
Numerous federal government sources, including public notices, regulations, guidances, 
conference proceedings, and other reports, yielded other essential information.  Resources were 
used from the spectrum of Department of Health and Human Services (DHHS) agencies and 
advisory committees, including the Agency for Healthcare Research and Quality (AHRQ)a; CDC; 
CMS; Clinical Laboratory Improvement Advisory Committee (CLIAC); Health Research and 
Services Administration; FDA; DHHS Office of the Inspector General (OIG); Office of the National 
Coordinator for Health Information Technology; and the Secretary’s Advisory Committee on 
Genetics, Health, and Society (SACGHS).  Federal agencies that provided additional useful 
information included the Bureau of the Census, Bureau of Labor Statistics, Government 
Accountability Office (GAO)b; Office of Management and Budget; Department of Defense (DoD); 
Veterans Administration; Department of Justice; Securities and Exchange Commission; and The 
White House.  Information at the state level was obtained from state departments of health.   
Market research reports 
Market research reports and newsletters provided key information about market trends, 
workforce, technological advances, and other aspects.  Particularly relevant were those from 
Washington G-2 Reports, including Lab Industry Strategic Outlook: Market Trends and Analysis 2007 
and Laboratory Market Leaders Report 2008, which drew from extensive survey data, CMS and other 
agency data, financial reports filed with the SEC, Bureau of the Census data, and expert 
interviews.  Also useful were Washington G-2 Reports newsletters, e.g., the Laboratory Industry 
Report, Diagnostic Testing and Technology Report, G-2 Compliance Report, and National Intelligence 
Report.  Supplying further data on the laboratory medicine market, regulation, new technology, 
and related trends were Knowledge Source Inc.’s Clinical Laboratory Testing Market Overview 2006 
and Kalorama Information’s Molecular Diagnostics: Major World Markets (2007). 
Internet searches 
Along with literature sources, Lewin used Internet search engines to gather web-based 
information on particular topics.  This included information posted by public and private sector 
organizations involved in the laboratory medicine and health care community, such as 
government agencies, accreditation organizations, professional societies, industry associations, 
standards organizations, research organizations, academic institutions, medical centers, 
manufacturers, and international public policy organizations.  Resources from these organizations 
were evidence-based where applicable, current, and relevant to topics addressed in the report.    
                                                     
a AHRQ was formerly the Agency for Health Care Policy and Research.  
b GAO was formerly the General Accounting Office. 
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Personal communications  
For clarification of important concepts or to gather information where literature or data sets were 
lacking, Lewin relied on personal communications with experts in industry, professional groups, 
government agencies, and other public and private sector organizations. 
LIMITATIONS 
Our extensive search of the sources described above did encounter certain gaps and other 
limitations.  First, publicly available information about the economic status and quality of the 
laboratory medicine sector is patchy, inconsistent, and of uneven quality.  Although the OSCAR 
database contains the most extensive set of industry data, there is no standardized mechanism for 
estimating such important parameters as volume for panel tests.  The lack of standardization, 
coupled with self-reported, irregular data collection by laboratories, results in gaps and 
inconsistencies in estimates of test volumes, spending on services, and market revenue.  This 
limits determinations of long-term trends and market value for laboratory testing and services.   
In addition, the inability of those outside CMS to directly query the OSCAR database further 
complicated the research process.   In terms of the market research reports, data from surveys was 
limited due to low response rates.  For example, one of the surveys conducted for the 2007 report 
was sent to 12,000 laboratories in their database but only 141 responded.   Such data could benefit 
from efforts to obtain higher response rates.    
Second, lack of data standardization confounds comparability of published study findings 
regarding laboratory quality and error rates.  Formal measurement and reporting on quality has 
been limited largely to analytic-related processes.  Data collection in studies examining preanalytic 
and postanalytic factors has been insufficiently standardized across participating providers and 
laboratories.  Many of the quality indicators used for the studies (e.g., specimen 
labeling/identification) have not been adequately validated.  This contributes to wide ranges in 
estimates of errors, and generally inconsistent quality measurement across these institutions.   
Third, understanding of the current status of laboratory medicine is constrained by the lack of 
research on many important aspects of the field.  For example, there are very few studies of 
laboratory practice outside the hospital setting (e.g., physician office laboratories), although the 
majority of clinical care takes place in the ambulatory care setting.  There is a notable lack of 
research on the needs of specific populations, such as pediatric patients, frail elderly patients, and 
those with multiple chronic conditions, as most published studies involve the non-elderly adult 
population and typically focus on a single health issue, e.g., diabetes.  Research also is 
underdeveloped on the relationship of laboratory services to patient outcomes and cost of care.  
Fortunately, there is growing recognition of the importance of such research.  Lastly, there is a 
notable lack of reliable data on the relationships among historical costs on which payment is based, 
costs of providing laboratory testing, what constitutes payment adequacy, and the effects of 
economies of scale and other cost-reducing effects of technological changes.  These limitations 
curtail understanding of important aspects of laboratory medicine related to the quality of services 
in physician office laboratories, quality of care for specific patient groups, trends in population 
health, and the efficiency and value of laboratory services within the broader health care system.   
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CHAPTER I 
THE VALUE OF LABORATORY MEDICINE TO HEALTH CARE 
Laboratory medicine is an essential element of the health care system.  It is integral to many clinical 
decisions, providing physicians, nurses, and other health care providers with often pivotal 
information for prevention, diagnosis, treatment, and management of disease.1  Laboratory tests 
and services supply clinicians with information necessary to provide high quality, safe, effective, 
and appropriate care to patients.  The key role of laboratory testing is reflected in evidence-based 
medicine (EBM) and clinical practice guidelines.  Health care providers, quality assurance 
organizations, and payers are incorporating selected laboratory tests into indicators to objectively 
assess quality of care for individual patients and populations and to support payment policies.     
Laboratory medicine has an essential role in risk management.  Not only can testing help to 
prevent certain adverse events, it can facilitate detection and recovery from adverse health events 
when they do occur.  Laboratory tests help to prevent infectious agents from getting into the 
blood supply and ensure the safety of organs and tissues for transplant.  Through effective and 
timely surveillance, tests can help to mitigate threats to patient and population health (e.g., 
influenza, nosocomial infections, severe acute respiratory syndrome).  
The contributions of laboratory tests and services as an essential component and partner in health 
systems remain under-recognized.  Despite the extensive role of laboratory medicine in informing 
medical decision-making, spending on laboratory services accounts for only 2.3% of national health 
care spending and 2% of Medicare expenditures.1, 2  As overall expenditures on health care continue 
to rise, appropriate use of laboratory tests can facilitate cost-effective care via early detection and 
improved management of priority health conditions.  Recent and emerging technological advances 
gained from mapping the human genome, including applications of genetic testing that enable 
personalized medicine, call greater attention to the contributions of laboratory medicine to patient 
care as well as the scientific and medical knowledge base.  This chapter summarizes the value of 
laboratory medicine to health care and patient and population health.  
VALUE TO THE QUALITY OF PATIENT CARE 
Despite the world’s highest per capita spending on health care, there is overwhelming evidence 
in the U.S. of gaps between well-founded standards of care and its actual delivery.  Among the 
main factors often cited to explain deficiencies in quality are:  
 Growing complexity of science and technology, some of which has advanced more 
rapidly than our ability to integrate it into safe, effective, and efficient health care  
 Longer life expectancy, which has significantly increased the chronic disease burden 
and the resources being devoted to chronic disease care  
 A highly decentralized health care system that is often bureaucratic, wasteful, and 
difficult to navigate 
 Underinvestment and disparities in access to health information technology, 
constraining the ability of technology to improve the quality of care3  
Laboratory Medicine: A National Status Report Chapter I – The Value of Laboratory Medicine to Health Care 
May 2008 20 
Health care stakeholders concur that the quality of care delivered in the U.S. is inadequate and that 
its organization and delivery must be fundamentally changed.  The IOM reports, To Err is Human: 
Building a Safer Health System (1999) and Crossing the Quality Chasm: A New Health System for the 21st 
Century (2001), and other sentinel studies such as the RAND report on the Quality of Health Care 
Delivered to Adults in the U.S. (2003) have helped to mobilize national action on prevention of 
medical errors and quality improvement.3-6   
Public and private sector efforts to redesign and improve the health care delivery system are 
grounded in the six aims of quality identified by the IOM:  safety, effectiveness, patient-
centeredness, timeliness, efficiency, and equity.5  Using these dimensions of quality, health care 
organizations, professional groups, private and public purchasers, and others are developing 
specific policies, practices, and measures for each element, with the overarching goals of 
diminishing illness, injury, and disability as well as increasing the health and function of the 
U.S. population.  Examples of how laboratory medicine supports each of the six aims are 
provided below. 
 Safety refers to protection of patients from harm due to care that is intended to help 
them and protection of health care workers from harm while providing care.3  
Laboratory medicine contributes to diminishing the risk of harm when patients and 
specimens are accurately identified, specimens are collected appropriately, measures 
are taken to prevent specimen contamination, process control measures are executed 
during analytic processes, and test results are complete and understandable.7   
 Effectiveness refers to measures of how well health care interventions (screening, 
diagnosis, treatment, etc.) achieve their intended outcomes or other impacts.3  Laboratory 
medicine supports effectiveness when test ordering is evidence-based, specimen collection 
follows science-based procedures, specimen analysis and results reporting conform to 
well-established standards, and testing results in improved patient outcomes.7      
 Patient-centered care is respectful of and responsive to individual patient values, 
preferences, and expressed needs, and ensures that patient values guide decision 
making.8  Laboratory medicine supports patient-centered care when test ordering 
reflects patient preferences, including end-of-life care, specimen collection is designed 
for patient comfort and satisfaction, and test results are understandable to and 
actionable by the patient and clinician.  These attributes can contribute to favorable 
patient experience of the health system and quality of care.    
 Timeliness of care minimizes, unnecessary delays that can result in emotional or 
physical harm.3, 9  Timely transport of specimens, decreased turnaround times (TATs) 
in routine and stata testing, and timely notification of critical or abnormal values are 
primary ways that laboratories support quality of care.7, 10      
 Efficiency refers to using resources to optimize production of desired results.3  
Laboratory medicine contributes to health care efficiency when waste is eliminated or 
reduced, including that associated with inappropriate test ordering (e.g., underuse, 
                                                 
a Stat testing refers to laboratory tests for which results are needed as quickly as possible and which are given 
priority by laboratories.  
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overuse, and misuse), redraws or recollection of specimens, repeating specimen 
analysis, and correcting inaccurately documented test results.7       
 Equity of care ensures that quality does not vary because of patient personal 
characteristics such as sex, race/ethnicity, geographic location, or socioeconomic 
status.3  Laboratories contribute to equitable care when they provide services in a 
manner that is unbiased, accommodate the special needs of patients during specimen 
collection, use reference intervals that account for population differences, and present 
information according to the language and literacy level of the patient.7        
Figure 1.1 portrays the dynamic role of laboratory medicine in the health care system.  This 
diagram has as its premise that value can be expressed in terms of achieving the six aims posed by 
the IOM.  
Laboratory indicators also provide a means to assess quality of care.  Test use as indicated by 
clinical practice guidelines and related protocols, as well as test results themselves, are being 
incorporated into indicators of provider performance and health care quality.   Clinical 
laboratories facilitate collection, analysis, and interpretation of data at the individual and 
population levels that are necessary for ensuring the public health, such as monitoring rates of 
nosocomial infections, development of drug resistance, infectious disease outbreaks, and 
biological and chemical threats.   
Figure 1.1:  Value of Laboratory Medicine to the Health Care System 
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VALUE TO EVIDENCE-BASED MEDICINE 
Though its antecedents extend to the mid-19th century, the widespread practice of EBM and its 
broader, yet not universal, acceptance in the U.S. is a more recent development spanning the past 
two decades.  EBM is commonly defined as the explicit use of best evidence in decision-making 
about the medical care of individual patients.11, 12  EBM derives from thorough, well-founded 
methods and resources for generating evidence, including the use of randomized controlled trials 
and other rigorous study designs as appropriate; use of meta-analyses, systematic reviews, and 
other structured approaches for integrating evidence from multiple sources; and standardized 
reporting of research results.13  In general, EBM is based on five main principles:  
 Decisions about health should be based on the best patient-, population-, and 
laboratory-based evidence 
 The problem determines the most appropriate source of evidence 
 The best evidence is identified by integrating epidemiological, biostatistical, and 
pathophysiological methods with personal experience 
 The value of searching for and appraising evidence is derived from translating 
evidence into actions that affect patients 
 The ways in which these principles are carried out and performed must be 
continuously evaluated14     
Laboratory testing plays a major role in supporting EBM in clinical practice.  As described in 
greater detail below, EBM increasingly informs the development of clinical practice guidelines.13  
The hemoglobin A1c (HbA1c) test, which measures the amount of glucose bound to hemoglobin, 
allows clinicians to monitor the average amount of glucose in a patient’s blood over the previous 
two to three months.15  Based on results of HbA1c testing in clinical trials such as the Diabetes 
Control and Complications Trial, a large randomized controlled clinical trial that involved more 
than 1,400 type 1 diabetic patients, researchers were able to assess glucose levels and determine 
optimal treatment protocols for individuals with this condition.16         
VALUE TO CLINICAL PRACTICE GUIDELINES FOR PATIENT CARE 
Clinical practice guidelines are systematically-developed statements intended to assist 
practitioners and patients in making decisions about health care in specific clinical and personal 
circumstances.17  While clinicians have long used such means as treatment recommendations, 
immunization schedules, practice bulletins, and algorithms to inform decision-making, clinical 
practice guidelines focus on summarizing research and external evidence to develop 
recommendations.18  This more rigorous approach typically involves a multidisciplinary team 
that reviews some systematic compilation of relevant evidence, working according to explicitly 
described methods.19, 20    
Among the factors underlying variation in clinical practice are overuse, underuse, and misuse 
of health care interventions.13, 21  Clinical practice guidelines are intended to reduce this 
variation and improve the quality, safety, efficiency, and effectiveness of clinical care.  
Guidelines have been developed for nearly all facets of medical care, spanning prevention, 
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surveillance, diagnosis, treatment, monitoring, rehabilitation, and palliation; and applying to 
drugs, devices, procedures, and systems.13, 19       
Quality indicators increasingly are incorporating laboratory testing.  For example, 102 (23%) of the 
439 quality indicators assessed in the RAND analysis of the quality of care delivered to U.S. adults 
involved diagnostic tests.4  The 2006 National Healthcare Quality Report from AHRQ includes eight 
clinical conditions, seven of which involve laboratory testing:  end-stage renal disease, colorectal 
cancer, diabetes, human immunodeficiency virus/acquired immune deficiency syndrome 
(HIV/AIDS), mental health/substance abuse, heart disease, and pneumonia.22  In a study 
conducted by The Lewin Group in 2005, a search of the National Guideline Clearinghouse and 
MEDLINE was undertaken to estimate the extent to which laboratory tests were included as part 
of evidence-based clinical practice guidelines across the 23 main condition/disease categories 
defined by the National Guideline Clearinghouse.  Of 1,230 guidelines identified, 460 (37%) 
focused on or involved laboratory tests.   
Table 1.1 outlines priority health conditions identified in these sources and corresponding 
estimates of the prevalence and spending on each.  For each health condition, common laboratory 
tests used in screening, diagnosis, and/or monitoring are shown.      
Table 1.1:  Sample of Priority Health Conditions, Associated Laboratory Tests,  
Prevalence, and Cost to the Health System 
Health condition 
Examples of laboratory tests 
used in diagnosis and/or 
patient management 
Number of Americans 
Affected Spending on Condition 
Heart disease Lipid panel, troponin 79.4 million (2004)a $403 billion (2006)b 
Respiratory diseaseI Blood gas test, bacterial culture, viral culture 
15.7 millionII  (asthma); 1.3 
millionIII (pneumonia)c,d $144.2 billion (2006)
b 
Cervical cancer Pap smear, human papillomavirus DNA testing  
11,150 cervical cancer diagnoses 
(2007)e $1.7 billion (2004) 
Colorectal cancer Fecal-occult blood test 112,340 colon cancer diagnoses (2007)e $8.4 billion (2004)
f 
Diabetes Glucose, HbA1c 20.8 million (2005)g $132 billion (2002)g 
End-stage renal disease Creatinine, BUN 472,000 (2004)h $32.5 billion (2004)h 
HIV/AIDS Antibody testing, CD4 testing, RNA 1.2 million (2006)i $21.1 billion (2006)i 
Maternal health 
(prenatal care) 
Blood and Rh type with antibody 
screen 
83.9% pregnant women began 
prenatal care in first trimester; 
3.6% began prenatal care in third 
trimester or not at all (2004)j  
$26.2 billion (2005)k 
Mental health/ 
substance abuse 
Drug tests, liver function 
24.6 million adultsIV (classified 
with serious psychological 
distress) (2005); 22.2 million 
peopleV (classified with 
substance dependence or abuse) 
(2005)l 
$104 billion (2001)m 
Influenza Viral culture, serology, rapid antigen testing 
5-20% of the U.S. population is 
infected with the influenza virus 
each yearn 
$200 on treatment per 
infected person (2003)o 
Health care-associated 
infections 
Viral culture, molecular typing of 
microbial pathogens 1.7 million (2006)
p $10,500-$111,000 per case (2004)p 
 
Based on review of the National Guideline Clearinghouse, Agency for Healthcare Research and Quality, and Medline, National 
Library of Medicine.  Tests identified from Lab Tests Online. 
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IIncludes, but is not limited to, severe asthma and pneumonia 
IIIndicates number of non-institutionalized adults 
IIIIndicates number of discharged patients 
IVIncludes people aged 12 and older 
VIncludes people aged 18 and older 
________________________________ 
aRosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics--2007 update: a report from the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115(5):e69-171. 
bFact book fiscal year 2005.  Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 2006.      
cFaststats: asthma.  Hyattsville, MD: National Center for Health Statistics, 2007.   
dFastats: pneumonia.  Hyattsville, MD: National Center for Health Statistics, 2007.   
eCancer facts and figures 2007.  Atlanta, GA: American Cancer Society, 2007.    
fCancer trends progress report--2005 update.  Bethesda, MD: National Cancer Institute, National Institutes of Health, 2005.   
gNational diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2005.  
Bethesda, MD: National Diabetes Information Clearinghouse, National Institute of Diabetes and Digestive and Kidney Disease, 
National Institutes of Health, 2005.   
hU.S. Renal Data System, USRDS 2006 annual data report: atlas of end-stage renal disease in the United States.  Bethesda, MD: 
National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2006. 
iHIV/AIDS policy fact sheet.  Menlo Park, CA: Kaiser Family Foundation, 2006.   
jHealth, United States, 2006 with chartbook on trends in the health of Americans.  Hyattsville, MD: National Center for Health 
Statistics, 2006.   
kInstitute of Medicine.  Preterm birth: causes, consequences, and prevention.  Washington, DC: National Academy Press, 2006. 
lResults from the 2005 National Survey on Drug Use and Health: national findings. Rockville, MD: Substance Abuse and Mental 
health Services Administration, 2006.   
mMark T, Coffey RM, McKusick T, et al.  National expenditures for mental health services and substance abuse treatment, 1991-
2001.  Rockville, MD: S Center for Substance Abuse Treatment, Center for Mental Health Services, Substance Abuse and Mental 
Health Services Administration, 2005.   
nKey facts about influenza and the influenza vaccine.  Atlanta, GA: Centers for Disease Control and Prevention, 2007.   
oSoni A, Hill SC.  Average annual health care use and expenses for influenza, 2001-2003.  Statistical brief #116.  Rockville, MD: 
Agency for Healthcare Research and Quality, 2006.   
pStatement by Denise Cardo, MD, Director, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers 
for Disease Control and Prevention, on CDC’s role in monitoring and preventing healthcare-associated infections before the 
Subcommittee on Oversight and Investigations of the House Committee on Energy and Commerce, 109th Congress, 2nd session. 2006. 
 
VALUE OF LABORATORY TESTS AND SERVICES ACROSS PATIENT CARE 
CONTINUUM 
Laboratory medicine provides value across the continuum of patient care.  In addition to 
providing objective data about patient health, laboratory medicine enables early assessment of 
disease risk, use of preventive and less invasive treatment, selection of appropriate treatment, and 
monitoring treatment.  Used appropriately to inform patient management decisions, laboratory 
testing can contribute to optimizing use of health care resources and decrease short-, medium-, 
and long-term costs of care.23   
Screening for Risk Factors of Developing Specific Disorders  
Screening tests may be conducted on asymptomatic individuals to check for risk factors and other 
indicators of developing or latent disease.24  Especially for children and young adults, such testing 
can avoid or diminish the impact of diseases and medical conditions that appear later in life.  
Screening tests for adults can detect certain common diseases that, when identified early, can be 
more easily treated.25, 26 
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Access to preventive and screening laboratory testing services in the U.S. varies.  Although 
Medicare’s authorizing legislation (Title XVIII of the Social Security Act) excludes coverage for 
preventive interventions and diagnostic laboratory tests for asymptomatic individuals, Congress 
has mandated Medicare coverage of selected screening and diagnostic procedures over the years.  
Pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), 
preventive benefits provided by Medicare effective in 2005 include a “Welcome to Medicare” 
physical exam and screening for heart disease and diabetes, along with earlier mandated tests for 
osteoporosis, glaucoma, and cancers of the colon, breast, cervix, and prostate.27, 28     
The disparities between insured and uninsured people in the U.S. in access to care extend to 
laboratory testing.  Compared to adults with any type of health insurance coverage, uninsured 
adults in the U.S. are less likely to receive preventive and screening services at all and are less 
likely to receive these services on a timely basis.29  People in the U.S. who are uninsured are more 
likely to report duplication of laboratory tests, laboratory test errors, and delays in receiving 
laboratory test results.30     
Screening to Determine Individual Risk 
Genetic testing involves analysis of human deoxyribonucleic acid (DNA), ribonucleic acid 
(RNA), chromosomes, proteins, or certain metabolites to detect genetic alterations related to a 
heritable medical disorder.31  A universal definition of genetic testing has not been recognized 
by regulatory or professional bodies. SACGHS defines a genetic test as one that involves the 
analysis of chromosomes, DNA, ribonucleic acid, genes, or gene products to detect heritable or 
somatic variations related to genes or health.32  In its draft 2007 report on oversight of genetic 
testing, SACGHS calls on relevant agencies to develop an appropriate definition of health-
related genetic tests.    
Genetic testing can be used to determine whether an individual is a carrier for a disease or 
condition or has a heightened risk of developing a disease years or decades later.33  It also can be 
used for diagnostic or prognostic purposes and as a predictive tool to assess an individual’s drug 
metabolism.  The main types of genetic testing include the following: 
 Carrier identification is used to determine whether an individual possesses a potentially 
harmful gene that can be passed on to progeny.  Prenatal/maternal serum screening is 
used to determine whether a fetus is at risk of having specific genetic conditions and to 
detect open neural tube defects and certain chromosomal abnormalities.  Current 
prenatal diagnosis is targeted at specific diseases and/or mutations rather than 
determining the general genetic make-up of the fetus. 
 Newborn screening is most often used to determine whether a newborn has a medical 
condition that requires immediate treatment, e.g., phenylketonuria, congenital 
hypothyroidism. 
 Late-onset disorder testing is used to determine an adult’s susceptibility or 
predisposition to complex diseases (e.g., cancer, heart disease, Huntington’s disease). 
The increasing role of genetic testing is due in great measure to advances in understanding the 
role of genetics and molecular biology in disease development.  Genetic tests are now available 
for more than 1,400 diseases.34  Tests for an estimated 287 of these diseases are being used only in 
research settings.  Many diseases are known or thought to be caused by inherited or spontaneous 
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acquired DNA alterations, e.g., Down syndrome, Huntington disease, sickle cell anemia, and 
hemophilia, and thought to cause or contribute to many others, including Alzheimer’s disease, 
breast cancer, leukemia, and osteoarthritis.35  Genetic testing for early-onset Alzheimer’s disease 
detects mutations in three single genes that are understood to lead to the development of the 
disease at an early age, typically before the age of 60.36  Breast cancer (BRCA) gene analysis, which 
is often performed by sequencing the BRCA1 and BRCA2 genes, identifies mutations in these two 
genes that are associated with predisposition to breast and ovarian cancer.  BRCA1 and BRCA2 
mutations have been identified in 1-2% of women diagnosed with breast cancer and 5-10% of 
women diagnosed with ovarian cancer.37   
Diagnosing Conditions and Evaluating Prognosis 
Early detection 
Laboratory tests are critically important for accurately diagnosing a disease in its earliest stages, 
determining disease severity, assessing the likelihood of recovery, and evaluating the potential for 
adverse outcomes.  Accurate and early diagnosis allows clinicians and patients to better evaluate 
the benefits and risks of various treatment options, begin treatment promptly and, in the case of 
contagious conditions, prevent a disease from spreading to others.  Laboratory tests are used by 
clinicians and, increasingly, patients, to inform prevention and treatment decisions and related 
courses of action.  
Early-stage detection via laboratory testing is established for such diseases and conditions as 
breast cancer, cervical cancer, skin cancer, thyroid dysfunction, high cholesterol, and diabetes.  
Using the Papanicolaou test (Pap test or Pap smear), a pathologist or cytotechnologist can identify 
cervical cells that are cancerous or potentially pre-cancerous.38  The American Cancer Society, U.S. 
Preventive Services Task Force (USPSTF), and American College of Obstetricians and 
Gynecologists recommend that young women receive Pap tests every year beginning no later 
than age 21; women over the age of 30 who have no new risk factors and who have had normal 
results for three consecutive years are advised to get retested every two-to-three years.  Broad use 
of the Pap test as a screening tool to detect pre-invasive lesions is credited with reduction in the 
annual incidence rate (from 14.8 to 7.0 per 100,000) and mortality rate (from 5.6 to 2.4 per 100,000) 
of malignant cervical cancer in the U.S. between 1975 to 2004.39-41   
When diseases are identified at an early stage or before symptoms have appeared, patients and 
their health care providers can take measures to prevent or reduce the risk of developing the 
disease or condition, including increased medical monitoring, lifestyle changes and, when 
needed, medical interventions.37  Similarly, early measures may minimize the severity of the 
disease and its effects on mortality, morbidity, and quality of life.  These measures also can 
diminish downstream health care spending that would have been caused by the disease.  For 
instance, early detection of incipient colorectal cancer (e.g., using fecal-occult blood testing) is 
associated with more successful treatment and increased survival.42 
Diagnosis 
Along with an individual’s signs, symptoms, personal history, and family history, laboratory tests 
are used to arrive at or eliminate possible diagnoses.43  A laboratory test used for “ruling in” a 
disease or condition indicates that it may be present if the test results are abnormal.  “Ruling out” 
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a disease or a condition allows the clinician to consider alternative diagnoses and make more 
efficient use of resources.   
Laboratory tests can be used to determine the degree to which the disease has progressed and the 
severity of the disease.  Laboratory tests, including studies of blood, urine, other bodily fluids, 
and bodily tissues play a major role in the “staging” of cancer and other diseases, i.e., describing 
the severity of a disease based on the extent to which it has spread throughout the body.44  Tests 
to determine the extent and severity of a disease can be the same or different from those for 
diagnosis.  For example, measurements of HbA1c and glucose are used to diagnose diabetes and 
to monitor diabetic individuals.45     
Among other examples, laboratory tests can direct a diagnosis in the case of pharyngitis, or 
inflammation of the pharynx, which can be caused by a variety of microorganisms.46  Group A 
streptococcus (GAS) is a bacterial cause of pharyngitis and can be treated with antibiotics.  Only 
about 15% of sore throats are caused by GAS; therefore, the results of a streptococcal screen 
provide a clinician with information about the underlying cause of the sore throat and inform 
determination of the optimal treatment.  This also highlights the importance of accurate 
laboratory tests in slowing increases in the prevalence of medication-resistant strains of disease 
bacteria.47  While antibiotics have little to no effect on the cause of many upper respiratory 
infections (including all viral infections) whose symptoms often resemble those cause by GAS, 
U.S. clinicians often prescribe antibiotics for these infections.48  As resistance to antibiotics 
commonly used to treat GAS has been documented,49 accurate diagnosis of GAS using laboratory 
testing is a key component for preventing inappropriate use of antibiotics.  Similarly, laboratories 
also conduct antimicrobial susceptibility testing to determine the ability of antimicrobial agents to 
inhibit the growth of pathogenic bacteria, thereby helping to optimize treatment and reduce the 
risk of antibiotic-resistant organisms.50      
Brain natriuretic peptide (BNP) is a peptide involved in the control of cardiovascular function; 
plasma concentrations of BNP are increased in individuals with heart failure and BNP levels are 
correlated with the severity of the symptoms.51, 52  The BNP assay is used by clinicians to 
determine whether or not an individual has heart failure.  For example, a 2004 study of patients 
presenting in the emergency department with acute dyspnea, or shortness of breath, found that, 
when used in conjunction with other clinical information, rapid measurement of BNP to diagnose 
heart failure improved patient evaluation and treatment and reduced the total time the patient 
spent in the emergency department.51  Study results indicated that 75% of patients in the BNP 
group were hospitalized, compared to 85% of the control group.  Similarly, 15% in the BNP group 
required intensive care, compared to 24% in the control group. 
Prognosis 
Once a diagnosis is made and the severity of the disease has been determined, laboratory test results 
can contribute to projecting the course of disease, including estimating the likelihood that an 
individual will recover from a disease or medical condition.  For instance, certain abnormal results 
in a panel of laboratory tests given to women who are suffering from severe pre-eclampsia are 
predictive of high risk of maternal morbidity.53, 54  Routine laboratory tests ordered upon hospital 
admission of patients following myocardial infarction that measure white blood cell, creatinine, 
glucose, lactate dehydrogenase, and platelet counts are predictive of the likelihood of mortality.55 
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Individuals who have had an unexplained thrombotic episode (i.e., clinical signs and symptoms 
associated with a blood clot in a vein or artery) before they are 50 years old or have had certain 
abnormal clots are encouraged to have a molecular diagnostic test to determine whether they 
have an inherited gene mutation that puts them at increased risk of developing additional blood 
clots.56  The test detects factor V Leiden, a variant form of a factor V, a coagulation factor that is 
activated following injury of a blood vessel.  Factor V Leiden is the most common inherited 
predisposition to abnormal clotting in the U.S. and individuals who are found to carry the 
mutation are counseled to avoid risk factors that can lead to additional blood clotting, such as oral 
contraceptive use. 
Although not yet in routine practice, laboratory tests are increasingly used to determine the 
potential for future adverse health outcomes following recovery from a disease, such as recurrent 
stroke or cancer relapse.  In February 2007, FDA cleared for marketing a test (MammaPrint®) that 
determines the likelihood of breast cancer returning within 5-10 years after a woman’s initial 
cancer.57  The test evaluates 70 genes located in the tumor to determine whether the patient is at 
low or high risk for spread of the cancer to another site.  Like other predictive tests, the results 
from this and others being developed to assess likelihood of disease relapse are not perfectly 
accurate and must be used with other information to support management of the disease.58  A 
similar laboratory developed test is the Oncotype DX™ that analyzes the expression of a panel of 
21 genes to quantify the likelihood of breast cancer recurrence and potential benefit from 
chemotherapy in women with newly diagnosed, early stage invasive breast cancer.59  Clinical 
practice guidelines of ASCO and NCCN include indications for using the Oncotype DX™ test, 
although these organizations await the findings of prospective clinical trials of this and other gene 
expression profile tests for offering more definitive guidance.  Major U.S. payers cover the cost of 
the test for particular indications, sometimes subject to prior authorization.60, 61    
Monitoring General Treatment Effectiveness 
Laboratory tests play a large role in monitoring and evaluating the efficacy of other medical 
treatments.62  They can assist clinicians in deciding whether to modify a specific course of treatment 
in order to optimize outcomes, including maximizing therapeutic impact.  For instance, tests to 
measure viral load, CD4 count, complete blood count, and blood chemistry tests are commonly 
used to assess treatment response in patients with HIV.63  Some laboratory tests used to monitor 
treatment effectiveness are the same as those used to make the initial disease diagnosis.  A very 
common instance of this involves tests to measure thyrotropin/thyroid stimulating hormone in the 
diagnosis and monitoring of thyroid disease.64  Laboratory testing is also important in monitoring 
patients following surgery to gauge the success and effectiveness of a procedure.  Laboratory tests 
to detect levels of human chorionic gonadotropin in women with trophoblastic disease, which 
involves abnormal growth of cells inside a woman’s uterus, are conducted regularly following 
surgery to determine whether or not further treatment is required.65  
Managing Acute Health Conditions 
Acute conditions are those that appear suddenly and follow a short, severe course (i.e., persisting 
for several days or weeks) and have the potential to be completely resolved.  Most acute care is 
relatively short-term.  In acute care settings such as the intensive care unit (ICU) or the emergency 
department, frequent laboratory testing can be used to monitor quickly and accurately an 
individual’s status and response to medical interventions.  The five most commonly ordered 
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types of laboratory tests in ICUs include basic metabolic panels, arterial blood gas profiles, 
complete blood counts, partial thromboplastin times, and measures of magnesium levels.66  The 
basic metabolic panel, which measures glucose, calcium, electrolytes, and analytes related to 
kidney function, is commonly ordered in hospital emergency rooms because its results can 
indicate several acute problems, including kidney failure, insulin shock or diabetic coma, 
respiratory distress, or heart rhythm changes.67      
Particularly in critical care settings, any intervention that shortens or improves the efficiency of care 
can dramatically affect patient outcomes and health care costs.68  There is great emphasis on 
providing quick and accurate laboratory test results for individuals in critical care settings.  One 
commonly used method of achieving short TATs is stat testing, which refers to the sequence of 
events to obtain urgently needed test results promptly.69  Many hospitals maintain designated stat 
laboratory space to meet urgent testing needs, usually located next to operating rooms, critical care 
units, or the emergency department.70  Recent research confirms that rapid analysis of cardiac 
markers D-dimer (a marker for patients at risk of a pulmonary embolism or deep vein thrombosis) 
and serum protein S100 (a marker of brain damage) improves outcomes.71-73 
Laboratory tests for certain critical conditions can be conducted using point-of-care testing 
(POCT) technology, which allows clinicians to obtain laboratory results in proximity to the 
patient.74  Measurements of glucose and oxygen saturation levels at the point-of-care allows 
clinicians to determine changes in a patient’s status rapidly and frequently.75  In critical care 
settings, nurses often perform POCT.70  Particularly in the emergency room, POCT has the 
potential to expedite decision making and allow for more effective triaging of patients.                        
While acute care is often provided in hospital settings (e.g., emergency department, ICU) it can 
also be provided in ambulatory care settings (e.g., physicians’ offices, other primary care sites).  
As in critical care, laboratory testing in non-critical primary care is vital to timely and accurate 
diagnosis.  For instance, testing for urine leukocyte esterase and nitrites to detect urinary tract 
infections, testing for H pylori to detect gastrointestinal disorders, and testing for C-reactive 
protein to detect bacterial infection are all commonly used in acute care provided in primary care 
settings.76-78  POCT is growing in use for non-critical acute care to provide rapid diagnosis and 
rule out other tests.79  Whereas urine specimen culture testing requires 24 hours to complete, urine 
dip-stick tests provide a means of rapidly detecting the presence of bacteriuria and urinary tract 
infections.80  Specimen culture and antimicrobial resistance susceptibility tests are usually 
conducted in a laboratory, while dipstick tests contain specially treated plastic strips that change 
color when exposed to infected urine and can be conducted in a doctor’s office or at home.  In 
many cases, negative urine dipstick tests alone can exclude the presence of infection.   
Managing Chronic Health Conditions     
Laboratory testing is an essential component in managing chronic diseases—health conditions 
that persist over an extended period of time and, in many cases, cannot be completely cured (e.g., 
type I diabetes).81  The burden of chronic disease in the U.S. population is high.  More than 90 
million Americans currently live with chronic illnesses.  About half of older adults have at least 
two chronic medical conditions.82  Care for chronic illness accounts for more than three-fourths of 
U.S. health care costs.83   
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Laboratory tests are useful tools for clinicians and patients in understanding the status of the 
disease(s), informing treatment decisions, determining the urgency of care required, managing 
symptoms, educating patients, and incorporating lifestyle changes into the treatment regimen.  In 
certain instances, regular laboratory testing can prevent the diseases from progressing or 
worsening.  For example, patients with coronary artery disease are at high risk for myocardial 
infarction.  Aggressive lipid management in individuals who have heart disease helps to prevent 
heart attacks and reduces mortality rates.84  Regular lipid testing of patients with heart disease 
helps physicians to tailor disease management regimens and provides a means to motivate some 
patients to implement lifestyle changes.  Similarly, laboratory tests are a key component in the 
management of chronic kidney disease, which can also lead to high blood pressure, anemia, weak 
bones, nerve damage, and progression to kidney failure.85  Laboratory tests that measure 
glomerular filtration rate are used to assess the severity of chronic kidney disease and to 
determine whether to initiate certain treatments.   
Disease management refers to the ongoing care associated with chronic conditions.  It is defined as a 
proactive, multi-component strategy for delivering health care services that aims to reduce adverse 
medical events by maximizing patient’s adherence to prescribed treatments and/or lifestyle 
changes.86  An important component of the strategy is self management, with patients being 
responsible for day-to-day self-monitoring, decision-making, and healthy lifestyle choices.87, 88   
Diabetes treatment has been used often as the focus of models for disease management, which 
traditionally involves a partnership between physicians, nurses, educators, and the patient.  
Physicians monitor patient blood glucose and HbA1c levels during regular office visits and track 
trends over the previous two-to-three months.  Frequent, daily self-monitoring of blood glucose 
levels also is critically important to determine medication and/or dietary changes needed.45  
Individuals usually self monitor by using a lancet device to obtain a small blood sample that is then 
applied to a reagent strip and inserted into a reflectance photometer for an automated reading of 
blood glucose levels.89  Patient education is needed for successful disease management at home.90  
Newer technologies support continuous glucose monitoring by measuring interstitial fluid using 
minimally invasive methods or by applying noninvasive electromagnetic radiation through the skin 
to the body’s blood vessels.91  Continuous monitoring provides clinicians and patients with greater 
insight into glucose levels throughout the day than does conventional self-monitoring, thereby 
helping to identify and ultimately prevent periods of hypo- and hyperglycemia. 
Therapeutic Drug Monitoring 
Standard laboratory tests are integral to the management of medication dosages for many 
conditions.  Therapeutic drug monitoring (TDM) refers to the measurement of specific drugs or 
metabolites in the body via blood testing to inform therapeutic regimens that maintain a target 
medication concentration in the body.92  Maintaining an appropriate dosage is particularly 
important for medications with a narrow therapeutic index, i.e., drugs with smaller dosage ranges 
for optimum effectiveness.  Medications with narrow therapeutic indexes, such as those used to 
treat cardiovascular, kidney, thyroid, and liver disease, typically require precise dosage 
modifications to fit the needs of an individual patient as well as close monitoring.  Drugs that 
have a wider therapeutic index, such as antihypertensives and antibiotics, can usually be 
prescribed based on pre-established dosing schedules.   
Laboratory Medicine: A National Status Report Chapter I – The Value of Laboratory Medicine to Health Care 
May 2008 31 
Laboratory tests associated with TDM are instrumental in establishing and maintaining the 
medication dosage that will yield the optimum blood level range for a specific individual.92  
Calculations are based on optimum therapeutic ranges developed through research and clinical 
testing of narrow therapeutic index medications in addition to individual patient testing.  TDM 
plays an especially vital role in ensuring that treatments are fully effective and that the 
individual does not experience any toxicity as a result of treatment.  TDM can also be used to 
evaluate the extent to which an individual is compliant with or adherent to a clinician’s 
prescribed course of treatment.  
Most TDM takes place in hospitals or other inpatient settings; however, newer tests are allowing 
TDM to be conducted in other settings, such as clinics, physicians’ offices, and at home.93  Certain 
medications, such as warfarin, also can be monitored at home between physician’s visits with 
portable monitoring devices similar to those used by diabetics to monitor glucose.94   TDM 
conducted on-site in physicians’ offices has the benefit of enabling clinicians to adjust therapeutic 
drug doses while the patient is still present in the office.95  On-site analyzers enabling TDM in  
physicians’ office laboratories (POLs) are available for measuring concentrations of 
anticonvulsant and anti-asthmatic medications, among others.  POCT available for POL-based 
TDM allows clinicians to obtain laboratory results more quickly and cost-effectively than when 
specimens are sent to a laboratory.  Immunosensor applications that use antibodies to detect drug 
concentrations can be plugged into handheld personal digital assistants to allow clinicians to 
obtain TDM results in 30 minutes or less in both hospital and outpatient settings.96  
Detection and Prevention of Medication Error 
Laboratory testing also provides a means to prevent and detect medication errors,b i.e., any error 
occurring in the medication-use process, such as wrong dosages prescribed, wrong dosage 
administered, failure to administer a medication by the provider, or patient failure to take the 
medication as prescribed.100  Computerized physician/practitioner order entry systems, which 
allow users to order medications electronically, can compare the medication orders to major 
elements of the patient’s history, including laboratory results.  Clinicians are alerted when 
medication orders conflict with a specific element in the patient’s history.101  Increased networking 
of computerized ordering systems, pharmacy information systems, and laboratory information 
systems should further increase the ability of laboratory medicine to aid in the prevention of 
medication errors.  Review of laboratory test results documented in a patient’s medical record 
aids in the detection and identification of medication errors.100, 102  
                                                 
b An adverse drug reaction (ADR) is any adverse effect resulting from the use of a medication in the recommended 
manner.  An adverse drug event is any injury due to medical harm, including physical harm (e.g., rash), mental 
harm (e.g., confusion), or loss of function (e.g., inability to drive a car), whether used in the recommended 
manner or not. ADRs and events may be preventable or nonpreventable.  A medication error is any error occurring 
throughout the medication-use process, including events resulting from use of a medication in both 
recommended and non-recommended manners. An error is the failure of a planned action to be completed (i.e., 
error of execution), or the use of a wrong plan to achieve an aim (i.e., error of planning), and may be an act of 
commission or omission.97-99  
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Individualizing Drug Treatments and Reducing Adverse Drug Reactions 
As scientists study the human genome and gain understanding of the genetic, behavioral, and 
environmental determinants of disease and therapeutic response, laboratory tests can be leveraged 
to individualize treatment protocols based on individual patient traits.  Pharmacogenomics (PGx)c 
uses information from the human genome to understand the spectrum of genes involved in drug 
response and studies the relationship between gene-based markers and pharmacology.104, 105  By 
assessing factors such as hormone levels and gene expressions that can vary among individuals, 
PGx allows clinicians to better understand how an individual is likely to respond to a specific 
treatment or therapy and, thereby, to tailor treatment most appropriately.  PGx is a key element of 
the broader concept of personalized health care.  
Molecular laboratory tests provide information used to apply PGx.  Tests for estrogen and 
progesterone receptors on the surface of cells from tissue biopsies of women with breast cancer can 
determine whether the growth of these cancers can be stopped by therapeutic molecules that block 
these hormones.106  Trastuzumab (Herceptin), a monoclonal antibody used in the treatment of 
breast cancer, is considered to be effective only in women whose breast cells express the HER2/neu 
protein, the presence of which is determined by laboratory tests.107  The efficacy of certain drugs for 
treating HIV infection is mediated by specific genetic polymorphisms; individuals expressing a 
single-nucleotide polymorphism on the MDR1 gene respond more favorably to anti-retroviral 
agents.108  Response to warfarin, a commonly prescribed drug for individuals at high risk of 
developing blood clots, varies; individuals with the *2 and *3 allelic variants of the cytochrome P450 
2C9 enzyme clear the drug much slower than individuals without this allelic variation, and 
therefore require lower doses.109, 110  A major goal of determining optimal warfarin dosage is to 
reduce adverse reactions and to determine the optimal therapeutic dosage.            
PGx testing can also be used to identify individuals who are at risk for developing an adverse drug 
reaction.97  When therapeutic drugs are indicated, PGx testing can improve appropriate drug 
selection and management of medication dosage, as well as reduce the potential for adverse drug 
reactions (ADRs).111,112 
Several PGx tests are readily available for preventing ADRs.  One example is laboratory testing 
using DNA microarray assays to identify variants in cytochrome P450, a group of drug-
metabolizing enzymes that exists in more than 50 forms and catalyzes the oxidation of many 
drugs, including beta blockers, antiarrhythmics, and antidepressants.d,114, 115  Similarly, 
administration of 5-fluorouracil, a chemotherapy used in the treatment of various types of cancer, 
can lead to potentially life-threatening toxicity in individuals with dihydropyrimidine 
dehydrogenase deficiency.116  Laboratory testing can be used to identify individuals with a defect 
in the gene that encodes for the dihydropyrimidine dehydrogenase deficiency enzyme, thereby 
allowing clinicians to make more appropriate treatment decisions. 
                                                 
c Pharmacogenomics is defined as the general study of all of the genes that influence and determine drug behavior.  
The term pharmacogenetics refers to the study of particular inherited differences in drug metabolism and 
response.  However, the two terms are used interchangeably, and this distinction is considered arbitrary.103   
d Research into targeted drug treatments is promising.  For instance, a 2007 systematic review prepared on behalf of 
CDC’s Evaluation of Genomic Applications in Practice and Prevention Project determined that there is a paucity of 
good-quality data addressing whether testing for CYP450 polymorphisms in adults who are about to enter treatment 
for non-psychotic depression leads to improved outcomes.113  
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Because PGx makes feasible developing laboratory tests capable of identifying patients and 
conditions that will be responsive to highly targeted therapeutic agents, clinical laboratories are 
expected to play a greater role in the development of this field over the next several years.117  In 
particular, clinical laboratories are expected to provide consumers with access to PGx testing and to 
provide clinicians with the evidence required to make decisions regarding medical applications.118  
As knowledge builds about the utility of genetic information for tailoring drug therapies, the 
number of PGx tests is expected to increase.  In order for PGx to make a significant contribution to 
personalized health care and have an impact on population health, many more molecular biology 
tests than are currently available to detect genetic polymorphisms will have to be validated.119, 120  
Laboratories will have important roles in studies to identify and verify polymorphisms and clinical 
trials of PGx-guided interventions.      
PROTECTING THE BLOOD SUPPLY AND TRANSPLANT RECIPIENTS 
Blood and blood products are vital health care resources that are required in a large number of 
medical procedures.  Availability of safe blood and blood products is essential for millions of 
people in the U.S., including accident victims, transplant recipients, and patients undergoing a 
wide range of surgeries.121  The health care industry relies on blood donations from volunteers in 
order to meet this demand.  In 2001, the most recent year for which data are available, U.S. 
institutions collected more than 15 million units of whole blood and red blood cells, 
approximately 14 million units of which were transfused to 4.9 million patients.122     
Through their blood banking responsibilities, clinical laboratories work to guarantee the safety of 
the blood supply.  Blood collection usually takes place at community blood centers, hospital-
based donor centers, or mobile sites temporarily constructed for blood donations.122  Following 
donation, the blood is taken to blood banking laboratories and tested to determine blood type and 
detect the presence of antibodies, bacterial contamination, and other agents that could potentially 
cause adverse reactions in transfusion recipients.  Once testing is completed, donated blood that is 
free of infection is stored for future use.e   
Screening blood donations for the presence of infectious disease is a high-value service provided 
by blood banks and clinical laboratories.  Laboratories screen donations for the presence of HIV 
and hepatitis B and C viruses, the three transfusion-transmitted viruses of greatest concern to 
public health.123  Blood donations have been tested for the presence of HIV-1 infection (the strain 
of HIV found most commonly in the U.S.) since 1985.124  Until 1999, testing for HIV-1 required 
that the donor’s immune system had already mounted a response against the virus, allowing for a 
“window period” in which HIV-contaminated blood would be undetected by laboratory testing 
for HIV antigens and antibodies.  The creation and implementation of nucleic acid testing (NAT) 
in 1999 under an FDA-approved Investigational New Drug application (followed by FDA 
approval of a commercial assay in 2002) reduced this window period by almost half, from an 
average of 22 days to 12 days.  Relative to antibody and antigen tests, which reduced the risk of 
HIV infection from a single blood transfusion to approximately 1 in 676,000, NAT reduces the risk 
                                                 
e Storage methods are determined by the component of blood being stored and how quickly the donation will be used.  
Red blood cells can be refrigerated for a maximum of 42 days or frozen for up to 10 years; platelets can be stored at 
room temperature for up to 5 days; and fresh frozen plasma can be frozen for up to 1 year.122   
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of transfusion-transmitted HIV-1 to about 1 in 1.9 million blood units.125, 126  Innovations in 
laboratory testing have also allowed donated blood to be screened for human T-lymphotropic 
virus types I and II, syphilis, West Nile virus, Chagas’ disease, and other infections.122 
Clinical laboratories also conduct blood compatibility testing, or hemocompatibility, to determine 
whether a particular unit of blood can be safely transfused into an individual.127  Pretranfusion 
hemocompatibility testing includes identifying an individual’s ABO blood group and Rh type, 
both of which are determined by the presence or absence of specific antigens on red blood cells, as 
well as testing blood for unexpected red cell antibodies.122  Cross-matching determines whether 
an individual’s blood has antibodies that will react with the donor’s cells.  In the event that a 
cross-match indicates a reaction, laboratory professionals identify the specific reacting antibodies 
and locate alternate donor blood that lacks the antigen.   
Compatibility testing, cross-matching, and other precautions taken by clinical laboratories help 
prevent adverse transfusion outcomes, which include acute hemolytic transfusion reactions, 
febrile nonhemolytic transfusion reactions, allergic reactions, volume overload, and acute lung 
injury caused by transfusing incompatible blood.128  ABO incompatibility is the most common 
cause of acute hemolytic transfusion reactions, which usually result from antibodies in the 
recipient’s plasma reacting to red blood cell antigens in the donor blood.  Technologies such as 
portable data terminals that scan patient wristbands at the bedside, bar-coded specimen labels, 
and electronic transfer of test results to the laboratory can decrease the risk of a mismatch 
between blood recipients and donor blood caused by misidentification and are increasingly the 
focus of laboratories, hospitals, and accreditation bodies in the U.S.129, 130                                    
DETECTING EXPOSURE TO ILLEGAL OR TOXIC DRUGS   
Exposure to illegal drugs, toxic substances, and incorrect use of therapeutic drugs are major causes 
of hospital emergency department visits in the U.S.  In 2004, the most recent year for which data are 
available, an estimated 1.08 million visits to the emergency department were attributed to poisoning 
and toxic effects, representing approximately 1% of all visits.131  As many as 23% of emergency 
department visits each year may be attributed to the abuse of alcohol and other substances.132  In 
addition to alcohol and drugs of abuse, accidental or inadvertent contact with substances such as 
organophosphorous compounds (used in pesticides), rodenticides, heavy metals, and carbon 
monoxide can also contribute to significant acute and chronic threats to health.133         
Rapid, accurate laboratory testing enables clinicians to identify specific toxic substances to which 
individuals have been exposed and to determine appropriate medical care, including what 
medications can be prescribed and how quickly treatment must be initiated.134  Toxicology 
screenings, most often performed on blood or urine samples and sometimes on gastric contents, 
allow clinicians to evaluate the type and approximate amount of legal and illegal drugs an 
individual has consumed.135   
In its 2005 guideline, the National Academy of Clinical Biochemistry (NACB) divides toxicology 
screening into two tiers: 
 Tier I testing includes stat testing for selected agents in serum, plasma, and urine. 
Laboratory Medicine: A National Status Report Chapter I – The Value of Laboratory Medicine to Health Care 
May 2008 35 
 Tier II testing is for individuals who have been admitted to the hospital who remain 
intoxicated or comatose and for whom tier I testing did not identify the nature of the 
problem.134  
NACB recommends that hospital emergency departments conduct serum toxicology assays to 
detect 14 different substances, including lithium, salicylate, valproic acid, digoxin, methyl alcohol, 
and iron, and urine toxicology screenings to detect seven substances, including cocaine, 
barbiturates, and opiates.   
Due to the nature of acute illness and poisoning and limitations in resources and technology, clinical 
laboratories are limited in their ability to provide real-time analyses of a full spectrum of 
toxicological screens for patients who appear to be impaired or overdosed.  This highlights the 
importance of TAT for laboratory tests ordered in the emergency department.  For a few tests, rapid 
bedside toxicological screening assays allow clinicians to obtain laboratory test results in real time at 
the point-of-care.  Many emergency departments use breath meters for determining alcohol 
concentrations in intoxicated patients at the bedside; these are accurate, precise, and relatively 
inexpensive.134  Point-of-care immunoassays are also available for a wide variety of drugs of abuse, 
including cocaine, methamphetamine, and antidepressants.136  However, many rapid toxicological 
screening tests have not yet been validated in the emergency department setting.137  Specifically, 
rapid assays for methanol and ethylene glycol poisoning, which can produce significant morbidity 
and mortality, are being tested currently but are not yet in wide use.138   
In 2002, 4 million adults in the U.S. diagnosed with serious mental illness also had a substance 
abuse disorder.139  Because substance abuse can exacerbate psychiatric symptoms, toxicology 
screening is especially important in the emergency treatment of serious mental illness.140  
Clinicians are often asked to perform laboratory testing on individuals presenting with acute 
behavioral emergencies in order to rule out illnesses that may be causing acute psychiatric 
symptoms.  The results of laboratory testing, particularly toxicology screening, can identify 
substance abusers and help guide treatment of psychiatric patients.      
VALUE TO THE MEASUREMENT OF QUALITY OF CARE  
The IOM defines quality of care as “the degree to which health care services for individuals and 
populations increase the likelihood of desired health outcomes and are consistent with current 
professional knowledge.”141  Health care quality measures enable health care decision-makers to 
compare quality of specific aspects of health care to relevant reference standards or criteria.  They 
are increasingly used to measure and assess the performance of the U.S. health care system.142  
Quality can be measured in three main dimensions: 
 Structure refers to the environmental factors that  support the capacity to achieve quality 
 Process refers to what is done to and for the patient  
 Outcomes refers to changes in patients’ health status as a result of care received143   
Most health care quality literature focuses on process of care measures, examining the 
appropriateness of the care provided and the adherence of providers to professional standards.144   
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Laboratories monitor quality in order to ensure that they are providing information that is timely, 
accurate, appropriate, and interpretable, and ensures high quality care.145  Quality indicators 
within laboratory medicine can also be classified under structure (e.g., staffing benchmarks of 
productivity, policies for documenting safe phlebotomy practices), process (e.g., patient 
identification errors, analytic accuracy, follow up with clinicians regarding results), or outcomes 
(e.g., health outcomes, customer satisfaction, cost-effectiveness).7, 146, 147   
Quality Measurement for Priority Health Conditions 
Data derived from laboratory testing is a key component in many of the current quality measures, 
particularly those that assess health outcomes, the quality measures most relevant to consumers and 
many health care plan purchasers.148, 149  Laboratory-based performance is assessed with process 
and outcome measures developed for such highly prevalent and/or burdensome conditions as 
diabetes, heart failure, ischemic heart disease, stroke, end-stage renal disease, pneumonia, cervical 
and colon cancer, and pregnancy and childbirth.7  For instance, the American Quality Alliance 
explicitly includes the use of laboratory tests to measure HbA1c and low density lipoprotein 
cholesterol as a performance measure to assess the quality of diabetes care.150     
Two national sources of validated quality measures include the Health Plan Employer Data and 
Information Set (HEDIS), maintained by the National Committee for Quality Assurance (NCQA) 
and the National Quality Measures Clearinghouse (NQMC), maintained by AHRQ.151, 152  HEDIS 
data can be used by purchasers and patients to make side-by-side comparisons of health care 
plans and by health plans to evaluate their own performance.  Approximately 90% of managed 
care organizations use HEDIS measures to assess provider performance.  CMS also requires plans 
participating in Medicare programs to report on HEDIS measures.153  The NQMC database 
provides information on evidence-based health care quality measures linked to a particular 
disease or condition and a particular treatment or intervention.  The information can be used by 
practitioners, providers, payers, and purchasers to inform health care decisions.  A search of the 
HEDIS and NQMC reported in 2005 found that 23% of HEDIS measures and 14% of NQMC 
measures used to assess the quality of care given by a specific provider or health plan are direct 
measures of laboratory test use for measuring health risks, diseases, or medical conditions.154   
Performance measurement, including in laboratory testing, can have a direct impact on delivery, 
quality, and cost of health care and on the establishment of best practices.  According to NCQA, in 
2005, more than 70 million Americans benefited from health care improvements facilitated by 
quality measurement.  Individuals enrolled in health plans that use and publicly report 
performance data are more likely to have received preventive care and care for chronic conditions 
in accordance with evidence-based clinical guidelines.155  Under-compliance with HEDIS 
measures is associated with an increase in the number of avoidable deaths and avoidable hospital 
costs.  For instance, failure to conduct regular HbA1c testing resulted in an estimated 7,400-15,000 
avoidable diabetes-related deaths and $1.35-1.62 billion in avoidable hospital costs in 2005, 
according to NCQA.155 
Indicators of Quality of Laboratory Processes 
Performance measurement is a valuable tool that can improve testing processes, benchmark 
progress, and standardize laboratory performance.  It also has the potential to decrease waste and 
inefficiencies in the laboratory and lead to better health outcomes.156   
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To date, performance measurement in laboratory medicine has focused mostly on the analytic 
processes (i.e., the actual testing of specimens) in order to meet regulatory requirements of the 
CLIA.  More specifically, regulatory agencies and accrediting organizations have impelled quality 
control and quality assurance initiatives during the last 15 years, mainly in the form of proficiency 
testing, a quality monitoring approach for evaluating laboratories’ performance of selected tests 
and their ability to arrive at the “correct” result.145  Other facets of laboratory performance 
associated with the preanalytic and postanalytic phases also are evaluated, such as test 
turnaround time and specimen identification errors.  As a result of these requirements, the quality 
and safety of laboratory testing has improved significantly over the past 20 years.157, 158    
Historically, quality measures for preanalytic and postanalytic phases of the testing process have 
received less attention, although some accreditation organizations and laboratories have taken the 
initiative to assess quality and errors in these areas.159, 160  The quality assurance measures employed 
by The Joint Commission, CAP, AABB, and COLA, have targeted certain elements of preanalytic 
and postanalytic processes including methods to improve patient identification, specimen 
collection, test turnaround time, notification of critical values, and customer satisfaction.161, 162   
Outside the context of proficiency testing, formalized performance measurement and public 
reporting on key quality indicators in a manner reflecting the broader health system (e.g., HEDIS 
measures) has not yet been instituted in the laboratory medicine sector.  However, CDC, CMS, other 
government agencies, accreditation organizations, and stakeholders have been collaborating to 
develop a set of such measures for national reporting and the determination of best practices.7, 163  
Studies and programs undertaken by accreditation organizations, academic researchers, and 
government agencies will provide an evidence-based foundation for more comprehensive quality 
measurement.  CDC announced a funding opportunity in 2007 to evaluate clinical laboratory 
practice by identifying evidence-based laboratory medicine practices, particularly those associated 
with the pre- and postanalytic stages of the total testing process.160  While the quality of laboratory 
testing is already high, implementing a comprehensive standardized performance measurement 
program will add further value to the overall health system and quality of patient care. 
Value-based Purchasing and Pay-for-Performance  
Value-based purchasing is among the evolving mechanisms being applied in various sectors of 
health care to address rapidly rising health care costs and concerns about shortfalls in quality.  It 
refers to arrangements in which buyers hold health care providers accountable for cost and 
quality, and includes the following attributes:  
 Contracts that specify the responsibilities of employers as purchasers and insurance, 
managed care, and hospital and physician groups as suppliers 
 Incentives that reward specific practices by providers and consumers 
 Information that supports purchasing activity management 
 Quality management that leads to continuous improvements in the health care 
purchasing process and in the delivery of health care 
 Education that helps employees to become better consumers of health care164 
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Pay-for performance (“P4P”), a reimbursement arrangement in which a portion of provider 
payments are tied to performance measures associated with quality of care, has been proposed as 
one means of enabling value-based purchases.165, 166  By 2005, there were more than 150 P4P 
programs and initiatives in the U.S., sponsored by various health care plans, employers, and 
government purchasers.147, 167  Approximately 80% of P4P programs are sponsored by private 
health plans, but some are sponsored by government payers, including Medicare and state 
Medicaid programs.147  Primary care physicians are the main target of P4P initiatives while 60% of 
programs involve specialists and 20% involve hospitals.   
Expert testimony to Congress on the subject of value-based purchasing of physicians’ services  
has routinely cited variation in laboratory testing and physicians’ use of laboratory testing as a 
way to measure the efficiency and quality of care being provided.168-170  For example, laboratory 
testing provides clinicians with objective means for improving performance, such as ordering 
appropriate follow-up testing for patients with test results indicating out-of-range or otherwise 
abnormal values.171   In turn, data that include laboratory testing can be used by consumers and 
purchasers to assess the quality of health care provided by different clinicians or organizations.  
Laboratory-related professional organizations, such as the College of American Pathologists 
(CAP), are partners in the development of P4P measures.  CAP led development of P4P 
pathology-related measures for breast and colon cancer, which were approved by the American 
Medical Association (AMA) in June 2007.172    
Still, P4P represents a relatively new type of financing mechanism for the health care system, and 
its evidence base is small.  A 2006 systematic review of the published literature examining P4P 
programs for the period 1980-2005 identified only 17 empirical studies of explicit financial 
incentives for quality, and could conclude little about the impact of these arrangements.173  No 
studies examined the optimal duration of financial incentives for quality or the persistence of their 
effects after termination, and only one study addressed cost-effectiveness.  The investigators 
called for ongoing monitoring of the impact of current programs and further research to guide 
implementation of financial incentives and to assess their cost-effectiveness.   
VALUE TO PUBLIC HEALTH AND SURVEILLANCE 
Public health surveillance refers to ongoing, systematic collection, analysis, and interpretation 
of data related to health that is vital to the planning, implementation, and evaluation of public 
health practice.  It relies on facets of clinical and public health laboratory testing.174   Services 
provided by clinical laboratories help to identify the nature of public health threats at both the 
individual and population level, including infections acquired during care, development of 
drug resistance, infectious disease outbreaks, and biological threats. 
Health Care Associated Infections 
Health care associated infections (also known as nosocomial infections) are those that develop in 
hospitalized patients in the absence of evidence that the infections were present or incubating at 
the time of admission.175  The greatest common risk faced by hospitalized patients is health care 
associated infection, a major source of morbidity and mortality in the U.S.  Up to 2 million 
patients experience a health care associated infection every year, and approximately 88,000 people 
die annually as a result of these infections.176  Monitoring health care associated infection rates 
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and understanding their causes are necessary for hospitals to reduce the incidence of these 
infections and their impact on health outcomes and costs.    
Microbiology laboratories help hospitals to monitor and control health care associated infection 
rates at individual and population levels.  They are responsible for providing easy access to high-
quality, timely data and support for epidemiological analyses.175  Activities may include providing 
training on basic microbiology to hospital infection control program staff, monitoring laboratory 
results for unusual findings (e.g., clusters of pathogens indicating an outbreak, emergence of multi-
drug-resistant organisms), strain typing of results, and storing specimens for further study. 
Hospital laboratories with infection control practitioners voluntarily report health care associated 
infection rates to CDC.  The National Nosocomial Infections Surveillance (NNIS) systemf was 
established by CDC in the 1970s to monitor the incidence of health care associated infections in 
the U.S. and to assist infection control professionals in managing endemic and epidemic health 
care associated infection outbreaks.178  NNIS has contributed to significant reductions in 
bloodstream infection rates in coronary, medical, pediatric, and surgical ICUs.179  More than 300 
hospitals participate in the NNIS; microbiology laboratories at each of these hospitals provide the 
NNIS with information related to health care associated infection rates.178  The system has been 
updated and expanded into the National Healthcare Safety Network, a web-based surveillance 
system that was launched by CDC’s Division of Healthcare Quality Promotion in 2005.  The 
National Healthcare Safety Network aims to improve patient and health care worker safety by 
monitoring adverse events associated with devices, procedures, and medications, providing 
comparative data for performance improvement, and ensuring access to prevention tools and 
information about lessons learned and best practices.177  
Multi-drug-resistant Organisms  
Another common problem faced by health care facilities is multi-drug-resistant organisms 
(MDROs).  MDROs are microorganisms, predominantly bacteria, that are resistant to one or more 
classes of antimicrobial agents.  They are difficult to treat and can result in increased length of 
hospital stay, higher cost, and greater chance of mortality in infected individuals.180-183  MDROs are 
often the cause of health care associated infections.  Health care facilities at particular risk for MDRO 
outbreaks include those caring for older patients, acute care settings, and ICUs.184  Varying 
temporally, geographically, and by health care setting, the prevalence of MDROs in the U.S. has 
increased steadily in recent decades.  While only 20-25% of Staphylococcus aureus was resistant to 
methicillin and other antibiotics in the early 1990s, resistance rose to 59% by 2003.185, 186 
Clinical laboratories monitor MDROs at the levels of patients, institutions, and populations.  At 
the level of individual patients, laboratories conduct antimicrobial susceptibility testing, which 
involves isolating and testing pathogenic bacteria to determine the ability of antimicrobial agents 
to inhibit their growth.50  The results of susceptibility testing help guide clinician decisions about 
how to treat specific infections.  Many of the roles played by microbiology laboratories with 
regard to health care associated infection surveillance and education also apply to MDROs.175  In 
                                                 
f The NNIS, with the National Surveillance System for Health Care Workers and the Dialysis Surveillance Network, 
is undertaking a major redesign to become the National Healthcare Safety Network, which will cover new areas 
of patient safety monitoring and evaluation.177 
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2000, the CAP Microbiology Surveys Program assessed the frequency and accuracy of 
susceptibility testing at 3,857 microbiology laboratories in the U.S.  CAP found that laboratories 
generally demonstrated acceptable test accuracy and reproducibility for the most commonly used 
antimicrobial susceptibility testing systems or methods.187                 
Laboratories support national monitoring of MDROs.  The National Antimicrobial Resistance 
Monitoring System for Enteric Bacteria is part of CDC’s Emerging Infections Program’s 
Epidemiology and Laboratory Capacity Program and the Foodborne Diseases Active Surveillance 
Network.188  In 2004, the most recent year for which data are available, public health laboratories 
from all 50 states sent isolates to CDC laboratories for antimicrobial susceptibility testing.189  CDC’s 
Epidemiology and Laboratory Capacity for Infectious Diseases program, part of the National Center 
for Infectious Diseases, has cooperative agreements with state and local public health agencies in all 
50 states to identify, characterize, and respond to infectious diseases, including MDROs.190 
Public Health Reporting of Adverse Events 
Laboratories participate in the reporting of adverse events related to testing technologies and 
abnormal test results that result in patient harm.  FDA’s MedWatch program gathers data on all 
marketed medical products submitted by clinicians, manufacturers, and consumers and includes 
adverse event reporting for laboratory test failures that result in harm to a patient.  The Joint 
Commission’s (formerly known as the Joint Commission on Accreditation of Healthcare 
Organizations) Sentinel Event database collects data on unexpected occurrences involving serious 
physical or psychological injury or risk thereof; laboratories accredited by the Joint Commission 
are required to submit reports to the database.191  The Joint Commission publishes Sentinel Event 
Alerts for its accredited organizations that identify specific events and their underlying causes 
and suggests ways to prevent such occurrences in the future.  
Natural Disasters and Biological and Chemical Threats 
Laboratories assist in meeting the challenges of natural disasters and biological and chemical 
events.  Several national programs aim to provide a mechanism for communication between 
laboratories and a means to link public and private laboratories.  Some of these initiatives include 
the following: 
 The National Laboratory System is an initiative founded by CDC to improve 
cooperation and coordination among all public and private U.S. laboratories.  
Development of this system is still underway.192  The goal of the National Laboratory 
System is to promote public health laboratory leadership by improving the overall 
quality of laboratory testing and communication between public health and private 
clinical laboratories.           
 The Public Health Information Network (PHIN) is a CDC initiative to promote national 
advancement of fully interoperable information systems in organizations that participate 
in public health and public health preparedness.193  The goal of PHIN is to ensure that 
public health programs have near real-time access to data during acts of terrorism or 
disease outbreaks by developing, promoting, and using industry standards for data and 
technology.194  In 2005, PHIN described functional requirements and general workflow 
for information systems responsible for managing laboratory testing.195  The 
interoperability requirements include such basic functions as assignment of 
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unambiguous identifiers to laboratory data, adherence to PHIN standards for message 
exchange systems, and vocabulary standards.  The Laboratory Response Network 
Results Manager supports the functional requirements established by PHIN.193 
 The Early Warning Infectious Disease Surveillance (EWIDS) was created in 2003 and 
is funded by DHHS.196  EWIDS comprises state, federal, and international partners 
working together to ensure rapid, effective laboratory confirmation of infectious 
disease reports in the border regions of the U.S., Canada, and Mexico.  Ongoing 
EWIDS projects include the development of cross-border surveillance protocols, a 
database directory of laboratories, and a Health Alert Network and cross-border secure 
internet information exchange.  In 2006, DHHS announced a $5 million contract to 
assist the six Mexican states in creating EWIDS systems at the U.S.-Mexico border that 
are coordinated and interoperable with currently existing EWIDS systems in the U.S.197           
 The Laboratory Response Network was established by CDC in 1999 as a network of 
laboratories capable of quickly responding to biological and chemical terrorism and 
other threats to public health.198  It includes approximately 150 laboratories responsible 
for biological response.  National laboratories located at CDC and the U.S. Army 
Medical Research Institute for Infectious Diseases in Maryland are the national 
laboratories that perform confirmatory testing for disease agents.199  Reference 
laboratories, such as those run by state and local public health departments, perform 
confirmatory tests for biological agents, allowing local authorities to respond more 
quickly to positive test results.  Sentinel laboratories are private, commercial, and 
hospital-based and test patient specimens as part of their daily testing regimen, 
allowing them to identify unusual results and refer suspicious specimens to the 
network’s reference laboratories.  This network provides a chain-of-command for 
reporting laboratory results and sharing laboratory data. 
Another laboratory role in public health surveillance is response to biological or chemical 
terrorism.  In cases of an overt biological or chemical threat, law enforcement officials are usually 
notified first, followed by notification of the Federal Bureau of Investigation, state emergency 
management, and state or local public health officials.199  These agencies, in turn, are to contact 
CDC for a joint assessment of the validity of the threat.  In the event of a valid threat, state or local 
public health laboratories that are part of the Laboratory Response Network are to test samples of 
the suspicious substance.  Laboratory staff can identify the unknown substance and perform 
confirmatory testing to validate test results.   
Laboratories are involved in mitigating adverse outcomes during natural disasters.  Laboratories 
diagnose and confirm the presence of communicable diseases and ensure that basic laboratory 
tests are available to use in caring for injured individuals.200  Increasingly, POCT is being used to 
enable faster and more accurate diagnosis, triage, and patient monitoring during disasters.  POCT 
was especially vital in the aftermath of Hurricane Katrina in August 2005.201  The hurricane 
resulted in temporary closing of 12 hospitals (and their laboratories), local trauma centers, and an 
independent laboratory.  POCT devices already on site, including glucose meters, whole-blood 
analyzers, and tests for infectious diseases, pregnancy, and prothrombin time, were used to 
provide care to thousands of affected people.  Public health laboratories in states not affected by 
the hurricane assisted Louisiana and Mississippi public health laboratories, providing such 
services as newborn screening and water safety tests.202   
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QUANTIFYING VALUE USING COST-EFFECTIVENESS ANALYSIS 
Analyses of the tradeoffs of the costs and benefits of health care are of increasing interest, 
particularly in instances where interventions offering marginal improvements over standard care 
are accompanied by large price increments.203  At present, coverage policies of Medicare and most 
commercial payers is based entirely or largely on clinical evidence rather than on cost-
effectiveness or any other economic-related assessment.204  However, more commercial payers, 
hospitals and other health care institutions, and policy makers are seeking information from 
manufacturers and vendors of health care technologies, including laboratory tests, regarding 
whether their new and existing technologies are cost-saving, and sometimes more cost-effective, 
than alternatives.  Interest in economic analyses that can inform these decisions appears to be 
growing among health plans and public and private sector payers.  Health plans are using this 
type of information to develop drug formularies and tiered co-payment systems.  At certain 
points throughout its history, CMS has proposed using, though has not employed, cost-
effectiveness as an explicit criterion for determining coverage of new medical technologies.205  
FDA performs cost analyses in certain instances, particularly to fulfill requirements for 
assessment of the economic impact of regulations; but the agency does not perform such analyses 
to inform market approval or clearance decisions for particular products.206  A survey conducted 
in 2001 of medical directors of 228 managed care plans found that 90% of plans considered cost in 
some regard when evaluating new medical intervention; however, only 40% reported using 
formal economic analyses for these purposes.207            
Cost-effectiveness analysis (CEA) is one main type of economic analysis that is used to evaluate 
and compare the economic impact of health technologies and medical procedures.  It quantifies 
the incremental (marginal) cost per incremental unit of effectiveness achieved with a technology 
versus the standard of care.  Units of effectiveness are typically “natural” health units, such as 
case of cancer detected or life-year saved.  Costs accrue differently to various stakeholders; 
depending on its purpose, a CEA can be conducted from the perspective of, e.g., the health care 
provider, payer/health plan, or society-at-large.   
Another unit used in CEA is the quality-adjusted life year (QALY).  QALYs are units comprising 
quality of life (assessed as patient utility for a given health state, ranging from 0.0 for death to 1.0 for 
perfect health) and length of life, and, thus, are not confined to use for particular diseases or 
conditions.208  (CEAs that assess tradeoffs between costs and some measure of patient utility for a 
health state or outcome are also known as cost-utility analyses.)  Though used more in other 
industrialized countries, cost per QALY is used informally as a means to gauge value-for-money by 
some commercial U.S. health plans, though not by Medicare.205, 209-211  Though no formal threshold is 
used by U.S. payers, there is informal recognition that incremental cost-effectiveness ratios (ICERs) 
of up to $50,000-$100,000 per QALY are of acceptable value.  It is also recognized that the ratios for 
many technologies in mainstream care exceed that magnitude.212  (In the U.K., technologies with 
ICERs approaching £30,000 per QALY tend to draw greater scrutiny by the National Health Service, 
although there is no formal cut-off level for inclusion as a health care benefit in that system.213)  Even 
though a laboratory test may result in a clinically significant improvement in health outcomes (e.g., 
via an informed treatment decision and course of care), doing so at a high cost may decrease payers’ 
willingness to cover it or to pay a premium price for it.   
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CEA of Genetics and Pharmacogenomic Tests 
Among laboratory testing services, the potential economic impacts of genetic and PGx testing are 
gaining greater scrutiny.  Even so, the number and quality of available CEAs remain limited.  A 
small numberg of systematic reviews of economic evaluations of genetic testing (not including 
PGx) have been published in recent years.   
Most of the economic evaluations of genetic testing found in the literature are CEAs, with 
relatively few cost-utility analyses and cost-benefit analyses.  One review counted 37 CEAs, 16 
cost-utility analyses, 12 cost-benefit analyses, and 4 cost-minimization analyses published 
between 1990 and 2004.  Another review counted 47 CEA, 13 cost-benefit analyses, 7 cost-utility 
analyses, and 22 “other” economic evaluations published between 1983 and 2005.217, 218  These 
systematic reviews are limited because they excluded all disease-specific studies that did not 
explicitly refer to “genetics.”  For example, at least 14 economic evaluations of screening for 
hereditary hemochromatosis (an inherited disorder that increases the amount of iron absorbed 
from the gut) were excluded in these four reviews.   
In one of the systematic reviews of economic analyses for genetic testing published during 1990 
through 2004, outcomes assessed in a majority of the studies were life-years gained or, simply, 
cases detected.  QALYs were used in another 25% of the studies.  Nearly 40% of the studies 
addressed cancer (21%) or aneuploidies (abnormal number of chromosomes) (18%). Common 
shortcomings among these analyses included lack of specifying the economic perspective, lack of 
discussion of potential bias, and lack of disclosure of funding sources.217  
As pertains to other interventions that involve the use of laboratory results to inform patient 
management decisions, the cost-effectiveness of PGx is subject to multiple factors or conditions.  
One paper suggested that a PGx strategy is likely to be cost-effective when:   
 The polymorphism under consideration is prevalent in the population and has a high 
degree of penetrance. 
 Genetic testing is highly sensitive and specific, and less costly alternative tests that 
could be used to individualize therapy are not readily available. 
 The disease state involves outcomes with significant morbidity or mortality if left untreated. 
 The treatment involves significant outcomes and/or costs that can be affected by 
genotype-individualized therapy.219 
As such, PGx strategies are not practical for all drug prescribing or dosing regimens, and 
decisions to invest in developing genomic-based therapies should be determined on a case-by-
case basis.   
                                                 
g One review, not discussed here, only addressed molecular genetic testing in familial cancers.214  Two reviews were 
restricted to predictive molecular genetic tests.215, 216  The remaining two reviews concerned biochemical, 
cytogenetic, and molecular testing.217, 218 
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CEA of Laboratory Tests: Four Examples 
Compared to therapeutic interventions and other diagnostic interventions, the literature on CEA 
of laboratory testing is small, although a stronger literature on how to apply CEA to laboratory 
testing is emerging.220  The following are examples of CEAs of four types of clinical laboratory 
tests that have been under economic scrutiny by payers, clinicians, and other stakeholders.  These 
examples illustrate how CEAs are conducted and reported across diverse population groups and 
indications, as well as the range of results of such analyses, including some suggesting that certain 
tests are good value for money and others that are not, at least based on incremental cost 
effectiveness ratio (ICER).  The four examples are:  screening for Chlamydia trachomatis, 
immunoassay fecal-occult blood testing for colorectal cancer, HER-2/neu testing of breast cancer, 
and nucleic acid testing (NAT) for safety of donated blood.  The example of immunoassay fecal-
occult blood testing includes discussion of how this rare request by CMS for a CEA was made and 
how it was used in a Medicare coverage determination.   
Chlamydia Screening 
The literature on economics of laboratory testing recognizes that cost-effectiveness of a given test 
can vary by the frequency and ordering of tests as well as characteristics of the target population.  
A CEA published in 2004 compared alternative strategies for screening for Chlamydia trachomatis, 
which clinical guidelines have recommended be conducted annually in women younger than 25 
years of age.  Using a simulation model, this analysis compared four strategies targeted to three 
specific age groups (15-19, 15-24, and 15-29 years) of sexually active women in the U.S.:  1) no 
screening, 2) annual screening for all women, 3) annual screening followed by one repeated test 
within 3-6 months after a positive test result, and 4) annual screening followed by selective 
semiannual screening for women with a history of infection.221   
This simulation showed that the most cost-effective strategy was annual screening in women 15-
29 years of age, followed by semiannual screening for those with a history of infection.  This 
strategy consistently had an ICER less than $25,000 per QALY compared with the next most 
effective strategy. All of the strategies became more cost-effective when the indirect transmission 
effects of a 10-year screening program on the probability of infection in uninfected women (that is, 
per-susceptible rate of infection) were incorporated into the simulation.  Results of the simulation 
were sensitive to such factors as the annual incidence of chlamydia, probability of persistent 
infection, screening test costs, and costs of treating long-term complications.  Accounting for 
feasible variations in these factors in a large number of simulated scenarios, the strategy of annual 
screening in women 15-29 years of age followed by semiannual screening for those with a history 
of infection maintained an ICER less than $50,000 per QALY in 99% of the simulations. 
A systematic review published in 2006 sought to produce comparable estimates of relative health 
impact and cost-effectiveness for services deemed effective by the USPSTF and DHHS Advisory 
Committee on Immunization Practices.  The review found that screening young women for 
chlamydia has an ICER less than $15,000 per QALY.222  The investigators concluded that screening 
young women for chlamydia was one of the most valuable clinical preventive services that can be 
offered in medical practice.    
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Immunoassay Fecal-occult Blood Testing 
CEAs can be used to inform coverage decisions by public and private sector third-party payers.  
Although this is rarely done for the Medicare program, CMS requested that AHRQ conduct a 
comparative clinical and cost-effectiveness study regarding screening immunoassay fecal-occult 
blood testing (iFOBT) for a coverage review in 2003.223  Medicare was already covering colorectal 
cancer screening with a payment level of $4.50 for the standard guaiac-based fecal-occult blood 
test (gFOBT).   
AHRQ tasked this study to a team of investigators at Erasmus University, Memorial Sloan-
Kettering Institute Cancer Center, and the National Cancer Institute.  The investigators used a 
micro-simulation model to derive cost-effectiveness estimates.  The analysis compared iFOBT 
(priced at the manufacturer-recommended amount of $28) to two gFOBTs, Hemoccult II® and 
Hemoccult Sensa®, at the Medicare reimbursement of $4.50.h  The sensitivities and specificities of 
the tests were varied according to their most likely values based on an extensive literature review.  
The investigators found that: 
 Assuming sensitivities of 40%, 70%, and 70% for Hemoccult II®, Hemoccult Sensa®, 
and iFOBT respectively, iFOBT would detect more cancers than Hemoccult II® and a 
similar number of cancers as Hemoccult Sensa.®  
 All FOBTs were cost-effective. Hemoccult II® at $4.50 had a cost-effectiveness ratio of 
$1,071 per life-year gained and iFOBT at $28 had a cost-effectiveness ratio of $4,500 per 
life year saved, assuming 100% compliance.  (Lower levels of compliance would 
increase the cost per life-year gained.)  
 At $28 for iFOBT and $4.50 for Hemoccult II, the ICER for iFOBT was $11,000 per 
additional life-year saved, assuming 98% specificity for iFOBT, and $21,000 per 
additional life-year saved, assuming 95% specificity for iFOBT.   
 Compared to Hemoccult II® gFOBT at $4.50, iFOBT would have an equal cost-
effectiveness if priced at $13 with the more favorable assumption of 98% specificity.224  
In the conclusion of its decision memorandum, CMS stated:  “While the unit cost of iFOBT is 
generally higher than gFOBT, both are considered cost-effective compared to other cancer 
screening tests.”  Noting that the major challenge of colorectal cancer screening was to increase 
compliance from current low levels, CMS added that “It is likely that simple interventions to 
increase compliance would be highly cost-effective as well.”  The decision summary stated that 
“CMS concludes that there is adequate evidence to determine that the iFOBT is an appropriate 
and effective colorectal cancer screening fecal-occult blood test for Medicare beneficiaries aged 50 
years and older.”  
HER-2/neu Testing 
The use of PGx to direct the use of therapies for targeted populations, especially where the 
therapies are expensive and where the burden of disease is great for the affected population, calls 
for careful weighing of health and economic tradeoffs.  An instructive example of this 
                                                 
h The analysis assumed that screening was confined to people aged 65 years and older, with a base case compliance 
level of 100%. 
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consideration involves testing HER-2/neu status in women with newly diagnosed breast cancer 
for informing the use of trastuzumab (Herceptin) for treatment of those with HER-2/neu positive 
breast cancer.  HER-2/neu gene testing limits the risk that patients whose breast cancers do not 
overexpress HER-2/neu will experience potentially serious side effects of treatment with 
Herceptin and helps to avoid associated costs.   
Two tests are used for HER-2/neu testing:  immunohistochemical assays (IHC) and fluorescence 
in situ hybridization (FISH).  These tests have different mechanisms; IHC detects protein 
overexpression and FISH detects gene amplification.  Decisions about using these tests involve 
tradeoffs between the additional costs associated with using FISH and the higher rate of false-
positive results associated with IHC.     
A Canadian study published in 2007 compared the cost-effectiveness of various strategies of 
testing HER-2/neu status in women with newly diagnosed breast cancer for informing the use of 
trastuzumab for treatment of those with HER-2/neu positive breast cancer.225  The study involved 
a systematic review and meta-analysis of data comparing the agreement of IHC and FISH testing 
to determine HER-2/neu status.  The investigators calculated the accuracy and incremental cost 
per accurate diagnosis for alternative testing strategies compared with the base strategy of IHC 
testing, followed by confirmation of 2+ scores (where the range of such scores is 0, 1+, 2+, 3+) by 
FISH.  They observed that the median percentage of patients in each category of IHC score was: 0: 
36.1%; 1+: 35.5%; 2+: 12.0%; and 3+: 16.2%. The median percentage of results of FISH that were 
positive in each IHC category was: 0: 1.6%; 1+: 4.9%; 2+: 29.8%; and 3+: 92.4%.  The base strategy 
was expected to determine correctly the HER-2/neu status of 96% of patients with breast cancer.  
Compared to the base strategy, confirmation of HER-2/neu status by FISH in cases that received a 
score of 3+ reduced the percentage of false positive results to 0% and increased the percentage of 
accurately determined HER-2/neu results to 97.6%.  This yielded a median ICER of CA$6,175 per 
case of accurately determined HER-2/neu status compared to the base strategy.  In comparison, 
the strategy of performing FISH testing in all cases of breast cancer yielded a median ICER of 
CA$8,401 per case of accurately determined HER-2/neu status.  The investigators concluded that 
the strategy with the lowest cost-effectiveness ratio involved screening all newly diagnosed cases 
of breast cancer with IHC and confirming scores of 2+ or 3+ with FISH. 
According to a CEA published in 2004 of HER-2/neu testing and trastuzumab for metastatic 
breast cancer, IHC with confirmatory FISH testing resulted in an ICER of $125,000 per QALY and 
initial FISH testing (without IHC) resulted in an ICER of $145,000 per QALY.226  These ratios are 
higher than the $100,000 per QALY level cited as an informal acceptable threshold in the U.S. by 
some health economists227 and thresholds cited in western Europe and certain other industrialized 
countries.  Even so, these ICERs for HER-2/neu testing are of similar or lesser magnitude than 
those for various other cancer therapies and many other widely used health care interventions.  
Continued improvements in testing, targeted treatments and lower costs that may arise with 
competing interventions should improve the cost-effectiveness of HER-2/neu testing and related 
tests for breast cancer.154   
A study published in 2007 modeled the incremental cost-effectiveness of adding trastuzumab to 
chemotherapy regimens in patients with HER-2/neu-positive breast cancer.  The model assumed 
that both IHC and FISH were used to determine HER-2 status.  The study assumed that, on 
average, five tests were performed for every patient identified for trastuzumab treatment; 30% of 
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tests were assumed to be FISH in the base case.  While this study did not analyze the cost-
effectiveness of the testing in particular, it projected that the incremental cost per QALY gained of 
adding trastuzumab to chemotherapy, including the cost of testing to inform the therapeutic 
decision, was $26,417.  The cost-effectiveness of treatment with trastuzumab over a 20-year 
horizon was projected to be $34,201 per QALY gained.228        
Nucleic Acid Testing for Blood Safety 
As described above, the accessibility of safe blood is vital for millions of people in the U.S.  The 
blood supply is rigorously screened and tested throughout the collection and transfusion process.  
Scientific and technological advances have led to continued improvements in the safety of the 
blood supply, so that transmission of infectious agents of greatest concern to health—HIV and 
hepatitis B and C viruses—is rare.  Recent advances have focused on decreasing the “window 
period” of detecting viral antibodies and antigens, so as to diminish the chances of failing to 
detect infected blood donations shortly after donors have contracted the pathogen.  To the extent 
that newer, more sensitive tests become available, any additional cost of detecting incrementally 
more cases raises questions about the cost-effectiveness of these tests.i,206  
NAT, which relies on polymerase chain reaction techniques, can detect the presence of viral genes 
in blood.  NAT can be conducted on “minipools” of 16-24 samples (minipool NAT) or on 
individual donations of blood (individual donation NAT).  Alternative testing strategies can yield 
significantly different cost-effectiveness ratios.  NAT has been the topic of several CEAs.      
Based on detailed CEAs, researchers have concluded that use of NAT to screen all donated blood 
for HIV and hepatitis C virus results in ICERs of more than $5 million per QALY saved.  In addition 
to the cost of testing many units of donated blood for the rare ones that cannot be detected by other 
means, the short life expectancy of many people who receive donated blood products constrains the 
health impact, and therefore the cost-effectiveness, of successful testing.203  A CEA published in 2003 
examined the marginal cost-effectiveness of using NAT for HIV and hepatitis B and C viruses in 
whole-blood donations using 2001 disease incidence data from the American Red Cross.231  This 
study estimated that the addition of minipool NAT to HIV antigen testing would add a total of 62 
QALYs per year in the U.S., while the addition of individual donation NAT would add a total of 90 
QALYs per year.   The cost per QALY gained for adding individual donation NAT in addition to 
HIV antigen testing ranged from $8.4 million to $9.1 million, depending on whether hepatitis B 
virus testing was included.j  Eliminating HIV antigen testing and using only NAT would reduce 
costs, but cost per QALY gained would remain above $4 million.  The investigators concluded that 
the cost-effectiveness of adding NAT to serologic testing is poor.      
An analysis published in 2004 examined the cost-effectiveness of adding either individual 
donation NAT or minipool NAT to pre-existing serologic testing protocols for HIV and hepatitis B 
and C viruses with scenarios that included and excluded HIV antigen testing for blood donated in 
                                                 
i As is so for many other avenues of health care, the increases in the safety of the blood supply achieved with additional 
testing have represented diminishing returns over time.203  Whereas the ICER of HIV antibody testing, implemented 
in 1985, was less than $5,000 per QALY saved,229, 230 the ICER for HIV p24 antigen testing, introduced in 1996, was 
estimated to exceed $2 million per additional QALY saved. 
j Adding minipool NAT to HIV antigen testing would result in a cost per QALY gained ranging from $5.8 million to 
$7.6 million, depending on whether or not a test for hepatitis B virus was included.   
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the U.S.  Compared with serologic testing alone, minipool NAT was found to save a total of 102 
additional QALYs and individual donation NAT was found to save an additional 115 QALYs.  
Serologic testing (excluding HIV antigen testing) coupled with minipool NAT resulted in an ICER 
of $1.5 million per QALY gained.  Serologic testing (excluding HIV antigen testing) in conjunction 
with individual donation NAT was found to be associated with an ICER of $7.3 million per QALY 
gained.  This study confirmed that the cost-effectiveness of adding NAT to current serological 
testing far exceeds the traditionally recognized, though informal in the U.S., threshold of $50,000 
to $100,000 per QALY gained.  The authors concluded that the cost per QALY of adding NAT 
screening is beyond the typical range for most health care interventions, but not for established 
blood safety measures.232   
Notwithstanding its unfavorable cost-effectiveness, NAT screening has been widely adopted.  The 
American Red Cross uses minipool NAT to test for HIV in all donated blood.  The main justification 
for implementing NAT screening was the concern of the public and policy makers arising from the 
potential, however rare, for patients to contract a catastrophic illness from the blood supply.231, 232   
CONCLUSIONS 
Laboratory testing is integral to many clinical decisions, providing physicians, nurses, and other 
health care providers with often pivotal information that aids in prevention, diagnosis, treatment, 
and management of disease.  Despite their impact, spending on laboratory services accounts for 
only 2.3% of health care expenditures and 2% of Medicare expenditures.   
 Laboratory medicine supports the practice of evidence-based medicine and 
development of clinical practice guidelines, which assist practitioners and patients in 
making decisions about health care in specific circumstances.   
 Laboratory tests provide objective data about patient health that enable screening for 
risk factors, accurate and early diagnosis, determination of disease severity and 
likelihood of recovery, selection and monitoring of treatment, and evaluation of 
potential adverse outcomes.   Laboratory tests also are vital to patient self management 
of chronic conditions, supporting their ability to monitor their health status daily, 
adjust therapies, and evaluate progress with healthy lifestyle choices.    
 Information provided by laboratory testing is a critical component of quality and 
safety, including the prevention of adverse reactions.  Laboratories protect the blood 
supply from pathogens and accurately match patients and blood products.  For 
managing medication, testing provides information for maintaining optimum drug 
levels, helps to detect and recover from medication errors, and enables use of genetic 
information to guide personalized health care. 
 Laboratory testing is incorporated into indicators used to assess quality of care, 
particularly for diseases of high health and economic burden such as diabetes, heart 
failure, and colon cancer.  Laboratory data also can be used in new and emerging 
approaches to value-based purchasing of health care.    
 The evidence base for the cost-effectiveness of laboratory tests, and the broader therapeutic 
regimens and other interventions of which they are a part, is growing, though still limited.  
This evidence is helping to inform test selection and sequencing, technology acquisition 
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decisions, formulary design (including for PGx-mediated therapies), and screening and 
other population-based interventions.  Though used less in the U.S. than in other 
developed nations, it is being considered in selected coverage and payment policies of 
some health plans and other third-party payers.         
 Services provided by clinical laboratories also are critical to public health at the individual 
and population levels by identifying nosocomial infections, antimicrobial resistance, 
infectious disease outbreaks, exposure to toxic substances, and chemical and biological 
threats.  Laboratories also help to mitigate the effects of natural disasters by enabling rapid 
turnaround of tests used during triage and emergency care of individual patients as well 
as tests to confirm the presence of communicable diseases that threaten the population. 
 Consistent with other sectors of health care, laboratory medicine is under greater 
scrutiny for demonstrating its value for patients, providers, payers, and other 
stakeholders.  Value must be documented based on rigorous clinical, public health, and 
economic evidence.  Whether in the form of quality indicators, practice guidelines, 
coverage policies, value-based purchasing or related payment policies, or simply 
market share for laboratory services, the value of laboratory medicine is being 
explicitly incorporated into health care decisions.   
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CHAPTER II 
MARKET PROFILE OF THE LABORATORY MEDICINE SECTOR 
This chapter provides an overview of the size and structure of the U.S. laboratory sector, 
including revenue, spending, test volume, and other key elements.  Market information is 
delineated by laboratory setting and test type.  Settings include hospitals, physicians’ offices, 
other clinical settings (e.g., skilled nursing facilities), and independently operated sites in the 
community.  Examining market by test type highlights trends in the traditional broad disciplines 
of clinical pathology and anatomic pathology as well as the emerging interdisciplinary areas 
associated with molecular pathology.  Depending on the type of test and the state of origin, 
consumers may perform self testing at home, work, or another site, or order tests directly through 
a clinical laboratory or the Internet.   
Publicly available information about the economic status and quality of the laboratory medicine 
sector is limited.  For purposes of this chapter, data were compiled from multiple public and 
private sector sources.  Among these sources were market research reports, such as Lab Industry 
Strategic Outlook: Market Trends and Analysis 2007a, the CMS OSCAR database, which contains 
information about laboratory certification, accreditation, and proficiency testing; other 
government reports; published literature; and personal communications with industry experts 
and government officials.   
U.S. MARKET SIZE 
The revenue, spending, and test volume of the U.S. clinical laboratory testing market has grown 
steadily over the past decade.  Market data indicate that: 
 Revenues have increased by more than 40% since 1998 (not adjusted for inflation).  In 
2006, laboratory industry revenues (i.e., gross earnings) were valued at approximately 
$48.5 billion, with predicted growth of 6.5% to $51.7 billion in 2007.1   
 Spending growth on clinical laboratory services averaged 7% annually over the 2003 to 
2006 period, just slightly less than the growth rate in total national health care 
spending at 8%.1  However, laboratory expenditures as a percentage of total health care 
spending have remained relatively stable at 2 to 3% from 1998 to 2007 (see Figure 2.1).  
                                                     
a The Lab Industry Strategic Outlook: Market Trends and Analysis, published by Washington G-2 Reports, compiled data 
from its own surveys; proprietary surveys of hospitals and independent laboratories; data from CMS; financial 
reports filed with the Securities and Exchange Commission; population and business data from the U.S. Census 
Bureau; and interviews with laboratory industry executives, hospital laboratory managers, consultants, and 
government executives.  One of the surveys conducted for the 2007 report was sent to 12,000 laboratories in their 
database, of which 141 responded.  Approximately 55% of respondents were hospital/health system laboratories, 
17% were independent or commercial laboratories, 2% were pathology groups, 7% were POLs, and 19% were 
categorized as “other” (i.e., a combination of one or more type of laboratory).  However, because of the very low 
response rate, the results of this survey may be limited in terms of generalizability to the larger laboratory sector.  
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 Total volume of laboratory testing was projected to be approximately 6.8 billion tests in 
February 2008, according to data self reported by laboratories and compiled in the CMS 
OSCAR database.2  However, higher figures have been reported by another organization.b  
Figure 2.1:  Total Health Care and Laboratory Expenditures, United States 
1998 - 2007 
Sources:  Terry M. Lab industry strategic outlook: market trends and analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
National health expenditures by type of service and source of funds: CY 1960-2005.  Baltimore, MD: Centers for Medicare and 
Medicaid Services, 2007.  (Accessed July 23, 2007, at   
http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage.) 
National health expenditures projections 2006-2016, forecast summary and selected tables.  Baltimore, MD: Centers for 
Medicare and Medicaid Services, 2006.  (Accessed July 23, 2007, at  
http://www.cms.hhs.gov/NationalHealthExpendData/03_NationalHealthAccountsProjected.asp#TopOfPage.)    
Many factors contribute to market growth in the laboratory sector, including: 
 Aging of the population and corresponding increase in the prevalence of chronic 
diseases, which are highly dependent on use of laboratory testing and services for 
diagnosis, treatment, and ongoing management.  More than 90 million Americans live 
with chronic illnesses, and about half of adults aged 65 and older live with at least two 
chronic medical conditions.3, 4   
 Growth of the U.S. population from 266 million in 1997 to 301 million in 2007, a 13% 
increase that has contributed to higher rates of spending on laboratory tests.1, 5, 6 
                                                     
b The true number of laboratory tests conducted annually in the U.S. is not known.  A 1996 report published by the 
National Inventory of Clinical Laboratory Testing Services estimated the annual number of tests to be 7.25 billion.  
Using the OSCAR database, CDC estimated annual volume at 6.8 billion tests in February 2008 (as cited above).2 
Yet, there are some limitations to the data. First, laboratories with a certificate of waiver usually do not provide 
updates of test volume after the initial application.  Second, OSCAR data is self-reported by laboratories and is 
not confirmed by CMS or any other organization.  Lastly, CLIA may count tests differently than other laboratories 
or other organizations (e.g., for chemistry profiles, CLIA counts each individual analyte separately). 
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Approximately 60% of this population growth is attributed to the net difference 
between birth and death rates; 40% is attributed to immigration.7   
 Research in molecular diagnostics and development of new tests in the areas of genomics 
and proteomics to support more targeted clinical care.8, 9  The U.S. government 
continues to devote great resources to expand research beyond the Human Genome 
Project.  Such efforts are complemented by a vibrant, innovative private sector. 
 Continued miniaturization of testing equipment, increasing use of point-of-care devices, 
and development of high-throughput automated systems.  Great advances in 
miniaturization of assay technologies enable more efficient, high-volume testing.10, 11     
 Increased incorporation of laboratory testing as an indicator of quality of care and provider 
performance.  Evidence continues to accumulate on the association of biomarkers with  
health care outcomes of interest to consumers, purchasers, and payers.12, 13   
 Increased media attention to health-related issues has increased consumer awareness of 
and requests for certain laboratory tests.1, 14  For example, a 2003 report by CDC found 
that providers in metropolitan areas where a genetic test for breast and ovarian cancer 
susceptibility was marketed directly to consumers ordered more tests.15  
MARKET BY LABORATORY TYPE AND SETTING 
Laboratory types vary according to their settings, including hospitals, POLs, independent 
laboratories, and public health laboratories, among others.  Laboratories must register with 
CMS, obtain the appropriate certificate, and comply with CLIA requirements.  Under CLIA, 
laboratory tests are categorized as either waived or non-waived.  Laboratories performing 
waivedc testing must obtain a certificate of waiver (CW), while those conducting non-waived 
PPM must obtain a certificate for PPM procedures.  Laboratories conducting other non-waived 
testing must obtain a certificate of compliance (COC) following inspection or a certificate of 
accreditation (COA) from a CMS-approved private sector accreditation organization.    
 
The number of CLIA-certified laboratories in the U.S. has increased steadily since 
implementation of the regulations.  The number of laboratories grew 28% from 154,740 in 1993 
to 198,232 in 2006.16  According to CMS, there were 203,939 CLIA-certified laboratories 
providing testing services in the U.S. as of December 2007.17  Figure 2.2 depicts the breakdown 
of the most common laboratories by type.  
 
                                                     
c Waived tests are those whose methods are judged to be sufficiently simple and accurate that the likelihood of 
erroneous results is negligible, that they pose no reasonable risk of harm to the patient if performed incorrectly, 
and that have been cleared by FDA for home use. 
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Figure 2.2:  Most Common Types of Laboratories, 2006  
Source: CLIA update—December 2006, laboratories by type of facility. 
Baltimore, MD: Centers for Medicare and Medicaid Services, 2006.  
Although the raw number of hospital laboratories displayed in Figure 2.2 is relatively small, 
they held the largest market share by both test volume and revenue in 2006, as presented in 
Figure 2.3.1  Independent laboratories had the second-highest market share, followed by POLs.  
 
Figure 2.3: U.S. Laboratory Industry Market Share by Test Volume, 2006 
Source: CMS-CLIA laboratory application forms. Terry M. 
Lab industry strategic outlook: market trends and analysis 
2007. New York, NY: Washington G-2 Reports, 2007.  
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Hospital-based Laboratories 
Hospital laboratories are the chief provider of laboratory services for their inpatient population 
as well as outpatient population receiving care from physicians who are affiliated with the 
hospital.18  Outpatient laboratory testing is conducted on patients who are receiving care from 
providers affiliated with the hospital but who have not been admitted to the hospital.  Also, 
hospital laboratories often conduct outreach testing, serving as the reference laboratory for 
others in the community with limited testing capabilities.1   
In 2006, there were 8,680 hospital-based clinical laboratories in the U.S., which together conducted 
about 3.3 billion laboratory tests.16, 19  The number of hospital laboratories increased by 6% 
between 2000 and 2004, but decreased by 0.8% between 2004 and 2006 due to competition from 
independent laboratories and consolidation through mergers and acquisitions.1  Generally, the 
number of hospital-based laboratories exceeds the number of hospitals (5,756 hospitals in 2006).20, 
21  In addition to a main laboratory, hospitals may operate laboratories in their emergency 
department, intensive care unit, pulmonary service, surgical service, and satellite sites.22-24    
Revenue.  In 2007, revenues for hospital laboratories are projected to reach $28.4 billion, an 
increase of more than 6% over 2006.1     
Volume.  In 2005, hospital test volume grew by a median of 5% and an average of 6% over 2004, 
including inpatient and outpatient testing.1  Hospital laboratories with the lowest test volumes 
(fewer than 250,000 tests per year) had the highest growth rates (see Table 2.1). 
Table 2.1:  Hospital Laboratory Median and Average Test Volume Growth, 2005 
Annual Volume Median Growth Average Growth 
<250,000 6.4% 7.5% 
250,000 – 499,999 4.3% 5.6% 
500,000 - 999,999 5.0% 5.9% 
>1 million 5.0% 6.7% 
Overall 5.0% 6.4% 
Source: Reprinted with permission from Washington G-2 reports.  Third annual outreach 
survey.  Terry M. Lab industry strategic outlook: market trends and analysis 2007. New 
York, NY: Washington G-2 Reports, 2007. 
Budget.  A 2005 survey of laboratories found that about 36% of hospital laboratories operated 
with a budget of less than $5 million per year, while the budget of another 37% was between $5 
million and $20 million.1  Over one-third of these budgets is spent on staff salaries, more than 
20% on supplies, nearly 9% on employee benefits, and approximately 7% on blood-related 
expenses.  The remaining 30% is devoted to rent, repairs, internal test transfers, and other 
expenses.  About half of the laboratories responding to the survey cited staff salaries as the 
fastest-growing component of their budgets.1   
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Staff.  Approximately 60% of laboratory technologists/scientistsd and 43% of technicians 
worked in laboratories based in general medical and surgical hospitals in 2006.25, 26  The 
percentages of these professionals employed in general medical and surgical hospitals has 
remained steady since 2002.   
Hospital Outreach Testing 
Hospital laboratories that perform outreach testing function as reference laboratories for other 
hospitals, community clinics, POLs, and other facilities.27  Specimens tested through outreach 
services are rarely collected by the outreach laboratory itself.28   
Hospitals have marketed outreach testing services to generate additional revenue and compete 
with independent laboratories.  While 74% of hospital laboratories actively marketed their 
outreach services in 2003, 91% marketed these services in 2005.1  Outreach testing volumes 
increased from 16% of hospital laboratory testing volume (2003) to 29% (2005) as a result of 
these marketing activities.  Profitability has risen as well—nearly 85% of hospital laboratory 
outreach programs surveyed in 2005 reported a profit.  Figure 2.4 provides a comparison of 
hospital inpatient, outpatient, and outreach testing.   
Figure 2.4: Components of Hospital Laboratory Testing, 2003 and 2005 
 
Source: Reprinted with permission from Washington G-2 reports.  First national hospital laboratory survey and third annual 
outreach survey. Terry M. Lab industry strategic outlook: market trends and analysis 2007. New York, NY: Washington G-2 
Reports, 2007. 
 
                                                     
d Clinical laboratory technologists/scientists conduct laboratory tests on tissues, blood, and other bodily fluids and 
perform a full range of complex chemical, biological, hematological, and immunologic tests.  Laboratory technicians 
work under the supervision of a technologist/scientist and conduct less complex tests in all areas of the laboratory. 
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To further increase competitiveness, many outreach laboratories have invested in Internet 
connectivity, improved billing and pricing of tests, and focused on faster test TATs.  The 
efficiency of their billing systems is close to that of their competitors.1   Efficiency gains, as 
determined by the number of days in accounts receivable,e are depicted in Figure 2.5.  In 2006, 
more than 45% of hospital outreach laboratories reported that they were holding their market 
share and 38% reported that they were gaining market share.     
Figure 2.5:  Median Days in Accounts Receivable, 2003 versus 2005 
Source: Park City Solutions (now Chi Solutions, Inc.). Fourth comprehensive national laboratory outreach survey 2005.  Ann 
Arbor, MI: Chi Solutions, Inc., 2005. 
Reprinted with permission from Washington G-2 reports.  First national hospital laboratory survey and third annual 
outreach survey.  Terry M. Lab industry strategic outlook: market trends and analysis 2007. New York, NY: Washington G-2 
Reports, 2007. 
Physician Office Laboratories 
POLs comprise the largest portion of clinical laboratories in the sector.  As of December 2006, 
there were 106,190 POLs, about 54% of the total number of CLIA-certified laboratories in the 
U.S.16  From 2000 to 2006, the number of POLs increased 12% and the total number of all 
laboratories increased by approximately 17%.16, 30  
Testing in POLs tends to be limited to a small number of specimens and is often conducted by 
medical assistants.31  On-site testing in POLs allows for immediate availability of results to 
clinicians.21, 32  More than 80% of POLs are certified to perform only waived and/or PPM tests.1  
However, some POLs that serve large group medical practices are certified to perform certain 
                                                     
e Days in accounts receivable can be calculated by determining the number of days between date of service to date of 
payment and averaging across all claims or by calculating the ratio of accounts receivable to average daily 
charges and multiplying by 365 days.29  Days in accounts receivable measures a company’s billing efficiency; a 
higher figure is inversely related to lower billing efficiency.1 
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moderate and high complexity tests that are typically provided by hospital and independent 
laboratories.     
Data provided by the American Academy of Family Physicians estimate that nearly 50% of testing 
conducted in family physician POLs is waived, 13% of testing is PPM, 22% is moderate 
complexity (e.g., tests to measure theophylline levels), and 4% is high complexity (e.g., tests to 
measure antibiotic susceptibility).33  Tests commonly performed in family physician POLs are 
highlighted in Table 2.2.f   
Table 2.2:  Ten Most Commonly Offered Laboratory Tests at Family 
Physician’s Offices and Percent of Offices Performing Test On-Site, 2005 
Name of Laboratory Test 
Percent of Physician’s Offices 
Performing Test On-Site 
Dipstick/tablet urinalysis 97.5% 
Fecal occult blood 92.2% 
Urine pregnancy test 87.2% 
Rapid strep (direct antigen) 86.5% 
Vaginal smear/wet mount 76.6% 
Glucose, using a waived instrument 68.3% 
Urine microscopic exam 61.1% 
Infectious mononucleosis screen 39.2% 
Prothrombin time 39.0% 
Glucose, visual whole blood glucose dipstick 
(performed via fingerprick) 35.3% 
Sources:  American Academy of Family Physicians.  Performance of laboratory services in family 
physician practice settings. Practice Profile II Survey, October 2006.  Leawood, KS: American Academy 
of Family Physicians, 2006. 
Reprinted with permission from Washington G-2 Reports. Terry M. Lab industry strategic outlook: 
Market trends and analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Revenue.   In 2006, POLs generated $2.5 billion in revenues, comprising 5% of total revenues for 
the industry.  Revenues from POLs increased between 2000 and 2003 by approximately 22%; 
however, slowed growth in the number of POLs is reflected in the small but consistent revenue 
declines since 2003 (see Figure 2.6).  Decreasing revenue also is attributed to shifts in the types of, 
and payments for, tests provided by POLs.  Manufacturers have significantly increased the 
availability and marketing of waived tests to POLs, promoting ease of use, point-of-care access to 
test results, and convenience for the patient.  The shift toward less expensive testing also has  
been fueled by declining reimbursement rates.  Medicare reimbursement for the top 20 tests 
provided by POLs in 2006 averaged almost $1.00 less than that for the top 20 POL tests in 2002.g,1  
    
                                                     
f Dipstick urinalysis, fecal occult blood, and streptococcal antigen detection also were among the top five most commonly 
offered tests according to two surveys, one conducted in 2003 by CMS of CW sites and one conducted of pediatric-
based POLs in 1996 by the Illinois chapter of the American Academy of Family Physicians.34, 35 
g This comparison was based on the difference between the average reimbursement for the top 20 tests in 2002 and 
2006; the sets of top 20 tests differed in the two years.  
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Figure 2.6:  Physician Office Laboratory Revenue, 2000 - 2006 
Source: Reprinted with permission from Washington G-2 Reports. Terry M. Lab industry strategic outlook: market trends and 
analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Volume.   POLs conduct an estimated 525 million laboratory tests annually; approximately 29.5% 
of these tests are waived.19  POLs accounted for approximately 8% of the total number of 
laboratory tests performed in the U.S. in 2005, a decrease of 3% from 2003.1   
Staff.   From 2002 to 2005, the proportion of the clinical laboratory workforce employed in POLs 
declined, including a drop from 10% to 8% for technologists/scientists and 18% to 17% for 
technicians (i.e., as a percentage of all technologists/scientists and technicians in the U.S.).25, 26, 36, 37  
This decrease may be due to slower revenue growth among POLs (and subsequently, fewer funds 
available for salaries) between 2003 and 2006.  The decrease in the number of skilled laboratory 
personnel is linked to the increase in waived testing during this time.35  The decline in the number 
of technologists/scientists and technicians employed in POLs accompanies the increasing number 
of POLs holding only a CW, under which there are no personnel requirements.     
Independent Laboratories 
In 2006, there were 5,414 CLIA-certified, privately-owned independent laboratories in the U.S. 
operated by non-profit and for-profit corporations.16  Privately-owned independent laboratories 
conduct approximately 1.5 billion tests annually.  Approximately 74% of these laboratories are 
certified to perform non-waived testing.19   
The independent laboratory sector accounts for 32% of clinical laboratory testing and 35% of the 
revenue produced by the industry.1  From 2000 to 2006, revenue produced by independent 
laboratories grew from $10.6 billion to $15.5 billion, an increase of approximately 46% (see Figure 
2.7).  Growth in independent laboratory revenue is expected to continue at a rate of nearly 6% to 
$16.5 billion in 2007.  Table 2.3 provides market data of the seven publicly traded companies with 
the highest revenue in the first half of 2005.  
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Figure 2.7:  Independent Laboratory Revenue, 2000 – 2007 
Source: Reprinted with permission from Washington G-2 Reports. Terry M. Lab industry strategic outlook: market trends and 
analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Table 2.3:  Publicly Traded Laboratory Companies with Highest Revenue 
First Half of 2005 
Company Revenue First Half 2005 
Quest Diagnostics  $2.70 billion  
LabCorp  $1.65 billion 
AmeriPath  $278 million 
LabOne  $252 million 
Genzyme Genetics  $107 million 
Bio-Reference*  $76.9 million 
Specialty Laboratory  $75.7 million 
*Bio-Reference’s revenue is for six months ended April 30 
Source: Reprinted with permission from Washington G-2 Reports. Laboratory 
Industry Report from company reports. Terry M. Lab industry strategic outlook: 
market trends and analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Market Competition.  Small- and mid-sized independent laboratories, as well as hospital outreach 
laboratories, face significant competition from the large laboratory corporations, which have 
sizable financial resources and economies of scale.  Eleven mid-sized independent laboratories 
with annual revenues between $10 and $500 million had combined total revenues of $1.04 billion 
in 2005, a 19% increase from 2004.  According to survey data, three small, independent 
laboratories with annual revenue of less than $10 million estimated an increase in revenue of 15% 
between 2006 and 2007.1   
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Several factors have contributed to the competitive advantages of the large corporations: 
national managed care contracts; efficient, centralized billing management; lower supply costs; 
extensive high complexity testing capabilities; and the ability to invest in Web-based systems.   
The two largest laboratories have contracts with the three largest managed care organizations 
(i.e., UnitedHealthcare, Cigna, and Aetna).1  These contracts generated 42 to 50% of their total 
revenues in 2006.   
Given their test volume, large laboratories are able to negotiate more favorable contracts with 
reagent and supply vendors, sometimes at costs 30 to 50% less than those paid by hospitals and 
smaller independent laboratories.  Financial resources have allowed large laboratories to build 
capacity for high complexity testing, upgrade billing management systems, and invest in Web-
based systems to improve efficiency in ordering, billing, and result reporting.  However, the sheer 
size of their operations can result in disadvantages in physician communication, specimen pickup 
scheduling, and test TATs, areas in which smaller laboratories can excel.  Smaller laboratories are 
often located closer to their clients, facilitating greater laboratory-client interaction.  They also may 
offer more flexibility in scheduling specimen pickup times than large laboratories that are tied to 
specific times for daily specimen pick ups.1  
Public Health Laboratories  
Public health laboratories are government laboratories dedicated to safeguarding the public’s 
health.38  While their responsibilities and roles intersect at many points, public health laboratories 
generally do not compete with private clinical laboratories because their focus is on population 
health and security rather than individual patient testing.  Responsibilities of public health 
laboratories include: 
 Specialized disease testing to detect and monitor newly emerging infectious diseases, 
such as West Nile virus, severe acute respiratory syndrome, and new influenza strains 
 Newborn screening to detect potentially life-threatening metabolic and genetic 
disorders, such as phenylketonuria, sickle cell disease, and cystic fibrosis 
 Molecular analyses to differentiate one strain of a disease organism from another (e.g., 
E. coli O157:H7, which causes foodborne illness) 
 Confirmatory testing to verify the identity of microbes and other suspect agents 
 Testing to detect the presence of sexually-transmitted diseases 
 Testing to detect the presence of bacteria, parasites, pesticides, and other potentially 
harmful agents in the environment, especially drinking water 
 Routine surveillance of public health threats and emergencies by analyzing samples, 
providing information to support effective response, and working with other health 
authorities to protect citizens38-40  
State Laboratories.  Public health laboratories include state and local facilities.  There are a total of 
56 state public health laboratories in the U.S., including one in every state and U.S. territory.h,41  
State public health laboratories, usually part of the state health agency, are responsible for 
                                                     
h U.S. territories include American Samoa, Guam, the Marshall Islands, Puerto Rico, the Mariana Islands, and the U.S. 
Virgin Islands. 
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participating in national public health surveillance activities and monitoring disease trends.38  
Often, state public health laboratories provide training to workers in private sector and local 
public health laboratories, and in some states provide regulatory oversight of clinical and/or local 
public health laboratories.    
Local Laboratories.   Local public health laboratories function at the city or county level.  The 
Association of Public Health Laboratories estimates that there are between 600 and 800 local 
public health laboratories in the U.S.  (The precise number and capabilities of these laboratories 
varies according to how the laboratory is defined.)41  Most states have several local public health 
laboratories that range from large urban laboratories employing hundreds of scientists to small 
rural laboratories staffed by one or two scientists.39    
In general, local public health laboratories have greater familiarity with local health problems and 
stronger ties to their communities than state-level laboratories.42  A 2003 survey of local public 
health agencies found that more than two-thirds rely on in-house public health laboratories for at 
least some of their testing needs.   Agencies located in larger counties or cities were more likely to 
use their own laboratory than those located in smaller or rural locations.  When testing is required 
beyond the local agency, the specimen is usually sent to the state public health laboratory.  Other 
referral sites include independent laboratories, hospital laboratories, other state public health 
laboratories, and university laboratories.   
A 2003 survey indicated that 39% of local public health laboratories were certified to perform 
waived testing.  Of the 61% that were certified to perform non-waived testing, 39% were certified 
to perform moderate complexity tests and 22% were certified to perform high complexity tests, 
e.g., tests for the fungal disease candidiasis and the enteric pathogen shigella.42  Nearly 70% of 
testing fell into the waived category, compared to 20% for moderate complexity, and 11% for high 
complexity.  Public health laboratories serving larger populations tended to offer higher-
complexity testing.   
Local public health laboratories derive revenue from a variety of sources, as shown in Figure 2.8, 
about half of which is provided by local and/or state governments.    
State and local public health laboratories are likely to face significant challenges over the next 
several years.  Emphasis on public health preparedness and its ability to respond quickly and 
effectively to biological or chemical terrorist threats has led to increased scrutiny of public health 
laboratory infrastructure.43  Public health laboratories are being called upon to foster and lead 
preparedness and response planning efforts for emerging infectious diseases, such as pandemic 
influenza.44  Biomonitoring, or the measurement of chemical levels in the human body (e.g., in 
blood, urine, or saliva) to assess human exposure to pollution is an area where state public health 
laboratories are continuously called upon to play a large and leading role.45  Collaboration 
between public and private laboratories and continued funding of current and future initiatives 
will remain vital components critical to the success of public health laboratories.    
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Figure 2.8:  Sources of Revenue for Local Public Health Laboratories, 2003  
 
Source: Assessing America's local public health 
laboratory capacity. Silver Spring, MD: Association of 
Public Health Laboratories, 2004. 
Skilled Nursing/Nursing Facility Laboratories 
Skilled nursing is health or rehabilitation care that can only be provided safely and correctly by a 
registered nurse or licensed practical nurse.46  According to CMS, there were 14,838 skilled 
nursing facilities in the U.S. in December 2003.47  As of December 2006, a total of 14,760 skilled 
nursing or nursing facilities had their own clinical laboratories, comprising 7.36% of all 
laboratories.19  Skilled nursing or nursing facility laboratories conduct approximately 60.4 million 
tests annually.  More than 99% of skilled nursing or nursing facility laboratories are certified to 
perform waived or PPM testing.    
Home Health Agency Laboratories 
Home health care usually refers to medical care that is provided to elderly and other patients with 
the goal of enabling them to regain their independence and retain the highest degree of self-
sufficiency without being confined in a hospital.48  Home health care can include skilled nursing 
care, physical and occupational therapy, speech-language therapy, mental health services, 
palliative care, and medical social services.49  Organizations whose main function is to provide 
home health care services and supplies must meet federal and state requirements for licensure 
and certification.50  As of March 2007, there were approximately 11,130 Medicare-certified home 
health agencies in the U.S.51   
Many home health agencies operate their own clinical laboratories to serve the needs of their 
clients.  In 2006, there were 10,134 home health agency-based laboratories, accounting for more 
than 5% of all laboratories in the U.S.19  The annual volume of testing conducted by home health 
laboratories is approximately 18.4 million.  About 98% of testing conducted in home health 
agencies is waived and more than 99% of home health agency laboratories are certified to conduct 
waived or PPM testing only.   
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Other Types and Settings of Laboratory Services 
Clinical laboratories are present in additional settings, including community clinics, ambulatory 
surgical centers, student health facilities, and pharmacies which, together, account for 
approximately 26% of all laboratories (see Table 2.4).16   
In 2006, their estimated combined revenue was $2.9 billion.  Growth among these laboratories is 
slowing primarily because of lower overall revenues at the contract level and costs associated 
with CLIA regulatory requirements.1, 35, 52  
Table 2.4:  Other types of laboratories by prevalence in the U.S., 2006 
Type of Laboratory Number 
Percent of 
Total 
Laboratories 
Total 
Annual Test 
Volume 
(million) 
Waived 
Testing as 
Percentage 
of Total 
Annual Test 
Volume 
Community Clinic 6,588 3.32% 75.9 28.7% 
End Stage Renal Disease Dialysis Facility 4,099 2.07% 12.9 83.0% 
Ambulatory Surgical Centers 4,023 2.03% 25.7 13.5% 
Pharmacy 3,815 1.92% 73.3 99.9% 
Ambulance 2,831 1.43% 3.0 73.5% 
Ancillary Test Site in Health Care Facility 2,722 1.37% 67.7 36.9% 
Other Practitioner 2,554 1.29% 29.2 11.9% 
School/Student Health Facility 1,873 0.95% 5.5 42.3% 
Hospice 1,872 0.94% 3.5 48.3% 
Industrial 1,677 0.85% 2.3 67.2% 
Rural Health Clinic 1,226 0.62% 3.9 47.6% 
Mobile Laboratory 1,117 0.56% 5.0 58.6% 
Interm. Care Facility, Mentally Retarded 985 0.50% 1.7  52.5% 
Health Maintenance Organization 677 0.34% 100.7 4.3% 
Health Fair 516 0.26% 13.0 7.0% 
Federally Qualified Health Center 444 0.22% 1.4 52.7% 
Blood Banks 375 0.19% 83.9 12.2% 
Comprehensive Outpatient Rehab. Facility 272 0.14% 1.7 67.5% 
Insurance 42 0.02% 5.4 0.8% 
Tissue Bank/Repositories 36 0.02% 0.895 1.3% 
Not Otherwise Specified 15,300 7.72% 267 25.3% 
Source: CLIA update―December 2006, laboratories by type of facility. Baltimore, MD: Centers for Medicare and Medicaid Services, 2006. 
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MARKET FOR LABORATORY TESTS 
There is no definitive estimate of how many clinical laboratory tests are available.  However, a 
large independent clinical laboratory currently lists over 4,000 tests on its testing menu.53  
According to the American Society for Clinical Laboratory Science (ASCLS), of the 1,162 tests 
reimbursed by Medicare, about 500 are performed regularly.54   
Laboratory tests are categorized by the following key areas:  
 Anatomic pathology 
 Cytology 
 Surgical pathology 
 Oncology 
 Neuropathology 
 Immunohistochemistry 
 Clinical pathology  
 Molecular pathology 
- Cytogenetics 
- Genetics 
 Histocompatibility 
 Microbiology 
 Immunology 
 Chemistry (including toxicology and drugs of abuse testing) 
 Hematology 
 Immunohematology 
 Radiobioassay14 
Most of the tests are performed at the request of a clinician, although patients and other 
consumers may order tests directly from the laboratory in some states.  Discussion of the market 
for consumer direct access testing (DAT)i and over-the-counter (OTC) tests is provided 
subsequently in this chapter. 
The market for clinical pathology is estimated to be $31.9 billion in 2006, comprising nearly two-
thirds of the industry (Figure 2.9).1  Anatomic pathology and cytology are estimated to have  
markets valued at $9 billion and $2 billion, respectively.  The market for molecular and other 
esoteric testsj is about $4.1 billion, and that for drugs of abuse testing is $1.5 billion.   
                                                     
i DAT is known by a variety of other names, including consumer ordered tests, patient-directed tests, consumer 
driven tests, patient authorized tests, and consumer self-orders.55, 56 
j The term “esoteric” refers to new molecular pathology tests and certain other relatively low volume tests.  Most 
esoteric tests use molecular-based laboratory techniques.   
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Figure 2.9:  Major Testing Segments in the U.S. Laboratory Industry, 2006  
Source: Reprinted with permission from Washington G-2 reports. 
Terry M. Lab industry strategic outlook: market trends and analysis 
2007. New York, NY: Washington G-2 Reports, 2007.  
Figure 2.10 highlights the two-year average growth rate in each category.  The market for all testing 
areas is expanding, except drugs of abuse testing.  Growth in clinical pathology and 
molecular/esoteric testing is expected to average 11% in 2007.  Contributing to the growth in 
molecular pathology testing are higher reimbursement rates, greater demand from both consumers 
and providers, and increases in the number of new predictive laboratory tests available.   
Growth in anatomic pathology is expected to average 5% in 2007.1 This growth is due mainly to 
changes in the burden of disease in the population, stakeholder interest in expanding methods 
of early detection to decrease health care costs, and technological innovation that has simplified 
testing techniques in areas such as flow cytometry and immunohistochemistry, allowing for 
more ubiquitous anatomic pathology testing in hospital and independent laboratories.  The 
largest increase in test volumes is expected to occur in FISH and polymerase chain reaction 
(PCR)-based testing.57     
 
 
Clinical Pathology
$31.9 billion
66%
Anatomic
Pathology
$9.0 billion
19% Cytology
$2.0 billion
4%
Molecular Pathology/
Esoteric Testing
$4.1 billion
8%
Drugs of Abuse
$1.5 billion
3%
Laboratory Medicine: A National Status Report Chapter II - Market Profile of the Laboratory Medicine Sector 
May 2008 v2 83 
Figure 2.10:  U.S. Laboratory Segment Annual Growth Rates, 2004 - 2006 
Source: Reprinted with permission from Washington G-2 reports. Terry M. Lab industry strategic outlook: market trends and 
analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Market for Anatomic Pathology Testing 
Anatomic pathology consists of the subspecialties of cytology, immunohistochemistry, 
neuropathology, dermatopathology, oral pathology, forensic pathology, autopsy pathology, and 
histology.  Cytology refers to the diagnosis of cells from all systems and areas of the body.58  
Histology involves the study of tissues and cells under a microscope.59  Immunohistochemistry 
involves use of antibodies to detect specific proteins that are expressed in tumors.k,60  
Neuropathology is the branch of medicine dealing with diseases of nervous system tissue, 
specifically the brain and spinal cord.61  Dermatopathology is the study of diseases of the skin, 
including infectious, immunologic, degenerative, and neoplastic diseases.62  Oral pathology refers 
to the study of diseases affecting the oral and maxillofacial regions.63  Forensic pathology concerns 
the examination of living or dead persons in order to provide an opinion on the cause, 
mechanism, and manner of disease, injury, or death.64  Autopsy pathology refers specifically to 
the external and internal examination of the body after death.65   
Together, anatomic pathology and cytology account for about 23% of the laboratory industry by 
testing volume.  Aside from cytology, market data for the other anatomic pathology testing areas 
are not available.   
Three major privately-owned independent laboratories collected an estimated $2 billion in 
anatomic pathology revenues in 2006.1  Despite consolidation efforts among privately-owned 
independent laboratories, the anatomic pathology market remains relatively fragmented.  More 
than 70% of the anatomic pathology market is occupied by thousands of pathology groups, 
including small and mid-sized private practices, independent laboratories, and hospitals.66  
                                                     
k Immunohistochemistry is considered anatomic pathology because it is conducted on biopsies and surgical 
specimens as opposed to bodily fluids (e.g., blood, urine).   
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According to CMS data, about 8,015 laboratories perform anatomic pathology tests, generating an 
annual volume of nearly 1.45 million tests.67     
Table 2.5 summarizes responses from 190 anatomic pathology laboratories to a survey regarding 
average annual testing volumes conducted in 2007.  Respondents self-identified as belonging to 
one of four groups, three of which were hospital-related.57  While average testing volumes in 
independent laboratories exceeds average testing volumes in some hospital-based laboratory 
arrangements for certain types of testing (e.g., surgical pathology accessions, 
immunohistochemistry), these results indicate that the majority of anatomic pathology testing is 
conducted in hospital laboratories.  For example, 82% of liquid-based Pap smears and 86% of 
other molecular diagnostic tests are performed in hospital-related laboratories.        
Table 2.5:  Self-Reported Anatomic Pathology Testing Volumes by Type of Practice, 2007 
Hospital-Related Sites 
 Hospitala 
Pathology 
Practice 
Groupb Otherc 
Independent 
Labd 
Total 
Volume 
by 
Testing 
Type 
% of Work 
Conducted 
in Hospital-
Related 
Labs 
Surgical Pathology 
Accessions (All) 18,322 30,057 29,723 48,577 126,679 78.4% 
 - Biopsies 12,914 17,368 20,451 23,937 74,670 83.3% 
 - Immunohistochemistry 5,305 3,290 4,010 10,334 22,939 80.3% 
Fluorescent In Situ 
Hybridization 469 215 86 1,331 2,101 72.4% 
Cytopathology 15,380 18,592 19,208 34,181 87,361 80.0% 
Liquid-based Pap Smears 
(All) 16,023 27,339 17,774 32,786 93,922 82.1% 
 - Thin-layer Automated 
Imaging of Pap Smears 9,540 13,530 10,308 22,476 55,854 79.3% 
Other Molecular 
Diagnostic Tests 501 10 3,541 879 4,931 86.3% 
Polymerase-Chain 
Reaction-Based Tests 926 2,162 1 3,106 6,195 73.7% 
All Other Non-Surgical 
Pathology Accessions 
(e.g., electronic 
microscopy accessions) 
9,652 13,169 15,226 21,108 59,155 64.3% 
Total Volume by 
Practice Type* 61,273 91,544 85,559 141,968 380,344 80.1% 
aRefers to pathologists who receive a salary from the hospital and conduct testing of specimens collected from hospital 
inpatients and outpatients 
bRefers to pathologists who have formed a private business group and who have contracted with a hospital to perform testing in 
that hospital’s laboratory.  These pathologists conduct inpatient, outpatient, and outreach testing.  They bill insurance 
companies directly for the work they perform (professional component only); they maintain their own billing and revenue 
systems 
cRefers to pathologists who work in multihospital systems, integrated delivery systems, academic medical centers, or university 
hospitals 
dRefers to pathologists who work in an independent laboratory where the laboratory, testing equipment, and office space is not 
owned by a hospital system.  These pathologists usually conduct testing on specimens collected in outpatient settings, but also 
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can function as reference laboratories for hospitals and other facilities.  They bill insurance companies for both the technical and 
professional components of testing. 
*Biopsies, immunohistochemistry, and thin-layer automated imaging of Pap smears were not included in calculation of total 
volume by type of practice because they are sub-categories of surgical pathology and liquid-based Pap smears, respectively.  
Volumes for these tests are included here to show breakdowns of specific tests. 
This category may include some molecular diagnostic testing (e.g., FISH, PCR-based testing) because some respondents may 
have included all molecular diagnostic testing in the “non-surgical pathology accessions” category rather than delineating these 
tests by specific category. 
Source: Modified and reprinted with permission from Washington G-2 reports. Business strategies for anatomic pathology, 
including state of the market report, 2007.  New York, NY: Washington G-2 Reports, 2007.   
Anatomic pathologists/technologists in all settings are becoming more specialized.68  Some 
laboratories and practice groups hire staff members with expertise in a particular organ system 
or testing method.  Other groups hire individuals with doctoral degrees in specific areas, such 
as molecular biology, to research and develop new testing procedures.69  To expand their 
business, these groups also are beginning to market specific tests or services directly to 
physicians and patients.70   
Cytology 
Cytologic testing remains the gold standard in detection of many types of diseases, including 
common forms of cancer (e.g., uterine and cervical cancers, leukemia, lymphomas).71  In some 
instances, traditional cytologic tests are being replaced by newer technology.  For example, an 
inexpensive point-of-care test to detect bladder cancer recently developed may be substituted for 
traditional laboratory-based cytologic testing.72   
The value of the cytology market is approximately $2 billion.1  From 2003 to 2006, cytological testing 
grew by 60%.66  Although the cytology market has been undergoing some consolidation, it remains 
fragmented, with the majority of the market held by independent laboratories and hospitals.   
A major contributor to the growth of cytology has been the nearly complete transition from 
traditional Pap smear tests to liquid-based thin-layer slide preparation testing methods for 
cervical cancer screening.73  Whereas traditional Pap smear testing involves using a fixative to 
spray specimen cells onto a glass slide prior to sending them to a laboratory for analysis, the thin-
layer testing method allows the specimen to be mixed into a vial of liquid preservative, which is 
then sent to the laboratory and made into slide samples, providing for cleaner and more uniform 
analysis.74  In 2006, 92% of laboratories used thin-layer Pap test method to conduct cervical cancer 
screenings; however, by 2007, this number was projected to increase to 99%.1, 75 
Thin-layer Pap smear tests are reimbursed approximately $10 more than conventional tests, and 
increased use of thin-layer tests has contributed significantly to the growth in cytology-related 
revenue over the past several years.l  From 1998 to 2005, revenue generated by gynecologic 
cytology testing has more than doubled, with revenues in 2005 exceeding $1.38 billion.1  More 
than 80% of the gynecologic cytology manufacturing market is dominated by two privately 
owned companies.  
                                                     
l Medicare reimbursed thin-layer tests at the same rate as traditional Pap smear tests until April 2001; Medicare’s 
increase in reimbursement for thin-layer tests is believed to have accelerated acceptance of this form of testing.1  
Laboratory Medicine: A National Status Report Chapter II - Market Profile of the Laboratory Medicine Sector 
May 2008 v2 86 
Market for Molecular Pathology 
Although molecular laboratory tests fall under the umbrella of clinical pathology, molecular  
testing techniques are increasingly applied in anatomic pathology.  Thus, many experts are now 
discussing the blurring of the traditional lines between clinical and anatomic pathology.  This 
discipline includes the categories of histocompatibility (e.g., assays to determine whether recipient 
and donor share antigens to ensure that a donated graft is accepted and remains functional); 
cytogenetics (e.g., analysis of amniotic fluid to detect fetal genetic abnormalities); 
hematopathology (e.g., tests to determine recipient genotype prior to bone marrow 
transplantation); infectious disease (e.g., HIV genotyping and determination of status of hepatitis 
B virus infection); inherited disease (e.g., cystic fibrosis carrier screening); and pharmacogenomics 
(e.g., genotyping to guide warfarin dosing).76-79 
In 2007, the U.S. molecular diagnostic testing market was valued at approximately $4.1 billion, 
representing the fastest-growing and most-profitable area of the clinical laboratory industry.80  
Market researchers anticipate continued growth in the molecular diagnostic market of 
approximately 19% per year over the next three years.  The exact number of genetic tests available 
is not known, but an estimated 1,430 diseases are currently detectable using genetic testing (287 
diseases are tested only in research settings).81   
Key areas of growth include infectious disease testing, pharmacogenomics, genetic testing, and 
oncology testing.  Figure 2.11 displays predicted revenues for each of these areas within the 
context of the worldwide molecular diagnostic market in 2016.  By then, the U.S. is expected to 
generate nearly $46.2 billion in revenues, half of the world market.  Infectious disease testing is 
the largest area of the molecular diagnostic market, due to the high incidence of infectious disease 
and the relative ease with which genetic information required for identifying pathogens is 
obtained from bacterial and viral species.82  Pharmacogenomic, genetic, and chromosome testing 
represent the next largest areas of growth.  For example, cytogenetic laboratory tests involve 
preparation of cells and isolation of chromosomes in order to identify chromosomal abnormalities 
(e.g., tests to detect the presence of fragile X syndrome, the most common inherited cause of 
mental impairment and the most common known genetic cause of autism).  About 1.6 million 
cytogenetic tests are performed annually in 373 laboratories.67   
Molecular diagnostic testing is changing the practice of laboratory medicine.  For example, 
laboratory testing is expected to have an important role in the growth of personalized and 
preventive medicine.83  Molecular testing techniques are increasingly being applied to oncology and 
cardiology and tests to determine genetic expression and gene profiles, allowing clinicians to detect 
disease at much earlier stages.  Although many molecular tests are currently still in the research 
stage, they are expected to become part of routine clinical practice over the next several years.   
Laboratory experts predict that all neoplastic tissues will eventually be analyzed biochemically 
and morphologically.84  Expression profiling, by which expression patterns of thousands of 
individual genes in a given cell or tissue sample can be discerned, may become standard practice 
alongside traditional histopathology.85  If the historical line separating anatomic and clinical 
pathology continues to dissolve, pathology residency programs will likely need to adapt to 
emphasize training in both the morphologic and molecular basis of disease.84   
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Figure 2.11:  Predicted Average Revenue in 2016 for Segments of the International 
Molecular Diagnostic Market 
Source: Molecular diagnostics: major world markets.  New York, NY: Kalorama Information, 2007. 
Techniques from molecular biology, identity testing, transplantation, and anatomic pathology are 
fueling many of the advances in molecular diagnostics.86  For example, rapid molecular testing is 
now available using nucleic acid extraction techniques, allowing for more immediate initiation of 
therapy.  Information derived from the sequencing of the human genome is enabling creation of 
molecular diagnostic tools that help to reveal the presence and roles of additional genes and gene 
products in complex diseases.  Advances in innovative automated systems to support molecular 
diagnostic testing technologies also are improving laboratory practice by decreasing TATs, 
improving precision of quantitative results, and reducing costs (relative to manual testing).87    
Higher reimbursement rates for molecular tests are contributing to the accelerated growth in 
this area.  According to a recent market analysis, the average charge for a non-molecular test is 
approximately $30.39, compared to $176.77 per molecular test.73  Automation of molecular and 
genetic testing will likely affect the budgets and operating costs of laboratories performing these 
tests. 
Market for Clinical Pathology Testing  
Clinical pathology comprises the largest segment within laboratory testing; the market is 
currently valued at $31.9 billion, or approximately 66% of the industry.1 
Waived Tests.  According to CMS, waived testing accounts for approximately 11% of annual 
laboratory testing volume.67   In 2006, annual volume of waived testing approached 700 million 
tests and generated annual revenue of $1 billion.  Approximately 75% of waived testing is 
conducted in laboratories certified to perform only waived or PPM testing, although about 17% is 
conducted by laboratories with a COA and about 8% by those with a COC (see Table 2.6).19 
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Table 2.6:  Number of Waived and Non-Waived Tests Performed According to Laboratory 
Data Self-Reported to CMS, 2006 
 
Laboratories 
Certified to 
Perform only 
Waived or PPM 
Testing 
Laboratories with 
Certificate of 
Accreditation 
Laboratories with  
Certificate of 
Compliance 
Total Number of 
Tests Performed 
Number of 
Waived Tests 
Performed  
523,797,097 121,240,212 54,890,056 699,927,365 
Number of  
Non-Waived 
Tests Performed 
Not applicable 4,614,509,645 921,013,600 5,535,523,245 
Source: OSCAR/CLIA data base: Test volume information based on laboratory self-reporting on CMS-116.  Zeller C, ed.  
Baltimore, MD: Centers for Medicare and Medicaid Services, March 2006. 
According to OSCAR data obtained by Washington G-2 Reports, the highest-volume waived tests 
performed by all laboratories include those to evaluate prothrombin, urinalysis, ovulation, 
glucose, fecal occult blood test, and the lipid panel (Figure 2.12).1  From 2000 to 2006, tests for 36 
analytes (for which waived tests were not previously available) were granted CLIA waived 
status.88  With new technology and simplification of testing techniques, the number of tests 
receiving waived status will continue to increase.   
Figure 2.12:  Five Highest Volume Waived Tests 
Sources:  Medicare part B physician/supplier national data CY 2005: Top 100 lab procedures.  Baltimore, MD: Centers for 
Medicare and Medicaid Services, 2005.  (Accessed November 10, 2007, at  
http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/Downloads/LabServ05.pdf?agree=yes&next=Accept.)   
Terry M. Lab industry strategic outlook: Market trends and analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Moderate and High Complexity Tests.  Although only 20% of laboratories are certified to perform 
moderate and high complexity tests, approximately 89% of laboratory testing volume is moderate 
or high complexity (non-waived) testing.19  In 2006, the volume of non-waived testing exceeded 
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5.5 billion (Table 2.6).  The majority of non-waived testing is conducted in laboratories that have a 
certificate of accreditation.   
As per CLIA regulations, CMS delineates non-waived clinical pathology laboratory tests into 
selected specialty areas.  For clinical pathology, these areas include: chemistry, hematology, 
diagnostic immunology, microbiology, immunohematology, histocompatibility, and 
radiobioassay.89  While the information provided here is based on data collected by CMS, CLIA 
specialties are not all inclusive of the menu of available clinical pathology laboratory tests.  For 
example, CLIA does not include a separate specialty for genetic testing or toxicology.  An 
overview of each CLIA specialty, including purpose, examples of specific tests, annual volume, 
and number of laboratories performing that type of test is displayed in Table 2.7.  
Data reported by laboratories to CMS indicate that 62% of all non-waived tests performed are 
chemistry tests, which measure compounds and chemical reactions in the body and include 
routine chemistry, endocrinology, urinalysis, and toxicology tests.67, 89  Commonly performed 
routine chemistry tests include measurements of total cholesterol, calcium, triglycerides, glucose, 
electrolytes, blood urea nitrogen, creatine, and prostate specific antigen (PSA).  Examples of 
endocrinology tests include measurements of testosterone, thyroid-stimulating hormone, and 
progesterone; toxicology tests include measurements of acetaminophen, blood alcohol, digoxin, 
and lithium.     
Accounting for 24% of all laboratory testing, hematology studies the blood, blood-producing 
organs, and cells of the body.67, 90  Examples of hematological laboratory tests include 
measurements of red and white blood cells, differential blood counts, prothrombin time, and 
activated clotting time.89  
Diagnostic immunology, which involves measurement of the body’s response to infection and 
inflammation, accounts for approximately 4.3% of testing.67  Frequently ordered immunological 
tests include mononucleosis assays, antibody assays for viruses such as herpes and hepatitis, 
mycoplasma pneumoniae assays, and tests to detect rheumatoid arthritis.78, 89   
Microbiological testing also comprises 4% of non-waived testing and refers to the detection, 
identification, and measurement of disease-causing microorganisms (e.g., viruses, bacteria, fungi, 
algae, parasites).67, 90  For example, antigen assays  detect streptococcal infection and culture 
assays detect and identify bacteria that cause urinary tract infection.89 
Immunohematology, or blood banking, involves the preparation of blood and blood components 
for transfusion and the selection of appropriate and compatible blood components for 
transfusion.91  Approximately 2.4% of moderate and high complexity testing falls into the 
category of immunohematology.67  Common immunohematology tests are those that determine 
blood and Rh type and that screen and identify antibodies.89  
Smaller percentages of non-waived testing falls into the areas of radiobioassay (0.2%), 
histocompatibility (0.7%), and cytogenetics (0.03%).67, 92  Radiobioassay tests determine the type, 
quantity, concentration, and location of radioactive material in the body (e.g., test of red cell 
volume, Schilling’s test for B12 absorption).89, 93  Histocompatibility tests assess the extent to which 
an organ donor and organ recipient share antigens and an organ can be successfully transplanted 
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(e.g., human leukocyte antigen typing to determine the proteins on white blood cells that make 
each person’s tissue unique).78   
Table 2.7:  Annual Testing Volume, and Number of Laboratories Performing Clinical 
Pathology Laboratory Testing According to CMS Laboratory Test Categorization  
Clinical Area 
Examples of Commonly Ordered 
Laboratory Tests 
Approximate 
Annual Test 
Volume 
Number of 
Laboratories 
Performing Tests 
Chemistry 
 Cholesterol, total 
 Uric acid 
 Glucose (blood sugar) 
 Ferritin 
 Folate 
 Blood alcohol 
 Acetaminophen 
3.5 billion 25,755 
Hematology 
 Red blood count 
 White blood count 
 Platelet count 
 Hemoglobin  
 Hematocrit 
1.4 billion 24,663 
Diagnostic 
Immunology 
 Mononucleosis assays 
 Rheumatoid arthritis 
 Febrile agglutinins 
 Human Immunodeficiency Virus  
 Hepatitis or herpes antibody assays 
238 million 12,804 
Microbiology 
 Streptococcal testing 
 Bacterial cultures 
 Gram stains 
225 million 20,056 
Immunohematology 
 ABO blood type 
 Rh(D) type 
 Compatibility testing (cross-matching) 
 Antibody screening 
131 million 6,956 
Radiobioassay± 
 Red cell volume 
 Schilling’s test 10 million 611 
Histocompatibility  Human leukocyte antigen typing 
(disease associated antigens) 
4.0 million 260 
±Radiobioassay testing may not always be considered part of the clinical laboratory and instead may be classified as a part of 
nuclear medicine.  
Sources: Histocompatibility and immunogenetics terminology.  Mt. Laurel, NJ: The American Society for Histocompatibility and 
Immunogenetics, 2007.  (Accessed April 27, 2007, at http://www.ashi-hla.org/).  
Consumer laboratory test information page.  Bethesda, MD: American Society for Clinical Laboratory Science, 2007.  (Accessed on 
April 25, 2007, at http://www.ascls.org/labtesting/index.asp).   
Kotrla, K.  Immunohematology.  Austin, TX: Austin Community College, 2004.  (Accessed April 27, 2007, at 
http://www.austincc.edu/kotrla/immunohe.htm).    
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Laboratory departments.  East Lansing, MI: Michigan Association of Laboratory Science Educators, 2007.  (Accessed on April 27, 
2007, at http://www.malse.org/labdepts.htm#).  
Definition of terms.  Raleigh, NC: North Carolina Department of Environment and Natural Resources, 2007.  (Accessed on April 
27, 2007, at http://www.ncradiation.net/RMS/rmsglossary.htm#B).  
Clinical Laboratory Improvement Amendments of 1988 (CLIA) application for certification.  Baltimore, MD: Centers for Medicare 
and Medicaid Services, 2007.  (Accessed April 27, 2007, at http://www.cms.hhs.gov/cmsforms/downloads/cms116.pdf). 
OSCAR/CLIA data base: Test volume information based on laboratory self-reporting on CMS-116.  Zeller C, ed.  Baltimore, MD: 
Centers for Medicare and Medicaid Services, April 2007. 
Market for Drugs of Abuse Testing 
Drugs of abuse testing is used to determine the presence or absence of illegal drugs in an 
individual’s body.  Such testing is periodically conducted for designated workers in the public 
and private sectors.m  In the federal government, specific federal employees are required to 
undergo random drugs of abuse testing, including federal employees determined to be “testing-
designated personnel” under the Federal Drug-Free Workplace Program, Department of Defense 
employees, Department of Transportation employees involved in aviation, railroads, mass transit, 
pipelines, and other transportation industries, and Nuclear Regulatory Commission employees 
and contractors.94  In total, this includes about 16 million people.  Under the Drug-Free Workplace 
Act of 1988, contractors and grantees of federal agencies must agree to provide drug-free 
workplaces prior to receiving a contract or grant; however, these programs do not require random 
drugs of abuse testing.95  In the private sector, companies can voluntarily elect to implement drug-
free workplace programs such as drug abuse prevention education.n 
The drugs of abuse testing market was valued at approximately $1.5 billion in 2006.  About 33 
million tests are conducted for employers annually.  About 20% of these tests (approximately 7.5 
million) are conducted for federal employees who are required to undergo drugs of abuse testing.  
A key factor contributing to market growth for drugs of abuse testing was the passage of the 
Drug-Free Workplace Act in 1988.  The new rules required that all federal contractors and 
grantees ensure a drug-free workplace, prompting steep increases in drugs of abuse testing from 
21% of employers in 1987 to 81% in 1996.  
In order to conduct tests for federal agencies, laboratories must be certified by the government 
through the National Laboratory Certification Program of the Substance Abuse and Mental 
Health Services Administration (SAMHSA).o, 96  While private companies can elect to use 
laboratories that are not certified by SAMHSA, many use these laboratories, considered to be the 
“gold standard” for drugs of abuse testing.  Of the 45 laboratories currently certified to conduct 
federal workplace drugs of abuse testing, 11 are owned or operated by the two largest laboratory 
corporations.97  In 2005, their combined revenue for drug testing was $264 million, almost 28% of 
the market but a small percentage of their total revenue.1  Other smaller companies may derive 
the majority of their revenue from drugs of abuse screening.  Table 2.8 provides the estimated 
revenue for top 8 laboratories engaged in drugs of abuse testing in 2005.  
                                                     
m  Drugs of abuse testing also are an important part of forensic testing, although this topic is outside the scope of this 
report. 
n Some states offer financial benefits to private companies that enact drug-free workplace programs.  Some insurance 
companies provide lower rates to companies that have such programs in place. 
o SAMHSA oversees the Federal Drug-Free Workplace Program.  
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Table 2.8:  Estimated 2005 Revenue at Top Eight Employee Drug Testing Laboratories  
Company Estimated Revenue 2005 
Quest Diagnostics $165 million* 
LabCorp $99 million* 
First Advantage Enterprise Screening $72 million 
Medtox $32 million 
Psychmedics $21 million 
Advanced Toxicology Network $19 million 
Kroll Laboratory Specialists $18 million 
Clinical Reference Lab $13 million 
Total, top 8 companies $439 million 
*Based on percentage of total revenue attributed to drug testing 
Source: Reprinted with permission from Washington G-2 reports. Terry M. Lab industry strategic outlook: market trends 
and analysis 2007. New York, NY: Washington G-2 Reports, 2007. 
Aside from federal employers, the number of employers requiring pre-employment drugs of 
abuse screening has decreased by 11% from 1999 to 2005.1  Drugs of abuse testing of all employees 
on a regular basis has declined steadily from 1999 to 2004.  Many employers have reported that 
drugs of abuse testing is not cost-effective, particularly when the actual number of positive test 
results is quite low.  In 1999, the most current year for which data of this nature is available, the 
American Civil Liberties Union reported that, of the $11.7 million (1990 dollars) spent by the 
federal government to screen 29,000 employees, only 153 tests were positive.98  
To decrease expenses, drugs of abuse testing for non-federal employees is increasingly being 
conducted in POLs, clinics, or on site in employer-based health departments or clinics using 
waived test kits.p  Kits sold over-the-counter through retailers (e.g., CVS, Wal-Mart) typically cost 
$3 to $5, compared to laboratory-performed tests, which cost $25 to $50.1  Although OTC testing 
of drugs of abuse may be less accurate and reliable than laboratory-performed tests, this shift in 
testing location has resulted in the closing of many drug testing laboratories.  From 1998 to 2007, 
the number of SAMHSA-certified laboratories decreased from 71 to 45, a 36% drop.1, 97  While 
many states do not have special requirements to govern employers who perform their own drugs 
of abuse testing, some states do require that all positive test results be confirmed in a SAMHSA-
certified laboratory.99  
Market for Consumer-Directed Tests 
An increase in the amount of information available to the public via the Internet and news media 
attention to personal health issues have enhanced consumer interest in understanding, directing, 
and managing their health care.84,100  The increasing number of Americans who are uninsured or 
underinsured may be contributing as well, to the extent that they seek personal health information 
outside of the health care system.  There is now a substantial market for health care services and 
products that support consumers in their self-care associated with prevention and disease 
management.  Two chief avenues for consumers to engage in self-directed laboratory testing are 
DAT at an established laboratory and OTC tests. 
                                                     
p Between 2000 and 2006, FDA approved 35 waived tests, 5 specifically for drug testing.   
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Direct Access Testing.  Consumers have demonstrated strong interest in the ability to order 
laboratory tests and obtain results independently of a health care provider.101  Typically, DAT 
services are purchased out-of-pocket by the consumer without physician consultation.55  A major 
concern regarding most DAT is that, in the absence of clinician prescribing and test interpretation, 
consumers are largely responsible for interpreting DAT laboratory results and may only follow 
up with their clinician if they deem it necessary.   
Since CLIA or other federal regulations do not address DAT, its governance falls under state 
law.55  Some states prohibit hospital laboratories from performing DAT, while others prohibit 
hospitals only from conducting DAT for inpatients.  In 2007, 13 states prohibited DAT completely 
and 12 states permitted DAT with specific limitations.102  The remaining 25 states and the District 
of Columbia allow DAT either because statutes explicitly provided for it or there is no law against 
it.  In 2004, 10-15% of hospital and commercial clinical laboratories offered some form of DAT.103     
Consumer access to DAT varies based on the type of test and geographic location.  Internet 
websites, telephone services, freestanding stores, hospital and commercial laboratory facilities, 
and pharmacies are currently the primary methods of access.  While many DAT laboratories offer 
only simple tests, other laboratories offer more complex tests.  Examples of tests commonly 
ordered via DAT services include those that measure complete blood counts, cholesterol levels, 
throat and urine infection, diabetes, HIV antibody tests, and blood type.56   
Another factor calling attention to DAT is direct-to-consumer advertising of laboratory tests, 
specifically genetic tests.  For example, a provider of clinical BRCA1/2 tests, for detecting genetic 
mutations associated with predisposition for inherited breast and ovarian cancer, directly marketed 
these tests to consumers over a 6-month period, marking the first time a genetic test was marketed 
to the public.15  Providers in the pilot cities reported ordering more tests and reported an increase in 
the number of patients who asked about testing, asked for genetic counseling referrals to consider 
testing, and requested testing.  The chapter on regulation of laboratory medicine in this report 
provides a more detailed discussion of direct-to-consumer advertising of genetic testing. 
Over-the-Counter Tests.  Consumers can purchase laboratory kits for certain types of tests and 
perform the tests themselves at home.104  These tests are purchased OTC at drugstores and 
supermarkets as well as on the Internet.  OTC laboratory kits available for home use include (but 
are not limited to) ovulation detection tests, pregnancy tests, and certain tests that measure and 
monitor cholesterol, glucose, fecal occult blood, and urinary tract infections.  The average price of 
individual tests varies, ranging from $20 for ovulation detection and cholesterol tests to $30-$100 
for instruments that monitor glucose levels. Currently, FDA has approved more than 800 
laboratory tests that can be sold OTC; more than 160 tests were approved in 2007 alone.105   
Laboratory tests performed at home by the consumer can offer certain advantages.  They provide 
a means by which individuals can monitor a disease that has already been detected by a 
physician.104  Secondly, home testing also allows individuals to detect certain conditions in the 
privacy of their home.  However, laboratory tests performed at home also pose the risk of 
inaccurate test results or incorrect interpretation of results, and failure to receive medical advice 
and attention if needed.   
Research examining the accuracy of home-use tests versus tests performed in a central laboratory 
show mixed results.  For example, a study of 111 patients with type 1 and 2 adult diabetes found 
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that, compared to blood glucose values obtained from a calibrated hand-held glucose monitor, 
53% of blood glucose measurements using home testing kits were within 10% of the control value, 
84% were within 20% of the control value, and 16% varied by 20% or more from the control 
value.106  A 2006 review of available evidence on self-monitoring using home-use glucose meters 
found that, while these devices are far more accurate than the earlier approach of matching colors, 
they are not as accurate as those derived from laboratory testing.  Even so, if used properly, they 
give an acceptably accurate reflection of immediate plasma glucose levels.  The authors noted 
that, in the relatively near term, self-monitoring of blood glucose could be replaced gradually by 
continuous glucose monitoring.107   
RESEARCH-SUPPORT TESTING 
Research-support testing is often used in clinical research trials.  Although research laboratories 
devoted to clinical trial support are exempt from CLIA requirements, they must comply with 
FDA regulations and inspections governing the studies.   
In recent years, the pharmaceutical industry has outsourced the management and design of clinical 
trials to contract research organizations (CROs).108  The CRO industry has grown with the expansion 
of clinical trials.  Enrollment of individuals in clinical trials also increased from 7 million in 1992 to 
20 million in 2001.  In 2006, the market for Phase I-IV studiesq by CROs was valued at 
approximately $8.5 billion; 8 firms hold 63% of the market.110  The largest providers of phase I-IV 
and central laboratory services in the CRO industry are Quintiles, Pharmaceutical Product 
Development, Inc., and Covance.  Together, these three account for 37% of the CRO market.  CROs 
can be involved in many different aspects of clinical trials, including preclinical safety analysis, 
study design, clinical trial management, laboratory services, statistical analysis, and regulatory 
services.108  There are approximately 1,500 CROs in existence today.111  Roughly 20 CROs conduct 
business on a global basis, while the remaining ones conduct clinical trials in smaller regions. 
While there are no reliable figures, approximately half of CROs in business today operate their own 
laboratories.111  Many of these laboratories tend to be small, focusing solely on either basic or 
esoteric tests.  The number of CROs offering laboratory services has increased as drug and medical 
device developers have demanded that CROs play a larger role in all phases of research.112     
Covance reports that it has increased its volume of laboratory testing by more than 40% during 
the last two years.  As part of this expansion, the company implemented a global automated 
specimen collection kit production line in which barcoded testing kits are assembled and sent to 
clinicians to simplify specimen collection and identification from research subjects.   This method 
of production also enables monitoring each step involved in kit production, thereby achieving 
greater process control.111, 113                      
Anecdotal evidence from industry experts suggests a synergistic relationship between larger and 
smaller CROs in regard to laboratory services and business markets.  For instance, larger CROs 
might use the framework and relationships established by smaller, ”niche” CROs to gain entry to 
                                                     
q Clinical trials of most pharmaceuticals and biologicals and some medical devices are conducted in phases.109  For most 
experimental products, Phase I and II trials involve determination of treatment safety, dosage, and side effects; Phase 
III trials involve confirmation of efficacy and side effects and allow comparison to commonly used treatments.  
Phase IV trials are post-marketing studies to obtain additional information about risks, benefits, and optimal use. 
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the clinical research market in a foreign country.  Smaller CROs, particularly those that do not 
house their own clinical laboratory services, may use the laboratories of larger CROs to facilitate 
their own clinical research.111   
CONCLUSIONS 
The revenue, spending, and test volume of the U.S. clinical laboratory testing market has grown 
steadily over the past decade.  Market expansion is attributed to changes in population 
demographics and burden of disease; scientific, medical, and technological advancements 
driving innovative research and development; and increased consumer awareness of and 
demand for high quality, safe health care.   
 According to CMS, nearly 6.8 billion laboratory tests are performed annually in the 
U.S., with projected revenues of $52 billion in 2007.   
 Clinical pathology testing comprises 66% of all laboratory tests and $32 billion 
in revenue 
 Anatomic pathology and cytology account for 23% and $11 billion in revenue 
 Molecular and esoteric testing account for 8% and $4 billion in revenue 
 Drugs of abuse testing accounts for 3% and $1.5 billion in revenue   
 Today, over 4,000 thousand laboratory tests are currently available for clinical use.  Of 
the 1,162 tests that are reimbursed by Medicare, about 500 are performed regularly.  
Medicare covers genetic tests only in a very limited capacity; most are not eligible for 
coverage unless they are indicated for symptomatic patients or are used to determine 
how a patient will respond to particular therapies.   
 The number of genetic tests available is growing, although many of these tests are only 
used in research settings.  Specifically, an estimated 1,430 diseases are currently detectable 
using genetic testing.  Of these, 287 diseases are tested only in research settings.   
 The number of CLIA-certified laboratories grew by 28% from 1993 to 2006, and 
exceeded 200,000 in 2007.  POLs represent the largest number of clinical laboratories in 
this sector (106,190 or 54%); approximately 80% are certified to perform only waived 
and/or provider-performed microscopy tests including urinalysis, fecal occult blood, 
urine pregnancy, rapid streptococcal, and glucose tests.   
 Hospital-based laboratories account for the largest proportion of total testing volume 
(55%) and generate the highest proportion of total testing revenue (54%), projected at 
$28.4 billion for 2007.  From 1999-2006, the average annual growth rates of both test 
volume and revenue were approximately 6 to 7%.  In 2006, privately-owned 
laboratories generated revenues of $15.5 billion (32% of total revenue), performing 
mostly routine, high-volume tests and molecular/esoteric tests.  
 Consumer-directed testing in the form of DAT and OTC tests is a key area for current 
and future market growth.  In 2004, 10-15% of hospital and commercial clinical 
laboratories offered some form of DAT.    
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Gaps, Needs, and Challenges: 
 Publicly available information about the economic status and quality of the laboratory 
medicine sector is limited.  The main sources currently available are CMS’ OSCAR 
database, ad hoc surveys, and commercial market reports used for investment 
purposes.  As a group, these leave certain gaps in covering the laboratory market, 
including precise figures of market revenues, spending, test volume, and laboratory 
testing trends.  As a result, estimates about these facets and other descriptors are likely 
to be incomplete and imprecise.  This lack of data inhibits the ability of researchers, 
regulators, payers, providers, and other stakeholders to adequately describe, anticipate 
the direction of, and influence this key health care sector.  Better data sources would 
support improved assessment of the value of laboratory medicine, workforce 
development, growth and directions of test use, financing, quality improvement, and 
organizational and strategic planning.   
 POLs are undergoing a major shift toward performing primarily waived testing. This 
shift is attributable to the growing number to FDA-approved waived tests available, 
industry’s targeted marketing of waived tests to POLs, higher costs associated with 
workforce training, and other expenses required to comply with CLIA regulations for 
moderate and high complexity testing.  The effect on quality of patient care of the shift to 
waived testing is unclear and may require further study.  
 As consumer-driven testing increases, laboratories should be prepared to assume a 
greater advisory role to individuals seeking DAT and using OTC tests.  Consumer 
demand for DAT is already creating incentives for laboratories to provide additional 
services.  For instance, some laboratories offer consumers the opportunity to consult 
with a medical doctor via e-mail prior to ordering tests and to receive test results via e-
mail.  In addition, for all tests, laboratories can develop consumer-friendly, easily 
understandable laboratory reports, written interpretations, and related support to 
promote more informed self care by consumers, patient safety, and quality of care. 
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CHAPTER III 
LABORATORY MEDICINE WORKFORCE 
The laboratory medicine workforce plays a vital role in the health care system, managing and 
applying evidence-based, scientific testing techniques to support patient care and protect against 
public health threats.1  However, there is growing concern regarding a significant shortage in the 
number of laboratory professionals entering the workforce.  The shortage could become 
pronounced soon with the forthcoming retirement of many laboratorians.  At the same time, the 
demand for laboratory services continues to increase given such factors as the aging of the 
population, growing prevalence of chronic diseases, and availability of new testing methods.  
Innovative technologies also are changing the practice of laboratory medicine and, in turn, the 
educational requirements and staff qualifications needed to provide quality testing services. 
This chapter provides an overview of the professionals in the laboratory medicine workforce, 
including their day-to-day responsibilities, demographic characteristics, vacancy rates, and 
wages.  The chapter also addresses the status of educational programs for each professional 
group, including specialty education programs, changes in curriculum, and data on program 
enrollees and graduates.  Lastly, this chapter discusses licensing and certification at the federal 
and state level.   
TYPES OF PROFESSIONALS 
Clinical laboratories typically are staffed with a medical team comprising pathologists, doctoral-
level laboratory scientists, laboratory technologists and technicians, and phlebotomists.  In addition 
to pathologists, personnel in anatomic pathology laboratories include histotechnologists/ 
histotechnicians, cytotechnologists, and pathologists’ assistants.  POLs are typically staffed by 
medical assistants and/or laboratory technologists and technicians.  Many of these professionals 
acquire additional training as a specialist within a subdiscipline of clinical laboratory testing.2  While 
there can be overlap in some of their tasks, their contributions and responsibilities differ in certain 
important ways.    
Pathologists and Doctoral-Level Laboratory Scientists 
Pathologists and doctoral scientists frequently operate at the more senior levels in clinical 
laboratories.  Often they serve as directors of clinical laboratories, responsible for oversight of 
staff, testing processes, quality control procedures, quality of laboratory care for patients, and 
other managerial functions.  Pathologists are licensed medical doctors who have graduated 
from an allopathic or osteopathic school of medicine.  They examine samples, interpret results 
of laboratory tests, ensure the accuracy of laboratory tests, and consult with clinicians.3 There is 
growing recognition of the vital roles of pathologists and doctoral-level laboratory scientists in 
the delivery of patient care by consulting with clinicians on ordering laboratory tests and 
interpreting the results.4  In most cases, pathologists and doctoral scientists can interpret and 
sign off on laboratory test results.a,5 
                                                     
a Some health care payers will not pay for laboratory test interpretation that is not conducted by a pathologist; in these 
cases, pathologists must interpret and sign off on laboratory tests.  Some hospitals also require pathologist approval.5   
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Pathologists in all branches of laboratory medicine (i.e., anatomic pathology, clinical pathology, 
and interdisciplinary subjects) tend to specialize in and practice specific clinical disciplines, as 
outlined in Box 3.1.  For pathologists and doctoral-level laboratory scientists, pathology-related 
subspecialties in which certification is available include:  immunohematology and transfusion 
medicine, chemical pathology, cytopathology, dermatopathology, forensic pathology, 
hematology, histocompatibility, immunology, microbiology, molecular diagnostics, molecular 
genetic pathology, neuropathology, oral pathology, and pediatric pathology.6   
Box 3.1:  Certifications Available for Anatomic, Clinical,  
and Molecular Pathology Specialties  
P= Certification available for pathologists 
DLLS= Certification available for doctoral-level laboratory scientists 
T/S= Certification available for technologists/scientists 
T= Certification available for technicians 
±Pediatric pathology can consist of one or both of anatomic and clinical pathology. 
* Pathologists can become certified as histocompatibility laboratory directors through the American Board of 
Histocompatibility and Immunogenetics. 
**Specialists in hemapheresis have knowledge of all aspects of donor and therapeutic procedures.  They have managerial 
responsibilities and make clinical and therapeutic decisions.  Apheresis technicians work in donor and therapeutic settings 
and perform basic and intermediate apheresis procedures; they do not have managerial responsibilities and are not 
generally involved in clinical and therapeutic decision-making.7   
Sources:  About physician specialties: pathology.  Evanston, IL: American Board of Medical Specialties, 2007.   
Clinical Laboratory Improvement Amendments of 1988 (CLIA) application for certification.  Baltimore, MD: Centers for 
Medicare and Medicaid Services, 2007.   
Candidate handbook. Lenexa, KS: American Board of Histocompatibility and Immunogenetics, 2008. (Accessed April 28, 
2008, at http://www.ashi-hla.org/abhi/ABHI-handbook.pdf.) 
Reference resources and publications.  Northfield, IL: College of American Pathologists, 2007.  (Accessed May 2, 2007, at 
http://www.cap.org/apps/cap.portal?_nfpb=true&_pageLabel=reference.) 
Anatomic Pathology 
Cytopathology (P, T/S) 
Neuropathology (P) 
Dermatopathology (P) 
Oral Pathology (P) 
Forensic Pathology (P) 
Histology (T/S, T) 
Pediatric Pathology± (P) 
Clinical Pathology 
Chemical Pathology (P, DLLS, T/S) 
Hematology (P, DLLS, T/S) 
Immunology (DLLS)  
Microbiology (P, DLLS, T/S) 
Histocompatibility* (P, DLLS) 
Immunohematology and Transfusion Medicine 
(P, T/S) 
- Hemapheresis** (T/S) 
- Apheresis** (T) 
Phlebotomy (T) 
Virology (T/S) 
 
Molecular Pathology 
Molecular Genetic Pathology (P, T/S) 
Cytogenetics (T/S)  
Molecular Diagnostics (DLLS) 
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Doctoral-level laboratory scientists have earned advanced degrees in such laboratory-related 
fields as clinical chemistry, immunology, genetics, or microbiology; some have also completed 
postgraduate fellowships.  They are often responsible for establishing new laboratory tests, 
interpreting test results, and ensuring accurate and appropriate test outcomes.8  Doctoral-level 
laboratory scientists can serve as laboratory directors, with responsibility for supervising the 
laboratory’s technical and scientific functions.9, 10  With greater automation of microbiological 
laboratory testing, doctoral-level laboratory scientists are shifting to emerging areas of laboratory 
testing involving genetics and pharmacogenomics. 
Technologists/Scientists and Technicians 
These laboratorians represent the two largest groups of laboratory professionals and can be 
involved in many aspects of laboratory specimen collection, preparation, and testing, depending 
on the nature of the test and their qualifications. 
Each group is referred to by interchangeable titles by professional organizations, educational 
programs, and other clinical laboratory professionals:    
 Medical technologists/clinical laboratory scientists (MT/CLSs)  
 Medical laboratory technicians/clinical laboratory technicians (MLT/CLTs) 
The largest certifier of laboratorians, the American Society for Clinical Pathology (ASCP), uses the 
titles of MT and MLT, whereas another certifier, the National Credentialing Agency for 
Laboratory Personnel (NCA), uses CLS/CLT.  In 2005, ASCP and NCA began discussing the 
formation of one credentialing agency for laboratory personnel and unifying professional titles.11, 
12  Discussions are ongoing.  
In order to minimize use of abbreviations and simplify terminology for this report, MT/CLSs will 
be referred to as technologists/scientists and MLT/CLTs as technicians.  Unless otherwise noted, use 
of these personnel titles includes individuals that have received general certification and those 
that have received subspecialty certification.   
Technologists/Scientists 
Technologists/scientists have earned a bachelor’s degree from an accredited college or university 
and have completed an accredited education program specific to medical technology or have met 
the education requirements and have obtained the laboratory experience defined by a certifying 
agency.13, 14  Their training allows them to conduct laboratory tests on tissues, blood, and other 
bodily fluids and perform a range of complex chemical, biological, hematological, and 
immunologic tests.15  In addition, they may evaluate and confirm the accuracy of test results, 
report laboratory findings to pathologists and other physicians, and develop and alter test 
procedures.15, 16  Technologists/scientists often advance to supervisory and 
managerial/administrative positions in which they provide day-to-day management of 
laboratory operations.              
Technologists/scientists can pursue additional education to become certified in the specific areas 
of laboratory medicine noted in the section on certification, below.   They may receive specialty 
certification in blood banking, chemistry, cytogenetics, cytology, hematology, 
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immunohematology, hemapheresis, histology, laboratory safety, microbiology, molecular 
pathology, and virology.13, 14  About 60% of technologists/scientists work in general medical and 
surgical hospitals, followed by 14% that work in independent laboratories, and 8% in physician 
offices, among other settings (see Figure 3.1).17  
Technicians  
Technicians perform less complex tasks under the supervision of a technologist/scientist.  They 
may prepare samples, operate automated analyzers, and perform manual laboratory tests in the 
areas of blood banking, chemistry, hematology, immunology, and microbiology.15  Technicians 
usually have an associate’s degree from an accredited college or university, with training from an 
accredited laboratory technician education program or the equivalent.13, 14  Technicians can pursue 
additional education to become certified as a technologist/scientist.13, 14   
About 43% of technicians are employed in general medical and surgical hospital settings, 16% in 
physician offices, and 14% in independent laboratories (Figure 3.1).18  
Figure 3.1:  Distribution of Settings of Work for Technologists/Scientists and Technicians 
Sources:  Occupational employment and wages, May 2006; Medical and clinical laboratory technologists. Washington, DC: Bureau 
of Labor Statistics, 2007. http://www.bls.gov/oes/current/oes292011.htm   
Occupational employment and wages, May 2006; Medical and clinical laboratory technicians. Washington, DC: Bureau of Labor 
Statistics, 2007. http://www.bls.gov/oes/current/oes292012.htm 
Pathologists’ Assistants 
Through special training, individuals may become pathologists’ assistants, who are often the first 
staff to look at an anatomic laboratory sample, provide the pathologist with a description of the 
sample, and assist in determining whether further analysis is required.19  Pathologists’ assistants 
perform a variety of tasks and are primarily responsible for gross examination of surgical 
pathology specimens and conducting autopsies.20  Prior to January 1, 2008, pathways to becoming 
a certified pathologist’s assistant included earning a bachelor’s degree and completing an 
accredited pathologists’ assistant program or completing three years full-time experience as a 
pathologists’ assistant under the supervision of a pathologist.19  This on-the-job training route has 
been discontinued; all certified pathologists’ assistants must now complete a formal training 
program in order to qualify for certification.  
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Histotechnologists/Histotechnicians 
Histotechnologists (HTLs) and histotechnicians (HTs) work in anatomic pathology laboratories to 
prepare tissue for microscopic examination by a pathologist.21  HTLs have advanced training in 
understanding how and why specimens are collected and processed.  They are responsible for 
solving technical and instrumental problems that may arise in the laboratory, understanding the 
reasons for unusual test results, and evaluating new laboratory techniques and procedures.  In 
order to qualify for certification as an HTL, individuals must have a bachelor’s degree and must 
complete an accredited HTL program or an associate degree and one year full time experience in 
a histopathology laboratory.13, 22   
Cytotechnologists 
Cytotechnologists are responsible for the microscopic examination of cell samples to detect signs 
of cancer and other diseases.23  Cytotechnologists specifically analyze cell changes, both in the 
nucleus and cytoplasm, and compare these changes to normal cells from the same site.  When 
findings for certain specimens are normal, cytotechnologists can issue the final laboratory report; 
when abnormal cells are detected, cytotechnologists work with pathologists to determine the final 
diagnosis.  Individuals must have a bachelor’s degree and complete an accredited cytotechnology 
educational program in order to become certified.24    
Medical Assistants 
Approximately 62% of medical assistants are employed in POLs.25  In this setting, medical 
assistants can be responsible for drawing blood and preparing laboratory specimens and 
performing basic laboratory tests.26  While some medical assistants receive on-the-job training, 
this is becoming less frequent, and medical assistants increasingly complete formal educational 
programs that include clinical and academic training in areas such as medical terminology, 
laboratory techniques, clinical and diagnostic procedures, and patient relations.25  Medical 
assistant educational programs must receive accreditation from designated agencies; graduates of 
these programs can apply for certification by organizations such as the American Association of 
Medical Assistants.      
WORKFORCE DEMOGRAPHICS 
Pathologists and Doctoral-Level Laboratory Scientists 
In 2005, there were an estimated 19,339 clinical and anatomic pathologists in the U.S.27 Of these, 
2,533 were residents and fellows in either discipline.  According to the Intersociety Committee on 
Pathology Information, 80% of pathologists work in community practice, 15% work in academic 
practice and medical school administration, 3% work in industry, and 1% hold government, 
public health, and regulatory positions.28  Data from 2006 show that slightly more than half of 
clinical and anatomic pathology residents and fellows were female and 34% were graduates of 
non-U.S. medical schools.6  While the percentage of female residents remained the same relative 
to 2005, approximately 37% of residents were graduates of non-U.S. medical schools in 2005.  
About 32% of full-time physician faculty members in clinical and anatomical pathology were 
female in 2006, compared to 31% in 2005. 
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According to the AMA, the pathologist workforce tends to be largely white (46% in 2005),27 with 
11% Asian, 3% Hispanic, 1.3% African American, 0.02% American Indian or Alaskan Native, and 
2% identified as other; race/ethnicity was not identified by 36% of respondents.  Figure 3.2 
compares race/ethnicity data for pathologists, technologists/scientists, and technicians.  These 
percentages are fairly representative of the ethnic and racial composition of the physician 
workforce as a whole.  The geographic concentration of clinical and anatomic pathologists is fairly 
evenly dispersed throughout the U.S.  In 2005, approximately 24% of the workforce was 
concentrated in the northeastern U.S., 22% were in the north central U.S., 34% were located in the 
southern U.S., and 19% were in the western U.S.29   
Demographic data for doctoral-level professionals in the laboratory medicine workforce are not 
available, though some rough inferences can be made from the profile of students receiving 
doctoral degrees in the life and physical sciences.  In 2003, 52% of students awarded a doctoral 
degree in the life sciences were male, as were 72% of students receiving doctoral degrees in the 
physical sciences.30, 31  More than 80% of life and physical science doctoral degree recipients 
identified themselves as white, non-Hispanic.  However, these percentages are shifting.  The 
percentage of women awarded degrees in the life and physical sciences has been increasing over 
the past several years.    
Figure 3.2:  Comparison of Racial and Ethnic composition of Laboratorians, 2005 
Sources:  Physician characteristics and distribution in the U.S., 2007 edition. Chicago, IL: American Medical Association, 2007.   
Employed civilians by occupation, sex, race, and Hispanic origin: 2005. Washington, DC: U.S. Census Bureau, 2005. 
http://www.census.gov/compendia/statab/tables/07s0602.xls 
Technologists/Scientists and Technicians 
The technologist/scientist and technician workforce also has a female majority and is more 
representative of the racial/ethnic makeup of the U.S. population.1  In 2006, there were an estimated 
160,760 technologists/scientists and 144,710 technicians employed in the U.S.17, 18  Of these 
professionals, 74% were female.32  The racial/ethnicity distribution of the combined laboratorian 
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groups was 69% white, 12% Asian, 11% African American, and 8% Hispanic (Figure 3.2).  In 2002, 
the last year in which such data is available, the median age of these laboratorians was 41.1   
The geographical distribution of technologists/scientists and technicians varies across the U.S.  
The Bureau of Labor Statistics defines workforce concentration as the number of people employed 
in a specific profession divided by the total number of people employed in all sectors in a defined 
geographic area.  Concentrations also vary by urban, suburban, and rural status, and may not 
reflect the state concentrations listed above.   
Based on data from multiple sources, the geographic distribution of these laboratorians is 
approximately as follows: 
 The five states with the highest workforce concentration of technologists/scientists are 
Massachusetts, South Dakota, Louisiana, Nebraska, and Pennsylvania.17  About 58% of 
technologists/scientists are employed in an urban environment, 24% work in suburban 
areas, and 18% are employed in a rural location.33   
 The five states with the highest concentrations of technicians are Massachusetts, 
Pennsylvania, Tennessee, Kansas, and Indiana.18   
VACANCY RATES 
There is significant concern across the laboratory medicine sector about the growing shortage of 
clinical laboratory workers, which is expected to worsen over the next decade, particularly for 
technologist/scientist and technician positions.1  Several factors are cited as contributing to this 
shortage: the pending retirement of many members of the workforce, competing career 
opportunities, and difficulty recruiting and retaining staff.1, 34  The effects of technological 
advancement on the workforce appear to be mixed.  While greater automation can decrease the 
need for personnel in the laboratory and enable non-laboratory personnel to perform tests, 
operating more advanced laboratory equipment can require more highly-trained 
technologists/scientists and technicians.  These effects may shift the skill sets required for 
laboratory personnel at all levels.15   
Pathologists and Doctoral-Level Laboratory Scientists 
Currently available data do not indicate a shortage of pathologists.35  However, virtually every 
academic department in the U.S. is reported to have a vacancy in pathology.28  According to the 
ASCP’s 2006 Resident Council Fellowship and Job Market Survey, 85% of respondents in their final 
year of residency or fellowship who had applied for a job had at least one offer of employment, an 
increase of 10% from the 2005 survey.36  The remaining 15% are reported to have taken fellowship 
positions.  Of those applying to pathology fellowship positions, 88% received at least one offer, a 
decrease from the 97% of applicants who were offered at least one fellowship in 2005.b 
Data on vacancies in doctoral-level laboratory scientists is not available, but anecdotal evidence 
from the American Board of Clinical Chemistry (ABCC) suggests that the number of individuals 
certified by the board each year has been decreasing over the past several years.37   
                                                     
b The decrease in the percentage of fellowship applicants who were awarded at least one fellowship is attributed to 
the increasing number of pathology residents applying for fellowships.36 
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Other Laboratory Personnel  
Vacancies for technologists/scientists and technicians, especially at the phlebotomist and 
cytotechnologist levels, are more extensive than for pathologists and doctoral-level laboratory 
scientists.  The ASCP Board of Registry has been collecting information on vacancy rates on a 
biannual basis since 1988.1  Their 2005 survey of wages and vacancies (Table 3.1) showed that 
vacancy rates for both were highest prior to 2002 before dropping in 2003.34  From 2003 to 2005, 
vacancy rates increased slightly for technologists/scientists at all levels (i.e., staff, supervisory, and 
managerial), and increased for technicians at the supervisory level (including phlebotomists).    
ASCP identified several trends in vacancy rates by laboratory setting: 
 Reference laboratories had higher-than-average vacancy rates for certified 
technologists/scientists and technicians.  
 Hospital-based laboratories reported slightly higher-than-average vacancy rates for 
phlebotomy staff and supervisors.   
 Vacancy rates for certified HTLs and HTs were higher for laboratories housed in 
facilities with 500 beds or more.  These laboratories also reported higher-than-average 
vacancy rates for certified technologists/scientists staff and supervisors.   
 Laboratories located in the northeastern U.S. reported high vacancy rates for certified 
HTLs.   
 Vacancies for certified technologists/scientists staff were higher than average in the far 
western and northeastern U.S., while vacancies for certified phlebotomy staff were 
highest in the far western U.S.c,34   
                                                     
c California recently began requiring certification of phlebotomists and imposing more stringent regulations 
regarding phlebotomy certification.38  The higher-than-average vacancy rate among phlebotomy staff in 
the far western U.S. may be attributable to California’s phlebotomy certification requirement.  
Laboratory Medicine: A National Status Report Chapter III – Laboratory Medicine Workforce 
 
May 2008  113 
Table 3.1:  Vacancy Rates for Various Clinical Laboratory Personnel Positions in the U.S. 
Selected Years 2000-2005   
Position 2000 2002 2003 2005 
Medical Technologist/Clinical Laboratory Scientist 
Staff 
Supervisory 
Manager 
11% 
13% 
13% 
7% 
6% 
4% 
4% 
3% 
2% 
6% 
4% 
4% 
Medical Laboratory Technician/Clinical Laboratory Technician 
Staff 
Supervisory 
14% 
n/a 
9% 
7% 
6% 
2% 
6% 
3% 
Phlebotomist  
Staff 
Supervisory 
18% 
n/a 
9% 
8% 
7% 
3% 
7% 
5% 
Histologist 
Histotechnician 
Histotechnologist 
Supervisory 
16% 
22% 
20% 
9% 
11% 
6% 
6% 
4% 
5% 
4% 
7% 
4% 
Cytologist 
Staff 
Supervisory 
21% 
10% 
8% 
6% 
4% 
2% 
3% 
2% 
Source: Steward CA, Thompson NN. ASCP 2005 wage and vacancy survey of medical laboratories. Laboratory 
Medicine 2006;37(8):465-469. 
Note:  Vacancy rates varied by geographic region.   
WAGES 
Pathologists 
Pathologists earn salaries comparable to other physicians.  Starting salaries for most pathologists 
exceed $125,000 per year and vary by geographic region and place of employment.3  The ASCP’s 
2006 job market survey asked pathology residents and fellows about their job offers.36  Of those 
respondents who had been offered a job, including both residents and fellows in their final year of 
training, 12% were offered less than $100,000 per year, 39% were offered a salary that ranged from 
$100,000 to $150,000, 44% were offered a salary between $150,000 and $200,000, and 5% were 
offered a salary greater than $250,000.  After their first and second year of training, another study 
of allied physicians found that pathologists earned a base salary of $169,000; those with more than 
three years of practice earned $321,000.d,39  In 2007, the Medical Laboratory Observer annual 
survey of 1,873 laboratory personnel found that the median annual salary of pathologists was 
$190,000.40  Table 3.2 provides summary datae compiled by the Modern Healthcare Physician 
                                                     
d This survey did not report whether figures represented median or average incomes. 
e The following surveys were included in the data:  American Medical Group Association: data from more than 32,000 
member medical group physicians in 123 specialties.  Hay Group: surveyed 98 organizations.  Hospital and 
Healthcare Compensation Service: 17,650 physicians in 44 specialties. Medical Group Management Association: 
40,295 physicians in more than 105 specialties.  Sullivan, Cotter and Associates: more than 175 organizations.  
Warren Surveys: more than 7,000 physicians in 32 specialties.  Merritt, Hawkins and Associates: 2,687 physicians. 
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Compensation Review of pathologist salary ranges from seven different survey instruments as 
reported in 2005.  
Table 3.2:  Comparison of Pathologist Salary Ranges to Other Physician Groups, 2005 
Physician Specialty Salary Range 
Pathology $193,477 - 350,286 
Anesthesiology $274,886 - 338,722 
Cardiology $287,907 - 387,800 
Internal Medicine $163,250 - 180,800 
Obstetrics/Gynecology $222,838 - 275,800 
Oncology $241,628 - 320,200 
Pediatrics $144,000 - 184,900 
Radiology $209,365 - 411,131 
Source:  2005 Modern Healthcare Physician Compensation Review. Irving, TX: Merritt, Hawkins & Associates, 2005. 
Doctoral-Level Laboratory Scientists 
Although salary information specifically for doctoral-level laboratory scientists is unavailable, 
surveys of laboratory directors and laboratory professionals with postgraduate degrees have been 
conducted.  A 2004 survey of 2,128 laboratory professionals conducted by Medical Laboratory 
Observer found the median salary for laboratory directors was $86,238, approximately 3% greater 
than the median salary reported in the 2003 survey.41, 42  Median salary for laboratory 
professionals with a postgraduate degree was $76,454. 
In addition, several organizations track salary information for professionals who have achieved 
doctoral-level chemistry and toxicology degrees.  A 2006 salary survey conducted by the 
American Chemical Society, completed by 8,580 respondents, found that the median base salary 
for professionals with doctoral-level chemistry degrees was $95,000.43  Average annual salaries 
increased by 3.4% between 1996 and 2006, adjusting for inflation. A 2004 survey of individuals 
with doctoral-level degrees in toxicology conducted by the American College of Toxicology and 
the Society of Toxicology found that salary varied by years of experience following terminal 
degree and by sex.44  Mean annual salary for individuals employed in contract laboratories with 
three to five years experience was $81,000 for men and $90,000 for women; mean annual salary for 
individuals employed by the federal government with three to five years experience was $78,000 
for men and $75,000 for women.        
Technologists/Scientists and Technicians 
Significant differences in salary for technologists/scientists are based on education, geographic 
location, job function, and work experience.40  Nationally, annual salaries in 2005 ranged from 
$24,419 for staff phlebotomists to $66,539 for technologist managers.34  Laboratory employees with 
a postgraduate college degree made about $22,000 more than employees with a high school 
diploma.  Table 3.3 provides specific wage information delineated according to position.   
ASCP found that the median average hourly salaries for personnel working in hospital-based and 
reference laboratories were more likely to be higher than personnel working in POLs.34  Salaries 
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also were higher in larger laboratories whose test volume exceeded one million tests per year.  
Other data indicate that most laboratory technologists/scientists working with management and 
technical consulting services earned higher wages.  Yet, laboratory managers and administrators 
and information systems managers earned more money on average than medical technologists, 
section managers and section manager supervisors.40   
Geographic assessment of wages indicate that California, Alaska, and Nevada were the top-
paying states for technologists/scientists, whereas Rhode Island, Alaska, and Hawaii were the 
top-paying for laboratory technicians.17, 18  Conversely, professionals working in the mountain 
and southeast areas of the U.S. were paid less on average than those in other regions.   
Table 3.3:  Median Average Wages for all 
Clinical Laboratory Positions and Levels in the U.S., 2005 
Position Median Average Annual Salary* 
Technologist/Scientist 
Staff 
Supervisory 
Manager 
$44,762 
$53,997 
$66,539 
Technician 
Staff 
Supervisory 
$35,838 
$41,642 
Phlebotomist  
Staff 
Supervisory 
$24,419 
$34,923 
Histologist  
Histotechnologist 
Histotechnician 
Histotechnican- Supervisory 
$44,990 
$38,418 
$54,018 
Cytologist 
Staff 
Supervisory 
$54,434 
$63,523 
*Median average annual salary calculated from median average hourly wage using 
assumption that employees are working 2,088 hours per year, or 40 hours per 
week for 52 weeks.  
Source: Adapted from Steward CA, Thompson NN. ASCP 2005 wage and vacancy 
survey of medical laboratories. Laboratory Medicine 2006;37(8):465-469. 
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EDUCATION, TRAINING, AND RECRUITMENT 
Medical Schools  
The educational requirements for pathologists, whether for an Doctor of Medicine (MD) degree or 
Doctor of Osteopathy (DO) degree,  match those of all medical doctors, which include pre-
medical school requirements, four years of medical school, and three-to-six years of post-graduate 
training.3, 45  For purposes of comparison, allopathic medicine (traditional medicine) is 
characterized as using remedies to counter the effects produced by the disease and emphasizes 
diagnosis and treatment of specific diseases within the body.46, 47  Traditional allopathic medical 
school curricula consist of two years of basic science education and two years of clinical rotations.  
Osteopathic medicine is characterized by its emphasis on the connection between structure and 
function and the body’s inherent ability to heal itself.48  Similar to MDs, doctors of osteopathic 
medicine can choose any medical specialty, prescribe drugs, perform surgery, and practice 
medicine anywhere in the U.S.49  Schools for osteopathic medicine also require two years of basic 
science education followed by two years of clinical clerkships and three-to-six years of post-
graduate training.50 
Current data indicate that: 
 There are 148 medical schools in the U.S., of which 125 teach allopathic medicine and 
23 teach osteopathic medicine.51, 52  In 2006, an estimated 69,167 students were enrolled 
in allopathic medical schools, a 5% increase since 2002.53  Male-female ratios were 
relatively even (49% female).  
 Enrollment in osteopathic schools of medicine, which totaled 13,406, grew at a 
substantially higher rate of 17% during this same period.54, 55  Approximately 50% of all 
osteopathic medical school students were female. 
The need for more physicians in the U.S. and predictions of physician shortages are contributing to 
a push for increased enrollment in medical schools.  The Council on Graduate Medical Education, 
an advisory group to the Health Resources and Services Administration, has recommended that 
allopathic and osteopathic medical schools increase their enrollment by 15% from their 2002 levels 
over the next 10 years, both by expanding the size of first-year classes and by building new medical 
schools.56  Emphasis on recruitment and enrollment are proving successful.  
 In 2007, a total of 42,315 people applied to allopathic medical schools, an increase of 8% 
since 2006.57  Earlier data (2005) found a similar trend with osteopathic medical 
schools, which received 8,258 applications, a 14% increase over the previous year.58   
 Actual enrollments in medical school are projected to increase.  First-year enrollment in 
allopathic medical schools is expected to increase by 17% to nearly 19,300 students by 
2012.59  Osteopathic medical school enrollment may double between 2002 and 2015.60   
Residency and Fellowship Programs 
Following medical school, allopathic and osteopathic graduates can apply to pathology 
residency programs through the National Residency Match Program (NRMP), which is a 
private, not-for-profit corporation that provides a uniform date of appointment to all entering 
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medical residents.61  The length of time required to complete residency and post-graduate 
training in pathology ranges from three to six years, depending on field of pathology in which a 
physician is specializing.45  Residency programs that combine clinical and anatomic pathology 
require four years of training, while those that focus on either clinical or anatomic pathology 
require three years.  Training in a specific pathology subspecialty requires an additional year, 
with the exception of neuropathology which requires an additional two years.  Residency 
programs for pathology have not been developed by osteopathic-related organizations. As a 
result, osteopathic graduates must enter NRMP allopathic residency programs in order to 
practice pathology.  However, the Osteopathic Postdoctoral Training Institute-Westf is 
developing pathology residencies in California and Oregon.62, 63   
Residency Programs 
As of 2007, there were 150 NRMP-accredited anatomic and clinical pathology residency 
programs.6  In 2006, there were an estimated 2,603 active pathology residents and fellows.36  There 
are notable differences in trends between the 2001-2005 and 2005-2007 periods, as follows.   
 The total number of pathology residency positions offered through the NRMP 
increased from 383 to 526 positions from 2001 to 2005, but decreased by 13 positions 
between 2005 and 2007.64 
 The number of allopathic medical school seniors entering pathology residency 
programs increased by an average of 19% annually from 2002 to 2005, but decreased by 
an average of 5% from 2005 to 2007.65  Still, only about 2% of all medical students enter 
pathology residencies.64    
 Allopathic seniors filled 50% of pathology residency positions in 2002, and 55% in 
2007.64 Graduates of international and osteopathic medical schools and prior graduates 
of allopathic medical schools filled approximately 34% of pathology residency 
positions in 2002 and 33% in 2007.64, 65  
 Approximately 9% of pathology residency positions remained vacant in 2007, 
compared to 16% in 2002.   
 Fewer than 1% of osteopathic graduates have chosen a career in pathology during the 
past 10 years.54  
Fellowship Programs 
Following completion of a pathology residency, many physicians pursue specialty training through 
fellowship programs.  According to the ASCP’s 2006 job market survey, which was completed by 
742 residents in their final year of training, 702 applied for fellowships.36  More than half of 
respondents attributed their pursuit of fellowship training to their long-term career interests; 29% 
indicated that the completion of a fellowship was necessary to secure eventual employment in their 
desired position.  Subspecialty training programs and enrollment for residents and fellows for 
pathology programs leading to subspecialty certification are provided in Table 3.4.       
                                                     
f Osteopathic Postdoctoral Training Institute is an educational consortium with 8 member institutions that supports 
osteopathic graduate medical education programs in the western U.S. 
Laboratory Medicine: A National Status Report Chapter III – Laboratory Medicine Workforce 
 
May 2008  118 
Table 3.4:  Number of Accredited Pathology Specialty Programs and Total Number of 
Active Residents/Fellows in Program in the U.S., 2006g 
Pathology Specialty 
Number of 
Accredited Programs 
Total Number of Active 
Residents/Fellows in Program 
Blood Banking/Transfusion Medicine 46 36 
Chemical Pathology 3h 2 
Cytopathology 85 109 
Dermatopathology 47 51 
Forensic Pathology 38 28 
Hematology 77 88 
Medical Microbiology 12 9 
Molecular Genetic Pathology 18 12 
Neuropathology 35 38 
Pediatric Pathology 25 18 
Source:  FREIDA online specialty training statistics information. Chicago, IL: American Medical Association, 2005.  Accessed 
February 28, 2007.  http://www.ama-assn.org/vapp/freida/spcstsc/0,1238,300,00.html.  
Doctoral-Level Laboratory Science Programs 
Professionals can enter the laboratory workforce as graduates of doctoral programs in laboratory-
related fields such as clinical chemistry, toxicology, and microbiology.  Requirements for entry 
into doctoral programs vary according to the institution, but most U.S. science graduate programs 
require applicants to have completed a bachelor’s and/or master’s degree and required entrance 
examinations.67, 68   
Doctoral study typically involves three stages of academic work.69  The first stage consists of 
preliminary course, seminar, and laboratory studies.  The second stage includes a set of advanced 
seminars and consortia during which students select a dissertation subject and design their 
research.  Independent research as well as the writing, presentation, and defense of the thesis 
encompass the final stage of doctoral education.  A doctorate of philosophy or doctorate of 
sciencei in a laboratory-related subject area is required for board certification.70, 71        
Most laboratory doctoral scientists also complete postdoctoral fellowships that last one or two years 
and prepare them to serve as a director and/or laboratory consultant in a variety of laboratory 
settings, including microbiology, immunology, and public health laboratories.72  Postdoctoral 
fellowship programs are accredited by a variety of professional societies.  For example, there are 
currently 12 postdoctoral training programs located in medical centers across the U.S. approved by 
the American College of Microbiology’s Committee on Postgraduate Educational Programs.73  The 
Commission on Accreditation in Clinical Chemistry currently accredits postdoctoral fellowship 
training programs at 18 institutions across the U.S. and Canada.74   
                                                     
g There is no subspecialty certification program for surgical pathology; therefore, it was not included in this table. 
h The Accreditation Council for Graduate Medical Education only recently began accrediting chemical pathology 
programs and, thus, the number of programs is currently low but expected to increase in coming years.66   
i In some cases, individuals who have earned a doctoral-level degree in osteopathic medicine, veterinary medicine, 
public health, or dental surgery can be accepted for board-level certification as a doctoral-level laboratory scientist if 
they have met the requirements for postdoctoral training and laboratory-related experience.70  
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A total of 15,560 doctoral degrees were awarded in biology, biomedicine, health and clinical 
science, physical science, and science technologies during the 2004-2005 academic year, an 
increase of approximately 16% relative to 2003-2004.75  About 61% were awarded by public 
universities.  Degrees awarded in these areas represent approximately 28% of all doctoral degrees.  
This percentage is representative of the overall increase in doctoral degrees awarded over the past 
25 years, as life sciences doctorates have increased 57% and physical sciences doctorates have 
increased 30%.30, 31  However, these professionals are not necessarily eligible to perform the duties 
of a doctoral-level laboratory scientist.     
ASCLS and other organizations are developing educational programs that lead directly to a 
doctorate in clinical laboratory science (DCLS).76  The DCLS would provide an alternative to 
traditional master’s and research-based doctoral degrees.  The National Accrediting Agency for 
Clinical Laboratory Sciences (NAACLS) approved standards for accreditation of DCLS programs 
in September 2006 and began reviewing applications for programs interested in offering the 
DCLS degree in April 2007.77     
Technologist/Scientist and Technician Education Programs 
Educational requirements for technologists/scientists are more stringent than those for 
technicians.  Becoming a technologist requires a bachelor’s degree in medical technology, clinical 
laboratory science, or one of the life sciences.1, 15  Technicians, on the other hand, typically have an 
associate’s degree from a junior or community college or  training from a hospital, a technical or 
vocational school, or from the U.S. Armed Forces.15  It also is possible to become a technician 
without obtaining an associate’s degree by completing required coursework in biology and 
chemistry at an accredited college or university.13  Along with formal training, both 
technologists/scientists and technicians must complete additional clinical education in a medical 
technology or clinical laboratory science program accredited by NAACLS.j,16  Depending on the 
state in which they practice and the setting in which they work, further training beyond these 
requirements may be necessary. 
As depicted in Figure 3.3, the majority of these educational opportunities are provided in 
hospital-based programs, universities, and community colleges.78  There are clear differences in 
educational sites between technologist/scientist programs and technicians.  
                                                     
j Depending on the route followed, not all certified technologists/scientists and technicians complete NAACLS-accredited 
programs.  For example, some technicians have an associate’s degree or 60 semester hours of academic credit, have 
completed required coursework, and have completed a 50-week U.S. military medical laboratory training course. 
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Figure 3.3:  Educational Program Settings for Technologists/Scientists and Technicians, 
2006 
Source:  Bugbee AC. ASCP Board of Registry’s 2006 annual survey of medical laboratory science programs. Lab Medicine, 
2007;38(8):463-471 
Programs 
All technologist/scientist and technician education programs must be accredited by the NAACLS 
or the Commission on Accreditation of Allied Health Education Programs.1  NAACLS accredits 
more than 469 programs for technologists/scientists and technicians, HTLs, HTs, pathologists’ 
assistants, diagnostic molecular scientists, cytogenetic technologists, and phlebotomists.15, 79  The 
Commission on Accreditation of Allied Health Education Programs accredits 47 programs in 
cytotechnology and 15 programs for blood banking specialists.80, 81  Figure 3.4 portrays trends in 
the numbers of NAACLS-accredited education programs for specific laboratory professional 
groups between 1970 and 2007.  Among these trends:   
 The number of education programs for technologists/scientists and technicians have 
declined since 1975, and enrollment in these programs has declined over 50% since 
1980.  (See discussion on student population.)1, 82   
 The most dramatic decline has been in technologists/scientists programs, 
approximately 71% of which closed between 1970 and 2007.83  Four programs closed 
between 2006 and 2007 alone.   
 From 1985 to 2007, the number of technician education programs declined by 
approximately 27.0%.  However, four new programs were created during 2006-2007.    
 Declines in the number of education programs fall into specific disciplines. The 
number of HTL and HT programs diminished from 49 in 1983 to 30 in 2006, a decline 
of 38.8%, while the number of phlebotomy training programs increased six-fold, from 9 
to 58 from 1987 to 2003. 
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Figure 3.4:  Trend in Number of NAACLS-Accredited Education Programs in 
Clinical Laboratory Sciences, 1970-2007 
Source:  NAACLS table of program and graduate numbers.  Tice D, ed.  Chicago, IL: National Accrediting Agency for the Clinical 
Laboratory Sciences, 2007.   
A variety of factors have affected the laboratory medicine educational programs.  The Medicare 
Prospective Payment System changed the hospital payment structure such that clinical laboratories 
(including outreach testing), once a source of revenue, became cost centers.82  Increases in treatment 
via the outpatient setting further decreased hospital revenue by diminishing the number of 
inpatients requiring laboratory tests.  Other factors often cited as reasons for the decline in 
laboratorian education programs include their operating expenses, the number of different 
instructors and faculty members required, and the lack of outside funding.  The decreasing number 
of students entering laboratorian education programs is attributed to additional factors.  
Historically, women have dominated the technologist/scientist  and technician workforce; 
however, as wider employment opportunities have arisen, they have been entering other positions 
in science and medicine.  Salary and career advancement opportunities associated with laboratory 
medicine often are less desirable than those in other health-related industries.  Work schedules for 
laboratorians, which can require long hours and overnight shifts, may be less attractive than for 
some other health professions and other competing employment opportunities.1, 84  
Curriculum 
Due to the changing nature of laboratory medicine (e.g., increases in genetic testing, increased 
use of technology systems and automation), more than half of all medical laboratory science 
program directors have reported changes to the educational curriculum in 2002, the last year 
that this data was reported by ASCP.  Among programs reporting curricular changes, 
approximately 24% adjusted molecular science content, 18% changed management skills 
content, and 15% altered online content during the 2002-2003 academic year (Figure 3.5).85  
Fewer than 5% of programs reported deleting any curricular content.  The long-term benefit of 
these changes is unclear at this time. 
0
100
200
300
400
500
600
700
800
900
1970 1977 1983 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007
Year
N
um
be
r 
of
 A
cc
re
di
te
d 
Pr
og
ra
m
s
Technologists/Scientists Technicians Histotechnologists/Histotechnicians
Laboratory Medicine: A National Status Report Chapter III – Laboratory Medicine Workforce 
 
May 2008  122 
Proposals for widespread, systemic changes include raising awareness of clinical laboratory 
professional’s role in health care, lowering the operational costs of training programs (e.g., 
incorporating distance learning, founding education programs at independent laboratories), 
and educating laboratory professionals in new technology-related areas such as POCT and 
informatics.1, 82  
Figure 3.5:  Percentage of Technologist/Scientist and Technician Programs 
Reporting New Content to Curricula, 2002  
Source:  Ward-Cook K, Chapman S, Lindler V. Executive summary: 2002 annual survey of accredited/approved medical 
laboratory science programs. Chicago, IL: American Society for Clinical Pathology, 2002.  
http://www.ascp.org/Certification/ForProgramDirectors/research/documents/Svy02.pdf 
Student Population  
Enrollment 
Data on the number of students entering technologist/scientist, technician, and HT/HTL 
programs are available only through 2002.k  In this year, a total of 4,782 students entered 
NAACLS-accredited programs for technologist/ scientist, technician, and HT/HTL.1, 83  In that 
year, 3,974 graduated.   
Of students entering laboratory medicine education programs, 40% entered technologist/scientist 
programs, 54% entered technician programs, and over 5% entered HT/HTL programs.  
Recruitment efforts targeting minorities and males have resulted in recent increases in enrollees 
for blood banking and histotechnology.  Given the importance of active recruitment, about half of 
programs have staff and one-third have special budgets dedicated to recruiting new students. 
                                                     
k Although NAACLS collects enrollment data, there are discrepancies in defining point of enrollment that affect 
counts (i.e., according to when the enrollee begins their educations, enters the professional sequence, or enters the 
clinical sequence).  For this reason, this enrollment data are used only internally by NAACLS.83 
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A 2006 survey that examined medical laboratory science program directors’ perceptions of the 
quality of applicants found that about 40% perceived no change in quality, 21% perceived an 
increase in quality, and 13% perceived a decrease in quality.  The remaining 27% gave more than 
one answer to this question.  Figure 3.6 provides a comparison of program directors’ perceptions 
in 2002 and 2006.78, 85       
Figure 3.6:  Change in Quality of Applicants as Perceived by 
Laboratory Science Program Directors, 2002 and 2006 
Note: Percentages for 2006 do not add to 100 because some respondents gave more than one answer. 
Sources:  Ward-Cook K, Chapman S, Lindler V. Executive summary: 2002 annual survey of accredited/approved medical 
laboratory science programs.  Chicago, IL: American Society for Clinical Pathology, 2002.  
http://www.ascp.org/Certification/ForProgramDirectors/research/documents/Svy02.pdf 
Bugbee AC. ASCP Board of Registry’s 2006 annual survey of medical laboratory science programs.  Lab Medicine 2007;38(8):463-471. 
Graduates 
There have been two periods of steep decline in the number of graduates from laboratory 
education programs.  The first was a decrease of 42% that occurred from 1977 to 1990; the second 
was a decrease of 45% that occurred from 1994 to 2002.83  Since 2002, the number of graduates has 
increased steadily by about 7% per year.  Figure 3.7 shows the student populations graduating 
from NAACLS-accredited technologist/scientist, technician, and HT/HTL programs for the years 
1970 through 2006. 
Concerted efforts to promote laboratory programs have succeeded in increasing some graduate 
rates.  Since 2002, the numbers of technologist/scientist and technician graduates have increased 
30% and 33%, respectively.83  The number of HT/HTL graduates increased by 17% from 2001 to 
2003, then declined by 11% from 2004 to 2006.  As noted above, these changes have accompanied 
the decrease in number of programs. 
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Figure 3.7:  Graduates of NAACLS-approved Technologists/Scientists, Technicians, and 
Histotechnologists/Histotechnicians Programs by Program, 1970-2006 
Source:  NAACLS table of program and graduate numbers. Tice D, ed. Chicago, IL: National Accrediting Agency for the Clinical 
Laboratory Sciences, 2007.   
LICENSING AND CERTIFICATION 
State licensure and certification requirements for laboratory directors are embodied in the CLIA 
regulations and are based on the type of testing performed in the laboratory.  Laboratories 
performing only waived tests do not have requirements for laboratory directors or other 
personnel.86     
Licensure 
Licensure, sometimes referred to as “right of practice,” is the most restrictive form of professional 
and occupational regulation.1  CLIA requires state licensure for individuals serving as directors of 
PPM laboratories and clinical consultants and for individuals with MD or DO degrees serving as 
directors of non-waived laboratories.9, 87, 88  Under CLIA, laboratory personnel performing PPM 
testing must also be licensed to practice in their state.89  CLIA does not require licensure of 
doctoral-level laboratory scientists.      
Pathologists 
As with all physicians, pathologists must receive a medical license to practice.  Licensure for 
physicians is granted by state boards of medicine and is required to guarantee to the public that a 
physician has successfully completed medical education and passed an examination or other form 
of certification demonstrating competency and appropriate qualifications to practice medicine.90  
All states, the District of Columbia, and the U.S. territories, a total of 54 jurisdictions, require 
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physicians to be licensed before they can legally practice medicine.91,l  A license is necessary for 
each state in which a physician wishes to practice.  According to the Federation of State Medical 
Boards and the Bureau of Labor Statistics, physicians must provide proof of graduation from an 
accredited medical school, complete at least one year of residency training, and pass a licensing 
examination.90, 91  Physicians who were educated outside of the U.S. or Canada are required to 
complete a residency in the U.S. prior to obtaining a license to practice medicine in the U.S., even 
if they are licensed to practice in another country.90   
There are no licensure requirements for doctoral-level laboratory scientists. 
Technologists/Scientists and Technicians 
In recent years, several state-based initiatives have been undertaken to institute licensure 
requirements for technologists/scientists and technicians.   Table 3.5 summarizes current status of 
licensure activities.   
Table 3.5:  Status of Licensure Requirements for 
Technologists/Scientists and Technicians by State, 2007 
Licensure of Laboratory 
Personnel Required 
Licensure Legislation 
Introduced/Will Be Introduced in 
Next Legislative Session 
Considering a Licensure 
Initiative 
California 
Florida 
Georgia 
Hawaii 
Louisiana 
Montana 
New York 
Nevada 
North Dakota 
Rhode Island 
Tennessee 
West Virginia 
Puerto Rico 
Illinois 
Massachusetts 
Michigan 
Minnesota 
Missouri 
Ohio 
Texas 
Indiana 
Iowa 
Nebraska 
Virginia 
Wisconsin 
Source: Garrott P.  American Society for Clinical Laboratory Science.  Personal communication.  December 10, 2007. 
In licensure states, laboratorians can practice only in the areas for which they are licensed.  
Employers can hire only licensed individuals to complete tasks within the defined scope of the 
licensure.  However, the provisions governing licensure can vary by state.  Most states require 
licensed personnel to pay an annual or bi-annual licensing fee, participate in continuing 
education, and meet minimum educational and professional competency requirements.93  Some 
states require fingerprinting, documentation of certification from an accredited certifying agency, 
and documentation of a defined number of hours of continuing education.   
                                                     
l State medical boards can prepare their own licensing examinations or they can administer one prepared by and 
purchased from a specialized agency, such as the U.S. Medical Licensing Examination or the Comprehensive 
Osteopathic Medical Licensing Examination.92 
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Certification  
Under CLIA, board certification is required for doctoral-level laboratory scientists, who are not 
previously grandfathered, to serve as laboratory directors or clinical consultants for non-waived 
testing laboratories.9, 87  Some routes by which a pathologist can serve as a laboratory director 
also require board certification.9, 87  Certification is a voluntary process for other clinical 
laboratory personnel (i.e., pathologists, technologists/scientists, and technicians) by which 
nongovernmental agencies grant recognition to professionals whose levels of competence meet 
specific standards.9, 15, 87, 94, 95 
Pathologists 
Physicians wishing to practice a medical specialty in the U.S. can seek certification from 24 
nationally recognized medical specialty boards.96  Certification of physicians practicing in a 
specialty is recognized by physicians, health care institutions, insurers, and patients as proof of a 
physician’s knowledge and skills.  Although physician certification is not required by law, some 
health care plans provide additional benefits and recognition to physicians who are board 
certified and who maintain their certification.97   
The American Board of Pathology (ABP), under the American Board of Medical Specialties, 
provides primary certification in clinical pathology, anatomic pathology, or both.m  ABP also 
offers certification in 10 pathology subspecialties.99  Examinations comprise written and practical 
components, both of which candidates must pass in the same sitting.99  In order to apply for ABP 
certification, applicants must have graduated from a U.S. or Canadian medical school accredited 
by the Liaison Committee on Medical Education or from an osteopathic medical school accredited 
by the Bureau of Professional Education of the American Osteopathic Association (AOA).  
Applicants for primary and subspecialty certification also must provide proof of valid licensure to 
practice medicine in a state or jurisdiction of the U.S. or Canada.  
The American Osteopathic Board of Pathology (AOBP), part of the AOA, is responsible for 
evaluation and recommendation of osteopathic physician candidates for certification in anatomic 
pathology, laboratory medicine, and forensic pathology.100  In order to receive AOBP certification, 
candidates must be a graduate of an AOA-accredited college of osteopathic medicine, licensed in 
the state or territory of practice, a member of the AOA or the Canadian Osteopathic Association 
for two years prior to the date of certification, complete one year of AOA-approved internship 
plus four years of additional training in clinical or anatomic pathology, and provide evidence of 
conformity to the AOA Code of Ethics.101   
Effective January 1, 2006, all primary and subspecialty certificates issued by the ABP expire after 
10 years.102  Pathologists must fulfill requirements in key areas to be recertified.n  Pathologists 
who received ABP certification prior to this date can participate in the maintenance of certification 
                                                     
m The ABP administers all certification examinations in computer-based format at the APB Examination Center in 
Tampa, FL.98  Primary certification examinations are offered twice a year; pathology subspecialty certification 
examinations in pathology, medical microbiology, molecular genetic pathology, neuropathology, and pediatric 
pathology are given every two years.   
n ABP recertification requirements include: proof of unrestricted license to practice medicine; participation in 
continuing medical education; completion of a recertification exam; and provision of peer attestations of 
interpersonal and communication skills, professionalism, ethics, and effectiveness in systems-based practice. 
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program on a voluntary basis.  Similarly, on January 1, 1995, AOBP’s recertificationo requirements 
for osteopathic pathologists became valid for 10 years.  However, for those certified prior to 1995, 
recertification is voluntary.     
Doctoral-Level Laboratory Scientists 
CLIA requires board certification for all doctoral-level laboratory scientists who are serving as a 
laboratory director and clinical consultant.  Four organizations are currently approved by DHHS 
to certify doctoral-level laboratory scientists: 
 American Board of Bioanalysis 
 American Board of Clinical Chemistry 
 American Board of Medical Laboratory Immunology 
 American Board of Medical Microbiology 
Candidates must demonstrate appropriate education, postdoctoral training, and laboratory 
experience.70, 71, 103, 104  The length of training or experience required varies by board and by the 
educational route chosen by the candidate (e.g., completion of a postdoctoral fellowship), but 
most boards require a minimum of three years of postdoctoral experience prior to certification.  In 
some cases, individuals who participate in postdoctoral fellowships are eligible to apply for early 
admission to the examination.  For example, applicants who have completed at least one year of a 
postdoctoral clinical chemistry training program accredited by the Commission of Accreditation 
in Clinical Chemistry are eligible to take the ABCC certification examination prior to completing 
their fellowship.p,103   
Candidates who have met all certification requirements are eligible to take a written certification 
exam.  Candidates who pass the examination are recognized as diplomates.  All four boards 
require diplomates to participate in continuing education programs in order to maintain 
certification.  Table 3.6 displays the number of diplomates certified by each board in 2007 and the 
total number of active diplomates certified by each board. 
The ABCC reports that, over the past 15 years it, has certified an average of 11 diplomates in 
clinical chemistry, 2 diplomates in toxicology, and 2 diplomates in molecular diagnostics.37  
According to this and other organizations, the number of diplomates has been decreasing over the 
past several years.  As in other areas of laboratory medicine, the decrease is attributed to increases 
in use of advanced technology systems in the laboratory and market consolidation.  Anticipated 
retirement of a significant number of doctoral-level laboratory scientists over the next several 
years is expected to increase the demand for new diplomates.  
                                                     
o For AOBP recertification, osteopathic pathologists must: hold certification for at least 8 years; present written 
evidence of continuous compliance with the initial requirements of the AOA for specialty certification; and 
submit documents that provide evidence of having attended, presented, or participated in at least 75 hours of 
education programs, seminars, lectures, or other academic sessions relating to pathology or a division of 
pathology during the preceding three-year period. 
p After obtaining certification, these applicants must complete their fellowship and meet all requirements before 
becoming a director of a high complexity laboratory or a clinical laboratory consultant. 
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Table 3.6:  Number of Diplomates Certified in 2007 and Total Number of 
Active Diplomates by Doctoral-Level Laboratory Scientist Certification Boards         
 
Number of Diplomates 
Certified in 2007 
Total Number of 
Active Diplomates 
American Board of Bioanalysis Not Available Not Available 
American Board of Clinical Chemistry 16 346 
American Board of Medical Laboratory Immunology 3 72 
American Board of Medical Microbiology 25 310 
Sources:  ABCC register of active diplomates.  Washington, DC: American Board of Clinical Chemistry, 2007.   
ASM ABMLI diplomates database.  Washington, DC: American Board of Medical Laboratory Immunology, 2007.   
ASM ABMM diplomates database.  Washington, DC: American Board of Medical Microbiology, 2007.   
Technologists/Scientists and Technicians 
Voluntary certification is the professional standard for technologists/scientists and technicians.  
Some employers require that employees maintain their certification for the duration of their 
employment.  Organizations offering certification for these laboratorians include the: 
 Board of Registry of the American Society for Clinical Pathology 
 National Credentialing Agency for Laboratory Personnel 
 Board of Registry of the American Association of Bioanalysts 
 American Medical Technologists 
 National Registry of Clinical Chemistry  
 National Registry of Microbiologists1   
 State certification programs, such as that in California105 
The ASCP and the NCA provide the majorityq of certifications for technologists/scientists and 
technicians.1  In 2006, ASCP certified 2,050 new technologists/scientists and 1,479 new 
technicians.  From April 2006 through March 2007, NCA certified 312 new 
technologists/scientists and 121 new technicians.106, 107  
Technologists/scientists can earn ASCP specialty certification in blood banking, chemistry, 
cytology, hematology, histology, microbiology, hemapheresis, laboratory safety, virology, and 
molecular pathology.13  In some instances, categorical certification in one of these areas can be 
obtained without first becoming a certified (general) medical technologist/clinical laboratory 
scientist.  For technicians, ASCP certification is available in apheresis, phlebotomy and donor 
phlebotomy, and histology.   
In 2004, the ASCP initiated a certification maintenance program that extends three years and 
initially applied only to newly certified individuals in the entry level categories.108  However, the 
requirement was extended to all individuals in 2006.  ASCP certification maintenance varies 
                                                     
q As of December 2006, the ASCP had certified a total of 223,958 technologists/scientists and 70,674 technicians.106  
NCA does not track the total number of professionals certified.107  In general, among first-time takers of 
certification examinations, ASCP certifies approximately 2,000 technologists/scientists and 1,300 technicians each 
year, while NCA certifies approximately 655 technologists/scientists and 200 technicians annually.1 
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according to certification type but generally involves participation in formal or employer-based 
continuing education courses relating to various aspects of the laboratory.  The NCA began 
requiring certification renewal in 1980 via continuing education or re-examination.109  
Recertification by either method extends NCA certification by three years.   
CONCLUSIONS 
Clinical laboratories conducting non-waived testing typically are staffed with a medical team 
comprising pathologists, doctoral-level laboratory scientists, technologists/scientists, and 
technicians.  While some of the tasks they perform on a daily basis may overlap, the contributions 
and responsibilities of each differ in several ways.    
 Pathologists (medical doctors) and doctoral-level laboratory scientists operate at the 
highest levels within clinical laboratories, often serving as laboratory directors 
responsible for staff oversight, testing processes, quality control procedures, quality of 
patient care, and other functions.  In 2005, there were an estimated 19,339 pathologists 
in the U.S.; 80% work in community practice.  Minorities are under-represented in the 
discipline of pathology with 10% identified as Asian, 3% Hispanic, and 1% African 
American. Slightly over half of pathology residents are female. 
 Approximately 160,760 medical technologists/scientists and 144,710 technicians were 
employed in the U.S. in 2006. While this workforce also is female dominated (74%), it is 
more representative of the diverse ethnic make up of the population with 12% Asian, 
11% African American, and 7% Hispanic.  Geographically, 58% of 
technologists/scientists work in an urban setting, 24% in suburban, and 18% in rural.     
 Overall, the number of technologist/scientist and technician education programs has 
declined by over 50% since 1970, with the most dramatic decline in 
technologist/scientist programs—71% closed between 1970 and 2007.  In contrast, the 
number of phlebotomy programs increased six-fold from 1987 to 2003.  Factors 
contributing to the changes include decreases in hospital revenues resulting from 
changes to the Medicare payment system as well as the expense of operating clinical 
laboratory science programs.   
 Current enrollment in specialized technologist/scientist and technician educational 
programs is lowest in blood banking and histotechnology.   However, recent recruiting 
efforts programs appears to be effective, specifically those targeted at recruiting 
minorities and male students, raising awareness of laboratory careers among students, 
and dedicating program staff and budget specifically to recruitment.   
 At present, 12 states and one territory require licensure of technologists/scientists and 
technicians, and 12 other states are involved in some phase of licensure activity.  
However, the specific requirements for licensure vary by state. 
Gaps, Needs, and Challenges: 
 There is significant concern regarding the growing shortage of technologists/scientists 
and technicians, which is expected to worsen over the next decade. The shortages are 
attributed to the aging of the workforce, competing career opportunities, and difficulty 
recruiting and retaining staff.  Although vacancy rates at the staff level were highest in 
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2000 (11 to 22%), they remained steady from 2002 to 2005 at an annual rate of 4 to 7%.  
Vacancies vary according to staff position, laboratory type and size, and geographic 
location.   
 Technological advancement of laboratory testing, emerging pharmacogenomic and 
proteomic testing, and greater laboratory automation could change the qualifications 
required of next generation laboratory professionals.  The laboratory sector needs to 
clearly redefine staffing qualifications and workforce level requirements to meet these 
forthcoming advancements.        
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CHAPTER IV 
QUALITY AND THE TOTAL TESTING PROCESS 
Improving quality has been a core goal of the laboratory medicine sector for decades, beginning 
with proficiency testing (PT) in the 1930s.a  Quality-related initiatives have been an important part 
of laboratory operations ever since.   
A milestone in quality improvement occurred in 1986, when CDC hosted the first in a series of 
Institutes on Critical Issues in Health Laboratory Practice devoted to improving laboratory quality.1  
Representatives assembled from diverse sectors within the health laboratory community including 
laboratorians, providers, public health practitioners, industry representatives, regulators, and 
payers.  Participants defined the roles and responsibilities to be assumed in the processes associated 
with laboratory testing.  At this critical meeting, participants were introduced to the concept of the 
total testing process (TTP), a systems-based framework for examining all possible interactions and 
activities that can affect the quality of laboratory tests.1  The aim of introducing the TTP was to 
design and implement interventions, restrictions, and limits that could reduce or eliminate errors 
that adversely affect testing and patient health outcomes.   
Today, the TTP remains the conceptual framework for understanding the dynamics of laboratory 
medicine as well as quality measures to improve care.  This chapter provides an overview of the 
TTP and examines the main types of error and other challenges to quality that occur in each phase.      
DEFINITION OF THE TOTAL TESTING PROCESS 
The initial definition of the TTP espoused at the 1986 CDC Institute still serves as the primary 
point of reference for addressing quality in laboratory medicine.  Since its inception, the 
definition has been refined and expanded to encompass all components that complete the test 
cycle, from the point of the clinical question to the point of clinical action, known as the “brain-
to-brain” model.2  In this regard, the TTP is defined by the activities in three distinct phases that 
align with clinical workflow outside and inside the laboratory: 
(1) Preanalytic:  clinician test selection, test ordering, patient preparation, specimen 
collection, patient and specimen identification, and specimen transport 
(2) Analytic:  specimen processing and preparation, testing of the specimen, results review 
and verification, and quality control (QC) checks  
(3) Postanalytic:  TAT, critical value reporting, report formatting, general results reporting, 
clinician interpretation and follow-up, laboratory interpretive consultation services, 
specimen storage and, if applicable, daily laboratory shutdown3, 4  
In most instances, preanalytic activities occur outside the laboratory.  The specimen is collected by 
the clinician at the site of care (e.g., hospital, physician’s office, patient’s home).  However, there 
are instances in which the specimen is collected at the laboratory.  Some experts in laboratory 
medicine include specimen preparation in preanalytic activities.  In the “brain-to-brain” model, 
                                                 
a Further discussion on the history and development of quality-related initiatives in the laboratory sector is provided in the 
Quality Systems and Performance Measurement Chapter and Federal Regulatory Oversight Chapter of this report. 
Laboratory Medicine: A National Status Report Chapter IV – Quality and the Total Testing Process 
May 2008 140 
these activities are identified as analytic-related and, therefore, will be included in the discussion 
of the analytic phase for the purposes of this report.  Similarly, postanalytic activities that involve 
laboratory communication with clinicians take place in both practice areas.  Figure 4.1 presents a 
streamlined diagram of the key components of each phase of the TTP.  
Figure 4.1:  Phases of the Total Testing Process  
Source:  Adapted from Boone J. Presentation at the Institute on critical issues in health laboratory practice: managing for better 
health, September 23-26, 2007. Atlanta, GA: Centers for Disease Control and Prevention.   
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QUALITY AND ERRORS 
Most quality initiatives in laboratory medicine have focused, historically, on the analytic phase of 
testing; however, root cause analyses and other medical error studies confirm that more errors 
occur in the preanalytic and postanalytic phases of testing.  The distribution of these errors by 
phase varies among settings and institutions.  An extensive review of reported errors in 
laboratory medicine published from 1992 to 2001 found great heterogeneity in study designs and 
reporting of errors.  The distribution of errors was 32-75% in the preanalytic phase, 13-32% in the 
analytic phase, and 9-31% in the postanalytic (administration) phase.5  This review included 
studies of error rates associated with clinical chemistry, the whole laboratory, primary care, stat 
laboratory, and molecular genetic testing.  One of these studies (whole laboratory) estimated that 
8% of errors had the potential for serious harm.6  Error distribution in transfusion medicine is 
reported to be somewhat higher in the postanalytic phase.  In a large study of errors detected in 
blood banks, the distribution was 41% in the preanalytical phase, 4% in the analytic phase, and 
55% in the postanalytical phase.7     
Poor communicationb between laboratory professionals and clinicians is generally cited as the 
chief issue affecting quality of laboratory services during the preanalytic and postanalytic 
phases.9-12  Throughout the health care system, communication failures are a leading cause of 
shortfalls in quality, particularly of preventable errors that harm patients.13-15  Widely overlooked 
in training of health care providers is that few clinicians or laboratory professionals receive formal 
training in effective communications.      
Preanalytic communication involves discussion between the clinician and the laboratory to select 
an appropriate test or set of tests and the communication of appropriate patient information on 
requisition slips.  These communications may involve an extensive set of medical professionals 
including physicians, nurses, pathologists, medical technologists, laboratory technicians, and 
clerical staff.  They may communicate about test orders, patient identification information, and 
specimen adequacy.  Postanalytic communication entails laboratory professionals’ 
communications with the clinician about critical values and interpretation of laboratory findings.  
Breakdowns in pre- and postanalytic communication lead to errors, patient safety events, and 
inefficient and ineffective use of health care resources.16, 17 
The next sections review each component of the TTP and provide examples of the types of quality 
issues and errors that are documented in the literature.  In addition, the general discussion of the 
TTP is followed by a more specific discussion of quality issues and errors associated with POCT.  
Much of the information is derived from research conducted by CAP through its Q-Probes® and 
Q-Tracks® studies.    
                                                 
b Communication is defined as the effective transmission of knowledge or information from one individual to 
another.  It requires clear and concise formulation of data, transformation of the data into useful information, and 
an agreed method of communication understood by the sender and receiver.8   
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PREANALYTIC PHASE 
Clinician Knowledge of Diagnostic Tests  
Many laboratory test selection errors arise because clinicians lack adequate knowledge for 
decision-making when ordering complex testing regimens.  Physician knowledge of laboratory 
tests and ability to order appropriately is complicated by two factors:  (1) rapid proliferation of 
new tests and tests for additional analytes; (2) lack of formal education in laboratory testing.  
Recent advances in biochemical, molecular, and genetic sciences have led to a plethora of new 
laboratory diagnostics for clinical use.  Currently, there are more than 4,000 different laboratory 
tests on the market, including new genetic tests that can be used for an estimated 1,430 diseases.  
Although orders for routine genetic tests and newer assays of increased breadth and complexity 
are increasing, medical students are exposed to only 29 hours on average of didactic coursework 
in medical genetics.18-20   
Primary care and specialist physicians need to be familiar with broadening sets of existing and 
emerging screening and diagnostic tests.  According to a 1999 survey, 25% of primary care 
physicians indicated that their medical knowledge base is insufficient for the scope of the care 
they are expected to provide.19  Some 38% of specialists believe that primary care physicians 
cannot maintain adequate expertise to deal with the overload of new clinical information.  Even 
when physicians lack knowledge for diagnostic or management decisions that poses threats to 
quality or medical malpractice, they only obtain definitive answers to address their uncertainties 
about 30-50% of the time.21  Day-to-day clinician demands leave little time to acquire this intricate 
knowledge.19, 20  Continued medical and scientific advancement will compound challenges 
associated with ordering the optimal sequence of tests, correctly interpreting results, and 
incorporating genetic information into clinical practice.9  
Appropriateness of Clinician Test Selection 
Definitions of appropriate care vary, e.g., as follows:  
 According to IOM, the best care is synonymous with appropriate care and results from 
the conscientious, explicit, and judicious use of current best evidence and knowledge 
of patient values by well-trained, experienced clinicians.14 
 RAND has defined appropriate care as that in which the expected benefits exceed the 
expected risks by a sufficient margin such that the service is worth doing. 
 CAP defines appropriateness as the extent to which a particular procedure, treatment, test 
or service is effective, clearly indicated, non-excessive, adequate in quantity and provided 
in the inpatient, outpatient, home or other setting best suited to the patient’s needs.22   
Principles of appropriateness in laboratory medicine are embodied in selecting the right test at the 
right time for the right patient.  Test appropriateness is inherent to an understanding of the 
specific clinical condition and the value of a particular test to the respective patient.  The ability to 
make these determinations varies among clinicians.  Standard measures of appropriateness do not 
prevail currently, though their development is viewed as important.  Instead, clinical guideline 
performance indicators of care quality and measures of test use (including underuse and overuse) 
have been the basis for drawing conclusions about appropriateness.  For example, the sentinel 
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2003 study by McGlynn et al. on the quality of U.S. health care evaluated clinician performance on 
439 indicators of quality, 131 of which involved laboratory testing or radiography.23  Only 61.7% 
of patients received the recommended laboratory or radiology tests for preventive, acute, and 
chronic care associated with priority health conditions.  The study findings called attention to 
serious shortfalls in use of key tests that support care quality.   
Studies of appropriateness can be undertaken for different applications of laboratory testing, 
including screening for disease in asymptomatic individuals, establishing a diagnosis in persons 
presenting with signs and symptoms of disease, and monitoring the course of disease or its 
treatment.  Screening may include panels of laboratory tests performed as part of periodic health 
evaluations, or tests performed at the time of hospital admission, pre-operative evaluation, or 
prenatal evaluation.  Examples of screening tests include fecal occult blood testing for colorectal 
cancer, cholesterol testing to detect risk of coronary artery disease, and Pap smears for cervical 
cancer.c,27  Underuse is a common problem for several tests that reduce mortality by early detection 
of disease or prompting interventions to control risk.  The 2006 National Healthcare Quality Report 
from AHRQ reported that 51.7% of adults over age 50 had colorectal cancer screening in the 
previous two years (i.e., sigmoidoscopy, colonoscopy, proctoscopy, or fecal occult blood testing), 
indicating that half of adults in this population are not receiving needed cancer screening.28   
Other studies have demonstrated overuse of certain screening tests.  For example, while Pap smears 
are recommended for most women, they are not routinely recommended for women older than 65 
or in women following hysterectomy (unless they have previous cervical neoplasia).  In 1996, the 
USPSTF recommended that routine Pap smears are unnecessary in women who have undergone a 
hysterectomy for benign disease and no longer have a cervix.  Yet, based on findings from large-
scale U.S. survey data for 1992 and 2002, among women who had ever had a hysterectomy, 68.5% in 
1992 and 69.1% in 2002 had a Pap smear within the previous three years of the survey.  After 
adjusting for Pap smears performed prior to a hysterectomy, and hysterectomies that spared the 
cervix or were performed for cervical neoplasia, the investigators estimated that 10 million women, 
or half of all women who had undergone hysterectomy, were being screened unnecessarily.29  Still, 
some clinicians and patients often prefer a cautious approach, especially if neoplasia was present.  
Other bodies of research show that some screening tests, such as routine admission or preoperative 
panels of tests, are of limited or no utility.30, 31   
Monitoring involves testing to track the course of disease, make necessary adjustments in therapy, 
or detecting complications of care.  Examples include testing for HbA1c in diabetic patients and 
lipid levels in patients with diabetes or known coronary artery disease.  According to the 2006 
National Healthcare Quality Report, performance rates of monitoring tests for diabetic patients 
were relatively good.  Of adult diabetic patients, about 90% had HbA1c measured in the past year, 
but only 45.5% had their HbA1c level under optimal control and only 48.1% had their total 
cholesterol under control.28  While these figures represent an improvement over previous years, 
improved use of laboratory testing likely would facilitate better control.  Of course, measurement 
alone does not ensure desired outcomes.  In a study of more than 1,700 diabetic patients at 30 U.S. 
academic medical centers during 2000-2002, high annual rates of testing for HbA1c, blood 
                                                 
c Use of other screening tests, such as glucose testing for diabetes, prostate specific antigen testing for prostate cancer, 
and thyroid stimulating hormone, testing for thyroid disease, is supported by some groups; however, a strong 
evidence-base for their preventive value is required by the USPSTF before recommendation.24-26  
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pressure, and cholesterol did not translate to effective metabolic control.  Only 40.4% of patients 
received needed therapeutic adjustments for high HbA1c values.32  
Estimates of diagnostic testing appropriateness are derived mostly from estimates of test use.  
However, drawing broad conclusions about rates of inappropriate use across tests, settings, and 
timeframes can be flawed.  In a review of 44 eligible reports in the laboratory utilization literature 
from 1966 to 1997, investigators found that reported rates of inappropriate use ranged from 4.5% 
to 95%, suggesting significant inconsistencies in the validity of implicit or explicit criteria for 
appropriateness and reliability of their application.16  Even for laboratory use among physicians 
treating patients with the same diagnosis, there is considerable variability.33  Further research to 
develop and validate criteria for appropriateness evaluations is needed.   
More recent studies using clearly defined algorithms found that, when guidelines were applied, 
20-25% of frequently ordered tests, such as autoantibody tests, infectious disease serologic tests, 
and hepatitis serology tests were inappropriately requested.34-36  Redundant test requests also are 
common and contributed to inappropriate use.  In a multicenter CAP study, 1.5% of thyroid 
stimulating hormone (TSH) requests appeared to be redundant.  When applied to high volume 
testing, even this apparently low rate can result in substantial unnecessary costs.  In 2005, an 
estimated 12.3 million TSH assays were performed at a cost of $288 million.37  Applying the CAP 
data, the annual cost of a 1.5% rate of redundant testing is $4.3 million.  A randomized trial of a 
computer-based intervention to reduce redundant test use found that 1.2% of tests were 
redundant, but use of computer alerts led to test cancellation of 69% of these redundant tests.  
Even so, the net impact of the computer alerts was small because less than half of the redundant 
tests were ordered via computer, only half of the computer orders were screened for redundancy, 
and almost one-third of the reminders were overridden.38   
Physicians often order certain laboratory tests habitually or because they are grouped together for 
convenience.  Multiple factors lead to inappropriate use of tests, including test panels that contain 
unnecessary tests, delays in performing tests, and difficulties caused by ordering forms or 
menus.33  Efforts to decrease utilization and improve appropriateness have focused on changing 
physician behavior by altering requisition forms, changing policy, instituting computer rules and 
reminders, and changing reimbursement.  Those that target multiple components of behavior 
modification appear to be most effective.39  For example,  
 In a randomized trial conducted in hospitals in France, redesign of laboratory ordering 
requisitions resulted in higher rates of compliance (83%) to ordering guidelines for 
thyroid function tests compared to conventional ordering (63%), reducing 
inappropriate test requests.40 
 In a time-series study of interventions to improve rates of appropriate testing in non-
hospital clinical laboratories in Ontario from 1991 to 1997, the combination of physician 
guidelines, laboratory requisition form modification, and changes in reimbursement 
policy for commonly used tests resulted in large shifts in the ordering of certain tests.  
Specifically, orders decreased for total thyroxine tests by 96%, iron-related tests by 
80%, urea-related tests by 58%, erythrocyte sedimentation rate tests by 57%, and TSH 
tests by 12%, along with increases in certain tests encouraged for substitution.41 
 A computer alert system with basic metabolic panel rules to be applied after hospital 
admission in a large U.S. academic medical center decreased panel orders by almost 
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60% without changing patient length of stay, mortality, readmission rates, or transfer 
rates to ICUs.42   
Because laboratory test results help clinicians determine diagnoses, therapies, and need for 
follow-up tests, inappropriate test use can compromise case management and increase cost per 
patient and rates of adverse health outcomes.16 
Test Ordering  
When a clinician decides to order a laboratory test, a requisition slip (order form) is completed in 
writing or electronically and submitted with the specimen to the laboratory.  Information on the 
order forms can directly affect processing and analysis of the specimens.   
Inaccurate or incomplete requisitions are another source of error and can affect the quality of 
laboratory testing.43  A CAP Q-Probes study of 577 institutions reported in 1995 that examined how 
accurately physicians’ test orders for inpatients were transmitted to the laboratory found that 97.1% 
of documented physician orders were completed by the laboratory.  However, 1.9% (median) of test 
orders were not completed and, of the 17,085 patient records examined, 10% were not completed at 
all.  Reasons given as the most likely cause for not completing ordered tests included: 
 Failure to enter orders correctly into hospital computer (41.8%)   
 Test requisition improperly filled out (12.8%) 
 Physician handwriting was unclear (4.1%) 
 Failure to enter orders correctly in the laboratory computer (1.4%) 
 Other (23.0%) and not applicable (16.9%) 
The study also found that the specific laboratory test was not listed on the requisition or in the 
patient’s medical record for 2.5% of the 224,431 laboratory tests performed; this occurred most 
often in hospitals where verbal orders are more frequent.44  
Similar findings were demonstrated in anatomic pathology.  A 1996 CAP study of surgical 
pathology specimens reported that missing or incorrect information on order forms accounted for 
77% of all deficiencies.  Specifically, the most common of these deficiencies was no clinical history 
or diagnosis (40%).  Smaller hospitals and laboratories had more cases with inadequate 
documentation than larger hospitals.  The additional clinical information, when obtained, 
confirmed the diagnostic impression in 59.4% or was not relevant to pathologic diagnosis in 25.1% 
of cases.  However, the diagnosis was changed substantially in 4.2% of cases and required a report 
revision in 1.9% of cases.45 
Computerized physician order entry (CPOE) systems have been promoted as a means of 
improving the quality of care, reducing errors, and increasing efficiency.15, 46-48  Because CPOE 
systems are complex and costly to implement, efforts thus far have focused primarily on the use 
of CPOE for medication ordering in hospital settings.49  However, a recently published literature 
review identified 19 studiesd of the impact of CPOE on pathology services from 1990 to 2004.50  
                                                 
d Fifteen studies compared CPOE with and without specific decision support mechanisms and four studies compared 
setting with and without CPOE systems. 
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Use of CPOE (as compared to conventional ordering) resulted in statistically significant decreases 
in the volume of test ordering for blood count, chemistry, serum, and stat tests; when CPOE was 
linked to additional decision support features, volume decreases ranged from 9.5% (per patient 
per day) to 45.6% (per hours per patient day).  Costs associated with laboratory ordering also 
decreased by up to 28% for certain tests.       
Direct access testing, in which individuals can directly request that certain tests be performed on 
their own blood or urine specimens, is permitted in 26 of 50 states and the District of Columbia.51  
An additional 12 states permit limited DAT.  About 10-15% of laboratories offer direct access 
testing.52  Although these tests are increasingly marketed and used, few data exist on their 
utilization, appropriateness,  accuracy, or impact on consumer decisions or health outcomes.53   
Patient Preparation 
During the next steps of the preanalytic phase, several factors can affect the quality of 
laboratory results.  Whether at the physician’s office, the laboratory, or the patient’s bedside, the 
most important factors include patient preparation and identification and specimen collection 
and labeling.  
Inadequate patient preparation is a common source of misleading laboratory test results.54  
Preparation factors that may affect laboratory test results are food intake, time of day, exercise, 
stress, posture, time in menstrual cycle, medications, smoking, and illness unrelated to the condition 
for which the test was ordered.55  For example, accurate glucose determination requires a fasting 
specimen and tests for drug levels need to be performed when drugs are at steady state.  
Calculating medication dosages based on inaccurate drug levels can have adverse consequences.  In 
a CAP Q-Probes study reported in 1993 of 666 institutions and more than 18,000 toxic levels, 22-31% 
of digoxin levels in the toxic range were collected before the steady state of the drug was reached.  
The investigators found that small institutions, outpatients, stat specimens, and laboratory policies 
not requiring the time of the last dose before measurement were associated with higher percentages 
of specimens drawn before the recommended time had elapsed.56  Laboratories do not have direct 
control over these factors, especially when non-laboratory personnel collect samples; however, the 
laboratory can develop and disseminate information about appropriate patient preparation.   
Patient Identification 
Patient identification problems are one of the most common causes of erroneous laboratory 
results.57  Quality assurance (QA) and professional organizations (e.g., The Joint Commission) 
have cited accurate patient identification as a key indicator in patient safety and quality 
improvement initiatives.  Progress with the use of patient wristbands with appropriate 
identifying information in the hospital setting have been made, though errors can still occur.  For 
example, a study of electronic barcode systems demonstrated their success in reducing and 
eliminating identification errors for all patients requiring blood transfusion from 1999 to 2002.  A 
portable, hand-held, scan-and-print device was used to verify and document patients’ identify at 
two critical points of transfusion: blood sampling for compatibility and blood administration.  In 
the first three years of hospital-wide use of the device, no incidents occurred of blood transfusion 
to wrong patients or wrong labeling of blood samples with 41,000 blood sampling procedures and 
administration of 27,000 units of blood.58  
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A two-year CAP study included wristband errors as a quality indicator.59  Continuous monitoring 
led to significant decreases in wristband errors of all types from 7.4% (mean) at the start of the 
study to 3.1% (mean) at its conclusion, although at the 10th percentile, there were wristband 
errors in 11.4% or more of patients.  As a percentage of all errors, the most common errors were: 
 Missing wristbands (71.6%) 
 Missing patient identification information (9%) 
 Illegible wristband (7.7%) 
 Erroneous identification information (6.8%) 
 Conflicting information (3.7%) 
 Wrong wristband (1%) 
Hospital practices associated with fewer patient identification errors include written protocols 
governing patient identification, placing new wristbands immediately when needed, and having 
dedicated phlebotomists collect blood specimens.  Laboratories with policies that required 
phlebotomists to refuse to draw blood from patients with wristband errors reported the fewest 
specimen identification errors.   
Barcode systems have been developed for use at the point of phlebotomy, but little data have 
been published on their use.  In one study, using a beta version of a commercial system reduced 
error by 77%.60  As with computerized order systems, however, use of barcodes may increase 
certain error types.  An evaluation of the Department of Veterans Affairs barcode medication 
administration system identified five common error patterns, including degraded coordination 
between physicians and nurses and decreased ability to adapt to changes from routine.61 
Specimen Labeling/Identification 
Patient identification problems can easily translate to specimen labeling problems.   
Typically, labels are generated and applied to containers prior to specimen collection. Additional 
labeling and numbering of the specimens may occur as specimens are processed for analysis.  
Different institutions use different rules for counting specimens.  Some assign a single accession 
number to each specimen, while others assign the same number to all specimens from a single 
phlebotomy or outpatient encounter, or assign separate numbers for aliquots destined for 
different laboratory divisions.62  In surgical pathology, a single case number is usually assigned to 
multiple specimens; then, each specimen is assigned a separate specimen identifier in addition to 
the case number. 
Specimen identification errors can result in serious patient injury such as wrong-patient cancer 
resections and fatal transfusion reactions.63, 64  While error rates for individual institutions may be 
relatively low, those error rates at the national level may yield a significant number of events.  For 
instance, one CAP study reported in 2002 detected specimen-related errors at 0.3% of total errors, 
of which 5.8% were associated with inadequate labeling.65  In a 2006 study of these errors in 
laboratories associated with 120 institutions (teaching, private, and local hospitals, independent 
laboratories, federal government facilities), the authors reported adverse events resulting from 1 
of every 18 specimen identification errors (5.6%), which, if extrapolated to the nation’s 6,000 
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hospital laboratories, would result in 160,000 events.66  Such extrapolations are difficult to validate 
because of the lack of standardized measurementse for reporting data in CAP studies and because 
the laboratories in the studies are not a representative national sample.      
Labeling errors have been studied extensively in transfusion medicine, where correct specimen 
identification is critical to avoiding fatal transfusion reactions.  In a study of transfusion errors in 
New York State, undetected phlebotomyf errors were the cause of 13% of ABO-incompatibleg 
transfusions, while failure to properly identify the patient at the time of transfusion caused 
another 38% of incompatible transfusions.67  An international study of 82 facilities in 10 countries 
determined that mislabeled specimens (defined as missing some or all identifying information 
needed for acceptance) occurred in 1 of 165 specimens, while  misidentified specimens (in which 
the blood appeared to be from a patient other than who was identified on the label) occurred in an 
estimated 1 of 1,986 specimens.68   
Mislabeling/misidentification of specimens is a common error in anatomic pathology.  Errors 
usually occur when patient or specimen information on containers is missing or inaccurate.  For 
example, specimen-related errors can include misidentification of the origin of the tissue 
specimen (e.g., stomach vs. colon), anatomic location (e.g., ascending vs. sigmoid colon), and 
laterality of the tissue (e.g., right vs. left breast).69  A 1996 study detected identification and 
accessioning errors in 6% of more than 1 million surgical pathology specimens.  Specimen 
identification errors accounted for 9.6% of these deficiencies, 77% of which were due to missing or 
incorrect information.  Among the specific deficiencies were: 
 Illegible patient name or universal patient identifier (UPI) on either container or requisition 
 No label on container 
 No patient identification on container 
 Patient name/UPI on container does not match that on requisition 
 Patient name/UPI on container or requisition does not match master list 
 Wrong patient name/UPI on both container and requisition 
 No tissue source indicated on container or requisition 
 No date of procedure 
 No name of submitting physician 
 Incorrect information other than patient name/UPI on container or requisition 
(e.g., sex, age) 
Laboratories performing 20,000 or more accessions per year had the highest rate of deficiencies at 
6.0% compared to those performing fewer than 20,000, which ranged from 3.2 to 4.5%.  Also, 
institutions that labeled containers with the patient’s name and UPI had fewer deficiencies than 
those that uses either one alone.45 
                                                 
e CAP data collection typically is not standardized with clear definition of a numerator and denominator.  Thus, data 
from each institution may measure indicators differently and may use different detection and reporting criteria.   
f Phlebotomy refers to venous blood drawing. 
g ABO-compatibility refers to the laboratory testing to determine blood type A, B, or O compatibility between the 
donor and recipient.  
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Use of relatively new information and communication technology has led to substantial 
improvements in patient and specimen identification.70  Computerized specimen-handling systems 
include portable data loggers for laboratory personnel, and automatically upload patient and 
specimen information into the laboratory information system (LIS).  Barcode identification systems 
are being used successfully in more institutions to create standardized labels for laboratory 
specimens.71, 72  Errors still can occur when barcoded labels are transferred to the specimen 
container.  The risk of this error is higher in busy emergency rooms or ICUs where multiple labels 
for different patients may be printed in advance of the specimen collection.  Other approaches 
under evaluation include radiofrequency identification chips and patient imbedded chips.73   
Specimen Collection  
Clinicians (e.g., nurses) or laboratorians (e.g., phlebotomists) may collect patient specimens.  
Blood is the most common specimen submitted to laboratories.  In CAP Q-Probe studies of 
phlebotomy,h reported rates of success (i.e., specimens judged by the laboratory to be suitable for 
analysis) have been 99.6% among ambulatory patients65 and 93.2% among inpatients.75  Lower 
rates have been reported for inpatients because phlebotomists had more difficulty in obtaining 
specimens (1.6%) or patients were not available (2.3%).  Other common types of clinical pathology 
specimens collected for analysis include urine, cerebrospinal fluid, serous fluids, feces, gastric 
fluid, and synovial fluid.  Anatomic pathology specimens are those obtained by aspiration, 
washing, smear or scraping for cytologic examination or tissue taken during biopsy or surgery.  
As a group, specimen collection problems are some of the more common causes of preanalytic 
variation and may be associated with failure to collect the correct type of specimen, correct 
volume of specimen, or collection of an unusablei or misleading specimen.  The specimen 
adequacy often cannot be determined until the analytic phase, when the specimen is assessed for 
acceptance or rejection.  There are limited data on error frequency associated with collection of the 
wrong type of specimen.  A 1997 study of the stat testing section of a university-based laboratory 
in Italy reported that 2.1% of all TTP errors were attributed to incorrect specimen collection.76   
Inadequate volume for testing is a common cause of specimen rejection.  This problem affects not 
only blood specimens, but other tests such as Pap smears.  In a multicenter study involving 768 
laboratories, 0.5% (median) of Pap smears had inadequate specimen volume and another 5.8% 
(median) had adequate volume but limited the ability to evaluate the specimen for cervical cancer 
due to other specimen-related factors.77  Two studies evaluated specimen rejection for complete 
blood count (CBC) and chemistry specimens.  Of 703 hospitals, 0.45% of CBC specimens were 
rejected; 10.1% of rejections were due to insufficient specimen quantity.78  The subsequent 1997 
study of chemistry specimens reported that 0.35% were rejected prior to testing; of these specimens, 
11.4% were rejected due to inadequate volume.79  In the stat testing study mentioned above, 
specimen volume and adequacy for analysis were affected when phlebotomy was performed from 
a patient’s infusion; this inappropriately diluted the specimen volume in 20.6% of cases.76   
                                                 
h Most medical and laboratory professional are trained to collect blood specimens but a specialist in this area is the 
phlebotomist.74 Blood specimens can be collected from various sources.  Venipuncture and phlebotomy refer to 
collection of blood from veins, while skin puncture refers to collection from capillaries. Arterial blood also is 
collected for blood gas measurements and pH. 
i An unusable specimen is generally due to trauma during its transport that results in hemolysis or clotting. 
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To ensure that specimen volume is sufficient for testing, laboratories often recommend specimen 
volumes that exceed those needed for testing.  Several studies noted collection of up to 45 times 
the amount of blood actually needed for testing, raising concerns about production of “iatrogenic 
anemia” in high risk hospitalized patients (e.g., ICU patients, neonates, elderly) who undergo 
repeated blood collection.80, 81  The decisive factor contributing to blood loss was rigid blood 
drawing schemes in which repetitive drawings were performed regardless of the patient’s clinical 
condition.82  Reporting of individual cumulative blood loss on the daily laboratory report may 
influence the requesting clinician’s behavior.  Earlier studies examined the use of a pediatric 
collection container for adult patients, which led to a 50% reduction in the mean daily blood loss; 
however, this change had no effect on the ordering clinician’s requests for laboratory tests that 
were not medically necessary.83, 82, 84    
Unusable (e.g., due to hemolysis, clotted blood specimens) or mislabeled specimens are the most 
frequent reasons for specimen rejection.  Proper specimen collection and labeling is essential for 
hematology and coagulation testing, where attention to specimen quality is necessary for an 
optimal laboratory result.17  Several studies reported that hemolysisj of chemistry specimens 
caused 54-60% of specimen rejections and occurred five times more frequently than the second-
most cited reason of insufficient volume; clotted specimens caused 65% of CBC specimen 
rejections.5, 78, 79  Among rejected chemistry and CBC tests, a higher percentage were collected in 
pediatric microcollection tubes.   
Contamination of specimens collected for bacterial culture is another common source of error, 
estimated at 2.5% of positive blood cultures and 18% of urine cultures in reports published in 
2007.85, 86  Because it can be difficult to distinguish a false positive from a truly positive culture, 
patients with contaminated cultures are often given unneeded care, increasing hospital costs by 
thousands of dollars per patient.87  Similar contamination rates have been reported in inpatient 
and outpatient specimens.85  Continuous monitoring, use of dedicated phlebotomists, feedback to 
those drawing specimens, and use of faster acting decontamination techniques all reduce the 
frequency of contaminated cultures.88-91  There are many other sources of error in microbiology 
testing, including wrong type of specimen collected for type of infection, insufficient specimen 
collected, contamination of specimen collection containers and solutions, and poor timing of 
specimen collection and transport.92-94  When microbiology specimens are collected during a 
surgical procedure, contamination of surgical blades also may cause errors.95  
Health care and laboratory settings also can affect specimen collection.  In a recent study 
comparing rates of and reasons for specimen rejection across different settings as well as 
associations with patient demographic factors, of the 0.74% of specimens that were rejected, 47% 
were from the inpatient setting, 27% from the emergency department, and 25% from outpatient 
setting. After adjusting for the total number of specimens per site, the emergency department 
rejection rates were twice as high as rates for inpatient services and five times as high as rates for 
the outpatient setting.  Also, the rejection rate of specimens from African Americans was twice 
that of the rates for Caucasians and 30% higher than the rate for other races in the hospital setting 
but indicated no difference in the outpatient setting.96 The investigators hypothesized that the 
severity and seriousness of the diseases and comorbidities of patients admitted to emergency 
department or inpatient services are contributing to the higher proportion of specimens rejected.  
                                                 
j Breakage of red blood cells membranes causing the release of hemoglobin and other internal components into the 
surrounding fluid.   
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In general, African American patients are more likely to choose the emergency department as the 
mode of entry to the system, independent of health insurance status, therefore increasing the 
likelihood of errors.97  
Specimen Delivery  
Specimen quality can be compromised during delivery by excessive delay, adverse temperature, 
or manual or mechanical trauma to the specimens.55  Different means have been employed to 
transport specimens to and within the laboratory, such as human couriers, pneumatic-tube 
systems, and other technologies, that have advantages and disadvantages.  For example, using 
human couriers is a “batch process” dependent on pickup at specific times.98  While reliable, it 
entails significant training and management costs.  Pneumatic-tube systems (i.e., tube transport 
systems that move contents via vacuum and positive pressure) provide cost-effective, rapid 
transport for specimen delivery in hospitals.99  Evidence on potential for specimen damage from 
acceleration and deceleration forces is mixed.  Although some evidence suggests that mechanical 
factors—tube length and speed, and number of times transported—may result in hemolysis of 
blood specimens,100 other evidence shows no clinically significant effect of these systems on 
hematology and coagulation results.101  Other technologies such as track vehicles, mobile robots, 
and conveyor belts are now widely used to transport specimens from one point within the 
laboratory to another.  Although safe to specimens, transport via these technologies tends to be 
slower.  Implementing all of these technologies entail capital expenditures for installation and 
costs for transition from old to new systems, training, and maintenance.    
Each specimen type has standards for timely delivery and conditions for transport in order to 
maintain its integrity.  Specimens for stat orders such as those collected in an emergency room 
need to be delivered to the laboratory immediately.  Most microbiologic organisms die quickly 
after removal from the body and should be transported quickly.  Specimens for some tests (e.g., 
cryoglobulins, cryofibrinogen) need to be kept at body temperature, while others need to be 
protected from light (e.g., bilirubin, vitamin A).74, 102  Transporting and processing delays can 
render a specimen invalid for analysis.  For example, a 2000 study of one-hour delays in the 
processing of blood samples found significant effects on the concentration of biomarkers.  
Decreases in the concentrations occurred for red and white blood cells, high-density lipoprotein 
cholesterol, glucose, and creatine.  Increases in concentration were observed for total cholesterol, 
total testosterone, free testosterone, alkaline phosphatase, total bilirubin, and thiobarbituric acid-
reactive substances.103  
CLINICAL PATHOLOGY TRANSITIONAL PREANALYTIC 
Specimen Processing and Preparation 
Once received, the laboratory processes the specimen for analysis.  Quality in processing requires 
that the laboratory verify specimen labeling (e.g., patient identification, time of collection, initials 
of sample collector) and information provided on the accompanying requisition (e.g., patient 
identification, tests ordered, relevant clinical information).74  Pertinent information must be 
accurately transcribed and logged manually or entered into the LIS.  Specimens may arrive at the 
laboratory with a barcoded label generated at the point of specimen collection.  Next, the 
specimen is evaluated according to guidelines on its acceptability for analysis. Accepted 
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specimens are distributed to specific laboratory sections for analysis or additional preparation 
(e.g., centrifugation).  If a specimen is rejected, another must be obtained, increasing the cost of 
care.  Specimens that cannot be tested immediately and those tested only during certain 
days/shifts are stored appropriately (e.g., refrigeration or freezing).  
Quality problems in specimen processing (aside from patient misidentification described above) 
include transcription errors and forwarding the wrong specimen type.  Transcription presents 
opportunities for multiple types of error.  A study published in 1999 reported that 4.8% of 
outpatient requisition slips had at least one laboratory order entry error type, including 
discrepancies in the test ordered, physician’s name, and test priority status.43  Order entry errors 
tended to be higher in facilities with a greater percentage of occupied hospital beds, those that 
made extensive use of verbal orders (in person and by telephone), and federal facilities in both 
urban and rural settings.  In contrast, an Australian study of pathology laboratories reported in 
1996 found transcription error rates of up to 39% among lowest performers and up to 15% among 
best performers.104  Error types in order of prevalence included those related to patient and 
physician identification, patient sex and age, tests requested, and patient ward location or 
address.  Transcription errors can be decreased through routine rechecking of orders entered 
against requisitions and substitution of verbal orders with written and facsimile orders.43, 105, 106  
The evaluation of specimen suitability is a critical factor in test result accuracy, precision, and 
usefulness.  Preanalytic problems (e.g., specimen collection) may not be discovered until the 
examination for acceptance.  Accepting unsuitable specimens can lead to erroneous information 
that compromises patient care.107  Guidelines for evaluating specimens are integral to QC 
procedures, and rates of and reasons for specimen rejection are evaluated as an indicator of 
quality.  The high rates of acceptance of inadequate specimens resulting in incorrect Pap smear 
interpretation with subsequent adverse effects on patients in the late 1980s precipitated increased 
regulation of the laboratory sector.  It also helped to prompt development of new technology to 
aid in detection of abnormalities.  Proceeding with microbiology or other testing of specimens of 
insufficient volume may result in false-negative blood cultures, adversely affecting antibiotic 
management.  As mentioned, leading reasons for rejecting specimens often are associated with 
problems in the preanalytic phase, including hemolysis, improper method of collection, empty 
specimen container, mislabeling of container, clotted specimen, delay in transport, and significant 
platelet clumps.108  
When accepted, specimens undergo additional preparation for analysis.  Preparation of clinical 
pathology specimens involves several activities:  centrifugation,k aliquoting,l pipetting, diluting, 
and sorting specimens with appropriate labels (often barcoded) into batches for introduction into 
automated analyzers or other methods of analysis.109  Molecular testing methods have the 
potential to replace many conventional microbiology laboratory assays.110, 111  Preparation of 
microbiology specimens for these new molecular-based testing methods may involve nucleic acid 
purification and amplification with automated systems instead of manual procedures.  Studies of 
resource allocation demonstrate that specimen preparation consumes a large portion of the 
laboratory budget (19%) and staff time (37%), and exposes laboratory workers to the risks of 
                                                 
k Centrifugation is the use of a mechanical device that uses centrifugal or rotational forces to separate substances of 
different densities, such as solids from liquids or liquids from other liquids. 
l Aliquoting is the separation of an equal fractional part from the whole, especially specimens of substances that have 
the same volume or weight. 
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handling infectious specimens.112  In addition, specimens requiring separation by centrifugation 
historically have been bottlenecks in laboratory processes because of the time required to 
manually load and unload the instruments.113  The introduction of automated preanalytical 
processing systems has reduced labor, hazard, and errors associated with specimen processing.  
In larger laboratories, preanalytic processing systems often are linked directly to analytic systems, 
forming total laboratory automation systems whereas in other, usually medium and smaller 
laboratories, they operate as modular or stand-alone systems.  Because these systems can include 
instruments for chemistry, immunoassay, hematology, coagulation, drug screening, and other 
tests, they allow for dramatic gains in consolidation of work and personnel and the integrity of 
specimen handling.114  Preanalytic processing units typically perform the basic tasks of reading 
barcodes, centrifuging specimens when required, and decapping and sorting tubes, as well as 
more complicated tasks such as checking the quality of a specimen with instruments designed to 
detect substances that interfere with testing, such as hemoglobin, bilirubin, and lipoprotein 
levels.17  Some units have capabilities for postanalytic storage and retrieval.  Most importantly, 
these systems eliminate much of the rote manual work of laboratory staff that causes errors due to 
fatigue or distraction.115  In a recent evaluation of an automated preanalytical blood specimen 
processing unit at two U.S. academic health centers, sorting and routing errors decreased from 
7,950 to 477 per month and biohazard exposures decreased from 2,658 to 6 per month.113  
CLINICAL PATHOLOGY ANALYTIC PHASE 
Specimen Analysis 
Along with preanalytic activities, the quality of test results depends on factors linked to the 
analytical systems or processes used for testing itself.  In clinical pathology, many tests are 
conducted using automated laboratory instruments that analyze the specimen and generate results.  
Technologies include, but are not limited to, chemistry analyzers; immunoassay instruments; 
hematology, coagulation, and urinalysis equipment; electrochemistry,m electrophoresis, 
chromatography, mass spectrometry, and flow cytometry instruments; and molecular diagnostic 
technology.117  Although some analyzers require more operator involvement than others, in general, 
high levels of automation have enabled laboratorians to concentrate more on QA and results 
interpretation.118  In addition, most laboratory QC and assurance programs have targeted accuracy 
and precision during specimen analysis.  As a result, the risks and rates of testing errors have been 
significantly reduced to the extent that analytic systems now have the lowest error rates when 
compared to any step in the preanalytic and postanalytic phases.119  This trend is expected to 
continue given recent advances in technology development supporting connections between 
analytic systems and preanalytic processing units to create total laboratory automation.  
The overarching goal of analytic system quality is to ensure run-to-run accuracy and precision 
(i.e., reproducibility).  Accuracy is the degree of conformity of a measured or calculated 
quantity to its actual, nominal, absolute, or some other reference value.  Precision refers to the 
closeness of agreement between independent test results obtained under prescribed conditions; 
it is a measure of reproducibility or random error.  Achieving accuracy and precision requires 
                                                 
m Electrochemistry involves the measurement of current or voltage generated due to the activity of specific ions.  
Several different types of instruments are used for these measurements.116  
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careful selection of reagents, rigorous use of controls, and strict adherence to established 
protocols.  While automated analytic systems have successfully minimized many errors, factors 
such as interference and calibration can alter the conditions of measurement, create variance 
and/or bias, and diminish accuracy and precision of testing systems, results, and interpretation.  
A 2001 report of a CAP survey of PT specimens for therapeutic drug monitoring that evaluated 
25 drugs among 5,000 laboratories found that 57.8% (range 35.3-73.7%) of variance was due to 
long-term, within-laboratory variance, 25.0% (8.8-50.6%) was due to short-term within-
laboratory variance, and 17.3% (5.0-35.4%) was due to between-laboratory variance; total 
laboratory variance was 82.7% (64.6-95.0%).120 
Bias, or systematic error, refers to the extent to which a measurement, sampling, or analytic method 
systematically underestimates or overestimates the true value.  Analytic bias can directly affect 
patient classification and clinical decision-making by shifting the distribution of test values.121  For 
example, a major study examined the relationship between matrixn effects and the accuracy of 
laboratory measurements for 11 analytes, based on CAP Comprehensive Chemistry Survey data for 
1994, and using definitive methods at the National Institute of Standards and Technology and 
CDC.  Among the findings were that matrix biases affected results in 69% test comparisons and 
that, because of matrix biases, the reference value was the correct target value only 32% of the time.  
Other error was introduced by random matrix effects and calibration biases.122  Minimizing bias is 
accomplished by examining contributors to variance in test values including sensitivity and 
specificity, interference, instrument calibration error, reagent lot differences, personnel performance 
error, and other factors.123-125 
A common cause of bias is interference, which is caused by specimen components other than the 
analyte that influence the concentration measurement.125  Interference may be caused by a single, 
identifiable substance or property of the material.  Major endogenous sources of interference 
include hemoglobin, lipemia, bilirubin, and proteins and extraneous antibodies, while exogenous 
sources include drugs, materials given to patients for diagnostic purposes, and additives from 
collection containers (e.g., anticoagulants, preservatives).125  Interference can lead to falsely elevated 
or lowered measurements.  A 2002 study of 5,310 patients in the UK for whom common 
immunoassay tests for TSH and/or gonadotropins were requested found that, of the instances of 
interference in immunoassays for TSH, lutenizing hormone, and follicle-stimulating hormone, the 
interference was large enough in 82% to cause inaccurate results and have potentially adverse 
effects on patient care and health care costs.126  The magnitude of interference can vary significantly.  
Whether or not the bias due to interference is clinically significant depends on the use of the test 
results and the allowable error rate.  In general, laboratorians are guided by the allowable error rates 
given in the criteria for acceptable performance in PT specified in the CLIA regulations.   
Other causes of bias that can result in spurious test results include instrument calibration error, 
reagent lot differences, inaccurate mathematical correction for specimen dilution, and 
misinterpretation of instrument codes.123, 124  Calibration is a measurable signal related to a 
substance concentration or other reported result.  It requires testing the specimen against one or 
more materials (calibrators) that behave similarly to the specimen and for which the true result is 
known (i.e., a comparator).  The response should be linear over the reportable range (i.e., the 
response should be proportional to the analyte concentration).  Calibration drift is a systematic 
                                                 
n A matrix is the biological medium such as blood, urine, or breath in which a substance is being detected or that is 
being used for a reference standard. 
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change in measurement that occurs over a time period of unadjusted, continuous operation of a 
test instrument.  In 2004, the National Institute of Standards and Technology released a report on 
the impact of calibration error in clinical decision making and health care costs.127   This report 
studied calcium results in about 89,000 Mayo Clinic patients during 1998-1999 and found that 
calibration error in measurements of serum calcium levels led to analytic bias in 15% of tests 
results.  Not only were some test results passing decision thresholds specified in practice 
guidelines, but estimated costs of the errors on a national scale were substantial, ranging from $60 
million to $199 million per year.  Similarly, in a study reported in 2000 of inaccurate test results 
based on data from the New York State Department of Health PT program to characterize the 
quality of toxicology testing, calibration drift was cited as the most frequent cause of analytic error 
(48%), followed by method bias (14%), indeterminate source (11%), reportable range (9%), and 
component failure (8%).  This study also noted that approximately half of laboratories used an 
allowable error for QC of analytic systems that exceeded the threshold error specified by 
manufacturers for stable instrument performance.124  Nonconformity is documented to be highly 
correlated with process complexity.128  There has been a growing trend to have all laboratory 
measurements traceable to a primary method of analysis reference material, but this may not 
always be possible when the material being analyzed is unstable. 
Lot-to-lot variations in the manufacturing of calibrator and reagent concentrations or volume can 
lead to bias affecting analytical performance.127  The lack of uniformity and standardization 
among manufacturers makes the implementation of laboratory-based guidelines difficult because 
each such guideline must have method-dependent decision limits.123, 129  The heterogeneity of test 
values also makes it difficult to integrate data or test results into a patient’s medical record, or to 
make use of the test results outside the institution or setting in which they are produced.  This 
issue is widely recognized in the laboratory medicine sector and efforts are underway to 
standardize values.  Certain tests, such as C-reactive protein, require higher sensitivity in order to 
correlate test values to clinical diseases (e.g., cardiovascular disease).  Efforts to define 
performance criteria for such high-sensitivity tests may lead to improved standardization, 
performance in quality assessment schemes, and enhanced risk prediction.130 
Report Review, Interpretation, and Verification 
Subsequent to specimen analysis, the next step in testing is report interpretation and verification.  
In most large clinical laboratories, test results are produced from and stored in the LIS.  In these 
laboratories, test data may be entered manually into the LIS or automatically transferred to the 
LIS from automated systems.  However, smaller laboratories, POLs, and providers using POCT 
devices often document values without use of an LIS.  In these instances, the results reports may 
be generated from a printer linked to analyzers or a POCT device, or documented directly in the 
patient’s medical record.     
Review of laboratory reports requires checking the results for any instrument error codes, 
markedly abnormal (especially critical) results, or specimen integrity issues; comparing multiple 
results on the same specimen if applicable; and determining appropriate commentary for 
inclusion in the final report.  Most laboratories have a few levels of review depending on the type 
of test and values in the report.131  At the first level, the technician or technologist analyzing the 
specimen reviews the test results.  Then, the supervisor (technologist) approves results for certain 
tests, and may report results to the clinician unless additional review by more senior professional 
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staff is required.  At the next level, a professional staff member (e.g., pathologist, doctoral-level 
scientist, microbiologist, biochemist, bioanalyst) reviews and approves the test results for release.  
Senior level review and approval usually is performed when test results indicate abnormal 
values.  Manual review of results is necessary in such instances as verification of anatomic 
pathology results and critical test results.  However, automated verification systems now exist for 
tests such as chemistry and hematology assays.   
Most laboratories continue to use manual processes for report validation.  Manual test validation is 
a time-consuming, tedious process with large interindividual variation that slows laboratory TAT.107  
Common errors associated with manual processes are data entry/transcription errors that account 
for about 4.6% of all hospital laboratory errors.43, 76    
Automated verification (or autoverification), shows promise in validating results without review 
when the results meet predefined criteria.132, 133  These mechanisms rely on knowledge-based 
techniques such as internal consistency checks, delta checks,o and checks for specific errors in 
addition to the standard reference range and pathological limit checks of the LIS.133  Also, report 
processing by these systems is fast and highly efficient.  For example, an immunoassay 
autoverification system, under the direction of a supervisor, can validate close to 500 results in 
about 30 minutes.135  Autovalidating can allow senior level laboratorians to focus on difficult cases 
and interact with clinicians.  Some autoverification systems lack the ability to scan control data 
before the report is generated.136  Beyond these advantages, it remains to be demonstrated that 
autoverification systems improve patient safety and outcomes.107 
Reference Intervals  
Reference intervals, also known as reference or normal values,p are pre-determined values against 
which laboratory test results are compared in order to allow clinicians to make physiological 
assessments, medical diagnoses, and management decisions.138  The intervals are established by 
testing a group of individuals selected on the basis of well-defined criteria.139      
The most common type of reference interval, health-associated intervals, is derived from a 
reference sample of people who are in good health.  For example, 95% of the healthy adult 
population tested by many laboratories has a serum potassium level that is between 3.5 and 5.1 
mEq/L; this range is used to define the serum potassium reference interval.  Disease-associated 
intervals, sometimes referred to as decision-based intervals, are specific medical decision limits 
that allow clinicians to classify patients as having a disease, as being healthy, or to otherwise 
manage patients.140  For example, hyperlipidemia guidelines typically recommend diet and 
exercise to lower cholesterol in otherwise healthy adults once their serum cholesterol level 
exceeds a certain threshold, e.g., 200 mg/dL.138  Disease-associated intervals are often defined 
during clinical trials and incorporated into the medical literature and adopted by laboratories. 
The creation of reliable reference intervals is an important task for both clinical laboratories and 
for manufacturers of diagnostic tests.  While individual laboratories independently may obtain 
                                                 
o A delta check is a comparison of consecutive values for a given test in a patient's laboratory file used to detect abrupt 
changes, usually generated as a part of computer-based QC programs.  If a delta exceeds its threshold, the value for 
“today” fails the check and is suspected of being erroneous.134 
p The term reference interval is preferred over normal values because it can be defined for a given reference population.137     
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similar test results, these results may be interpreted differently if different reference intervals are 
being employed, leading to differences in what is considered healthy or pathological.109  
However, reference intervals historically have been poorly defined and not determined using a 
uniform process, leading to considerable variation in clinical laboratories.139  Inter- and intra-
laboratory differences in preanalytic and analytic factors also have been implicated as sources of 
variation in the development and application of reference intervals.140   
Some work has been done to standardize the reference interval process.  CLIA requires that 
laboratories introducing an unmodified, FDA-cleared or approved non-waived test system verify 
that the reference intervals supplied by the manufacturer are appropriate for the laboratory’s 
patient population before reporting patient test results.141  CLIA also requires that laboratories 
modifying FDA-approved tests or developing their own tests establish reference intervals for their 
assays prior to reporting patient test results.  In all cases, reference intervals must be included in 
laboratory reports or made available to individuals who order tests.142  In 2000, the Clinical and 
Laboratory Standards Institute (CLSI) published a voluntary standard for clinical laboratories and 
test manufacturers that provides information on defining and determining reference intervals with 
the intention of achieving a level of reliability and accuracy across reference intervals.139  Assay 
harmonization also has been proposed to eliminate the requirement that each laboratory establish 
its own reference intervals.140  At present, however, there are few enforced regulations to ensure the 
validity of the reference intervals defined by individual laboratories.  A 2007 CAP Q-Probes study of 
163 laboratories found that approximately half of all laboratories adopted reference intervals from 
manufacturers without testing them on-site using healthy individuals.138                                
For many laboratory tests, no single reference interval applies to everyone because the test may be 
affected by factors such as age and sex.137  For instance, the concentration of alkaline phosphatase, 
a cellular enzyme responsible for creation of bone, rises in proportion to the production of new 
bone cells.  While children and adolescents should have high alkaline phosphatase levels, high 
levels in adults can be indicative of disease.  Similarly, hemoglobin and hematocrit both decline 
naturally as part of the aging process.  In many cases, reference intervals that are appropriate for 
pediatric populations and elderly populations have not been widely developed.  Thus, test values 
that are considered healthy compared to aggregate reference intervals may be abnormal if age-
specific intervals are used.140  The 2007 CAP Q-Probes study described above also found that few 
laboratories test healthy children to establish pediatric reference intervals; most of the laboratories 
that do test healthy children use in-laboratory testing only to validate reference intervals supplied 
by manufacturers rather than to establish their own reference intervals.138                 
ANATOMIC PATHOLOGY TRANSITIONAL PREANALYIC 
Specimen Processing/Accessioning and Preparation 
Anatomic pathology tissue processing/accessioning,q preparation, and examination in the 
analytic phase are generally more labor-intensive than for clinical pathology, which, in many 
large laboratories, relies more on automated modules for analyzing specimens.  The exception is 
microbiology, which also relies on labor-intensive microscopic examination.  Some of the 
                                                 
q Accessioning refers to the process of recording and assigning a surgical pathology identifier number to a case and 
specimen(s) that meet the laboratory’s acceptance criteria. 
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processing tasks of anatomic pathology are analogous to those in clinical pathology.  When 
specimens arrive, information from requisition slips and orders must be accurately transcribed 
and entered into the LIS or retrieved from a computer-based system designed for anatomic 
pathology; a sheet of labels is created, the specimen and labels are forwarded to the appropriate 
pathology section, and the specimen undergoes gross examination for acceptance or rejection.  
The similarities between processing in anatomic and clinical pathology end there.   
Preparation of an anatomic pathology tissue specimen is a complex, multistep process in which 
the tissue is repeatedly cut, transferred, and relabeled.  After initial preparatory cutting, the tissue 
is embedded in wax to create blocks for sectioning from the gross (whole) specimen and produce 
slides for examination under a microscope.  Most tissue cutting is performed manually by trained 
professional histotechnologists or pathologists’ assistants with the use of a microtome blade or 
scalpel, though automated cutting systems are in early development.  Though infrequent, injuries 
to the laboratorian can occur during early stage specimen cutting.  Usually, such injuries can be 
avoided by complying with safeguards such as use of protective gloves, use of handles with 
cutting blades, and avoidance of inherently dangerous maneuvers.143  
There are many points along the anatomic pathology workflow where errors and other threats to 
quality can arise.62  The most prevalent problems during the preparatory steps involve patient or 
specimen identification errors and mix-ups, cognitive errors in the gross room, tissue cutting- or 
staining-related issues, and specimen defects.  As noted above, patient and specimen 
identification errors that affect the analytic phase can begin in the preanalytic phase as a result of 
incorrect information on the patient or specimen requisition slip, specimen placement in an 
incorrectly identified container, specimen mix-ups and incorrect test ordering at the time of log in, 
or transcription errors.45  In a broad study of identification errors and mix-ups in all three phases 
of the testing process for surgical pathology, investigators found numerous sources of 
identification error, many of which pertain to specimen accessioning or preparation of tissue 
blocks and slides, including: 
 Specimen accessioned to wrong patient in the laboratory 
 Case misidentified in the gross room and dictated with wrong accession number or 
wrong specimen number 
 Specimen placed in or embedded into incorrect cassette 
 Specimen sections mixed up in water bath 
 Specimen placed on slide labeled for another specimen 
 Incorrect permanent label affixed to slide 
 Incorrect history/paperwork associated with slide62 
Additional identification-related errors that take place during and after microscopic examination 
are listed in the next section.  
Cognitive errors can occur during preparatory gross room tasks or microscopic examination.  
Little detailed information is available about these types of error.144 An example of a cognitive 
error of omission, defined as the failure to perform pertinent ancillary studies at the tissue, block, 
or slide level, may be the failure to take fresh tissue for flow cytometry or the failure to perform a 
Laboratory Medicine: A National Status Report Chapter IV – Quality and the Total Testing Process 
May 2008 159 
culture.  Other cognitive errors in the gross room may be inaccurate examinations with poor 
descriptions (e.g., lack of appropriate measurements), lack of or incomplete lesional sampling, 
and lack of sampling of pertinent areas necessary for proper lesional characterization or staging.  
Cognitive errors associated with gross room tasks can be common though difficult to detect.  
However, there is virtually no evidence on rates of cognitive errors in the laboratory.   
Incorrect conclusions can be drawn from poor technique associated with tissue cutting (i.e., 
undercutting or overcutting specimens) and tissue staining (e.g., misidentification of the 
appropriate stain, incorrect selection of reagents and staining protocol).  Cross contamination by 
“floaters” (i.e., foreign tissue fragments carried over from other sections or specimens) is a better 
documented quality problem. In a 1996 CAP study of 275 laboratories, extraneous tissue 
fragments were found in 0.6% of 321,750 slides examined prospectively and 2.9% of 57,083 slides 
examined retrospectively.  For the prospective study, 59.4% of the contaminants were found on 
slides, 28.4% on paraffin blocks, and 12.2% were undocumented.  In comparison, for the 
retrospective study, 72.9% of contaminants were associated with slides, 15.9% with paraffin 
blocks, and 11.2% were undocumented.  The majority of extraneous tissue came from different 
cases (63.2% in the prospective study and 48.5% in the retrospective study).  Study findings 
confirmed that more than 92%of instances of extraneous tissue originated in the laboratory.145 
ANATOMIC PATHOLOGY ANALYTIC PHASE 
Microscopic Specimen Examination 
In anatomic pathology, microscopic examination is the primary method for making clinical 
diagnoses, although innovative, automated technologies are increasingly being developed and 
used in cytology and molecular pathology.146  Digital microscopes with advanced capabilities for 
taking, storing, replicating, and cataloging digital images are used widely among laboratories.147  
Certain microbiology tests also rely on microscopic examination. 
Histotechnologists and cytotechnologists play an important role in the microscopic examination 
of tissues.  They formulate and document interpretive conclusions for presentation of cells, 
biochemical components, tissue vascularity and, if applicable, presentation of disease, which may 
include definition of grade and stage of disease, tumor type, measurements, and characteristics.148  
These laboratorians also play an important role in the examination of infectious agents present in 
tissue specimens.  Once the result is approved by the technologist, the pathologist reviews the 
findings.  A secondary case review may be undertaken or required as part of a QC check or if the 
diagnostic findings are unclear, as discussed further, below.  
Because of pathology’s dependence on visual association, technologists and pathologists must 
possess the cognitive and interpretive skills needed to evaluate accurately tissue specimens and 
establish diagnoses beyond a reasonable doubt.  The skill set requires visual pattern recognition of 
cells and structures, recognition of whether the arrangement is normal or abnormal, association of 
the features to diseases that mimic the pattern, development of multiple hypotheses or differential 
diagnoses, and investigation of the clinical or histological possibilities to rule-in or rule-out 
diagnoses.149  In surgical pathology, cognitive and interpretive skills are applied to histologic 
grading and staging, considered the most important prognostic indicators.  Although several 
grading systems exist, the National Cancer Institute’s three-grade system based on histologic 
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type, tumor necrosis, and mitotic activity serves as the general standard for determinations.  
Similarly, the American Joint Committee on Cancer pathologic staging system is the standard to 
guide evaluations of tumor size and depth.  For gynecologic cytology, standards for examination 
have been codified in CLIA.   
QC, performance evaluation, and test reproducibility to minimize diagnostic discrepancies and 
errors have been more easily defined and applied in clinical pathology than in anatomic 
pathology.150  The reliance on subjective judgment and somewhat variable diagnostic thresholds 
between individuals limits reproducibility and may introduce bias in areas of cytology and 
surgical pathology.  For example, one study conducted in 1995 in the area of neuropathology 
found discrepancies between general pathologists and neuropathologists.  The pathologists were 
in disagreement in 42.8% of cases.  Of those cases, 20.6% were considered serious (e.g., tumor 
diagnosis changed to non-tumor, diagnosis changed within benign or malignant), 44.9% were less 
serious but substantial (e.g., glioma type or grade changed), and the remaining 34.6% were minor 
(e.g., tentative or doubtful diagnosis confirmed).  These differences can have detrimental effects 
on patient management and costs.151   
When errors occur in anatomic pathology analytic processes, they can be classified as either 
cognitive or identification/clerical.  Cognitive errors at the microscope include slips and lapses 
while analyzing slides, poor cognitive formulations, knowledge problems, communication 
problems (e.g., poorly worded or unintelligible reports), and difficulties in using classification 
models that have poorly defined criteria.  Correct patient and specimen identification and record 
keeping throughout the processes associated with microscopic observations and documentation 
are crucial to quality and accuracy.17  Examples of identification and clerical errors include:  
pathologist examines wrong slide, pathologist dictates/writes incorrect case number, 
transcriptionist types diagnosis for incorrect case or specimen; downtime/temporary medical 
number updated incorrectly, and report prints with wrong patient identifier due to LIS error.62   
A literature review published in 2004 reported wide variability in anatomic pathology errors, 
ranging from less than 1% to 43% (with mean error rates of 1%-5%) among institutions 
participating in the studies reviewed.152  Error rates tended to be higher in cytology compared to 
surgical pathology, with false-negative diagnosis as the greatest source of error.  Most cognitive 
and identification/clerical errors are discovered before sign-out, although a small percentage are 
discovered thereafter.  Discovery in either regard may be precipitated by receipt of additional 
information or material for the current case or a different recent case, results review by the 
pathologist or other laboratorian, or pathologist-initiated external consultation with an expert.69  
Other methods of detection include intradepartmental review or a double-read of the results 
before sign out, and preparation for or presentation at a conference with clinicians (e.g., board 
review) after sign-out.  The patient’s clinician also may question the pathologists’ diagnosis and 
request re-evaluation of the specimen and/or findings, at which time an error may be discovered. 
Results Review 
In general, laboratory test results are transcribed into the LIS or another computer application, 
reviewed and approved by the pathologist, and delivered to the clinician.  In certain instances 
(e.g., a difficult case), the pathologist may seek an external consultation with another pathologist 
for a second opinion or specific expertise prior to finalizing the report.  When an experienced 
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pathologist finds that immediate recognition of the pathologic process does not occur, and that 
applying familiar rules and criteria do not lead to a clear diagnosis, the pathologist may face an 
unfamiliar scenario and can be prone to the same types of errors as the novice.17, 153  As such, 
seeking consultation is based on self-knowledge of one’s limitations and the severity of 
consequences of error.154  A study published in 2002 reported findings on the rates and 
characteristics associated with expert consultation.  Consultations were sought for 0.5% of cases, 
of which 52% were sent to nationally known experts and 32% were went to local experts.  Among 
the consultations, 54.6% confirmed the original diagnosis.  The referring pathologist’s assessment 
of possible diagnoses was correct in only 21.5% of cases, 15.9% of consults confirmed the original 
diagnosis but added significant information, 6.5% were discordant with the original diagnosis, 
1.4% were attributed to unidentified other factors, and 0.7% were ambiguous and not helpful.155 
After report sign-out, discrepancies and errors can be detected through secondary case review, 
e.g., via conference review (such as an oncology board) or institutional review.  The specific 
methods employed to determine discrepancies are correlation of findings and assessment of 
amended reports.  In general, rates of discrepancy and errors after cases are signed out are 
relatively low for cytology and surgical pathology.  One study involving 74 hospitals reported 
variability in rates and causes of laboratory discrepancies in anatomic pathology.  While 10% of 
hospitals reported no discrepancies, another 10% reported errors in at least 5% of diagnoses.  The 
mean frequency of laboratory discrepancies was 6.7%.  About 47.8% of discrepancies resulted in a 
change within the same category of interpretation (e.g., one tumor type was changed to another), 
20.9% resulted in a change across categories of interpretation (e.g., benign diagnosis was changed 
to malignant), 18.5% were from typographical errors, 9.1% were from a change in patient 
information, and 3.7% were from a change in margin status.  According to the investigators, 5.3% 
of discrepancies had a moderate or marked effect on patient care.156  
The most common method of detecting errors, before and after sign-out, is through the 
correlation of findings between different tests on the same tissue specimen.  Correlations of 
frozen-permanent sections and of cytologic-histologic findings are well-documented in the 
literature.  For gynecologic cytology, correlation of cytologic and histologic findings is mandated 
by CLIA.  Discrepancy rates using correlation are generally low.  For example, in a hospital study 
published in 2002, investigators reported discrepancies in nongynecologic cases of 2.26% for 
cytology and 0.44% for histology, and in gynecologic cases of 0.87% for cytology and 7.37% for 
histology.157  These rates were consistent with error frequency rates of other studies.  Several CAP 
studies that examined diagnostic errors on frozen sections also published discrepancy rates in the 
range of 1.4-1.7%.158, 159   
Error rates and types have been assessed by calculating the rate of reports that must be 
amended.  In a large CAP Q-Probes study conducted in 1996 of surgical pathology in 359 
laboratories, the aggregate rate of reports amended to change clinically significant information 
was 1.9 per 1000 cases.160   
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POSTANALYTIC PHASE 
The main components of the postanalytic phase focus on results reporting and interactions 
between laboratorians and clinicians.  The core challenges for pathologists and other laboratory 
professionals in their communication with physicians concern timeliness of reporting, notification 
of significant abnormal test results, and presentation of relevant information through reports and 
interpretive comments.  Customer satisfaction surveys have found that all of these factors receive 
high percentages of below average and poor ratings.12  These challenges are often cited as the 
chief concerns in the postanalytic phase.  
Test Turnaround Time 
The timeliness with which test results are delivered is one of the most prominent parameters of 
laboratory medicine and a common indicator of performance.161, 162  Common among these are test 
TAT and time for notification of critical results.  Automation of various steps in the analytic 
phase, increased use of electronic results reporting, and development of automatic electronic 
alerting systems for critical values have helped to decrease TATs.  
TAT is typically assessed by determining the difference between recorded starting times (test 
ordering) and ending points (test reporting time).163, 164  Some laboratories also analyze intervals 
that comprise TAT, such as test order to specimen collection, collection to laboratory specimen 
receipt time, and receipt time to reporting time, in order to determine the specific points at which 
delays occur.164  A few laboratories also are expanding the scope of measurement by evaluating 
”therapeutic TAT,” the time from initiation of the test order to the implementation of clinical 
decisions (e.g., change in treatment).165   
Regardless of method, TAT is viewed as a quality measure that reflects the performance of the 
testing process as a whole.  Prompt and predictable reporting of test results can increase efficiency 
of patient care and improve clinician and patient satisfaction, even when it does not affect health 
outcomes.163  Actions taken as a result of regularly monitoring TAT and other factors may 
improve certain aspects of performance.162, 164  However, researchers also recognize that shorter 
TAT measurements do not necessarily indicate superior service.162  That is, absolute 
measurements of TAT do not reflect whether the laboratory services meet the expectations of the 
clinicians using those services.  Also, improving TAT can be challenging, not only because of the 
contributing factors outside the control of the laboratory, but because laboratories frequently try 
to improve TATs for a specific test, location, or specimen type by immediately identifying and 
assaying those specimens in question, thereby extending the TATs of other tests.166   
Most TAT studies have focused on inpatient and emergency care settings, though a few researchers 
have ventured to outpatient settings.  TAT varies depending on the location of the laboratory (e.g., 
satellite laboratories often have shorter turnaround times than central laboratories) and the analyte 
(if other variables stay the same).  Typical TAT for routine testing in the emergency setting is 12-48 
minutes or less, particularly if POCT is available, a few hours for general testing in the inpatient 
setting, and a few hours to the next morning or 24 hours for testing in the outpatient setting.  One 
study of stat laboratories for the emergency department and ICUs evaluated outlierr test TATs, 
                                                 
r Outlier events are test TATs that exceed targeted or tolerable reporting times.  These events are used to assess the 
degree to which laboratory services meet the needs of clinicians.162 
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accounting for about 10-15% of total events.  The majority of problems directly affecting TAT for 
selected chemistry tests are associated with preanalytic-related test ordering and specimen 
collection (57%) and analytic-related personnel and technical problems (28%).164  Staff shortages in 
both phases were the major cause of delays.  The percentage of delays was 4.7% higher in ICUs than 
emergency departments.  Shortened TATs have been associated with rural locations, delivery of 
specimens as collected, pneumatic tube delivery systems, and continuous versus batch testing.167  
Innovative POCT devices also have had a significant impact of the reduction of TAT.  For example, 
a study of stat TAT in an academic health center reported TATs that were 1-2 minutes shorter for 
bedside testing compared with a satellite laboratory and 9-12 minutes shorter in the satellite 
laboratory compared to the central laboratory.165  
Data from studies of TAT for outpatient testing in hospital laboratories has produced different 
results.  In 1997, a Q-Probes study of TAT for three common assays reported that 50% of 
laboratories were able to verify 90% of results within 2.7 hours for the CBC, 3.5 hours for the 
biochemical profile, and 21.6 hours for TSH.168  For half of participants, outpatient testing 
accounted for about 46% of the typical hospital laboratory workload.  A follow-up study reported 
in 2002 found increases in TATs to 3.9 hours for the CBC, 4.9 hours for the biochemical profile, 
and 38.1 hours for the TSH.169  TATs increased for specimens received later in the day for all 
analytes and when specimen transport was not under the control of the laboratory.   
TAT, laboratory practices, and specimen characteristics (e.g., type of specimen and findings) 
associated with anatomic pathology (e.g., cytology, surgical pathology) have been examined as well.  
Result availability and timeliness are considered indicators of quality for anatomic pathology.  
Turnaround times varied substantially according to specimen type. A study of gynecologic cytology 
found that 50% of laboratories had a mean TAT of 6 days or less, though the average laboratory 
could complete 90% of their cases within 8 days; 10% of laboratories needed 13-19 days.s,170 TATs for 
nongynegologic cytology (e.g., fine needle aspirations) are much shorter; 50% of laboratories had a 
mean TAT of 1.6 days or less (3 days for 90% of cases); 10% needed 3.2-6 days.171  These cytology 
studies found that longer TATs were associated with the need to contact the physician’s office for 
additional information, and use of students, residents, or fellows in the evaluation.  In addition to 
these factors, gynecologic cytology TATs were influenced by use of reference laboratories for all or 
part of the evaluation and provision of service on the weekend, whereas TATs for other cytologic 
specimens were influenced by issuance of atypical/suspicious findings for malignancy diagnosis; 
having to pull prior case material for review; having to perform cell blocks, special stains, or other 
activities; and not having transcriptionists working weekends.   
Many laboratories also monitor TAT for surgical pathology with the goal of having the majority 
of cases signed out within 1-2 days.17  A 1995 Q-Probes study of biopsies and complex specimens 
documented mean TATs of 1.5 days for complex cases, 1.3 days for routine cases, and 2.6 days for 
cases requiring special handling.172  Factors associated with increased TAT included:  institutional 
bed size greater than 450, responsibility for gross section dissections assigned to residents only, 
slides not available to pathologist before 12:00PM, resident involvement in sign-out, interposing a 
day between availability of slides and final sign-out for resident education purposes, and a 
greater number of pathologists on staff.  These findings were confirmed in a subsequent study 
                                                 
s They concluded that, if one week is acceptable TAT and actual screening time is 5-10 minutes per slide, there is 
room for improvement.   
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published in 1998.  Pathologists had signed off on 85.9% of biopsy diagnoses by the second 
working day, and surgeons received the hard-copy reports by the fourth working day.   
Notification of critical values/test results 
A critical value or test result represents a pathophysiologic state at such variance with normal as to 
be potentially life-threatening unless something is done promptly and for which some corrective 
action can be taken.173  Timely, if not immediate, notification of critical values or results is crucial to 
patient safety.  Regulatory bodies now require laboratories to have policies for notification of such 
values, although performance benchmarks and definitions of specific critical values can vary by 
accrediting organization, laboratory, or health care setting.174  In many instances, providers will 
order laboratory tests stat even though the patient is not in a life-threatening pathophysiologic state. 
The variance may be in the high and low limits of the analyte values.175  In 2002, a CAP study of 
623 institutions confirmed wide variation in critical values for routine chemistry and hematology 
tests, with no value being the same in 80% or more of laboratories.176  For certain common 
analytes (e.g., glucose, potassium, hematocrit, white blood cell count), almost all laboratories had 
high and low critical values.  For other analytes, laboratories had either a high or low critical 
value.  About 72% of laboratories did not have a policy on repeat critical values for the same 
patient.  Of particular note is that more than 45% of critical values were unexpected and 65% 
resulted in therapeutic change.   
The Massachusetts Coalition for the Prevention of Medical Errors and the Massachusetts Hospital 
Association are leading a state-wide initiative to standardize critical values and reporting 
mechanisms for laboratory, cardiology, radiology, and other diagnostic tests across all health care 
institutions.177  The initiative aims to address “errors in the process of communication of test 
results that are both frequent and have the potential for serious harm.” A set of safe practice 
recommendations has been developed to promote successful communication of test results.  In 
addition, the group established a standardized set of abnormal test values widely agreed to be 
critical to patient health.   
The limits chosen for any clinical result directly affect the institution’s workload, as notifying 
clinicians of critical values is labor intensive.  A CAP Q-Probes study of 623 institutions, published 
in 2002, found that telephone contact is the primary method of reporting critical values by more 
than 90% of laboratories, with calls taking an average of 6 minutes for inpatients and 14 minutes 
for outpatients.  The calls were made by the laboratorian performing the test, most often a 
technologist.  For certain types of tests, other methods of notification include facsimile, computer, 
and voice mail.176   
Misreading values is not the only problem of communication.  In hospitals, accrediting 
organizations have required communication only with the responsible physician or caregiver 
(usually a nurse) since 2000.  To minimize miscommunication of values during notification calls, 
The Joint Commission requires the receiving clinician to ”read-back” the critical value along with 
patient identifiers.178  They also recently added monitoring of TAT for critical value reporting as a 
measure of quality and patient safety.   
Previously, communication followed CLIA provisions, which permit reporting with the entity 
or individual ordering or responsible for using the results, including unit secretaries.  This is 
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still the case in the outpatient setting.  Nurses receive 65% of reports in hospitals and 
unit/clerical staff receive the largest percentage (40%) of reports in physicians office practices.176  
Communication with clerical staff instead of clinicians can result in another type of error—
undocumented critical values in the patient’s medical record.174  Lastly, some critical values 
result from preanalytic problems, such as with specimen collection or analytic interference, 
rather than medically significant values.179    
While critical results in clinical pathology are time-sensitive, anatomic critical values are typically 
viewed as information-sensitive in that the report content is highly important but usually does 
not require immediate action.180  Occasional diagnoses in surgical pathology and cytology require 
immediate notification of the clinician to rapidly initiate treatment.181  Guidelines for critical 
results reporting in anatomic pathology have not been established.  Consequently, there is a wide 
range of opinion among pathologists about the need for an immediate telephone call and the 
degree of urgency.  Furthermore, most anatomic pathology results are not quantified with values 
and limits.  A 2004 study examined the potential for developing parameters to address critical 
results in surgical pathology and identified 11 possible cases including, but not limited to, renal 
biopsy specimens, vasculitis, and bacteria in heart valves or bone marrow.182  Differences in 
opinion prevail; only 58% of these reports documented calls to the clinician.  There was a greater 
difference of opinion when a new metastasis was identified in a patient and when an organism 
was identified in an immunocompetent patient. 
Report Formatting  
Laboratorians are trained to convert valuable data to useful clinical information in the form of 
laboratory results reports—the major communication link between laboratorians and clinicians.  
The reports are communicated to the clinician most often with the assumption that the basic 
pathologic process described is understood correctly.  While the clinician’s level of experience and 
training has direct impact on their understanding, this is not always the case, particularly with 
growing use of genetic tests and microbiology tests.  Yet, little attention has been focused on 
educating and training clinicians to more fully understand pathology reports.13  Few published 
studies have evaluated comprehension of laboratory reports and, of those available, most focus 
on anatomic pathology. 
The content, format, and physical presentation of the information significantly affect the 
interpretation and use of laboratory data by clinicians.76, 183  Mistakes in the content and 
completeness of laboratory reports as well as misunderstanding by the treating physician as to the 
significance of the information in the report, among other factors, can delay treatment of a serious 
disease and alter outcomes.144  Problems can be magnified when a critical result is unanticipated 
by the clinician.     
Specific report content issues can include any of the following: uninterpretable information, 
incorrect data or reference intervals, inaccurate patient identification, or incorrect physician or 
patient location for reporting results.  A 1992 CAP study of mistakes in clinical pathology 
laboratory reports found that the frequency of content errors was lowest in blood bank reports, 
intermediate in chemistry and microbiology reports, and highest in hematology reports.184   
Clinicians’ limited willingness or ability to interpret laboratory reports may result in their 
focusing inordinate attention on certain values while disregarding others of potential importance 
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or failing to discern broader clinical implications.  For example, in a survey of attending and 
house staff physicians in a major hospital system reported in 2002, only 4 of 11 analytes routinely 
reported in the CBC battery were selected as frequently or always useful by more than by 90% of 
responding physicians:  hemoglobin, hematocrit, platelet count, and white blood cell count.  
Primary care physicians also chose mean cell volume as a useful parameter in the evaluation of 
anemia.  The investigators suggested that modifications to report formats were needed to 
facilitate physician perceptions of the importance of hematology laboratory results.185  
Laboratories also must be cognizant of how new medical findings affect results interpretation and 
reporting.  The incorporation of new evidence into clinical guidelines can expand indications for 
treatment, requiring laboratories to update report content and interpretations.  For example, in 2001, 
the U.S. National Cholesterol Education Program issued new guidelines for the prevention and 
management of high cholesterol in adults, based on accumulated evidence concerning the 
contribution of lipoproteins (and other risk factors) to the development of coronary heart disease.186  
The guidelines necessitated changes in laboratory analyses, reporting, and interpretations including:  
modification of cut-points, standardization of measurements, fasting profile at initial screening, and 
testing for emerging risk factors and secondary dyslipidemias.187  Values must be presented clearly 
in reports with appropriate interpretive comments reflecting current guidelines.   
Several organizations have developed voluntary minimum standards outlining the data elements 
that should comprise reports.  For example, CMS endorsed the Bethesda System for reporting 
cervical cytology results, CDC issued standards for reporting HIV results, CLSI has suggested 
standards for microbiology test results and others, CAP established several standards for specific 
types of clinical and anatomic pathology reports, and the Association of Directors of Anatomic 
and Surgical Pathology has focused on its respective areas of expertise.   
The data elements for reports are selected with the primary aim of promoting accuracy and 
completeness.  The different standards are widely accepted; however, variability in report 
accuracy and completeness remains among laboratories.  For example, a CAP Q-Probes study of 
bladder biopsies and curettings in 268 institutions noted that the presence or absence of 
muscularis propria should be routinely included in reports of all biopsies. Yet, for invasive 
carcinomas, definitive assessments were reported in only 53.3% of cases, and in only 30% of 
noninvasive carcinomas.188  Another CAP study of breast biopsies, published in 1997, found that 
23% of reports of malignant cases were missing information on tumor size, 17% on tumor grade, 
and 8% on margin status, and 24% did not have information on the extent of intraductal 
carcinoma.189  These studies and others also found that the single practice that was most effective 
in ensuring completeness of reporting was use of a checklist.  The checklist guides laboratorians 
in documenting test results to ensure the inclusion of specific data in the final report.189, 190 
The physical presentation of test results can influence the clinician’s understanding of them.8  Poorly 
designed reports can result in misunderstandings and/or undervaluation of important 
information.191  More specifically, the spacing, highlighting, font size, and formatting of content can 
affect comprehension of computer-generated reports for clinical and anatomic pathology.  
Grammar and word selection also are important for anatomic pathology reports where, unlike 
clinical pathology reports, results are documented via selection of predefined phrases and drafting 
of free text commentary.  In general important, unusual, or critical results in clinical and anatomic 
pathology reports can be emphasized with capitalization, a special mark in the margin, or 
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underlining.192  Color highlighting in electronic reports or printouts can highlight a result for the 
viewer’s attention.  Unfortunately, most computer-generated reports still crowd data into columns 
on each page, are single-test focused, and employ limited use of graphics for certain tests.123, 193   
Because specific details of interest to the user are more difficult to abstract from sentences and 
paragraphs, clinical and anatomic pathology reports now organize content in synoptic formats.194  
Key information provided in tabular form is generally a reproduction of the checklist data. Variable 
amounts of free text can be added in the form of special gross features and comments on other 
important findings and implications.  In general, the data elements are relatively consistent from 
one computer program to another, but the presentation may differ according to vendor.  
Laboratorian selection of data elements also may result in content differences.  Synoptic formatting 
generally has improved report legibility relative to straight textual summaries, although more work 
is needed to ensure timely comprehension of test results and accompanying information. 
A few researchers have examined the impact of redesigned report formats to more graphically-
oriented models.183  One recent study of surgical pathology reports assessed the effect of report 
redesign on physician comprehension and found a 30% discordance rate between pathologists’ 
intended meanings and interpretation by surgeons.183  The authors stated that stylistic 
improvements have the potential to interfere with comprehension and increase the number of 
misunderstandings, and that further research is needed.  Generally, researchers believe that the 
forthcoming proliferation of proteomic and genomic tests will challenge clinical informatics and 
prompt changes to existing report formats.193  To meet this challenge, the next generation of 
laboratory reports must make better use of graphical displays to facilitate the rapid assimilation and 
comprehension of important data.  Developers have been using these concepts to improve the 
design, function, and comprehensibility of electronic health records (EHRs) over the last decade.  
Further advancements should incorporate user-friendly graphical displays of laboratory data.      
Physician Interpretation and Follow-up 
In the TTP, a laboratory test is not complete until its result has been interpreted by the clinician 
and incorporated into patient care, as appropriate.  There is considerable evidence indicating that, 
for a variety of reasons, physicians often do not take, or do not document, appropriate actions in 
response to abnormal laboratory test results.  In a CAP Q-Probes study of elevated calcium levels 
in 525 institutions, published in 2000, 3.5% of reports of abnormal levels were not entered into 
patient medical records.  Of reports that were entered, 23% did not contain physician progress 
notes responding to elevated calcium results; this figure rose to 93% for patients with no known 
history of hypercalcemia.  Also, follow-up tests were not ordered for 13.8% of the elevated values.  
However, in a follow-up survey of physicians for whose patients there was neither physician 
documentation of an abnormal test nor ordering of the designated follow-up test, the majority of 
responding physicians indicated that they did order the test and that the results led to further 
action that was not documented in their notes.195  A retrospective study of 2000-2002 data in 30 
U.S. academic medical centers reported that only 40% of diabetic patients with high HbA1c and 
only 5.6% with high low-density lipoprotein cholesterol had adjustments in treatment based on 
these results.32  A similar study of 1999-2000 data of elderly non-insulin-requiring diabetics in 
Ontario showed that fewer than half of the patients of endocrinology specialists or primary care 
providers had adjustments in treatment based on elevated HbA1c levels.196  
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Interpretive Consultation Services 
The actual and potential benefits of laboratorians providing information and consultation to 
physicians  on laboratory test selection and interpretation of patient-specific results is generally 
recognized.10, 197, 198  While most laboratories provide some form of interpretive comments in 
anatomic pathology reports, this is not always the case with clinical pathology reports.  Medicare 
reimburses consultations only for the 20 clinical pathology tests that frequently require 
interpretation by a pathologist.199  Most private insurers and managed care organizations follow 
this Medicare policy.   
The primary barrier to interpretive commenting is the shortage of true experts with high 
subspecialty expertise in clinical pathology.  Other barriers contributing to this problem include:  
generally low reimbursement for professional activities within clinical laboratories; more complex 
criteria for reimbursement of selected clinical pathology tests; and a shift toward the practice of 
anatomic pathology where reimbursement for interpretive comments is provided for all anatomic 
pathology tests.197, 199  As a consequence, most current pathologists and scientists do not provide 
clinically valuable interpretations in areas such as coagulation, autoimmunity, and other complex 
areas of laboratory medicine, although some of these professionals do so despite lack of 
incentives.  A 2004 report of an evaluation of interpretive commenting in clinical chemistry found 
that many of the comments were automatically generated by a computer, whereas others were 
individually generated depending on the results and availability of clinical information.  The 
majority of comments were acceptable; however, some comments were inappropriate, 
misleading, or, in few instances, dangerous to patient care.198  Inappropriate comments were the 
result of inaccurate assumptions by staff when the clinical information available was insufficient 
or when the expertise in clinical chemistry subspecialty areas (e.g., toxicology, endocrinology, and 
tumor markers) was inadequate.   
Despite these few challenges to interpretive commenting, the service generally is well received by 
physicians.10, 12  Several organizations have been studying methods of improving the quality of 
communication between clinicians and laboratorians during ordering and results interpretation by 
developing programs that expand the use of interpretive commenting in combination with other 
tools.  For example, a major academic medical center instituted a broad laboratory medicine 
interpretive service and undertook a series of studies to assess improvements.  The service provides 
a physician expert-written, evidence-based, patient-specific interpretation that accompanies the 
results of complex laboratory testing panels.9, 197  A study of its coagulation service found that 98% 
of physicians perceived the interpretations as useful or informative, 59% perceived reduced time to 
diagnosis, 72% perceived that the interpretation reduced the number of laboratory tests required to 
make a diagnosis, and 72% believed that it helped them to avoid misdiagnoses.10   
POINT-OF-CARE TESTING 
POCT, also known as bedside, near patient, decentralized, or alternative site testing, refers to 
clinical laboratory testing that is conducted close to the site of patient care outside of the 
traditional, core, or central laboratory.200, 201  The main objective of POCT is to produce a result 
quickly, facilitating decisions about appropriate treatment and care to improve clinical or 
economic outcome.202  POCT can be performed in various settings, including sites of primary care 
(e.g., physician’s office and community clinic, community pharmacy, health center, workplace 
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clinic) and secondary and tertiary care (e.g., emergency room, ICU, outpatient clinic, ambulatory 
diagnostic and treatment center).t, 203        
Similar to traditional laboratory testing, POCT can be delineated by preanalytic, analytic, and 
postanalytic components.204, 205   Some benefits of POCT include decreases in the amount of 
specimen required and minimization of delays that are associated with specimen transport, 
processing, and preparation203 
Ensuring high quality in POCT poses several challenges.  Many POCT devices are granted CLIA-
waived status and are operated by personnel whose primary training may not be in the clinical 
laboratory sciences and who may, therefore, be unfamiliar with testing practices.202, 206  Unlike 
laboratorians in the central laboratory, POCT operators often have minimal time to reflect on the 
TTP and may not have access to ancillary information such as QC data.  Non-adherence to test 
protocols and procedures and operators’ use of reagents that are not controlled are two other 
sources of error in POCT.204  Improved QC performance in POCT blood glucose monitoring has 
been directly associated with supervision of QC programs by laboratory personnel rather than 
nursing personnel.207   
Laboratory experts have also identified possible sources of POCT error amplification, i.e., 
conditions that increase the frequency or likelihood of POCT error, including those that become 
preventable adverse events.204  For example, suboptimal use of real-time POCT results, such as 
initiating the incorrect therapeutic action or failing to immediately recognize the significance of a 
test value, can amplify errors in POCT.  While the immediate availability of POCT results can 
significantly enhance the quality of care, additional research is needed to determine the best 
methods for integrating POCT into day-to-day clinical processes (i.e., care pathways).208    
PREANALYTIC PHASE 
Selection of Testing Method 
In the hospital setting, professional laboratory consultation and inclusion of the laboratory in the 
selection of test methods and ongoing management of POCT are important components of 
successful POCT programs.209, 210  Consultations with the core laboratory can assist clinicians by 
providing information about the advantages and disadvantages of POCT versus core laboratory 
testing in specific patient settings.205  Laboratory participation in the development of practice 
guidelines for laboratory order sets can decrease practice variability and ensure that POCT 
operators are following the most cost-effective pathway to the best patient outcome.  Laboratory 
staff also can create reference manuals for each nursing unit (or physician office) that contain 
written procedures, policies, training checklists, and other information.205    
Testing in physician offices differs considerably from that conducted in the hospital setting, 
particularly in such matters as testing menus and knowledge of quality-related procedures.  
Physician office personnel usually have been trained only in performing a few tests of limited 
complexity.211  If questions arise pertaining to POCT, these personnel typically contact the 
diagnostics manufacturer rather than consult with a hospital or independent laboratory.       
                                                 
t While certain POCT can be conducted at home by individuals, this chapter focuses on clinical uses of POCT; home 
laboratory testing and direct access testing are discussed elsewhere in the report. 
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Test Ordering 
Excessive or incorrect test ordering can contribute to medical errors at the point of care.204, 208, 212    
Excessive ordering can confuse and overwhelm test interpreters.  Increased use of CPOE, clinical 
decision support systems (CDSSs), and EHRs may prevent incorrect, excessive, and redundant 
POCT ordering by standardizing test ordering and reminding clinicians about previously ordered 
laboratory tests.38, 213, 214  CPOE and CDSSs are discussed in greater detail in the Laboratory 
Information Systems chapter of this report. 
Another source of error related to test ordering is mistimed or uncoupled testing, which occurs 
when the delivery of laboratory test results is not synchronized with the therapeutic intervention 
during dynamic treatment.204  For example, if incorrectly timed or interpreted, receiving results of 
POCT pH and bicarbonate tests during infusions of bicarbonate for patients undergoing 
cardiopulmonary resuscitation may prompt test interpreters to react to test results stemming from 
a transient or recent pathophysiologic state, rather than to the patient’s current state.         
Patient/Specimen Identification 
POCT error patterns related to patient and specimen identification tend to differ from those that 
occur during traditional laboratory-based testing.  Patient misidentification is more likely with 
POCT in emergencies when there is a greater potential for a staff member dispatched to perform 
POCT on a patient to mistakenly test or record results for a different patient.204  POCT operator 
entry of an incorrect patient identification number can lead to such problems as posting of results 
to the incorrect patient medical record, inappropriate medical treatment, and unavailability of 
POCT results for comparison with previous and subsequent test results.204, 205  Incorrect patient 
identification also can result in failure to post test results in the LIS and improper billing.      
Patient identification errors in POCT can be reduced.  Computerization of POCT devices 
increasingly allows for electronic capture of information such as the date, time, operator and 
patient identification, device serial number, reagent and control lots, and control ranges, thereby 
automating this information capture.215  Some POCT devices have mechanisms that lock out 
operators who repeatedly make identification errors, facilitating corrective counseling of these 
operators prior to further use.205  For example, one health system that implemented a “three-strike 
rule” found that glucose meter testing errors decreased significantly, although there was no 
impact on the rate of blood gas errors.216  Other POCT devices can lock out testing if patient 
identification is invalid or unavailable.217  Another method for safeguarding hospitalized patients 
prior to POCT includes cross-checking patient information against the bed location.   
Electronic barcodes have been installed in hospitals recently to automate data entry, and many 
POCT devices have built-in barcode scanners.218  In order to be successful, all of the components 
that must be identified to the system must be barcoded, including the patient, operator, testing 
strips, and QC materials.  Following implementation of an automated barcoding system, one health 
system found significant reduction in error rates in the glucose and blood gas devices.216  Another 
example of barcoding is a POCT system that uses a special syringe with a unique barcode identifier 
that scans the barcode, the patient’s wrist band, and the phlebotomist’s identification badge.208  In 
this system, the patient’s identification is maintained throughout all phases of testing and is linked 
to the test results and other relevant information.  However, limitations in barcoding (e.g., difficult 
to read through blood stains and moisture, limited number of encodable characters, need for proper 
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physical alignment of barcode and reader) have prompted interest in other systems for automatic 
identification, including radiofrequency identification.218   
A POCT error that is characteristic of outpatient settings results from batching of specimens.204  This 
error most often occurs with urine tests and rapid tests for GAS antigen that are left on the counter.  
Labeling of containers and swabs immediately upon collection reduces batching-related errors.  
Specimen Collection 
Specimen collection errors include inappropriate or inconsistent specimen type, volume, or 
application to the testing surface or reaction chamber on the POCT device.204  Operator variability 
and error rates in POCT specimen collection are influenced by several factors, including the extent 
and effectiveness of operator training and the frequency with which POCT operators perform 
specific tests and progress along the learning curve for each test.204  Several approaches can be 
employed to reduce the likelihood of specimen collection error.  For example, minimizing the 
number of different types of POCT devices and the number of staff performing testing and 
selecting a single manufacturer and model of device for hospital-wide use allow for using one 
testing protocol and training program, resulting in less confusion for POCT operators who work 
at several sites.205  Operators also need to be trained and revalidated.  Several studies have 
reported that non-laboratory professionals can obtain measurements that are just as accurate as 
those obtained by laboratory professionals if properly trained in QA and device maintenance 
prior to using the POCT device.219, 220 
Automation in POCT devices can prompt the operator to enter specific information, ensuring that 
every test follows the same sequence.205  Some POCT devices have functions that warn the 
operator about common preanalytic errors and lock out untrained operators.       
ANALYTIC PHASE 
The relative importance of precision and accuracy in POCT depends on the site of testing.  For 
home-use POCT, precision is likely to be more important; while a POCT device may be biased, 
the device is functional as long as the patient knows how to track and interpret results over time 
and determine treatment based on the results generated by that device.221  In those circumstances, 
absolute accuracy is not as important as the precision and daily consistency of results.  Whether 
they are evaluated in an emergency room, operating room, ICU, general medical unit, or 
outpatient setting, the results of POCT must correlate closely to those generated by the central 
laboratory via results verification, including delta checks, and interpretation. 
An important POCT issue concerns the tradeoffs between rapid results and analytical test 
performance.203  Several studies have assessed the analytic validity of POCT devices, primarily 
comparing POCT results to those obtained in the central laboratory.  Findings vary by the setting of 
device use.  For example, two recent studies confirmed the precision and accuracy of POCT glucose 
meters using blood samples from patients attending outpatient clinics for routine checkups and 
who were not suffering from underlying disease that required immediate hospitalization.222, 223   
A study investigated the performance of POCT glucose meters in hospitalized patients with 
serious underlying disorders in addition to their diabetes found that, at high and low glucose 
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levels, there was significant disagreement between glucose meter readings and laboratory 
analyzer readings.  The authors concluded that clinicians should be cognizant of POCT meter 
readings at the hypo- and hyperglycemic levels and corroborate these results with those obtained 
by central laboratory analyzers whenever possible.224  Another study measured the accuracy and 
clinical impact of three common POCT methods for glucose measurements in critically ill patients 
receiving insulin infusions:  glucose meter analysis of capillary blood (finger stick); glucose meter 
analysis of arterial blood; and blood gas/chemistry analysis of arterial blood.225  All patients were 
enrolled for a maximum of three days and had at most nine sets of measurements.  Glucose meter 
analysis of arterial and capillary blood tended to provide higher glucose values than blood 
gas/chemistry analysis of arterial blood.  The study reported that the magnitude of these 
differences led to frequent clinical disagreements regarding insulin dose titration in insulin 
infusion protocols for aggressive glucose control.                         
Specimen Analysis 
Several factors can interfere with the operator’s ability to detect factors that can degrade POCT 
test quality.  Most POCT assays accept small sample volumes, in which evidence of hemolysis 
(i.e., the breakdown of red blood cells) or clots can be difficult to detect.  Some POCT devices now 
contain a mechanism to detect the presence of clots or bubbles in the specimen.205  Common errors 
also result from patient-related interference (e.g., non-specific agglutinins in precipitation slide 
tests), specimen-related non-target influences (e.g., drugs that cause false results in chemistry 
POCT devices), and specimen-reagent combination-related matrix effects.204  The design of most 
POCT devices hides specimen reaction sites from view, making it difficult or impossible for the 
operator to assess the progress of the reaction or to distinguish patient, specimen, and matrix 
sources of error. 
Another opportunity for error in the analytic phase of POCT arises from failure to calibrate a 
POCT device, deviating from the calibration protocol, and misrecording calibration data.204  
Similar to all laboratory instruments, calibration requirements for POCT devices differ depending 
on such factors as how frequently the device is used and whether it is disposable after single use.  
Among other requirements for non-waived POCT devices, the CAP 2006 checklist requires that 
calibrators for POCT devices are properly labeled, calibration results are documented, criteria are 
established for calibration verification, and test systems are recalibrated when calibration 
verification fails to meet the established criteria.226  The CAP checklist for waived POCT requires 
calibrators to be properly labeled and that POCT programs follow manufacturer instructions for 
calibration and calibration verification. 
Quality Control   
Because central laboratory and POCT methods and techniques differ, traditional QC applied to 
POCT can be costly and ineffective for identifying problems that can compromise the quality of 
POCT results.227  It is difficult to apply conventional QC procedures to POCT for several reasons, 
including:  the number of different instruments, the diverse training and experience of POCT 
operators, and the inability to view and assess the analytic reaction chamber  of the devices.228  
Some laboratory experts contend that QC is irrelevant and unnecessary in POCT because the 
instruments are relatively error-free and the prevalence of preanalytical errors renders QC of the 
analytical process useless.229  However, most experts believe that POCT must have a QA and QC 
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program equivalent to those used in the central laboratory.  The latter position is supported by the 
findings of the CDC Pacific Northwest Monitoring Network study, which reported that 42% of 
POCT waived tests were regarded as providing a definitive diagnosis without further 
confirmation and 9% were used to monitor patients and whose results had the potential to 
directly affect therapeutic interventions.230      
The design of POCT devices, particularly those for single-use testing, has forced manufacturers to 
assume responsibility for building QC into POCT products, a process often referred to as 
“autonomation.”208, 229  Increasingly, if the instrument-controlled analytic process fails to meet the 
manufacturer’s quality criteria, the patient’s data are not released, thereby allowing the 
manufacturer to guarantee a statistically defined level of quality associated with each test result.208  
Internal QC systems may encompass electronic checks to assess the performance of the 
instrument’s electronic circuits, temperature, sample flow, electronic stability, and sensor 
response.231  Built-in basic positive and negative controls (i.e., “test worked/test failed”) are 
capable of assessing the viability of the analytic testing process, and more sophisticated, 
quantitative measurements can provide numerical responses to the analyte concentrations in the 
control.  More advanced systems may include a series of integral liquid controls and calibrators 
contained in closed reagent packs that have been validated by the manufacturer.208  Also, POCT 
devices may automatically record QC data, producing charts and statistics and applying QC 
algorithms to the data.231      
In addition to these built-in QC functions, other forms of POCT QC are recommended.  Specifically, 
POCT operators should directly observe instrument or method function by performing and 
recording results of QC testing each day.204  POCT supervisors should observe operators 
performing and recording QC and quiz operators on various scenarios of QC failure.  For both 
operators and supervisors, checklists help to ensure that procedures are being followed.  
Instrument or worksheet records can be compared to patient or maintenance records to identify 
any inconsistencies in the transfer of information.   
Laboratory experts agree that a QC check must be performed following the initiation of a new 
batch of reagents and when the system is recalibrated.u,203  Many experts also suggest that QC be 
performed when each sample is run and when each new operator uses the system.  Methods to 
determine the frequency of QC testing often are based on factors such as the overall analytic 
performance and reproducibility of the system and the number and competence of the operators.  
Typically, the frequency of QC depends on the type of POCT device.  For bench top analyzers, QC 
may be run at least once per shift (i.e., three times per day), whereas for critical care analyzers, QC 
can be preprogrammed to occur at specific intervals.     
Failure to perform QC has been cited as a common problem among facilities using POCT.233  CAP 
Q-Probes studies demonstrated that POCT operators commonly neglect to perform QC and/or 
report patient test results, even when QC procedures do not follow specified control guidelines.234  
Several studies have examined optimal QC techniques for POCT used in a variety of medical 
settings.  A large university-based health system studied nearly 600 technicians and nurses who 
had verified competency to perform POCT using two different devices to measure blood gas, 
chemistry, and hematocrit levels.  In this study, reported in 1999, investigators compared POCT 
results and core laboratory results extracted from the LIS and from POCT data management 
                                                 
u CLIA requires that operators of waived tests follow manufacturers’ QC directions.232 
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stations.  Discrepancies were noted and changes were implemented to improve POCT reliability 
where problems were identified, including in-service training and provision of additional POCT 
equipment.  The investigators concluded that POCT processes could be monitored and corrected 
using continuous quality improvement techniques.227   
A similar study involved a formalized continuous quality improvement program in which all 
testing sites in a large medical center were reviewed on a monthly basis for quality indicators 
such as QC and maintenance performance, PT, patient identification, and alert value 
confirmations.235  Major aspects of quality improvement requiring attention included 
instrument maintenance documentation, QC documentation for manual tests, and 
documentation of actions taken with the correction of failed QC tests.  Significant improvement 
was made in QC documentation of urine dipstick testing, including that the number of POCT 
sites not documenting more than 5% of QC results was reduced from 30% to 15%.          
 
Another facility’s QA program involved a database designed to incorporate five main 
components:  
 Documentation of initial device performance and reagent/control lots 
 Documentation of operator competence and compliance with daily QC regulatory 
requirementsv 
 Storage of proficiency and patient correlation results 
 Monitoring of performance and policy compliance 
 Determination and documentation of the effect of POCT on patient outcome using 
links between the POCT database, EHR, and LIS221   
Drawing from a national survey and consensus process reported in 2001, a multidisciplinary 
group of experts in critical care POCT programs and other hospital disciplines determined that 
QC in POCT must involve a mechanism for blocking patient testing if required QC procedures 
are not performed.217  These experts also recommended that requirements for QC and QC timing 
be matched to clinical priorities, patient test results be suppressed if QC results are unacceptable, 
exceptions to QC procedures be recognized for emergency situations, and that decisions be made 
about when to implement routine, urgent, or critical interruptions to QC processes. 
Result Generation and Verification 
Because POCT data are generated in series, operators often are not afforded a real-time review of 
trends and deviations in the sequence of test results that could enable identifying possible 
errors.204  Whereas delta checks of routine and stat central laboratory testing tells whether a 
patient’s laboratory test result differs significantly from previous results reported with the same 
assay, POCT operators do not usually have automatic access to previous results or automated 
statistical analysis, both of which are needed to perform delta checks. 
Potential errors in POCT report generation also can occur when patient test results are outside the 
device’s validated range.204  Organizations performing POCT must first ensure that the 
                                                 
v By using QC conducted during routine POCT device use, this institution could avoid having to visually inspect 
operators regularly and the additional testing and cost involved in routine inspections. 
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manufacturer’s suggested reference interval range applies to their respective patient populations.236  
Lack of QC, operator failure to recognize failures and problems in QC, and the absence or failure of 
performance-control monitors also can lead to acceptance of invalid results.204  Linking the POCT 
device to the hospital or laboratory information system allows for age-specific reference ranges, 
physician alerts, and other warnings to be included with the test results.208   
Verification of POCT results can be conducted using computer workstations; in this situation, 
information flows from the POCT device to the data manager and awaits LIS verification.237  
Expert decision-support functions in the LIS can autoverify the test results using predetermined 
expert system rules that are consistent with pre-existing rules for results reporting.238, 239  While 
few studies have examined autoverification of results received from POCT devices, the benefits of 
autoverification have been assessed in central laboratory testing.  Autoverification of results can 
speed TAT, improve laboratory workflow, and ease the effect of shortages in laboratory 
personnel; however, the autoverification process is not error-proof.240, 241  In order to prevent 
autoverification of potentially invalid results, the LIS must be able to capture all error flags 
generated by an instrument.  While it raises other concerns, it is likely that autoverification of test 
results received via POCT offers similar benefits.     
Few studies have examined error during autoverification of results received via POCT devices.  In 
a study reported in 2005, a core laboratory located in a large health system analyzed data to 
improve the rate of amended test results (i.e., correction of reported values after results 
verification).  Investigators reported that 34% of defects identified resulted from autoverification 
errors made by the LIS.242  However, in a study reported in 2005, a large clinical chemistry and 
urinalysis laboratory found that the number of inappropriately verified test results decreased 
following implementation of results autoverification.  In instances where results were 
inappropriately autoverified or prevented from being autoverified, modification of exclusionary 
setup rules eliminated the problem.241     
POSTANALYTIC PHASE 
Results Interpretation 
Incorrect interpretation of POCT results is a source of error that can severely affect the quality of 
patient care.  The potential for results misinterpretation emphasizes the importance of training in 
all phases of the testing process, including POCT results interpretation.205  It is vital for POCT 
operators to be aware of the strengths, weaknesses, and limitations of POCT devices, particularly 
where false positive results may arise from cross-reactivity with foods, medications, and/or 
metabolites present in the specimen being tested.243, 244  The NACB’s laboratory medicine practice 
guidelines recommend that organizations agree on and implement procedures that allow only 
those individuals recognized as being competent to interpret POCT results to do so.245 
Relatively few peer-reviewed scientific studies have examined the incidence of POCT errors that are 
related to results misinterpretation.  One study, reported in 2001, used simulated patient case 
examples with results of blood glucose and urine dipsticks to assess the interpretive abilities of 250 
nurses who routinely conduct point-of-care glucose testing.  When the results simulated a 
hypoglycemic patient, 84.1% of nurses correctly interpreted the results; 95.7% of nurses correctly 
interpreted results simulating a patient with diabetes mellitus.  However, only 5.4% of nurses 
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correctly interpreted the POCT results of a simulation of a case in which the puncture site had 
become contaminated, falsely raising the capillary blood glucose measurement that, if gone 
unnoticed, could have led to inappropriate dosage of insulin and other potential consequences.205, 246  
While this study reported no difference in test interpretation ability according to nurse seniority, 
others have reported differences in interpretation of POCT results when experienced laboratory 
personnel read the results versus when non-laboratory personnel perform the interpretation.247    
As noted above, linkages between the POCT device and hospital and laboratory information 
systems also have the potential to diminish errors in POCT results interpretation.  Particularly in 
critical care settings, a POCT operator who has access to the patient’s EHR and real-time 
knowledge of the patient’s treatment regimen and other critical physiologic measurements (e.g., 
pH, PO2, and hematocrit levels) is more likely to avoid the adverse effects of drugs and 
confounding variables on POCT device results.248, 249     
Critical Value Reporting 
The importance of timely and accurate critical value reporting for quality of care and medical 
error prevention is receiving national recognition.250, 251  Reporting of critical values received via 
POCT presents several opportunities for error.  Among these, criticality of the results may not be 
immediately recognized, criticality may not be noticed by the effective or designated clinical 
decision maker; and critical results may not be documented sufficiently for subsequent 
retrieval.204  These errors also can occur during reporting of non-critical POCT results.             
In the national survey and consensus process noted above, a group of experts in POCT programs 
in critical care and other hospital disciplines generated recommendations regarding critical, panic, 
and alert value reporting and documentation in POCT situations.217  Specifically, a list of relevant 
critical limits should be built into POCT devices and critical results should be stored in an easily 
accessible manner and annotated.  The individual obtaining or the clinician receiving the critical 
results should be recorded, and verification of critical test results should be requested.   
Improved techniques for critical values reporting have arisen from practical experience.  As 
described in a 2007 report, one emergency department at a tertiary care referral center with an 
annual volume of more than 50,000 patients found that, after implementing arterial blood gas 
testing at the point of care, critical values were not appropriately reported to physicians in 10 of the 
first 664 samples run (1.5%).252  After adding a physician “pick list” as a mandatory field, this 
problem was eliminated for future samples.  Emphasis on establishing and improving linkages 
between the POCT device and the laboratory computer system has played a major role in ensuring 
that critical values derived from POCT are reported and marked appropriately.  A detailed 
discussion of connectivity can be found in the chapter on Laboratory Information Systems.        
Report Formatting 
Several types of error can occur during report formatting.  Reports that lack units of measurement 
or use inappropriate units of measurement can lead to harmful misinterpretation of results, 
particularly when POCT is being used in critical care situations.204  Some POCT devices are not 
connected to printers, and results are displayed on the device itself; in these cases, results can be 
misperceived due to their appearance on a small screen.253  For printed results, POCT device 
outputs that are unclear also are associated with errors.204   
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Report Management 
The error potential in the final postanalytic step, report management, has not been as widely 
researched as results reporting.  Errors that can occur during report management may result from 
failure to check initially generated results against subsequently recorded results, leaving users 
unaware of discrepancies between a POCT device’s test result and the patient record; failure to 
record how clinical users acted upon POCT device results; and delayed recording of results, 
thereby delaying clinical users’ awareness of potentially critical information.204 
CONCLUSIONS 
The TTP defines the preanalytic, analytic, and postanalytic phases of the laboratory testing cycle, 
providing a systems-based framework for examining all possible interactions and activities that 
can affect the quality of laboratory tests.  This framework serves as the basis for designing and 
implementing interventions, restrictions, or limits that can reduce or remove the likelihood of 
errors that adversely affect testing and patient outcomes.   
 Quality activities in laboratory medicine have historically focused on the analytic phase 
of testing; however, available evidence demonstrates that a higher percentage of errors 
occur in the pre- and postanalytic phases of testing.  The distribution of errors varies 
widely among institutions and settings.  A review of several key studies found error 
rates of 32-75% in the preanalytic phase, 13-32% in the analytic phase, and 9-31% in the 
postanalytic phase.  
 Poor communication between laboratorians and clinicians during test selection/ordering 
and interpretation of laboratory findings is an important issue affecting the quality of 
laboratory services.  Although one out of four primary care physicians perceives that the 
scope of care expected of them is beyond their current knowledge base, they reportedly 
seek additional information when ordering tests only 30-50% of the time.  Medical and 
scientific advances, such as in genetic testing, will compound challenges associated with 
ordering the optimal sequence of tests, correctly interpreting results, and incorporating 
this information into clinical practice. 
 While consultations for anatomic pathology are standard practice and reimbursed, this is 
not always the case in clinical pathology. Yet, when provided, clinical pathology 
interpretive consultations are well received by physicians.  As reported in one study 
described in this chapter, 98% of physicians found this information to be useful, 59% 
perceived reduced time to diagnosis, 72% perceived that it reduced the number of tests 
needed for diagnosis, and 72% believed consults helped to avoid misdiagnosis. 
 The most common errors and reasons for specimen rejection during the preanalytic 
phase are associated with patient and/or specimen misidentification and specimen 
collection (e.g., insufficient volume, incorrect type of specimen, unusable specimen).  
Other errors include missing or incorrect information on laboratory test order forms.   
Among the strategies that are in place or evolving to reduce preanalytic errors are use of 
barcoded labels for containers and slides, inpatient wristbands with accurate identifying 
information, and CPOE.  
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 Analytic errors in clinical pathology typically relate to transcription errors; failure to 
reject an inadequate or damaged specimen; or bias often caused by interference, 
instrument calibration error, lot variations, or lack of uniform test values across 
manufacturers. Automated analyzers and results verification has decreased error rates in 
clinical pathology substantially over the past decades.  Errors that occur in the analytic 
phase are often the result of errors that originated during preanalytic processes. 
 In anatomic pathology, errors may occur during accessioning, in the gross room, or at 
the microscope, and are classified as specimen/patient identification-related, cognitive-
related (e.g., inaccurate conclusions, poor descriptions, knowledge deficits), or cross-
contamination-related.  External, secondary consultation is common in anatomic 
pathology; as summarized in one study, original diagnosis was confirmed in 70% of 
consultations, but significant information was added in 16%. 
 Core postanalytic challenges include improving TAT and notification of critical values.  
Both are key quality measures of the testing process, but are frequently cited for ratings 
of below-average to poor in customer satisfaction surveys.  In clinical pathology, TAT 
varies by setting, and delays are attributed to staff shortages in preanalytic and analytic 
phases.  In anatomic pathology, TAT varies by specimen type, with delays resulting 
from difficulty in reaching the clinician for additional information.  
 Better integration of laboratory automation and LIS could enable laboratories to identify 
and diminish error rates in the TTP.  This will require much improved communication 
within and among health care institutions, including, but not limited to systematic 
provisions for appropriate, timely communication between laboratorians and clinicians.   
 Inappropriate test use―including overuse and underuse―can compromise case 
management, result in adverse health outcomes, and increase health care costs.  It arises 
in tests for screening, diagnosis, and monitoring, and pertains to multiple types of 
cancer, cardiovascular disease, diabetes, and other prevalent conditions with high 
clinical and economic burdens and whose course can be affected by proper testing.  
Sentinel studies in recent years continue to identify and call public attention to 
inappropriate testing and its contribution to national shortfalls in quality of care.  
Principles of appropriateness in laboratory medicine are embodied in selecting the right 
test at the right time for the right patient.  Multiple factors lead to inappropriate test use, 
including test panels that contain unnecessary tests, poorly designed ordering forms, 
delays in performing tests, failure to use earlier test results, financial incentives, and 
malpractice concerns.  While evidence-based practice guidelines are helping to reduce 
inappropriate use, continued progress will require greater attention to how elements 
across the TTP mediate test appropriateness.     
Gaps, Needs, and Challenges: 
 The day-to-day demands of clinical practice leave physicians with little time to acquire 
knowledge of new laboratory tests.  Furthermore, the average medical student receives 
10 weeks or 70 hours of didactic coursework in medical genetics. 
 While CPOE has been shown to reduce the frequency of medication order errors, no 
research has examined the effect of CPOE on correctness of laboratory test orders.  As 
CPOE becomes more prevalent, this effect will need to be better understood.   
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 Thirty eight states currently allow individuals to directly request that certain laboratory 
tests be performed on their own blood or urine samples (some in limited capacity) and 
its popularity is increasing; however, little data exists on the frequency, appropriateness, 
and quality related to such orders. 
 Lack of uniformity and standardization of clinical pathology test values among 
manufacturers hinders implementation of laboratory-based guidelines, which require 
method-dependent decision limits.  Heterogeneity of test values also makes it difficult for 
clinicians to work in an integrated health system using more than one testing method. 
 The primary barriers to interpretive consultations in clinical pathology reports are lack of 
reimbursement for such consults and the shortage of true experts with high subspecialty 
expertise in coagulation, autoimmunity, and other complex areas.   
 QC, performance evaluation, and test reproducibility standards to minimize diagnostic 
discrepancies and errors have been better defined and applied in clinical pathology than 
in anatomic pathology.  Efforts should be undertaken to develop such measures for 
anatomic pathology. 
 The growth of innovative laboratory testing techniques is prompting changes to 
laboratory report formats.  Laboratory reports will need to make better use of graphical 
displays to facilitate rapid assimilation and comprehension of important data by 
clinicians, other laboratory professionals, and patients.  Standardization of data elements 
and report formats for laboratory tests is necessary to improve physician comprehension 
and use of results as well as integrate report data into clinical practice IT applications. 
 While the immediate availability of POCT results has the potential to significantly 
enhance the quality of care, additional research is needed to identify the best methods 
for integrating POCT into daily clinical processes.  Operators of POCT devices must be 
appropriately trained in testing practices, particularly QC.  In addition, methods to 
improve the accuracy of POCT results relative to those produced in the central 
laboratory warrants research.        
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CHAPTER V 
QUALITY SYSTEMS AND PERFORMANCE MEASUREMENT 
Quality generally refers to the level of performance or other attributes of interest that are achieved 
by a product or service.  The performance of a product or service can be defined and assessed 
quantitatively or qualitatively against designated standards or goals, whether for conformance to 
certain technical standards or specifications or realizing customer satisfaction.  Quality 
improvement programs and systems-based approaches to quality management can contribute to 
achieving and sustaining high levels of quality.     
As described by the IOM, quality in health care is the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are consistent 
with current professional knowledge.1  High-quality health care is:  safe, effective, timely, patient-
centered, efficient, and equitable.2   
Laboratory medicine contributes significantly to quality of care when tests and related services 
are clinically appropriate and provided in a technically competent manner with good 
communication.  This chapter provides an overview of the status of systematic approaches to 
quality and performance measurement in laboratory medicine.  
APPROACHES TO QUALITY SYSTEMS IN LABORATORY MEDICINE 
Public and private sector organizations in health care, including those associated with laboratory 
medicine, have described the need for patient care that consistently provides the highest levels of 
quality and safety.  Serious adverse events resulting in patient harm or death have prompted 
consumer and provider demands for greater quality and led to many of today’s quality 
improvement initiatives.  Even so, most initiatives to address quality and safety issues are 
undertaken with limited resources.2, 3 
Quality assessment in laboratory medicine has evolved from narrowly focused activities of QC to 
more comprehensive, systematic methods.  For over 50 years, laboratories have instituted diverse, 
evolving mechanisms to improve the quality of testing.  Until 1967, efforts generally targeted 
improvement in testing accuracy and precision for common analytes through the use of PT.  This 
is an external quality assessment process that evaluates and grades the laboratories’ analytic 
performance of selected tests.  Unfavorable performance rates decreased somewhat with use of 
PT as the sole means of measurement.  Passage of the Clinical Laboratory Improvement Act of 
1967, corresponding Amendments of 1988 (CLIA), and 1992 implementation of the final CLIA 
regulations standardized the approach to laboratory quality.  The regulations established minimal 
standards for QC; QA practices; PT; personnel qualifications and responsibilities; patient test 
management; and recordkeeping.  The specific requirements that laboratories must meet are 
based on the complexity of the testing performed.4 Laboratories performing moderate and high 
complexity testing, including hospitals, reference laboratories, and POLs, meet these standards in 
order to be certified.a  Laboratories performing relatively simple tests categorized as “waived” are 
                                                 
a Refer to the chapter on Federal Regulatory Oversight and Appendix A of this report for additional information 
about CLIA regulations. 
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not subject to CLIA standards, but are required to follow manufacturers’ instructions for test 
performance and QC.b  (Definitions of QC and QA are provided in Box 5.1 below.)  
QC and PT activities are reported to have had key roles in the reduction of errors associated with 
the analytic phase of testing.5, 6  According to the American Proficiency Institute, PT failure ratesc 
for chemistry and hematology laboratory tests decreased from 1994 to 2004 for eight analytes 
most often tested in physicians’ office and clinical laboratories.7  PT failure rates decreased from 
18.7% to 3.2% for cholesterol, from 6.3% to 1.1% for potassium, and from 5.7% to 2.4% for 
creatinine.  Failure rates for testing microbiology analytes decreased for both positive and 
negative cultures between 1994 and 2004.  Another study demonstrated decreases in deficiencies 
associated with inspections.  During 1995-1996, 30% of laboratories inspected to assess compliance 
with CLIA failed to perform QC testing and 13% failed to follow directions outlined by 
manufacturers.  By 2001-2002, 18% of CLIA inspected sites failed to perform QC testing and 6% 
were not following manufacturers’ directions.8   
While performance in the analytic phase of testing as evaluated by basic QC, QA, and PT has 
improved substantially since CLIA’s implementation, further improvements are necessary to 
achieve quality and safety.  The findings of CMS oversight activities, academic studies, and 
accrediting organization surveys reinforce the need to move beyond analytic-focused activities to 
a mechanism that supports integration of preanalytic, analytic, and postanalytic components as 
described in the chapter on the TTP in this report.  Such concerns arise, for example, when 
inadequate specimen volumes are obtained during collection, affecting the laboratory’s ability to 
test the specimen in the analytic phase.  Improvements in quality and safety at each critical 
control point along the path of the TTP require the extensive framework and methodologies 
inherent in systems-based approaches to quality management.  A critical control point is a point, 
step, or procedure at which control can be exercised to prevent, eliminate, or minimize a hazard.9 
The introduction of comprehensive systems-based approaches has been of interest to public and 
private sector stakeholders associated with laboratory medicine.  Several laboratory accrediting 
organizations took the lead in promoting the adoption of systems approaches voluntarily or as a 
condition of accreditation during the 1990s and early 2000s.  The Joint Commission, CAP, AABB 
(formerly the American Association of Blood Banks), COLA, and American Society for 
Histocompatibility and Immunogenetics (ASHI) advocate the implementation of comprehensive 
quality management systems (QMS), beyond the basic requirements of CLIA.10-13  
 In 2003, CMS restructured the QC and QA provisions in CLIA to reflect the flow of specimens 
through the laboratory, and integrated QA into all phases of testing.  The requirements now 
correspond to the broader framework of formalized systems-based approaches to quality 
management.  
                                                 
b Some states (e.g., New York, Washington) have more stringent requirements. 
c Failure rate is defined as: (number of unacceptable responses/ total number of responses) x 100. 
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Beyond the Basics to Quality Management Systems 
The Clinical and Laboratory Standards Institute (CLSI) d adopted a hierarchical model defining 
five tiers of quality.15-17  As presented in Box 5.1, QC and QA are precursor, lower-tier activities.  
Mid-level tiers include the introduction of quality management systems and quality cost 
management.  Long-term success in all tiers is necessary to maintain the highest levels of 
excellence and total quality management (TQM), generally known as continuous quality 
improvement (CQI) in health care.  
Most health care organizations are operating at or below the level of QA, although some 
organizations, such as the Veterans Health Administration (VHA) and Latter-day Saints hospital 
(Salt Lake City), are working successfully with strategic tools to implement quality management 
systems (e.g., CQI, failure mode and effects analysis [FMEA]).18, 19  Efforts over the last decade to 
redesign health care delivery systems have promoted adoption of the two higher-level activities:  
QMS as a tool for quality, safety, and performance measurement; and pay-for-performance 
programs, which, though largely unproven to date, may contribute to quality cost management.   
QMS have been used in a wide variety of applications to achieve major improvements in the 
quality, efficacy, safety, and/or customer-centeredness of processes, products, and services in a 
full range of manufacturing and service industries.20  QMS incorporates principles of engineering, 
manufacturing, and human factors science to establish an integrated infrastructure that optimizes 
and continually improves health care operations.  Structures, processes, and/or events are 
considered together as they interact to produce an outcome.21  Whether or not system components 
cross departmental or organizational boundaries, a single change anywhere in the system can 
affect other parts of the system.  The systems approach supports workflow design; performance 
monitoring; management of organizational, personnel, and informational factors; and leveraging 
technology and other contributing factors for a well-defined, constantly evolving, coordinated 
mechanism to produce desired outcomes and continuously improve quality.   
Organizations that implement the QMS model can greatly enhance their ability to reduce or 
eliminate errors, meet customer needs, perform well on accreditation assessments, and maintain 
quality objectives.22  However, the broader health care sector largely has been slower to adopt 
QMS, even though the small but growing number of health care organizations that have applied 
them are reporting favorable returns.23-25 
 
                                                 
d CLSI is a non-profit standards-developing organization that promotes the development and use of guidelines and 
standards within the health care community, including clinical laboratories.14   
Laboratory Medicine: A National Status Report Chapter V – Quality Systems and Performance Measurement 
 
May 2008 200 
 
Box 5.1:  Five Levels of Quality—Definitions 
Level 1:  Total quality management is intended to sustain high quality by focusing on long-term success 
through customer satisfaction.  TQM holds quality as the driving factor behind leadership, design, planning, and 
improvement.  Variations from quality are artifacts of poorly designed systems, rather than the fault of one or 
more individuals.19, 26 
Level 2:  Quality cost management (QCM) includes all activities involved in QMS, QA, and QC, along with 
related economic aspects (i.e., “cost of quality”).27  QCM promotes integration of quality processes throughout 
an organization subject to the constraints of the organization’s financial resources.28  Budgeting and resource 
allocation are integrated within the context of the larger organization and oriented to meeting physician and 
patient needs.  Recent efforts to implement pay-for-performance programs may be considered a form of QCM.  
Level 3:  Quality management systems refers to a systematic approach to achieving quality objectives.18  
QMS constitutes a coordinated and comprehensive effort to meet quality objectives using management systems 
standards such as those developed by the International Organization for Standardization (ISO) and CLSI.28  
Standards for QMS are implemented in laboratory medicine via such models as CQI, Six Sigma, failure mode and 
effects analysis, and Toyota “lean production.”   
Level 4:  Quality assurance/assessment monitors the totality of components or characteristics that affect 
quality and customer satisfaction.29  QA involves planned and systematic activities to provide confidence that 
an organization fulfills requirements for quality.  Regulatory and compliance issues are generally handled 
through QA-related policies and procedures.  In laboratory medicine, characteristics such as turnaround time, 
patient preparation, and specimen collection may be monitored at a basic level internally and externally.  
Proficiency testing is an external mechanism for QA.  
Level 5:  Quality control refers to laboratories’ internal procedures for day-to-day monitoring of instruments, 
monitoring work processes, detecting problems, and making corrections prior to the delivery of products or 
services.29  Typically, QC procedures for monitoring analytic performance rely on statistical measures (e.g., 
mean performance and within ±2 standard deviations) as an indicator of quality.28  For example, the precision 
of clinical laboratory tests performed for a specific analyte is assessed relative to its reference standard.  QC is 
a targeted, internal mechanism. 
Source:  A quality management system model for health care. Approved guideline: HS1-A2; second edition. Wayne, PA: 
Clinical and Laboratory Standards Institute, 2004. 
 
Standards and Guidelines for Quality Management Systems 
Formalized standards and guidelines for QMS that encompass these properties have been 
developed by the International Organization for Standardization (ISO)e as well as other 
institutions involved in a specific sector such as CLSI for health care and laboratory medicine.  In 
many instances, accreditation organizations use the standards as a framework for developing 
detailed criteria and benchmarks appropriate to the respective medical discipline or subspecialty.   
Standards can serve several purposes.  They can establish consistency or uniformity across multiple 
individuals and organizations, and set expectations of quality and safety for organizations, health 
professionals, patients/consumers, and purchasers.  Because the standards for QMS are based on 
the day-to-day activities of health care professionals, they are an effective means for improving care 
delivery.21  Measurement of performance against designated standards and feedback about that 
performance are important parts of QMS-related quality improvement initiatives.   
                                                 
e ISO develops international standards that outline the requirements for products, services, processes, materials, and 
systems and are designed to be implemented by organizations worldwide.30  The American National Standards 
Institute is responsible for endorsing consensus standards in the U.S. and for representing U.S. interests at the ISO. 
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ISO and CLSI standards for QMS are internationally recognized.  The ISO 9000 seriesf is 
considered the world standard for establishing, verifying, and certifying QMS.  It was developed 
to assist diverse organizations with implementation and operation of effective QMS, regardless of 
the service or product provided.32, 33  Aside from manufacturing-related industries such as 
medical devices and pharmaceuticals and select high-risk specialty areas, ISO 9001:2000 has not 
been implemented on a widespread scale in the U.S. health care sector.  As of 2005, about 100 
health care entities in North America were certified to ISO 9001:2000, including 12 hospitals and 
10 medical groups in the U.S.34  ISO 9001:2000 has been more widely adopted by international 
health care facilities.  A 2006 survey estimated that 14,180 certificates for ISO 9001:2000 have been 
issued worldwide in the health care and social work sectors.35  
Historically, the standards have been employed in other sectors; about 90% of facilities in the U.S. 
certified to the ISO 9001:2000 standard are involved in manufacturing.34  However, public and 
private sector stakeholders are interested in shifting the largely fragmented U.S. health care 
system that produces inconsistent levels of quality to more integrated, dynamic system capable of 
producing and sustaining high levels of quality.  Their efforts have prompted renewed interest in 
the use of standardized QMS, including ISO 9001:2000, to facilitate this transformation.20  Certain 
U.S. government agencies, including CMS, are requiring certain health sector contractors be 
certified to ISO 9001:2000 or undergo a third-party validation process.36    
Because of the broadly applicable nature of ISO 9001:2000, more targeted standards for QMS have 
been developed for health care, often according to specialty area.  CLSI is the chief developer of 
standards for laboratory medicine and serves as the Secretariatg for the ISO Technical Committee 
on Clinical Laboratory Testing (ISO/TC 212).  Through the ISO/TC 212 workgroup on quality 
management, CLSI led the development of ISO 15189 – Medical Laboratories—Particular 
Requirements for Quality and Competence, a standard for process-based QMS specifically in clinical 
laboratories.  ISO 15189 addresses all aspects of laboratory operation, from patient preparation 
and identification to the collection and examination of clinical samples, as well as document 
control, contracts, and relationships with referral laboratories.37  Other standards target specific 
uses or elements of QMS.h  Since the approval of ISO 15189, CLSI has sold at least 280 copiesi of 
the standard to laboratories in the U.S.38  Beyond this expression of interest, it remains to be seen 
how many of these laboratories will implement the standard.    
As a complement to the ISO standards, CLSI developed two guidelines that advance the 
implementation of QMS.  The first, GP26-A3 - Application of a Quality Management System Model for 
Laboratory Services, defines the laboratory path of workflow and provides direction on the design of 
policies, processes, and procedures to build required levels of quality into day-to-day operations 
and reduce the potential for errors and wasted resources.39  The second guideline, HS1-A2 – A 
Quality Management System Model for Health Care, supports ISO 9001:2000 and 15189 and describes 
                                                 
f ISO 9000 was established in 1987.  Its precursor was BS 5750, developed during the 1960s and 1970s by the British 
Government.31  
g As Secretariat for ISO/TC 212, CLSI coordinates international standardization of clinical laboratory testing in four 
areas:  quality management in the clinical laboratory; reference systems; IVD products; and antimicrobial 
susceptibility testing. 
h Other standards related to QMS include: ISO 15190 – Medical laboratories – Requirements for safety; ISO 22869 - Clinical 
laboratory testing—Guidance on application of ISO 15189; ISO 22870 - Point-of-care testing—Requirements for quality and 
competence; and ISO 22367 - Medical laboratories - Reduction of error through risk management and continual improvement. 
i This figure does not account for copies of the ISO 15189 standard sold by ANSI, which was unavailable.   
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the set of 12 essential components that must be in place for an organization to function in a manner 
that meets QMS standards and quality objectives (see Box 5.2).18  These components, known as 
quality system essentials (QSEs), provide guidelines to describe, document, integrate, measure, and 
monitor the implementation and effectiveness of the work operations of any organization, service 
unit, or support function in the organization.  Subsequent editions of GP26-A3 also incorporated 
laboratory-specific guidelines for implementing essential components of QMS identified in HS1-A2.j  
The 12 QSEs are applied to every step in the path of workflow (e.g., test ordering, specimen 
collection) to ensure that all quality management issues are identified and addressed in the 
organization’s policies and procedures. 
 
Box 5.2:  Quality System Essentials 
• Documents and records 
• Organization 
• Personnel 
• Equipment 
• Purchasing and inventory 
• Process control 
• Information management 
• Occurrence management 
• Assessment: external and internal 
• Process improvement 
• Customer service 
• Facilities and safety 
Source:  A quality management system model for health care. Approved 
guideline: HS1-A2; second edition. Wayne, PA: Clinical and Laboratory 
Standards Institute, 2004. 
 
Standards for QMS have been most broadly adopted in transfusion medicine.  Beginning in 1990, 
the AABB recognized the need for QMS specifically applicable to blood banking in order to move 
from an error-detection approach to an error prevention approach.40  Initially, the AABB Quality 
Program was designed to meet FDA requirements for Current Good Manufacturing Practices and 
QA guidelines.  To enhance user friendliness and encourage greater acceptance, AABB revised 
the program in the late 1990s by relying on ISO 9001:2000 standards to develop a specific set of 
QSEs for blood banking.  In 1998, AABB began requiring full implementation of quality systems 
for accreditation.41    
Use of ISO 9000, ISO 15189, and CLSI GP26-A3 in laboratory medicine has accelerated in recent 
years as CMS and other laboratory accreditation organizations incorporate QMS-related 
standards and guidelines into their regulatory requirements.42, 43  In 2003, CMS used the path of 
workflow as the model for restructuring the CLIA requirements.  CMS also has mapped the 
revised CLIA provisions to the QSEs outlined in CLSI GP26-A3 to demonstrate that laboratories 
interested in using the QSEs can achieve CLIA compliance concurrently.     
                                                 
j Other CLSI documents supply discipline-specific details (e.g., QC for quantitative measurements, reference 
intervals) as a compliment to HS1-A2 and GP26-A3. 
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Also in 2003, CAP endorsed ISO 15189 accreditation as a value-added program,k with optional 
use of CLSI QSEs as a supplement.44  CAP’s Laboratory Accreditation Program General 
Checklist requires that laboratories have a documented quality management program that can 
be based on ISO 9000, ISO 15189, or programs designed by CAP, other organizations, or 
laboratories themselves.45  At this writing, at least three laboratories are seeking accreditation to 
ISO 15189 through CAP.46  Similarly, COLA announced the launch of new interactive QMS 
training courses based on ISO 15189 and CLSI guidelines in 2005.47  COLA supports 
implementation of QMS voluntarily; its standards for laboratory self assessment do not require 
QMS as a condition for accreditation.   
Among the main potential benefits of U.S. harmonization to ISO standards are: 
 Laboratories can implement proven quality improvement strategies without additional 
regulation  
 Accreditation organizations can maximize their ability to evaluate laboratories worldwide 
 Vendors can standardize instruments more easily 
 Researchers can undertake cross-laboratory and cross-national comparisons of 
performance48, 49 
The following section provides a brief summary of available research on specific QMS-related tools.  
Implementing Quality Management Systems 
The strategic tools for implementing systems-based approaches to quality management and 
improvement in health care and laboratory medicine include methods such as CQI, Toyota 
“lean production,” Six Sigma, and FMEA.  These methods have been validated as effective 
quality management tools in various sectors in the U.S. and worldwide, such as the automobile 
industry, telecommunications, mining, banking, and construction.20  Although use of these 
methods is not widespread in laboratories at this time, an increasing number of laboratories, 
from small POLs to large reference laboratories, are employing them to meet and exceed 
regulatory and accreditation requirements as well as clinician and patient expectations for 
quality and financial management objectives.   
Among the most commonly used QMS tools, CQI, lean production, Six Sigma, and FMEA share 
several key features:  
 Scientific approach to process analysis and systems improvement 
 Decision-making based on data derived from regular performance measurement 
 Improvement focus 
 Preventive orientation toward potential quality problems and errors 
 Interdisciplinary teams9  
                                                 
k CAP’s program supporting ISO 15189 is separate from its CLIA accreditation program.   
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Continuous Quality Improvement  
CQI applies the scientific methods of TQMl to process improvement in health care and may be 
employed to improve clinical quality, patient satisfaction, error rates, waste, unit production 
costs, productivity, and market share, among other aspects of care.19  It embodies a disciplined 
approach to managing competitive challenges and enhancing customer satisfaction.  CQI is 
intended to reduce variation and improve performance through a four-step cycle:  The teams plan 
an intervention to improve the process; do the hypothesized intervention; study the results of the 
intervention; and act on the results.  Cross-cutting teams devise a flow chart of a work process to 
be studied and use data to understand variations in performance.9 
The CQI movement began in academic research institutions during the mid-1980s and gained 
momentum when The Joint Commission adopted the philosophy to advance health care quality 
improvement goals.50  The movement is helping to promote dynamic quality management, 
establishing the patient as the true “consumer” of health care services, and motivating health care 
organizations to initiate quality improvement programs.  Although some health care leaders have 
claimed successful use of CQI to achieve quality goals, few studies are documented in the 
literature.  For example, a regional group of cardiothoracic surgeons that implemented a CQI 
intervention reported reduced mortality associated with coronary bypass surgery by 24%.51  A 
Veterans Administration medical center used CQI to increase operating room efficiency, noting 
procedure start time improvements ranging from 30 to 55 minutes.52  In a randomized controlled 
trial, patients assigned to protocol-directed weaning from ventilation tubes as developed via CQI 
methodology had significantly shorter durations of mechanical ventilation compared with 
patients assigned to physician-directed weaning.53 
Laboratories have demonstrated some successes with CQI.  Implementing CQI for physicians’ 
ordering of blood for surgical cases at a regional hospital facilitated savings of more than 500 
hours of technologist time and $350,000 in patient charges over a two-month period.  Reduced 
inventory and blood banking costs added further to cost savings.54  A dedicated stat laboratory 
implemented CQI to improve TAT for various clinical pathology tests, after which TAT decreased 
from 61 to 36 minutes for clinical chemistry tests.55  In a two-year study  applying CQI to 
physician ordering of preoperative tests for elective surgery, the volume of tests ordered 
decreased by 50% and 60% in the first and second years, respectively,  the appropriateness of test 
orders improved by 81% and 86%, and overall cost savings were $76,000.56  CQI also has been 
applied successfully to POCT, leading to more reliable results and helping resolve discrepancies 
between test results received at the bedside versus in the core laboratory.57, 58     
There are notable challenges to implementing CQI.  Lack of hospital or physician administrative 
and financial support were identified as barriers to CQI implementation by 4 of 9 hospital 
catheterization laboratories participating in a CQI initiative during 1998-2002.59  The extensive 
time involved in educating staff about CQI principles and forming and working together as 
teams, along with insufficient commitment to CQI on the part of hospital management were cited 
as key obstacles to implementation by a hospital-based pathology department.60                                           
                                                 
l Originally introduced to Japanese manufacturers in the 1950s, TQM gained popularity in the U.S. in the late 1970s 
and early 1980s as an alternative to QA.19   
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To date, the impact of CQI on the health care sector has not been as widespread as initially 
expected.  This apparent lag in uptake has been attributed to such reasons as:  
 The literature documenting quality improvement and clinical outcomes stemming 
from CQI remains relatively sparse. 
 Administrators, rather than clinicians, were the first who sought to incorporate CQI, 
which may convey to some observers that it is a mechanism for cutting costs rather 
than improving quality. 
 Implementation was not as easy as anticipated, frustrating many of the leaders who 
initially advocated CQI.19 
While the concept of continuously improving performance to achieve quality remains intact, 
other methods have emerged for improving quality.  
Six Sigma  
Developed by the Motorola Company in the early 1980s, the Six Sigma system is a means of 
improving quality by identifying and taking action at the root cause of a problem, rather than on 
symptoms arising from the cause.28, 61  Six Sigma identifies direct relationships between the 
number of defects in a given product or process, wasted resources, and the level of customer 
satisfaction.62  Six Sigma is similar to TQM but has been described as having a more aggressive 
goal.  The objective of Six Sigma is to reduce defect rates to low frequencies in a statistical 
distribution, based on multiple standard deviations from a specified average, such as fewer than 
3.4 defects per million opportunities.   Table 5.1 displays the Six Sigma performance scale. 
Table 5.1:  Six Sigma Performance Scale 
Process Sigma Percent Accuracy Defects per million opportunities 
6 99.9997% 3.4 
5 99.98% 233 
4 99.4% 6,210 
3.5 97.7% 22,700 
3 93.3% 66,807 
2 69.1% 308,537 
Source:  Westgard JO, Westgard SA. The quality of laboratory testing today: an assessment of sigma metrics for 
analytic quality using performance data from proficiency testing surveys and the CLIA criteria for acceptable 
performance. Am J Clin Pathol 2006;125(3):343-354. 
Six Sigma can be used in laboratory medicine to establish tolerance limits necessary to define 
good quality.  Westgard has described two methods for calculating the sigma metric—one 
method is based on measuring the outcome of the process, whereas the other method is based on 
measuring the variation of the process directly.63  The outcome measurement approach involves 
counting defects, calculating defects per million, and using a statistical table to convert the defect 
rate per million to a sigma metric.  This approach is applicable to any process but usually requires 
extensive efforts to collect and analyze the data.  As such, it is typically applied to preanalytic and 
postanalytic processes.  Direct measurement of process variability (i.e., standard deviation) allows 
for determination of process capability.  It assumes that the process distribution is stable and can 
be characterized by repetitive measurements.  Thus, this methodology is used to determine the 
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precision and accuracy of analytic processes through experimental procedures.  A sigma metric is 
calculated from the defined tolerance limits and the variation observed.64 
Studies using both sets of metrics have reported that laboratory testing falls short of the minimal 
acceptable performance level demanded by other industries.  Based on CLIA criteria for acceptable 
performance in PT, the national quality of cholesterol testing is estimated at 2.9 to 3.0 sigma, glucose 
at 2.9 to 3.0, calcium at 2.8 to 3.0, and PSA at 1.2 to 1.8.64  This level of quality was deemed adequate 
only if performance was controlled with QC above that required by CLIA.  Reported defect rates for 
other common laboratory measures are approximately 2.8 sigma for Papanicolaou smears, 2.3 
sigma for therapeutic drug monitoring, and 3.6 sigma for transport of red blood cells.65 Among 
other factors, these lower levels resulted from missing information in test requests (preanalytic 
errors) and incorrect laboratory measurement (analytic errors).  However, designating a tolerance 
level such as 3.4 defects per million for all processes is arbitrary; it may be unacceptably high for 
some critical processes and unnecessarily difficult and costly to achieve for others. 
Six Sigma provides clinical laboratories with the methodology and measurements to determine 
specific QC actions necessary to achieve the desired level of quality.64 Also, Six Sigma allows for 
communication of quality metrics in a format that is understood outside the health sector.61  
Health care institutions and laboratories can compare performance against that of other sectors.     
Six Sigma is gaining acceptance in health care and laboratory medicine as a method to generate 
objective metrics and estimates of quality, though implementation is still in the early stages.66  The 
following examples highlight case studies of organizations that have experienced modest 
improvements in use of Six Sigma for measuring and improving performance. 
In 2004, West Tennessee Healthcare’s core lab built its new laboratory using lean production and 
Six Sigma principles.  Focusing on phlebotomy, Six Sigma principles were used to assess the 
timeliness with which phlebotomists worked and to identify best practices.67  As a result, the time 
required to get phlebotomy specimens to the laboratory decreased from over 20 minutes to an 
average of 5.2 minutes.  Not one patient identification error was detected and documented during 
the subsequent 11 months.   
In another study using a combination of lean production (described in the next section) and Six 
Sigma, Washington Hospital Center’s Automated Services Laboratory (Washington, DC) identified 
6 changes that could improve laboratory quality and turnaround time, including decreasing 
centrifuge times and taking steps to eliminate blood clotting.68  The laboratory reduced mean TAT 
for blood tests from 75 to 46 minutes and decreased its annual operating cost by nearly $80,000. 
North Shore-Long Island Jewish Health System (Great Neck, NY), which includes a network of 
laboratories that together process 3.5 million examinations annually, used Six Sigma to reduce the 
number of accessioning errors, or errors occurring when patient data is entered, tests are ordered, 
or samples are labeled.69  Six Sigma methods helped staff to identify specific steps in the accession 
process that were most often completed incorrectly or incompletely.  Following implementation 
of barcoded labels and a new training program for accessioners, the performance of the accession 
department improved from 3.9 sigma to 4.5 sigma. 
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Toyota (Lean) Production System 
Lean production, also known as the Toyota Production System, was developed and perfected by 
the Toyota Automotive Company over the latter half of the twentieth century.  It is based on the 
tenet that consistently eliminating waste in each step of a process leads to increased efficiency (i.e., 
the best quality and lowest cost), while improving safety and morale.70, 71  Lean production aims 
to meet internal and external customer needs through a one-by-one continuous flow process with 
integrated quality indicators and elimination of system waste related to materials, time, idle 
equipment, and inventory.  The system design highlights problems in real-time where the work is 
performed and is intended to solve problems at their root cause.  Front-line workers are 
empowered to participate in decision-making, design changes, and problem-solving at the time 
errors occur.  The overarching goal is to reduce all system defects to zero.    
Studies of lean production in laboratory medicine have reported successful results.  One study 
sought to improve chemistry test turnaround time in a central laboratory by addressing preanalytic 
variables using existing resources and lean production.  The redesigned preanalytic process had 
fewer steps and employed the one-piece flow systemm to move specimens through the accessioning, 
centrifugation, and aliquoting process.  Five new workstations were added and others redesigned 
for efficiency.  Median preanalytic processing time was reduced from 29 to 19 minutes and the 
laboratory met the goal of reporting 80% of chemistry results in less than 1 hour for 11 consecutive 
months.  Introduction of lean production also eliminated systemic waste, including reduction in 
mislabeled and missing tubes, and elimination of the unwritten and unapproved practice of 
collecting an extra tube of blood, which decreased the number of tubes used for collection, number 
of tubes processed per month, and amount of biohazardous waste discarded.72 
One study examined implementation of lean production in a single clinician’s office practice and 
cytology laboratory to determine its impact on Pap test quality and errors.73  The clinician’s goal 
was to obtain a perfect specimen for every patient, i.e., one that adequately sampled the 
transformation zone in which preneoplastic lesions usually develop.  Test quality improved, as 
the percentage of Pap tests without a transformation zonen component decreased from 9.9% to 
4.7%; the percentage of tests with a diagnosis of atypical squamous cells of undetermined 
significance decreased from 7.8% to 3.9%; and the frequency of error as measured by cytologic-
histologic correlation decreased from 9.52% to 7.84%. 
Use of lean production in process redesign was used to diminish diagnostic errors associated with 
examination of thyroid gland fine-needle aspirations by cytologists and cytotechnologists at two 
different hospitals.74  This procedure was chosen due to the wide variability in diagnostic 
accuracy indicated in the literature.75-77  For the study, the investigators created a specimen 
adequacy scoring system, used standardized diagnostic terminology, and incorporated an 
immediate interpretation service.  Performance changes following the use of standardized 
terminology included (but were not limited to) an increase in test sensitivity from 70.2% to 90.6%, 
decrease in the false-negative rate from 41.8% to 19.1%, decrease in the discrepancy rate from 
31.0% to 24.2%, and increase in the uninterpretable specimen rate from 5.8% to 19.8%.  With the 
                                                 
m In a one-piece flow system, all activities involved in a process are performed on each object before work is begun 
on the next object. 
n On the cervix, there are two cell types, squamous cells and columnar cells, which meet at a place called the squamo-
columnar junction, also known as the transformation zone.  It is in this transformation zone that abnormal growth 
or dysplasia develops. 
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addition of the immediate interpretation service, the noninterpretable specimen rate decreased 
significantly from 23.8% to 7.8%.   
As with any QMS tool, the success of lean production depends on the commitment of the 
organizational leadership and staff in adopting the methodology and managing expectations for 
realizing practical gains.78 
Failure Mode and Effects Analysis 
Though it is not considered to be a comprehensive approach to quality management, FMEA is a 
tool that supplements and contributes to QMS by providing a mechanism to systematically 
evaluate and prevent errors (“failures”) that can cause harm.  FMEA is a team-based, proactive 
approach for identifying the ways that a process or design can fail, why it might fail, and how it 
can be made safer.79  Although originally developed and used by the U.S. military and space 
program, the VHA and Tenet Health System have adapted the approach for identifying and 
preventing medical errors and other process-related problems.19  In 2001, the VHA’s National 
Center for Patient Safety introduced Health Care Failure Mode and Effect AnalysisTM.80  That 
same year, The Joint Commission established a new standard that requires all accredited hospitals 
to proactively assess at least one high-risk process per year, such as the preparation of medication 
or plans for infection control, using such methodologies as FMEA.10, 81  When sentinel events 
occur, organizations must undertake not only the traditional retrospective root cause analysis, but 
the prospective FMEA as well. The requirements were extended to home care programs in 2004.82  
Typically, organizations initiate an analysis when a near miss or concern for risk occurs rather 
than only when a sentinel event occurs.83 
FMEA facilitates identification, evaluation, and calculation of risk for each failure mode (e.g., 
problem or defect) according to severity, frequency, and detectability.  Each characteristic is 
assigned a value between 1 (highest) and 10.28  The ultimate “effect” or risk priority number for a 
particular failure mode is determined by multiplying the scores for each characteristic: Effect = 
Severity x Frequency x Detectability.  Higher risk priority numbers indicate the need to prioritize 
actions to correct problems.19  Health care organizations report positive results from use of FMEA 
in a range of clinical processes such as trauma care, chemotherapy, case management, blood 
transfusion, and other areas of laboratory medicine.84-87   
FMEA has multiple functions in laboratory medicine. First, FMEA can be used in product 
development.  CLSI guideline EP18-P2, Risk Management Techniques to Identify and Control 
Laboratory Error Sources,o refers to FMEA as a means for manufacturers of POCT devices to 
evaluate potential failure modes during the design and development of new products as well as 
to ensure the ability of users to detect and remedy possible causes of error.88  Second, FMEA can 
reduce risk in all phases of the laboratory testing process through  evaluation and measurement 
of hazards associated with process malfunctions, decision making to determine where and how to 
execute improvement actions, and measurement of outcomes from improvement actions.28, 85 
 Several laboratories have successfully implemented FMEA.  For example, in 2003, the Los 
Angeles County and University of Southern California Healthcare Network used FMEA to 
decrease the time in which they reported critical laboratory values to licensed caregivers of 
                                                 
o EP18-P2 is a revision of a previously developed guideline EP18-A, Quality Management for Single-Use Testing. 
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outpatients and non-critical care inpatients.89  Average monthly notification time declined steadily 
over the 8-month period after system redesign to target areas likely to result in improved 
outcomes.  Another study of a children’s hospital network used FMEA to identify the preanalytic 
specimen labeling phase as the key focus area for improvement.90  After laboratories adopted the 
practice of accepting only those patient specimens that met Joint Commission standards for 
labeling, the number of mislabeled and/or unlabeled specimens decreased by 75%.  In a study of 
transfusion errors in a hospital setting, laboratorians used FMEA to ascertain vulnerabilities in 
day-to-day procedures and redesign processes to prevent errors.84  The new process accomplished 
its goal of preventing all serious avoidable errors during the three-month pilot study and in the 
eight months following laboratory-wide implementation.  Although a few measures indicated the 
need for occasional coaching to reinforce the procedural changes, the number of variances among 
staff continued to steadily decrease.     
Laboratories and other health care organizations can encounter challenges when using FMEA.  As 
noted by the VHA, groups that attempt to implement too many actions, fail to communicate with 
team members who will actually be responsible for implementing changes, and do not gain 
backing from senior management often find the FMEA process ineffective.80              
Considerations for Designing Quality Management Systems 
QMS implementation presents specific challenges in different laboratory settings.  Hospital and 
physician office laboratories often cite resistance to cultural change as a major obstacle barring 
implementation of QMS.   A leadership team that is competent, effective, and enthusiastic is vital 
to successful implementation in POLs and hospital laboratories.  In particular, team members 
should possess substantial knowledge about the processes in need of improvement as well as the 
QMS methodology being implemented.91-94  Commitment to change by other laboratory 
personnel also is necessary and can be achieved by involving all staff in QMS deployment, data 
collection and analysis.69, 91, 92  Recognition of team members’ progress is important to group 
learning and continued internal support for QMS implementation.92     
Some POLs, hospital, and reference laboratories have cited financial constraints and the belief that 
QMS costs more than it saves as obstacles to its implementation.  Strategies to minimize the cost 
of QMS implementation include thorough review and selection of the QMS methodology that 
most closely matches the organizational goals and budget and partnership with other health care 
professionals whose work is significantly related to the laboratory (e.g., clinic administrators, 
physicians, nurses).91, 95   From these strategies, laboratories have reported increasing returns on 
their investment and additional opportunities for funding of QMS.96 
Certain observers question the ability of QMS tools (i.e., CQI, lean production, Six Sigma, FMEA) 
to improve the quality of patient care.49  Despite their face validity, the use of QMS tools may not 
have been studied sufficiently to date, providing limited evidence of their effectiveness.  There is 
considerable variation in QMS applications, which may create challenges to comparisons of one 
methodology to another.  Further study of these tools in accordance with clearly defined 
standards would help to build an objective evidence base. 
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PERFORMANCE MEASUREMENT 
The development and use of objective measures to evaluate the quality of health care is essential 
for improving health care delivery.97  Information derived from measurement facilitates an 
understanding of how health services, organizational factors, and financial factors affect patient 
and population health, and other important effects arising from differences in patient population, 
health conditions, and settings of care.98  This information can support decisions to change 
resource use and delivery.   
Measurement of quality serves key health care objectives, specifically to: 
 Inform quality improvement efforts 
 Inspect and certify that a facility or provider meets previously established standards 
 Compare groups for a variety of purposes, including selective contracting by 
purchasers and choice of providers and practitioners by individuals  
 Support decisions by patients, families, and employees about selecting health care 
providers and facilities  
 Identify substandard performers, particularly those whose performance is so far below 
an acceptable level that immediate actions are needed  
 Highlight, reward, and disseminate best practices  
 Monitor and report information about changes in quality over time98 
The data from measurement allows an organization to assess performance, use that information 
to improve, and increase the likelihood of achieving desired health outcomes based on current 
professional knowledge.99  Performance measurement has been a core feature of improvement 
programs for many public and private sector QA organizations in health care for more than 15 
years (see Box 5.3 for a brief synopsis).  While laboratory testing is incorporated to some extent in 
most of these organizations’ performance measurement programs, the focus tends to be on 
clinician ordering and patient receipt of appropriate tests for screening, diagnosis, or disease 
management purposes.  These organizations do not directly address measurement and reporting 
of key components of quality and performance related to the total laboratory testing process.  
Assessments of this nature, though very limited, are performed by laboratory sector oversight, 
research, and professional organizations. 
The need for a standardized set of measures to report on key aspects of quality across the TTP has 
been under discussion for the last decade.100  In the last few years, CDC and other organizations 
have sponsored studies that may facilitate the development of a national framework and 
performance measures for laboratory medicine.    
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Box 5.3:  Performance Measurement Initiatives in Health Care 
The importance and utility of routine, externally reported assessments of the quality of health care delivered is 
widely recognized and accepted.101  Efforts to standardize quality measurement and reporting in the health care 
system have been underway for more than 15 years.102  Largely driven by federal and private sector payers and 
accrediting organizations, early leaders in performance measurement include: CMS, AHRQ, The Joint Commission, 
and NCQA (a coalition of private sector health plans)  NCQA’s Health Plan Employer Data and Information Set 
(HEDIS)p is one of the most successful quality measurement initiatives to date.  Initially, health plans seeking 
accreditation by NCQA were required to report on HEDIS measures.  However, when the measures were adapted in 
the mid-1990s for use by public purchasers, CMS began to require plans participating in Medicare programs to 
report on the measures as well.103  Today, the measures also are used by private purchasers in nearly 90 pay-for-
performance programs.104    
Other organizations have joined efforts to develop, coordinate, and harmonize performance measurement and 
reporting.  These include the Pacific Business Group on Health, the Leapfrog Group, American Medical Association, 
Hospital Quality Alliance, Ambulatory Care Quality Alliance, the Foundation for Accountability, and National 
Quality Forum (NQF).  Standards and requirements for quality assessment, performance measurement, and public 
reporting have extended to long-term and ambulatory care settings.  Performance measures also are becoming 
more specific for patient populations (e.g., children, elderly), health conditions (e.g., substance abuse disorders, 
venous thromboembolism), and infrastructure (e.g., health information technology).105 
 
Basics of Performance Measurement 
Types of Performance Measures 
Generally, performance measures are classified into three broad categories based on 
Donabedian’s classic paradigm for evaluating quality of care.1  Each dimension has a direct 
influence on the next. 
 Structural measures are used to evaluate the organizational (e.g., policies and 
procedures), financial (e.g., funding of health care programs), technological (e.g., use of 
computerized order entry systems), and human resources (e.g., staff training and 
competency) aspects of care.106-108  
 Process measures are used to assess activities involved in patient care (e.g., services for 
prevention, diagnosis, and treatment).  These measures may reflect the interpersonal 
aspects of care/service (e.g., convenience, communication) or technical aspects of care 
such as the timeliness of diagnosis, appropriateness of therapy, complications, errors, 
and coordination of care.98  In some frameworks, intermediate health outcomes, such 
as HbA1c as a marker for diabetes control, are included in the process category.109 
Process measures are the predominant quality indicators for inpatient and ambulatory 
care, although they are applied only occasionally for surgery.109  The majority of 
measures target quality of care for specific health conditions, usually those determined 
to have high disease burden (i.e., morbidity and mortality) in the population, highest 
rates of utilization of health care services, and highest costs to the health system.110  
Laboratory tests are a core component of the condition-related measure sets, i.e., to 
assess whether or not the patient received the appropriate test.       
                                                 
p HEDIS consists of 71 measures (e.g., whether or not a patient received beta blocker treatment after a heart attack) 
across 8 domains of care (i.e., effectiveness, access/availability, satisfaction, health plan stability, use of service, cost 
of care, informed health care choice, health plan descriptive information).  HEDIS is designed to provide purchasers 
and consumers with the information they need to reliably compare the performance of health care plans.  
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 Outcome measures are used to determine change in patient health status, 
experiences/satisfaction with care, and cost-related analyses.111  Health-related 
outcome measures include indicators of mortality (e.g., infant death rate), physiologic 
state (e.g., blood pressure), clinical events (e.g., adverse drug events), symptoms (e.g., 
level of pain), functioning (e.g., disability), and patients’ and clinicians’ satisfaction 
with services (e.g., Consumer Assessment of Health Plan survey).112, 113  Outcome 
measurement increasingly includes assessment of patient quality of life.  Laboratory 
values are important clinical endpoints in outcomes measurement. 
The measures are employed to document differences in medical practices, variations in 
the quality of care, and the efficacy or effectiveness of particular interventions.114, 115  In 
addition, cost-related outcome measures are increasingly applied to determine 
efficiency and effectiveness in the use of scarce health care resources.   
This quality paradigm is an important part of the framework espoused by the IOMq and adopted 
by AHRQ in the National Health Care Quality Report.116, 117  The desirable attributes of a measure 
are importance in the clinical sense to the general population or the quality of care; scientific 
soundness in terms of reliability, validity, and explicitness of evidence base; usability in that it has 
been successfully used in the past and is compatible with other measures; feasibility to implement 
with existing prototypes and considerations pertaining to data availability and cost; alignment 
with leading measure sets; and comprehensiveness as part of a measure set that can reflect quality of 
care for a given condition. (Refer to Appendix A for further information.) 
Quality Indicators 
Quality indicators are specific attributes of structure, processes, or outcomes whose measurement is 
capable of providing accurate estimates of the degree to which designated standards were achieved.  
Although the term “performance indicator” is often used interchangeably with “quality indicator,” 
it is possible to make inferences about performance without making inferences about quality.118  
Activity indicators measure the frequency of an event (e.g., screenings for cancer).97 
Indicators are often based on clinical guidelines and performance standards issued by specialty 
societies, government agencies, or others, but require greater specificity to be implemented.110  
They are designed to convey a finding about the quality of care being provided or health 
outcomes.119  In particular, they can identify problems that may need to be addressed, usually 
identified by low indicator scores, statistical outliers, or unexplained variations in care.   
To the extent possible, indicators should link processes and outcomes in quality assessment.  
When cause-and-effect relationships or other associations are established, improvement on 
process measures can be linked confidently to improvement in patient and population health.101  
Linking process measures to outcome measures can demonstrate the capability of clinical 
approaches to improve patient and population outcomes.  Establishing such linkages between 
indicators and quality or outcomes can be challenging.120-122  Table 5.2 summarizes AHRQ’s 
                                                 
q Other components of the framework include the IOM’s six aims of quality (safety, effectiveness, patient-centeredness, 
timeliness, efficiency, equity); the Foundation for Accountability’s four domains of consumer needs (staying healthy, 
getting better, living with illness or disability, and coping with end of life); and the priority areas for quality 
improvement identified by the IOM, the National Quality Forum, and CMS. 
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application of performance measure characteristics to evaluate potential quality indicators for its 
programs as well as that of other organizations. 
Indicators can be defined by various metrics such as a rate, ratio, index, or percentage that 
contributes to qualitative interpretation of a contribution to health care or outcomes.123, 124  For 
dichotomous metrics, an indicator is presented as a proportion where a numerator and 
denominator are defined,125 such as the proportion of diabetic patients who received HbA1c 
testing.  Other metrics may be continuous measures that can be averaged, such as time to an event 
(e.g., TAT for a clinical chemistry test), a rate defined as a proportion within a given timeframe, or 
scores on a pain or patient satisfaction scale.   
Table 5.2:  AHRQ application of criteria for evaluating quality indicators 
Quality indicator evaluation framework criteria 
1. Importance 
 Assesses an important leverage point for improving quality; significant to target audiences; impact on health 
 Opportunity for improvement, considerable variation in quality of care exists 
 Aspect of quality is under provider or health system control 
 Should not create incentives or rewards to improve without truly improving quality of care 
2. Scientific acceptability 
 Relationship to quality is based on scientific evidence 
 Well defined and precisely specified  
 Valid, measures the intended aspect of quality; accurately represents the concept being evaluated; data sources are comparable 
 Adequate proportion of total variation is explained by provider performance and amount of variation in measurement 
is small after provider performance and patient characteristics are taken into account 
 Reliable, producing the same results a high proportion of time in the same population* 
 Precise, adequately discriminating between real differences in provider performance and reasonable sample size exists 
to detect actual differences; captures all possible cases and bias related to case exclusion or limited data is minimal. 
 Risk adjustment is adequate to address confounding bias 
3. Usability 
 Effective (understandable and clear) presentation and dissemination strategies exist  
 Statistical testing can be applied to communicate when differences in performance levels are greater than would be 
expected by chance*  
 Has been used effectively in the past and/or have high potential for working well with other indicators currently in use 
 Compelling content for stakeholder decision making 
4. Feasibility 
 Consistent construction and assessment of the measure* 
 Feasible to calculate; benefits exceed financial and administrative burden of implementation* 
 Confidentiality concerns are addressed* 
 Audit strategy can be implemented, quality of data is known* 
* Indicates the criterion was not in the initial evaluation framework but has been addressed through incorporation in subsequent 
work such as quality indicator software. 
Source:  Guidance for using the AHRQ quality indicators for hospital-level public reporting or payment. Rockville, MD: Agency for 
Healthcare Research and Quality, 2004.  
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Collecting and Reporting Data on Performance 
Various instruments are employed to collect and report performance data.  Some common 
approaches to data collection include surveys of a targeted population; focus groups; interviews; 
data abstraction during chart reviews or claims reviews; use of disease registries; reporting 
through performance monitoring, patient safety, and surveillance systems; and competency 
assessments.  Advances in health information technology are enabling more of these data to be 
collected electronically.  The data derived from measurement often are used to describe patterns 
of care, detect variations and deficiencies in quality and/or utilization, and perform intra-and 
interorganizational comparisons.  Data may be analyzed and reported at the patient, population, 
and system levels depending on the purpose of the measurement.r   
Measurement data are reported publicly through assessment tools such as benchmark comparisons, 
report cards, and balanced scorecards.  Benchmark comparisons assess a technical aspect of 
performance against a designated standard or indicator.  Report cards grade performance according 
to established criteria and indicators.  Balanced scorecards give a multidimensional view of 
performance including technical quality of care, cost, access, patient satisfaction, health status, 
waiting time in clinics, TAT for laboratory and radiology reports, efficiency, and clinical pathway 
variances.126  Report card data pertaining to laboratory testing are generally limited to utilization.  
For example, NCQA collects data on whether or not appropriate screening and other laboratory 
tests for selected medical conditions were performed as an indicator of quality of care.  The data are 
used in annual reports on clinician and health plan performance.127 
Performance Measurement Initiatives in Laboratory Medicine 
A key part of performance improvement in laboratory medicine is the generation of data 
substantiating the level of practice and defining where practice improvements can have the 
greatest impact.   For clinical and anatomic pathology, this involves collection of data on practices 
at points along the TTP where risks to quality and safety are likely to arise and where corrective 
action can result in learning, recovery, and improvement.  Historically, this has entailed detecting 
and correcting errors.  However, errors are only one type of shortfall in quality, and the methods 
used to select quality indicators do not appear to conform to the AHRQ criteria.128  Today’s 
quality improvement initiatives have incorporated a more patient-centric, systems-based 
approach desired by many stakeholders.    
As noted above, formal measurement and reporting on quality in laboratory medicine have been 
limited largely to QC and PT activities to meet regulatory obligations.  The effort dedicated to 
evaluating performance and finding and avoiding errors in the analytic phase has been greater 
than that for the preanalytic and postanalytic phases.  In particular, extensive data on analytic 
performance has been generated for clinical pathology and certain cytology tests to comply with 
regulatory and accreditation requirements.  These focus on accuracy and consistency of reagents, 
equipment, and/or methods through internal process control, external PT, and on-site 
                                                 
r Federal, state, and private sector initiatives in performance measurement are increasingly concerned with data 
collection at the level of the individual patient, which can be aggregated along three important dimensions:  (1) 
composite measures of the care provided to the individual patient that may document whether that person 
received recommended care; (2) population-oriented results defined by socioeconomic status, race, and ethnicity; 
(3) system-oriented results to identify gaps in performance and accountability at the level of the provider, 
provider group, hospital, and community, and the use of composite measures.102   
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inspections.129  CMS and accreditation organizations use the data generated from these activities 
to determine compliance with standards for analytic processes; accreditation organizations also 
use the data in training sessions to assist laboratory staff in improving their performance.130   
Private and public sector organizations have sponsored research and quality improvement efforts 
to address specific issues in the pre- and postanalytic phases of clinical and anatomic pathology.  
Most of the studies measure specific variables (e.g., patient and specimen identification errors, 
results reports correction rates) in order to discern ways to reduce errors, improve safety, and 
identify best practices.41, 131-133  These research studies were not conducted with indicators that 
have been evaluated against the AHRQ criteria presented previously, and are not included in 
AHRQ’s National Quality Measures Clearinghouse.  Nevertheless, these studies may offer useful 
opportunities to assess the characteristics of quality indicators and practices that warrant further 
research and development.  Brief descriptions of the studies undertaken by CAP through its Q-
Probes and Q-Tracks programs, The Joint Commission’s initiatives, and activities of other 
organizations and government agencies are provided below.   
College of American Pathologists    
CAP launched the Q-Probes program in 1989 to establish performance measures for laboratory 
quality.134  Targeted short-term studies in these programs assess the effects of specific practices 
and attempt to establish benchmarks for measuring performance.  Typically completed within 4 
months, these studies aim to provide a snapshot of participants’ performance on QA variables, 
which can be used for external peer-comparison, goal setting, and improvement.  Most of the 
variables are process-oriented, although a few are structural or outcome oriented.  To date, CAP 
has published more than 120 studies involving Q-Probes in peer-reviewed journals on a limited 
number of indicators and topics.  As noted above, they have not been evaluated against AHRQ’s 
criteria for inclusion in the National Quality Measures Clearinghouse.135  
The same holds true for the CAP Q-Tracks program initiated in 1998 for longitudinal tracking of 
laboratory performance on key indicators.  The program was designed to satisfy accreditation 
requirements for continuous monitoring and benchmarking in clinical and anatomic pathology.  
In 1999, the Q-Tracks program was approved by The Joint Commission for inclusion in its ORYXs 
quality indicator monitoring system.  Q-Tracks provide continuous monitoring of 12 indicators 
(see Appendix B) and variables previously defined in Q-Probes studies (e.g., patient identification 
accuracy, blood culture contamination, laboratory specimen acceptability).  Users subscribe to the 
program for a 12-month period during which they are provided with quarterly reports about 
their performance as well as the practices and policies of other participants associated with 
improved performance based on the non-standardized, self-reported data.133  Since the program’s 
inception, about one-third of Q-Tracks indicators have been retired.t  Given current efforts to 
establish national, standardized performance measures across the health system that can be used 
for external public reporting, the applicability of CAP Q-Tracks indicators remains unclear.   CAP 
measures were designed for internal process improvement purposes, and may continue to be 
useful in this regard.   
                                                 
s ORYX is a performance monitoring system developed by The Joint Commission. It was designed to collect data on 
standardized core and non-core performance measures approved by The Joint Commission. In order to maintain 
Joint Commission accreditation, hospitals are required to collect and submit data on some of the measures.  
t Since the inception of Q-Tracks, 17 indicators have been developed; 12 are in use and 5 have been retired. 
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Many institutions participating in Q-Probes and Q-Tracks studies have documented performance 
improvements.  Even so, such improvements were based largely on self-reported, longitudinal 
data of participating institutions, as opposed to comparisons to control groups, characteristic of 
more rigorous scientific studies.133, 136, 137  Another factor that may have a modest effect on 
performance comparisons is the degree of variability among participating laboratories in such 
aspects as test menus, employee skill levels, and utilization by physicians.  CAP programs adjust 
for some of the differences by restricting interlaboratory comparisons to peer groupings of 
laboratories that are similar with respect to unmanageable characteristics.  Even so, the 
adjustments are likely insufficient to counter the lack of standardization, the most relevant issue 
pertaining to validity of laboratory performance measures.  As a result, laboratories participating 
in CAP studies are reporting error rates and other measurss that may have been determined 
differently.  This may in part explain the large variation in error rates among the various studies.    
There appear to be no published studies evaluating CAP or other measures according to criteria 
appropriate for quality indicators (e.g., health importance, scientific acceptability, usability, 
feasibility) as defined by AHRQ.   Similarly, the CAP measures do not appear to have been 
assessed for generalizability across laboratory settings or studied for applicability and feasibility 
in POLs.138  Although CAP measures were not designed for the purpose of accountability and 
public reporting, they have established face validity, feasibility for data collection, and that they 
are actionable.138    The CAP measures are in need of further testing to ascertain their validity, 
accuracy and reliability for potential use in external reporting. 
Along similar lines, in 1993, CAP initiated the Laboratory Management Index Program, a fiscal 
management tool that provides peer comparisons to assist laboratories with the annual budget 
process, contract negotiations, and daily operations management.139, 140  The program uses 
management ratios and total standard billable tests as performance indicators to assess the three 
main management-related factors affecting laboratory performance:  productivity, utilization, and 
cost-effectiveness.  Their favorable impact notwithstanding, CAP indicators of management quality 
also are based on self-reported, non-standardized data.   
 The Joint Commission 
In addition to the ORYX monitoring system, The Joint Commission issues National Patient Safety 
Goals (NPSGs) annually to advance specific improvements in patient safety by highlighting 
problematic areas and prescribing expert-based solutions.141  Four of the NPSGs for health care 
organizations apply directly to the laboratory (see Table 5.3).  For example, based on expert opinion, 
The Joint Commission states that the goal of improving patient identification accuracy can be 
reached by using two patient identifiers when administering medication, collecting blood samples, 
or providing other treatments.  It suggests not using the patient’s room number or physical location 
for identification, labeling containers for blood and other specimens in the presence of the patient, 
and maintaining a sample’s identity throughout all stages of laboratory testing as methods to reach 
this goal.142  Because these actions recommended by The Joint Commission are considered to be 
viable means of reducing errors, they warrant further study and evaluation.      
A few studies that examined areas important to The Joint Commission’s work cite modest 
decreases in error rates based on high-level interventions; however, it is difficult in these studies 
to establish causal relationships or evaluate an explicitly defined measure.  For example, from 
2002 to 2004, UCLA Clinical Laboratories studied patient identification and specimen labeling 
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errors, a priority area for The Joint Commission.  Laboratories implemented three patient safety 
improvement strategies: (1) increased the number of phlebotomists on staff and expanded 
services to 24 hours daily, (2) implemented an online electronic event reporting system, and (3) 
instituted an automated processing system.143  Errors associated with mislabeled specimens 
decreased significantly.  In another example, three microbiology laboratories assessed the impact 
of requiring “read-back” from the recipient of telephone results reports and noted reduced risk of 
medical errors.144    The measures used in such studies are not necessarily validated, and it is 
difficult to determine which of the interventions, if any, had a causal effect on error rates, or 
whether there were other factors that influenced the observed changes in error rates.    
Some researchers have experienced challenges when incorporating NPSGs into their information 
systems.  For example, staff at Massachusetts General Hospital analyzed its reporting of critical 
values, i.e., those laboratory results indicating the patient is in imminent danger and requires 
immediate initiation of appropriate therapy.  The hospital uses computer applications (e.g., 
CPOE, clinical decision support systems, electronic results reporting) that apply rule-based logic 
to determine which values are truly critical and which are within acceptable reference limits for 
certain medical conditions and given the patient’s previous test results.  However, the researchers 
concluded that these more nuanced approaches to critical value reporting are constrained by the 
Joint Commission’s requirement that all critical values be reported.145  
In addition, results of a recent study funded by the CDC may contradict current and long-held 
conventional wisdom underlying critical values reporting.  For example, preliminary findings 
presented at the September 2007 CLIAC meeting indicate that reporting of non-critical 
potassium values (within a certain range) had a greater impact on patient treatment and 
outcomes than critical values.146  This implies the need to re-evaluate traditional beliefs about 
effective measures, practices and requirements to improve safety and quality. 
Table 5.3:  2008 National Patient Safety Goals, Laboratory Services Program 
Goal 1 Improve the accuracy of patient identification. (Introduced in 2004) 
1A Use at least two patient identifiers when providing care, treatment or services. 
1B Prior to the start of any invasive procedure, conduct a final verification process (such as a “time out”) to confirm the correct patient, procedure and site, using active—not passive—communication techniques. 
Goal 2 Improve the effectiveness of communication among caregivers. (Introduced in 2004) 
2A 
For verbal or telephone orders or for telephonic reporting of critical test results, verify the complete 
order or test result by having the person receiving the information record and "read-back" the 
complete order or test result. 
2B Standardize a list of abbreviations, acronyms, symbols, and dose designations that are not to be used throughout the organization. 
2C Measure and assess, and if appropriate, take action to improve the timeliness of reporting, and the timeliness of receipt by the responsible licensed caregiver, of critical test results and values. 
2E Implement a standardized approach to “hand off” communications, including an opportunity to ask and respond to questions. 
Goal 7 Reduce the risk of health care-associated infections. (Introduced in 2004) 
7A Comply with current World Health Organization (WHO) Hand Hygiene Guidelines or Centers for Disease Control and Prevention (CDC) hand hygiene guidelines. 
7B Manage as sentinel events all identified cases of unanticipated death or major permanent loss of function associated with a health care-associated infection. 
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Goal 13 Encourage patients’ active involvement in their own care as a patient safety strategy. (Introduced in 2008) 
13A Define and communicate the means for patients and their families to report concerns about safety and encourage them to do so. 
Note:  Gaps in the numbering indicate that the Goal is inapplicable to the program or has been “retired,” usually because the 
requirements were integrated into Joint Commission standards. 
Source: 2008 National Patient Safety Goals, laboratory services program. Oakbrook Terrace, IL: The Joint Commission, 2007. 
(Accessed November 14, 2007, at 
http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/08_lab_npsgs.htm.)  
Other Accreditation Organizations and Government Initiatives 
While other laboratory accrediting organizations do not collect and evaluate specific measures 
in the manner of CAP or The Joint Commission, some are developing alternative methods of 
tracking performance.  In 2007, ASHI developed an online database of the deficiencies reported 
from inspections to assist laboratories it accredits with fulfillment of CMS requirements.  AABB 
requires blood banks to implement QMS with internal processes for monitoring and addressing 
transfusion practices as a condition for accreditation.  Monitored performance indicators are 
related to ordering practices, patient identification, sample collection and labeling, infectious 
and noninfectious adverse events, near-miss events, usage and discard practices, 
appropriateness of use, blood administration policies, ability to meet patient needs, and 
compliance with peer-review recommendations.42 
Several federal health agencies have undertaken efforts to support development of laboratory 
performance measures, including AHRQ, CDC, and CMS.  AHRQ funded the creation of a 
national anatomic pathology errors database in 2002 to track the frequency and severity of 
errors detected by cytologic-histologic correlation for both gynecologic and nongynecologic 
cytologic and histologic diagnoses.147   
CDC launched a project in 2006 to develop an evidence-based process to identify and evaluate 
laboratory medicine practices and to recommend “best practices.”  The first phase of the project 
(2006-2007) completed initial development of the Laboratory Medicine Best Practices review and 
evaluation methods, and the second phase (2007-2008) is intended to refine and improve methods 
to review these practices, including development of a new investigational component to obtain 
unpublished studies to supplement the available published studies.  The investigational 
component will rely on establishing a network of laboratories who have previously completed 
practice evaluations to pilot test the process.  These methods are being developed under a contract 
with Battelle Memorial Institute with the guidance of a 14-member multi-disciplinary expert 
advisory workgroup that will also make recommendations relating to an organizational structure 
and other requirements for future implementation and sustainability of a laboratory medicine 
best practices evaluation and identification process, among other things.u  CDC also announced a 
funding opportunity in 2007 to evaluate clinical laboratory practice by developing evidence-based 
laboratory medicine quality and performance measures associated with the pre- and postanalytic 
                                                 
u Specifically, phase I of the project (2006-2007) established definitions of best practices, developed inclusion and 
exclusion criteria for candidate practices, created a classification scheme, established methods for a systematic 
review, created a framework for making best practices recommendations, conducted a proof of concept exercise, 
and defined strategic organizational and implementation constructs.  Phase II (2007-2008) aims to refine and 
develop process review and evaluation methods, pilot test the process, develop and test the investigational 
component, and evaluate alternative organizational mechanisms for implementing the process. 
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stages of the TTP.  These measures are to be based on important gaps and opportunities for 
improvement in laboratory medicine quality consistent with available evidence and national 
health care priorities to improve public health.148 To date, cooperative agreements have been 
awarded to the following entities to develop measures for the pre- and postanalytic stages:  
 Texas Department of State Health Services—linking the quality of patient care with the 
quality of pre- and postanalytic stages of the newborn screening process 
 Kaiser Permanente Center for Health Research Research Institute—evaluating laboratory 
medicine quality in chronic kidney disease associated with improved patient outcomes 
 University of Colorado—associated with specific pathology and laboratory processes 
affecting clinical and patient-related outcomes149 
CMS maintains the OSCAR database of information collected by surveyors during laboratory 
inspections.150  Another database houses information on laboratory PT results.  The database 
systems are not accessible to the public; however, CMS will provide information by request.  
While CMS has not undertaken performance measurement initiatives directly assessing the 
quality of laboratory medicine, it recently launched the Physician Quality Reporting Initiative, 
which provides a financial incentive for physicians to participate in this voluntary quality 
reporting program.  For example, physicians reporting from July 1 through December 31, 2007 
were eligible for an incentive payment in 2008.  One of the measures pertains to physician 
ordering of laboratory tests.151                  
A Model for a National Laboratory Performance Measurement System 
In 2006, CDC funded an initiative led by Raj Rehal in association with the National Quality Forum 
(NQF) to develop a framework for collecting, measuring, and reporting performance data on 
laboratory tests associated with priority health conditions, processes of care, and infrastructure.138   
As a first step, the study examined the strength of evidence for health condition-specific 
guidelines and associated laboratory-related performance measures recommended by 
professional societies.v  The priority health conditions include diabetes, obesity, heart failure, 
ischemic health disease, stroke, kidney disease, hypertension, depression and mental illness, 
pneumonia, cervical and colon cancer, pregnancy and childbirth, asthma, and patient safety.  
For example, the clinical guidelines published in the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended 
a set of laboratory tests prior to initiating therapy:  blood glucose, hematocrit, potassium, 
creatine and estimated glomerular filtration rate, calcium, low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol, triglycerides, and urinalysis.  Tests for urinary albumin 
excretion or albumin/creatine ratio are described as optional.152  However, according to the 
NQF study, laboratory-based performance measures to assess the quality of laboratory testing 
and services have not been specified by professional societies.  The lack of such measures was 
consistent across each health condition reviewed in the study.  
 
                                                 
v The professional societies included in the NQF study are: the American Diabetes Association, American College of 
Cardiology, American Heart Association, The Joint Commission, Hospital Quality Alliance, National Committee for 
Quality Assurance, Physician Consortium for Performance Improvement of the American Medical Association. 
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Subsequent to this review, NQF commissioned the development of a framework based on the 
structure established for the AHRQ National Health Care Quality Report.  In addition, the 
framework is consistent with the IOM reports, Priority Areas for National Action: Transforming 
Health Care Quality (2003) and Performance Measurement: Accelerating Improvement (2006).  NQF 
drew from the design principles espoused in the latter report, including:   
(1) Comprehensive measurement that advances the six aims identified in the IOM Quality 
Chasm report 
(2) Longitudinal measurement that spans care settings over time 
(3) Individual patient-level, population-level, and system-level measurement instead of a 
provider-specific or silo-of-care focus 
(4) Shared accountability instead of focusing on individuals’ actions 
The framework is depicted in Figure 5.1.  The intention of  this approach is to address needs of 
multiple stakeholders and link evidence-based laboratory tests with national initiatives in 
performance measurement.  It allows for data collection on specific tests associated with priority 
conditions at the level of the individual patient, which can be rolled up to the levels of the 
populations and systems.  The framework addresses laboratory performance in key dimensions 
of the TTP:  ordering, specimen, analysis, reporting, and follow-up.   
Figure 5.1:  A Framework for performance measurement in laboratory medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
Source:  Behal R. Identification of performance measures of importance for quality in laboratory medicine. 
Washington, DC: National Quality Forum, 2007. 
The framework was designed with flexibility for evaluation of both clinical and anatomic pathology 
testing processes.  However, several limitations of the current framework have been identified.138  
First, all but one of the laboratory tests associated with the health conditions are clinical pathology 
tests.  The exception is cancer screening for women, which includes gynecologic cytology tests.  
Anatomic pathology tests may not be sufficiently represented.  However, the extensive research on 
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anatomic pathology tests associated with cancer could provide sufficient evidence base for selecting 
specific indicators.  Second, there are few, if any, measures for children with special needs, frailty 
due to old age, mental illness, self management, care coordination, care at the end of life, and pain 
management.  Third, few laboratory tests that are considered evidence-based are included in the 
performance measures.  Fourth, measures to evaluate appropriateness of laboratory tests (e.g., 
overuse, underuse, misuse) have not been developed.  Generally, HEDIS and other condition-
related measures are used as substitutes to determine underuse; only a few studies of clinical 
decision support systems relative to physician test ordering and payer utilization reviews have been 
employed to assess overuse or misuse.153, 154    
Current Measures Used in Laboratory Medicine 
Specific areas for evaluation and development of performance measures in laboratory medicine 
are depicted in Figure 5.2.  Structural measures are affiliated with core environmental factors that 
may affect quality.  Process measures assess the preanalytic, analytic, and postanalytic 
components of the TTP, also considered to be the critical control points at which errors and other 
problems can be corrected and/or prevented.  Outcome measures tie the laboratory testing 
process to patient health and costs of care.  The facets identified in the structural, process, and 
outcome categories may be used for internal or external assessment and quality improvement 
programs, as depicted by the arrows in the diagram.  Each structural, process, and outcome 
measure also may be evaluated independently.  The status of the measures is discussed more 
fully in the next section.  Appendix B provides examples of specific structural, process, and 
outcome measures identified in the literature.      
Structural Measures  
With the exception of PT, most of the regulatory provisions to support quality systems mandated 
under CLIA are structural requirements. The majority of provisions outline basic requirements for 
policies, procedures, and documentation that must be in place for preanalytic, analytic, and 
postanalytic phases as a condition of certification/accreditation.     
A few studies have examined other structural measures such as workforce productivity and staffing 
ratios and use of web-based error reporting systems.  A study examined the impact of workforce on 
quality and factors associated with favorable staffing ratios.  They measured productivity of 
technical staff and management staff span-of-control ratios.  The study found wide variability in 
staffing levels among institutions, suggesting opportunities to improve staff productivity in many 
facilities.155  In studies of health or laboratory information technology infrastructure, basic metrics 
are developed to determine the rates of implementation, often delineated by initiation of specific 
software programs, cross-departmental data exchange networks, and database systems.9   
Another study of POCT systems evaluated the implementation of specific error-prevention 
systems and safeguards, most of which are structural factors influencing quality because they are 
associated with technology systems and workforce training.  The study produced a summary of 
actions for preventing medical errors: (1) adopt operator certification and validation in POCT 
testing; (2) implement security, validation, performance, and emergency override systems on 
existing and new devices; (3) require flexible, user-defined error prevention system options on 
instruments as a prerequisite to federal licensing of new diagnostic tests and devices; (4) integrate 
connectivity standards for bidirectional information exchange; (5) preserve fast TAT of POCT  
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Figure 5.2:  Diagram of Categories for Performance Indicators in Laboratory Medicine 
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results; (6) monitor invalid use, operator competence, quality compliance, and other performance 
improvement indices to reduce errors.156 
Most structural measures are insufficient or too general to serve as indicators of performance or 
quality of care .116  Links between structure and processes of care and structure and outcomes 
tend to have adequate evidence-based support only in limited areas (e.g., mortality at high 
volume hospitals is up to 10% lower than at lower volume facilities).157, 158  Furthermore, structural 
measures have limited use outside the hospital setting, are not readily actionable, and do not 
adequately discriminate performance among individual clinicians.  With the exception of 
laboratory medicine, national initiatives assessing quality have shifted focus to outcome-validated 
process measures and disease- or process-specific outcome measures.116   
Process Measures  
Process-related performance measures in laboratory medicine are associated with the TTP as 
presented in Figure 5.2 and Appendix B, and discussed at length in the previous chapter of this 
report (Quality and the Total Testing Process).  Thus far, the non-standardized methods 
employed to evaluate quality and estimate error rates have formed a growing body of research on 
all three phases of the laboratory testing cycle.  Error rates and a few other dimensions for certain 
aspects of pre- and postanalytic phases of testing have been evaluated through the CAP programs 
and other research studies.159  Studies of the preanalytic processes typically measure performance 
via error rates tied to specimen collection (e.g., phlebotomy success, specimen acceptability, 
specimen contamination), followed by specimen labeling (e.g., ABO typing or various errors), and 
patient identification (e.g., wristband error).160-165  A few published studies have examined errors 
associated with clinician ordering, in terms of the accuracy and completeness of requisition slips 
and/or the appropriateness of test orders (e.g., duplicate orders).166   
For postanalytic processes, performance measures have targeted measurement of TAT in various 
capacities (i.e., routine TAT, critical value TAT, and stat TAT) and report accuracy (e.g., 
completeness of descriptors, discrepancies, amended report rates).134, 167-172  More recent studies 
measured interpretive consultation rates and report delivery errors.173-175  Very few studies have 
examined appropriate interpretation of laboratory test results and ensuing laboratory-driven 
clinical/preventive actions and related patient outcomes.  
Most published studies of preanalytic and postanalytic factors calculated total error rates, but not 
all collected sufficient data to determine the nature of and specific causes of the errors for 
identification of potentially effective quality improvement strategies.  For example, in a Q-Tracks 
study of specimen acceptability, the overall specimen rejection rate served as the primary 
performance indicator, with secondary data submitted on specific reasons for rejection such as for 
clotted specimen, container leaking, specimen contamination, hemolyzed specimen, insufficient 
volume, tube over/underfilled, specimen lost/not received, and improper container.133  
In contrast to pre- and postanalytic measures, analytic phase process measures are better 
developed and accompanied by a stronger evidence base, such as for error rates as measured by 
internal QC and PT.  Routine QC checks can provide important data about the potential for 
accuracy versus the potential for error in testing and sources of variation for each analyte.  These 
data are tracked over time to evaluate within-laboratory factors as well as to ensure achieving 
specified levels of performance.  Similarly, PT is a standard measure of analytic performance for 
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purposes of external evaluation and regulatory oversight.  PT data, including root causes of 
errors, serve as key measures to provide insight into how well a laboratory is performing 
compared to other laboratories.  (Refer to the Federal Regulatory Oversight chapter of this report 
for additional discussion of QC and PT.)   
Figure 5.3 summarizes the process-related performance measures.  Experts participating in CDC’s 
Institute for Quality in Laboratory Medicine in 2005 expanded on the measures initially employed 
by CAP through its Q-Tracks program.  CDC recently undertook an evaluation of process 
measures published in the literature and found a general lack of evidence supporting health 
importance, scientific soundness, relevance, and usefulness.176  Significant variability and gaps 
were identified in terms of standardized terminology, measurement specifications, data collection 
methods, and relationships to process, clinical, health, and economic outcomes.  For example, 
although specimen adequacy can affect the accuracy and usefulness of laboratory test results, 
there is no standard definition or measure to evaluate adequacy aside from overall rejection 
rates.160-162, 177  A systematic study that relates specimen adequacy or rejection to other outcomes 
has not been conducted.     
When CDC assessed the process measures for their applicability to the IOM’s six domains of 
health care quality, they fell short, especially in the areas of patient-centeredness and equity.  
Other areas not adequately addressed include laboratory testing for preventive care and the use 
of health information technology (e.g., order entry and decision support) as a tool to enhance 
quality and safety.178-181 
Overall, an important limitation of current laboratory process measures is the variable extent to 
which they link to outcome measures, along with sample size constraints and potential to be 
affected by such confounding factors as patient compliance.  Some measures can be linked to 
outcomes (e.g., false-positive and false-negative results) supported with scientific evidence, while 
the relationship for others is weak (e.g., patient identification, specimen collection, TAT).109  
Additional work is needed to standardize the indicator metrics (i.e., numerators and 
denominators, or other methods for calculation) for pre-and postanalytic process-related 
performance measures.  As most research to date has focused on the needs of larger, hospital-
based laboratories, further research also is needed to ascertain the specific challenges that smaller 
POLs may confront when implementing process-related performance measurement and quality 
improvement programs.   
In efforts to address these issues, the Behal/NQF framework presents a different approach to 
performance measurement.  The particular indicators for the preanalytic and postanalytic phases 
of the total testing process have yet to be evaluated using AHRQ criteria; however, the paper 
identified general areas for additional evaluation that included test ordering, specimen collection, 
proficiency testing, results reporting, and physician actions.  Rather than measure performance in 
the broad sense, evaluations are proposed based on laboratory tests associated with the national 
priority health conditions.138   This approach may facilitate understanding of the relationships 
between laboratory testing and outcomes.   
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Table 5.3: Potential Areas for Performance Measure Development and Standardization  
CAP (2002), Howanitz (2005),  
and IQLM (2005) 
NQF (2007) 
Preanalytic 
 Test order accuracy and appropriateness 
 Patient identification  
 Specimen rejection (chemistry & 
hematology) 
 Blood product wastage(transfusion 
medicine) 
 Blood culture contamination 
(microbiology) 
 Adequacy of specimen container 
information 
 
Analytic Phase 
 Cervical cytology-biopsy correlation 
 Accuracy of POCT 
 Proficiency testing 
 
Postanalytic Phase 
 Test TATs (chemistry & hematology) 
 Critical values reporting 
 Clinician follow-up (abnormal Pap test, 
hypercalcemia) 
 Clinician satisfaction (all lab disciplines) 
 
Additional special areas 
 Diabetes monitoring 
 Hyperlipidemia screening 
 Timing of therapeutic drug monitoring 
 Intraoperative  consultations 
 
Preanalytic Phase 
 Test order 
 Specimen collection 
 
Analytic Phase 
 Specimen analysis (proficiency testing) 
 
Postanalytic Phase 
 Results reporting (TAT, critical values) 
 Physician follow-up 
 
Specific health condition-related tests 
 Diabetes 
 Obesity 
 Heart failure 
 Ischemic heart disease 
 Stroke 
 Kidney disease 
 Hypertension 
 Depression and mental illness 
 Pneumonia 
 Cervical and colon cancer screening 
 Pregnancy and childbirth 
 Asthma 
 Patient safety  
Sources:  Zarbo RJ, Jones BA, Friedberg RC, Valenstein PN, Renner SW, Schifman RB, et al. Q-tracks: a College of American 
Pathologists program of continuous laboratory monitoring and longitudinal tracking. Arch Pathol Lab Med 2002;126(9):1036-1044.   
Howanitz PJ. Errors in laboratory medicine: practical lessons to improve patient safety. Arch Pathol Lab Med 2005;129:1252-1261.   
Hilborne L. Quality Indicators Workgroup presentation. 2005 Institute for Quality in Laboratory Medicine Conference: Recognizing 
Excellence in Practice. April 29, 2005.  Atlanta, GA: Centers for Disease Control and Prevention, 2005. 
Behal R. Identification of performance measures of importance for quality in laboratory medicine. Washington, DC: National Quality 
Forum, 2007.  
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Outcome Measures and Indicators 
As is the case for other types of health care interventions, laboratory testing can be assessed for its 
impact on health outcomes, humanistic outcomes, and economic outcomes.138  Health outcomes 
include mortality, morbidity, adverse events, and biomarkers (e.g., laboratory values).  Some 
biomarkers are used as intermediate or surrogate outcomes, in that they are known to be 
predictive of health outcomes.  Humanistic outcomes typically include quality of life, functional 
status, patient satisfaction, and other patient-reported outcomes.  Among the many types of 
economic outcomes are cost per test, patient, treatment and episode of care; budget impact; and 
analyses of tradeoffs, including cost-effectiveness, cost-utility, and cost-benefit analysis.   
Outcome studies in laboratory medicine address questions of the form:  Is use of test X associated 
with outcome Y?182  For example, does fecal occult blood testing decrease the incidence of colorectal 
cancer?  These studies have focused on the usefulness of screening tests in the prevention and 
early detection of disease, such as various cancers, and comorbidities associated with certain 
conditions (e.g., diabetes), among others.183-185  For example, a systematic review examined the 
evidence that screening and earlier treatment are effective in reducing morbidity and mortality 
associated with Type II diabetes.  The review found that, for high-risk populations, screening tests 
can detect diabetes in its preclinical phase, and that over the 10-15 years after clinical diagnosis, 
tight glycemic control can improve patient outcomes by reducing the risk for blindness and end-
stage renal disease.186  The USPSTF relies on outcome studies of this nature to develop evidence-
based guidelines for priority health conditions.   
Outcome studies also have identified adverse events arising from incorrect test results.  These 
studies assess the relationships between analytic accuracy (i.e., false-negative or false-positive 
results) to detrimental effects on patient health (e.g., disease progression that would have otherwise 
been discovered or unnecessary surgery).187-189  An example concerns a study in which 12 women 
were diagnosed with having postgestational choriocarcinoma on the basis of false-positive test 
results for human chorionic gonadotropin.190  The errors had adverse consequences for patient 
outcomes, as most of these women were subject to unnecessary surgery and chemotherapy. 
Other outcome studies examined provider or patient satisfaction with aspects of care.  For 
example, an ongoing Q-Tracks study is using two high-level measures, i.e., overall patient 
satisfaction score and percentage of patients more than satisfied, to assess satisfaction with 
outpatient specimen collection.191  A Q-Probes study relied on more detailed data collection to 
assess patient satisfaction, including aggregate scores, percentage of excellent/good ratings, 
below average/poor ratings, and satisfaction for 10-13 specific aspects of laboratory service.192   
While patient outcome studies are gradually becoming more common in laboratory medicine, 
they are not yet a regular part of ongoing quality improvement practices.  Laboratory-related 
outcome measurement is underused for several reasons, including the high cost of capturing 
outcomes data, lack of standardization of data collection and reporting methods, and lack of 
agreement regarding appropriate analysis of data (e.g., whether or not to risk-adjust data).  
Furthermore, outcome measurement can be severely constrained by sample size, test results 
missing from patients’ medical records,  limited risk adjustment capability with data abstracted 
from administrative records, and higher cost to abstract data from medical records.109  Other 
problems consistently identified in the literature include the inability to conceal the identity of 
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tested versus non-tested patients, the relative remoteness of an outcome to the test itself, and the 
number of patients or volunteers required for a study to achieve statistical significance.114, 115, 182, 193   
Intermediate outcomes association with biomarkers, such as HbA1c and glucose for diabetes, are 
generally easier to measure than patient outcomes to assess the impact of health care 
interventions and thus, are more commonly used.  A biomarker is a variable that is objectively 
measured as an indicator of normal biological processes, pathogenic processes, or 
pharmacological response to a therapeutic intervention.  A surrogate (or intermediate) endpoint is 
a biomarker or physiological marker that is intended to act as a substitute for or predict a patient 
outcome.  They are relatively quickly or easily measured and their use is based on evidence that it 
is a reliable predictor of the patient outcome of interest.  Certainly, some biomarkers are better 
predictors of patient outcomes than others.  Examples are:  blood pressure or cholesterol levels for 
predicting the incidence and course of cardiovascular disease, T-cell counts for predicting survival 
of AIDS patients, and PSA levels for predicting the incidence and course of prostate cancer.   
Cost-related Measures and Indicators 
Cost-related outcome assessment is growing in use, although relatively little research has been 
conducted as pertains to laboratory testing.102, 194  An example of such studies in laboratory 
medicine is one that assessed the cost-effectiveness of periodic, population-based dipstick 
screening for early detection of urine protein in adults with neither hypertension nor diabetes and 
in adults with hypertension.  Using a Markovw decision analytic model, the study compared a 
strategy of annual screening with no screening (usual care) for proteinuria at age 50 years 
followed by treatment with an angiotensin-converting enzyme inhibitor or an angiotensin II-
receptor blocker.  Among the findings, for persons with neither hypertension nor diabetes, the 
cost-effectiveness ratio for screening vs. no screening (usual care) was an unfavorable $282,818 per 
QALY,x but $53,372 for persons age >60 years, and a highly favorable $18,621 per QALY for 
persons with hypertension.  The analysis showed that factors that tend to improve cost-
effectiveness of screening for the general population include a greater incidence of proteinuria, 
age >60 years at screening, and lower frequency of screening.  The investigators concluded that 
early detection of urine protein to slow progression of chronic kidney disease and decrease 
mortality is not cost-effective unless selectively directed toward high-risk groups (older persons 
and persons with hypertension) or conducted at an infrequent interval of 10 years.198   
Another study modeled the cost-effectiveness of routinely using tandem mass spectrometry to 
screen newborns for inborn errors of metabolism based on data from a large health maintenance 
organization.  Depending upon assumptions in three scenarios, the cost per QALY ranged from 
$736 to $11,419.  These findings led the investigators to conclude that costs per QALY saved by 
                                                 
w The Markov model is a statistical state-transition model in which the transition probabilities depend only on the 
current state and not on previous states or the pathway by which the state was entered.195 
x The QALY is a composite unit of length of life and utility for particular levels of quality of life.  Ones’ utility for quality 
of life is measured on a scale from 1.0 (utility for perfect health) to death (0.0).  For example, 1 year of life lived in 
perfect health (utility of 1.0) health yields 1.0 QALYs, 0.5 years of life lived in perfect health yields 0.5 QALYs, and 1 
year of life lived in a lesser state of health (e.g., bedridden) with a utility of 0.5 is also equivalent to 0.5 QALYs.  The 
QALY may be used as the unit of patient/user outcomes in a cost-effectiveness (or cost-utility) analysis.196, 197  In 
developed economies, a health care intervention is considered to be cost effective if its cost per QALY falls under a 
certain threshold, (e.g., $30,000 per QALY or $50,000 per QALY or $100,000 per QALY).  In the U.S., such thresholds 
are generally regarded as informal only, and do not have bearing on payment decisions. 
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tandem mass spectrometry for inborn errors of metabolism compare favorably with other mass 
screening programs such as for breast and prostate cancer.199   
Several studies have examined the cost of POCT relative to central laboratory testing using 
metrics such as cost-per-test (including estimates for the cost of equipment, supplies, labor, and 
other variables) and laboratory test TAT.200, 201  For example, a study reported in 2004 compared 
the analytical costs of central laboratory glucose testing and semiautomated bedside glucose 
testing (BGT) among 445 institutions enrolled in the Q-Probes program.  Results showed different 
distributions of costs across three main types of sites.  The median (10th-90th percentile range) 
analytical costs per glucose test were $1.18 dollars ($0.36-$5.59) for central laboratories, $1.96 
($0.77-$9.51) for high-volume BGT sites, and $4.66 ($1.02-$27.54) for low-volume BGT sites.  In 
addition to being higher than costs for central laboratories, costs for BGT were highly variable and 
dependent on volume.  The investigators observed that data that would be used for financial 
justification for BGT were widely aberrant and in need of improvement.202  
CONCLUSIONS 
To achieve consistently high levels of quality in laboratory medicine requires moving beyond 
analytic-focused QC and PT activities to more comprehensive, systematic approaches to quality 
management that support the integration of preanalytic, analytic, and postanalytic components, 
external assessment and accountability.  An important tool of QMS and improvement programs is 
the use of performance measurement to assess achievement of quality standards for structural 
features that support quality, processes of care, and health outcomes. 
 Relative to the five levels of quality,y most health care organizations, including 
laboratories, are operating at or below the stage of QA, although some have 
implemented and are working successfully at the level of QMS.  Organizations that 
implement QMS are better equipped to reduce or eliminate errors, meet customer 
needs, score well on government or accreditation assessments, and maintain quality 
objectives.  CLSI and ISOz have developed standards for QMS.  
 By adopting ISO 9000 standards, QMS has been most broadly adopted in transfusion 
medicine to meet FDA requirements for Current Good Manufacturing Practices and 
Quality Assurance Guidelines.  Use of ISO 9001:2000, ISO 15189, and CLSI guidelines in 
laboratory medicine has accelerated in recent years as CMS and laboratory accreditation 
organizations incorporate QMS-related standards into their regulatory requirements.   
 CQI, Toyota “lean” production, Six Sigma, and FMEA are strategic tools for 
implementing QMS that are realizing benefits among early adopters, from small 
physician office laboratories to large reference laboratories.  Use of CQI and Six Sigma 
has contributed to financial savings and decreased TAT, lean production has improved 
test quality and reduced errors, and FMEA has decreased time to report critical 
laboratory values.   
                                                 
y The CLSI five tiers of quality are: (1) QC; (2) QA, including PT; (3) QMS; (4) quality cost management; and (5) TQM, 
known as CQI in health care.   
z International Organization for Standardization (ISO) has developed two standards for QMS:  the more general ISO 
9000 series and ISO 15189, which is focused on health care.  CLSI guidelines HS1-A2 and GP26-A3 facilitate the 
implementation of these standards. 
Laboratory Medicine: A National Status Report Chapter V – Quality Systems and Performance Measurement 
 
May 2008 229 
 The great bulk of effort on formal performance measurement and improvement has been 
devoted substantially to the analytic phase, rather than the pre- and postanalytic phases.  
Public and private sector organizations have sponsored research and other initiatives to 
address some aspects of the deficit of information on pre- and postanalytic quality.  
However, the indicators used to date have not been uniformly defined or assessed for 
generalizability, and are subject to wide variation in their implementation. 
 The emphasis of provisions under CLIA is largely structural, outlining policies, 
procedures, and documentation requirements as a condition for accreditation and 
certification.  Aside from PT and corresponding false-negative and positive rates, process 
measures to assess the quality in the TTP remain relatively underdeveloped and are 
selected based on expert opinion rather than evidence-based outcomes and gaps in 
quality.  Typically, research studies rely on high-level calculations of error rates (e.g., 
specimen rejection, specimen labeling, TAT).  The evidence pertaining to the impact of 
laboratory testing on outcome measures― health outcomes, humanistic outcomes, and 
economic outcomes― remains sparse.  A small body of research has examined such areas 
as the costs of the analytic phase of particular tests and the adverse consequences of 
incorrect test results.  
Gaps, Needs, and Challenges: 
 Stakeholders in laboratory medicine must address organizational obstacles to the 
implementation of QMS in order to achieve higher levels of quality, including 
resistance to culture change, lack of leadership and staff commitment to QMS, and 
insufficient funding of QMS activities. 
 Most research on the adoption and results of laboratory quality to date has focused on 
the larger, hospital-based laboratories.  Further research is needed to examine the 
specific challenges that smaller laboratories and POLs may confront when implementing 
process-related performance measurement and quality improvement programs.     
 Substantial work is needed to support the selection, development and standardization 
of pre- and postanalytic process-related performance measures that are important to 
health care quality and patient-related outcomes, and satisfy minimum criteria such as 
those used by AHRQ’s National Quality Measures Clearinghouse.  Data collection, 
analysis, and reporting methods also need to be standardized.   
 The evidence for the impact of laboratory medicine on patient outcomes, humanistic 
outcomes, and economic outcomes must be augmented.  The lack of a substantial and 
evolving body of such evidence diminishes the ability to assess and demonstrate the 
value of laboratory medicine.  Taking on this effort is essential in a health care market 
that increasingly demands evidence of value for adoption, use, and payment, 
especially for new health care technologies.       
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CHAPTER VI 
LABORATORY INFORMATION SYSTEMS  
Laboratory information systems (LIS) have evolved over the past 30 years from simple systems 
designed to generate accurate reports to complete systems that can link laboratory data “end to 
end” across the TTP, including clinician-related pre- and postanalytic activities (e.g., test selection, 
interpretive consultation).  Health information technology (HIT) and Web-based applications 
have enabled dramatic improvements in the ways in which laboratories communicate, provide 
services, educate their workforce and clients, market themselves to clients, and track clinical data 
and information.1  Health care organizations have played a key role in advancing such 
communication by linking the LIS with hospital information systems, pharmacy database 
systems, etc.   
As a strategic tool, the LIS should enhance quality and efficiency of health care professionals, 
allowing them to deliver high quality, cost-effective service.2  In fact, several studies of urban and 
rural facilities have reported a direct association between the implementation of an LIS and 
improved financial performance.3-5 
This chapter provides a brief overview of the basic structure of LISs in integrated delivery systems 
(IDS) and POLs.  Particular attention was given to data management capabilities and clinical 
practice applications of interest to public and private sector stakeholders as they pursue 
comprehensive health information systems integration.  In addition, the chapter discusses 
important informatics issues that continue to inhibit data exchange between applications both 
internal and external to clinical laboratories.    
STRUCTURE OF LIS 
Today, the LIS is a complex computer system of clinical and administrative applications programs 
with widely varying configurations in different types of laboratories (see Figure 6.1).6  An LIS may 
be a single, integrated software package running on one or more database systems.  It also may be 
comprised of different modules (e.g., specimen accessioning, chemistry tests, and microbiology 
tests), often supplied by different vendors.  Larger organizations may operate several LISs.  For 
example, one LIS may be designated for general laboratory services, another for transfusion 
medicine, and a third for anatomic pathology.  The traditional preference for interfaced,a 
heterogeneous, best-of-breed systems appears to be shifting to integrated, single-source systems.7 
 
                                                     
a An interface is a point of interconnection between a computer terminal and a network or between two networks. 
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Figure 6.1:  Integrated Comprehensive Laboratory Information System  
Adapted from:  Cooper SD.  The role of the laboratory information system in diagnostic services.  In: Clinical diagnostic 
technology: the total testing process. Volume 1: the preanalytic phase.  Ward-Cook KM, Lehmann CA, Schoeff LE, Williams RH, 
ed.  Washington, DC: AACC Press, 2003. 
Integrated Systems and Large Laboratories 
An IDS is a group of health care service units (e.g., hospitals, outpatient clinics, ambulatory 
surgery centers, long-term care facilities, physicians’ offices, and hospital, POL and reference 
laboratories) that provide a spectrum of health care services across a geographic region.8  The LIS 
may operate across the network or group of networks in an IDS, although occasionally some 
operate in a closed or proprietary environment.  
Within the IDS, a “core” laboratory serves as the primary testing site for the network.  Smaller, 
rapid response laboratory systems operate locally where needed.9  While networking models vary 
by testing menus and location, the core laboratory usually performs most non-stat (non-urgent) 
and high complexity testing, including outpatient and outreach settings.8 In essence, the core 
laboratory functions as a reference laboratory serving both internal and external users.   
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The inter-laboratory connections are established by either a single LIS with multifacility function or 
multiple LISs that interface with the core laboratory.8   Multifacility systems typically rely on the 
computing hardware at one main data center and a common application interface standard such as 
health level 7 (HL7) for data exchange.  Although all users can access the system, restrictions 
according to patient, provider, and facility identifier can be applied.  Hardware standardization can 
increase efficiency in multifacility systems; however, this must be weighed against costs of replacing 
legacy systems.  The multi-LIS model incorporates a central application interface engine in the IT 
architecture that routes and translates messages among the disparate systems based on predefined 
rules.  Each site preserves its own security and access rules.  While this option allows organizations 
to retain legacy systems, integration (via standardization and consolidation) requires major efforts 
to redefine certain database elements and standards across the different systems.   
Linkages between hospital information systems and LISs are critically important to institutional 
systems and integrated delivery systems.  The most “wired” interconnections are ordering of tests 
and reporting of results, claims and billing for tests, and links to the inpatient pharmacy database.  
The American Hospital Association (AHA) reported that, in 2007, 78% of hospitals had electronic 
reporting of laboratory results and 72% had laboratory test electronic order entry, either by the 
physician or within the laboratory.10  According to AHA, connectivity for laboratory reporting 
and ordering functions ranked on par with those for radiology (77% for reporting and 70% for 
ordering respectively), and ahead of pharmacy-related order entry (61%).    
The VHA provides a real-world example of an integrated system, among the many in the public 
and private sector.  In 1996, the VHA reorganized its 173 hospitals into 22 Veterans Integrated 
Service Networks (VISNs); each VISN is a regional health care system that provides a continuum 
of services to veterans residing in a specific geographic area.11, 12  Laboratory Electronic Data 
Interchange software consolidates electronic laboratory test ordering and results reporting 
throughout all VHA medical care facilities within and between VISNs.13  The VHA and Military 
Health System (i.e., TRICARE) are redesigning their networks to allow health information to be 
shared between the systems.  Two of their demonstration projects specifically involve the LIS: the 
Bidirectional Health Information Exchange allows two-way exchange of health information, 
including laboratory results on shared patients in text format; and the Laboratory Data Sharing 
Interface application facilitates electronic transfer and sharing of laboratory orders and results.14   
Modules 
Most hospital and reference laboratory LISs are composed of multiple, separate clinical and 
administrative hardware and software modules (e.g., order entry, specimen tracking, report 
generation, accounts receivable, QC and QA, and automated instrument monitoring) that can 
operate either independently or be used as a system component.  The main functions of hospital 
LISs are identified in Table 6.1.  Currently, most LISs in reference laboratories do not link 
directly to clinical practice applications such as CPOE, POCT devices, EHRs, and pharmacy 
systems; however, data from their systems can be sent directly to providers electronically (e.g., 
results reporting) or be made available through regional health information organizations.b   
                                                     
b A regional health information organization (RHIO) is a group of organizations that are capable of electronic health 
care data exchange within a defined geographic region, usually via interoperable electronic health records.  
RHIOs are the building blocks of the National Health Information Network initiative proposed by the DHHS 
Office of the National Coordinator for Health Information Technology.  
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Table 6.1:  Functions of a Laboratory Information System  
LIS-related Application Characteristics 
Preanalytic 
Order entry/CPOE/accessioning 
• Built-in functions for test ordering from standardized menus; may include automatic confirmation of medical 
necessity for performing the test 
• Clinicians may enter orders in hospital information system that will automatically transfer to the LIS, including 
appropriate laboratory location, time of day, priority status, or client 
• Algorithms may be used to assess appropriateness of test order in light of information contained in the LIS and in the 
patient’s medical record 
Barcode specimen labeling • Electronic identification of the health care provider, the patient, the specimen container, what specimen to collect, 
and the order in which the specimens were drawn 
Analytic 
Specimen tracking 
• Barcoded labels with unique identifiers for each specimen allow specimen to be tracked through the highly 
automated areas of the laboratory or from station to station during specimen examination 
• Tracking may be accomplished via scanning, either automatically or manually by the technician 
Applications for clinical 
pathology, microbiology, 
transfusion medicine, and 
anatomic pathology 
 
• Clinical pathology modules support specimen collection and tracking, order entry, rule-based decision making, 
results reporting, and interfacing with automated instruments  
 Hematology modules allow for manual differential counts to be added, deleted, or masked to automated results 
when sent to the LIS and for the creation of histograms 
 Immunology modules transmit data from enzyme-linked immunosorbent assay (ELISA) readers to LISs  
 Toxicology modules automatically rerun positive results, generate complex random drug testing schedules for 
organ donors, and produce utilization reports to study testing trends   
• Microbiology modules allow for recording observations, additional test ordering, and creation of antibiograms (used 
by hospitals in the review of antibiotic usage) 
• Transfusion medicine modules automate transfusion services, including inventory, distribution of blood, quality 
control, and emergency release capabilities 
• Anatomic pathology modules provide access to patient clinical histories, links to clinical pathology department, 
correlation studies, and links gross and/or microscopic images to case worksheet and patient reports 
Automated systems interfacing 
• Allows laboratorians to manage and review large volumes of data and support QC requirements 
• QC functions track and review QC data from all workstations and perform statistical analyses to ensure that 
laboratory testing accuracy and precision are maintained at acceptable levels 
• Automatic functions for repeat testing on the same sample for either the same test, a different test, or different 
instrument, following an abnormal result or specific decision criteria  
• Enables manual results entry or automated result generation followed by automated results review and release 
(autoverification) 
• Blocking function prevents autorelease of results based on flags for abnormal results, delta check failure, panic 
value, improbable results, results failing user-defined criteria 
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LIS-related Application Characteristics 
POCT 
• Supports POCT devices that link to the LIS via docking devices or infrared data transmission 
• Capable of receiving POCT data, creating and storing appropriate records, and generating final results reports 
Digital pathology 
• Digital photography, storage, cataloging, archiving, and dissemination of pathology images at the gross and 
microscopic levels 
• Supports electronic, multimedia communication of digital images between laboratories and clinicians, including 
telemedicine 
Links to knowledgebase systems • Links in LISs provide laboratorians access to knowledge bases containing clinical, genetic and molecular information 
(e.g., clinical definitions, gene ontology, protein structure and sequencing, mass spectrometry) 
Postanalytic 
Results reporting 
• Report formatting 
• Results reporting communications via fax, email, or Internet (usually through a virtual private network) 
Links to EHR • Links between LISs and EHRs being developed to allow laboratory results to be directly deposited into an EHR; 
eventually will include the ability to order tests directly from the EHR  
Links to pharmacy database • Supports linkages of pharmacy database systems to LISs for selection and management of medications and 
prevention of medication errors; links are generally from pharmacy system to LIS, not vice-versa 
Other 
Billing systems 
• Allows for generation of bills with minimal effort, automated coding of tests, generated from test orders 
• Supports accounts receivable to assist with management, receipt, collections, banking, and reporting 
Supplies management 
• Manages use, ordering, and inventory of supplies in the laboratory 
• Tracks lot number, quantity, and date received, opened, closed, and expired for reagents and other laboratory 
supplies 
Patient safety and error reporting 
• Alerts laboratorians when critical value has occurred and provides protocol to be followed, contact information for 
clinician, and log of time that message was delivered and name of person receiving it 
• Automation of quality assurance functions (e.g., documentation of abnormal results, TAT, list of corrected 
laboratory reports, comparison to standards set by CAP and other professional bodies) 
• Links between LISs and laboratory error databases in development to allow tracking of diagnostic errors made in the 
laboratory 
Public health surveillance 
• Surveillance and management reporting of infectious diseases and hospital acquired infections. 
• Communication functions with public health networks in the event of chemical or biological threats, emerging 
infectious diseases, and natural disasters 
Online education • Online laboratory manuals and handbooks, most often in Web-based form, to support knowledge and regulatory 
requirements 
Sources:  Adapted from Cooper 2003; Goh 2003; Li 2004; Grzybicki 2005; Asare 2000; Yuan 2005; Cimino 2004; Marchevsky 2002. 
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For hospitals and reference laboratories, certain more advanced modules such as digital pathology 
and telepathology already have been implemented.  In addition, many hospitals are creating 
interconnections from LISs to clinical practice applications, such as CPOE, POCT devices, EHRs, 
and patient safety reporting systems.  These advanced functions are vital components to the 
development of comprehensive information systems in hospital and ambulatory care settings.   
Automated instruments for each subspecialty area (e.g., chemistry, hematology, microbiology) 
are linked to the LIS architecture.  The combination of innovative automated equipment and IT 
has dramatically improved throughput, precision, convenience, and data handling.15  Linkages 
between modular systems and the LIS support QC and QA, consolidation of work and 
personnel, and more efficient integration and management of laboratory operations.  Process 
control software allows the operator to monitor hardware, software, and work cell modules 
from one PC workstation.16 
The LIS architecture is designed around workflow of analytic processes in order to enhance 
efficiency, decrease errors, and improve the overall quality of testing.  Workflow analysis 
measures the impact of change in relation to laboratory costs and efficiencies.9  For each 
workstation involved in producing analytical test data, several factors are evaluated, including 
the age of analyzers, capital cost, throughput, service cost, supplies, and the labor associated 
with producing results.  The data summary provides an estimate of the cost for each assay that 
is performed at each workstation.  Computer simulation programs facilitate workflow analyses.   
The programs can imitate and capture dynamic system behavior, support workflow design, and 
evaluate alternative ways of improving efficiency and management.17 A good simulation model 
assists laboratory staff in determining the best configuration to reduce risks, costs, and 
turnaround time without disrupting the working system. 
Interconnectivity 
Each module or application can be used independently as a stand-alone unit or component, 
although some also have the capacity to import, export, imbed, or exchange data with other 
modules or applications.  There are challenges to attaining optimum interconnectivity when the 
LIS modules are developed by different vendors using different data standardsc (e.g., data 
exchange, terminologies, document architectures, knowledge representation).  As a result, many 
health care institutions must depend on middlewared for connectivity and enhanced data 
management, especially for new, more complex laboratory testing technologies.  Using “if-then” 
rule-based algorithms, newer middleware systems not only process data but offer flexibility in 
filtering, sorting, and displaying data.19  Development of middleware for data management stems 
from the need to resolve problems between instruments and the LIS (i.e., via workarounds) and to 
address the shortage of laboratorians available to manage and evaluate data.20  Middleware serves 
the functions needed for today’s clinical laboratory that have not been met in the designs of 
                                                     
c Data standards encompass methods, protocols, terminologies, and specifications for the collection, exchange, 
storage, and retrieval of information associated with health care applications, including EHRs, medications, 
radiological images, laboratory information, payment and reimbursement, medical devices and monitoring 
systems, and administrative processes.18 
d Middleware is software that facilitates communication between laboratory instruments and the LIS, or two 
applications, and management of workflow within a workstation or the system as a whole.19  Functions may 
include autoverification of results, addition of new orders to test files, insertion of comments, or take other actions 
for specific patients or physicians.20 
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automated systems and interconnections with the LIS.  A challenge arising from this third party 
approach is the integration of multiple, additional vendor applications and standards to the 
already complex pool, increasing opportunities for error.   
Another important feature of LIS interconnectivity is the growing adoption of Web-based 
mechanisms to support electronic test ordering and results reporting executed from a hospital, 
physicians’ office, reference laboratory, or other health care facility.21  Internet browsers running 
on personal computers allow direct data exchange between these facilities while portals provide 
gateways to the hospital LIS to access online ordering functions and retrieve results reports.  Some 
Web-based applications allow results to be reported directly into a patient’s EHR or a physician’s 
practice management system.   
Physician Office Laboratories 
Increased regulatory requirements, testing costs, and coding complexity following the 
implementation of CLIA in 1992 accelerated adoption of certain LIS functions by some POLs.22  
Similar to IDS, these systems help POLs comply with QC, PT, QA, and patient test management 
requirements.  For QC, the LIS receives data from each instrument and evaluates whether values 
are within the control range.  Along with PT data, the QC data are then stored for retrieval and 
review during inspections and for troubleshooting.  LIS applications also are used to comply with 
CLIA patient test management requirements by automatically loading key data points (e.g., 
patient identifiers, lab name, address, age-specific normal ranges, units of measure, testing 
analyst, tests ordered).  
For most POLs, use of other LIS applications is quite limited, because the majority of these 
laboratories perform waived tests and non-waived microscopy tests.  Regarding interconnectivity, 
POLs that perform certain moderately complex chemistry and hematology tests (e.g., CBC) tend to 
structure analyzers as independent modules connected only to printers for report generation.  If the 
POL has an electronic labeling function, it is usually connected to the office administrative 
application or the patient’s EHR.  Printed test results are added to a paper chart or manually entered 
into the EHR.  Often, the EHR application includes an electronic ordering/reporting function that 
can link via the Internet to a larger reference laboratory with which the POL has an established 
business relationship.  Generally, the need for broader access and more cost-effective networking 
solutions is boosting adoption of Web-based ordering and reporting capabilities in POLs.8 
There is sizable cost involved in implementing and linking EHRs to other functions.  While more 
physician offices are implementing them, it has become standard practice for reference 
laboratories to directly provide and/or finance basic electronic connectivity for ordering tests and 
reporting results.  In doing so, however, external data exchange is limited to the “sponsoring” 
reference laboratory.23  As this limitation inhibits compliance with open standards and 
development of health care data exchange, efforts are underway to require interoperability with 
other vendor systems.  For example, MedPlus, Inc., an HIT subsidiary of Quest Diagnostics, has 
developed a program (now available) called “Universal Laboratory Orders and Results” that 
allows physicians’ offices to electronically order and receive results and track patient laboratory 
and prescription data from both Quest laboratories and other hospital laboratories.24  
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ADVANCED APPLICATIONS FOR COMPREHENSIVE SYSTEMS 
Clinicians must have access to potentially pivotal patient information (e.g., laboratory results, 
medication list, and medical history) and to current scientific information (e.g., infectious 
diseases, medical evidence, guidelines) in order to provide high quality care.  A comprehensive 
IT infrastructure is essential for: 
 Managing the expanding volumes of clinical and administrative data generated from 
patient encounters 
 Transforming clinical data into information that can be used to improve the safety, 
effectiveness, and efficiency of health care delivery25 
The infrastructure must ensure that laboratory and other data are accessible through efficient 
networks and clinical practice applications that link to the EHR.   
Public and private sector initiatives to build the health information infrastructure have started 
with the ancillary services that generate the highest volume of data critical to patient care and 
safety—laboratory, pharmacy, and radiology.  These services also tend to rely on sophisticated 
data management systems (e.g., LIS or pharmacy database) and innovative technologies (e.g., 
automated analyzer, robotic dispensing) for day-to-day operations.  Links between the ancillary 
disciplines are necessary for accurate clinical diagnosis, treatment, and disease management.  
For example, links between clinical pathology and pharmacy data are needed for therapeutic 
drug monitoring, and links between anatomic pathology and radiology data are needed for 
diagnosis of cancer metastases and guidance of complex surgical procedures.   
UNRESOLVED ISSUES RELATED TO ADVANCED APPLICATIONS 
Automating Data Management 
Effectively automating data management capabilities is an important factor in the evolution of the 
LIS and automation systems for clinical and anatomic pathology and requires informatics 
standardization, expanded computing power for new testing technologies, and other support for 
networked systems.  
Automation of data management already has yielded several advantages to the clinical laboratory, 
including higher productivity and efficiency (e.g., higher test volume, fewer instruments), more 
streamlined workflows and easily reproducible processes, and decreased costs.26   
Current data management system designs have progressed from a hardware-based approach to a 
software-based approach that incorporates middleware and/or process control software.  These 
applications generally automate such features as repeat testing, dilutions, reflex orders, and 
adjudication of instrument errors. e, 16, 27  For a middleware system to release results automatically, 
it must select from a range of actions based on various criteria and the desired scope of the 
                                                     
e Repeat testing will be automated ultimately so that a specimen yielding a specific result can be returned to the 
system for additional testing using an alterative method or confirmatory testing on the same or different 
instrument.  “Reflex testing” refers to additional testing performed automatically when a specific rule is applied 
to the result of the first test. 
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application which can differ by vendor, the type of test, and the nature of the patient population.28  
More sophisticated integrated systems incorporate knowledge-based process control software 
features and expert rules, such as algorithm testing, disease pattern checks, specimen integrity 
checks, clinical range checks, and delta checks.29  
Process control automates routine tasks and employs standards of practice to support the human 
operator.  Although most common in large hospital and reference laboratories, process control 
software for automating data management is expected to increase sharply over the next several 
years.  Process control features in development will facilitate the transportation, storage, and 
retrieval of laboratory specimens; physically identify and track specimens throughout the system; 
and support automated test cancellations and workload management.  Next generation laboratory 
automation software will consolidate and integrate all aspects of laboratory, data, and instrument 
management from sample logistics to results management, archiving, and retrieval.30  Successful 
integration of these process control data management features requires multidirectional, 
coordinated communication that links the LIS, preanalytic processing components, the specimen 
transportation system, analyzers, and the postanalytic archiving system.28 
Data Management for New Testing Technologies  
The LIS must be flexible enough to handle the demands posed by new laboratory tests and 
technologies.  In particular, the quantity of specimens involved in genetic, proteomic, and PGx 
testing pose significant challenges for LISs.31  The complete mapping of the human genome will 
continue to enable creation of new laboratory tests and LIS applications programs to support them.6 
Greater use of genetic testing is increasing the need for LIS applications that support cytogenetic 
and molecular diagnostic testing.  Examples of such applications include increased capacity for 
data storage, ability to detect genetic rearrangements and other abnormalities associated with 
malignant disease and hereditary genetic abnormalities, and ability to access patient records that 
contain personal gene databank and family tree information.32-34   Decision support, specimen 
tracking and automation of QA and QC documentation features also must accommodate the 
demands of genetic testing.  In order to accomplish these goals, additional software applications 
and more sophisticated, high-speed computer processing capabilities are required of the LIS.35   
Extension of data management to genetic findings requires an LIS to standardize information and 
support genomics-based inference.31  Current medical vocabularies are insufficient to describe the 
findings generated by some new molecular tests.31, 36  Vocabularies such as the Clinical 
Bioinformatics Ontology have been designed for clinical molecular diagnostics and cytogenetics.37 
In order for LISs to handle the nature and volume of genomic tests, current discrepancies between 
how genetic mutations are described in the literature and how they are described in internet 
databases must be resolved.f, 36  Use of separate, specialized modules or systems in the laboratory 
that transmit summarized information to EHRs has been proposed as another means to allow 
LISs to meet the needs of genetic testing.39          
The upswing in genomic testing is speeding the integration of patient-specific genomic 
information into EHRs.  Entering and formatting molecular diagnostic and cytogenetic laboratory 
                                                     
f One example of an online database is RefSeq, a collection of genomic DNA, transcript, and protein products for 
major research organisms compiled by the National Center for Biotechnology Information.38 
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findings into EHRs is necessary to support clinical decision-making and to automatically flag 
PGx-based risks.31           
The volume and complexity of data generated from proteomic profiling, especially from high-
throughput analyses and increased reliance on automation, demands that LISs be capable of 
storing large quantities of data.40, 41  In particular, LISs need to be able to search large internal and 
external databases containing information about proteins, which requires greater computing 
power than is currently available in these settings.40, 42 
PGx testing presents particularly difficult challenges to the LIS due to the potential enormity of its 
data requirements—molecular biology (e.g., sequences, structures, pathways), clinical medicine 
(e.g., medications, diseases, side effects) and pharmacology (e.g., pharmacokinetics and 
pharmacodynamicsg).45  Among other roles, PGx entails linking genetic information and clinical 
data in order to identify genotype-phenotype associations.   
Patients also will need support when seeking, interpreting, and acting upon personal genetic-
based data.  The 2006 NACB draft guidelines on the application of PGx to the clinical laboratory 
recommends that laboratories develop educational resources to recipients of test results and that 
interpretative reports include a summary of the patient’s metabolic status and its effect on the 
drug regimen being considered.46   
Computerized Physician Order Entry 
Growing awareness of prescription errors and their associated costs provide some of the rationale 
for development and implementation of CPOE systems.  These are online computer applications 
that allow physicians to order laboratory, pharmacy, and radiology services and therefore have 
the potential to prevent common medication ordering errors (e.g., selecting the wrong drug or 
dose, overlooking drug allergies).47, 48  Laboratory data are a vital component of CPOE systems 
and are often displayed for physician review prior to ordering.49  CPOE systems must be able to 
exchange data with LISs using standardized communication protocols.47, 50         
CPOE adoption remains relatively low.  A study reported in 2006 estimated that national 
adoption of CPOE is 15% in integrated delivery systems,h 9% in stand-alone hospitals, and 1% in 
skilled nursing facilities and rehabilitation hospitals.51  Despite the use of interfacing standards 
such as HL7, messaging between the CPOE and LIS still requires customized programs and close 
collaboration between the laboratory and the team implementing the CPOE system.52  LISs face 
additional significant challenges in enabling CPOE, including how to provide real-time access to 
data stored in the LIS and how to ensure that the software-based rules governing the CPOE are 
appropriate and do not result in unacceptable rates of false positive and false negative alerts.53   
In 2000, the Ohio State University Health System implemented a CPOE system that linked 
bidirectionally with its LIS, automating the laboratory process from order entry to results 
reporting.54  Compared to areas of the hospital in which CPOE had not been implemented, 
                                                     
g Pharmacokinetics refers to the activity of drugs in the body over a period of time, including the processes by which 
the body absorbs, distributes, localizes, and excretes drugs.43  Pharmacodynamics refers to the reactions between 
drugs and living systems.44   
h An integrated delivery system is an aggregation of acute care hospitals, rehabilitation hospitals, and ambulatory 
care practices. 
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laboratory TAT decreased by 25% and both work flow accuracy and efficiency increased.  Extensive 
modifications made to their commercially available vendor-based CPOE system allowed the health 
system to interface with its other information systems and be tailored to physician needs.  The 
ability to customize or adapt a CPOE system to an organization’s needs is cited as a major 
consideration in a consensus statement on successful CPOE implementation published in 2003 by a 
group of 13 international CPOE experts.55              
The Leapfrog Group established an initiative to increase adoption of CPOE.  Hospitals can meet 
Leapfrog’s CPOE standard by assuring that physicians enter at least 75% of medication orders via 
a computer system with prescribing-error prevention software.  In addition, the inpatient CPOE 
system must be able to alert physicians of at least 50% of common, serious prescribing errors, as 
well as allow physicians to electronically document a reason for overriding an interception prior 
to actually doing so.56  Some vendors  have offered CPOE systems as part of their information 
system products, making readily integrated CPOE systems more accessible to organizations that 
cannot develop their own systems.50   
Clinical Decision Support Systems  
CDSSs rely on software algorithms designed to improve clinical decision making by matching 
characteristics of individual patients to a computerized knowledge base and generating patient-
specific clinical options, recommendations and other support.57  Such support may include alerts, 
reminders, order sets, reference information, and education.58  Although currently available 
CDSSs require providers to enter patient data, forthcoming applications will automatically link to 
patient data held in EHRs and generate support features without duplicate entry.59 
Laboratory data are a key component of CDSSs.  Currently, the most common laboratory-related 
feature of CDSSs is flagging abnormal test results.59  Another feature in use among early adopters 
alerts physicians if they order additional, potentially redundant laboratory tests before results of 
previous tests can be obtained.60  Eventually, CDSSs will include laboratory information that aids 
provider interpretation of medical symptoms, signs, and diagnoses.  For example, systems 
developed at the Massachusetts General Hospital and Kaiser Permanente in Escondido, 
California, use symptoms, signs, laboratory data, and other clinical findings to produce a ranked 
differential diagnosis list.61, 62   
To supply laboratory data to a CDSS, an LIS must generate data interpretable by the decision 
support application.  Laboratory data must be transparent enough to be understood, 
computationally unambiguous, and capable of being linked or adapted to multiple platforms.63  
Once laboratory data are transmitted to the CDSS, they may need to be reformatted to ensure 
their maximal clinical efficiency and efficacy.52  A major obstacle to the ability of a LIS to interact 
with and provide data to a CDSS is lack of interoperability between laboratory and clinical 
applications.  The Clinical Context Object Workgroup (CCOW) of HL7 developed a standard to 
facilitate the integration of applications from many different systems at the point of use to give the 
clinical user the experience of interacting with a single system.i, 64  Widespread adoption of the 
                                                     
i The CCOW standard is based on context management, or the coordination and synchronization of applications so 
that they are mutually updated with the set of their common data objects (e.g., patients or medical encounters) 
that frame the user’s interactions with applications.64   
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CCOW standard would enable laboratories to seamlessly and efficiently exchange information 
with CDSS and other clinical tools.52    
To support CDSS, an LIS must have several complex capabilities.  Decision making relies in part 
on rule-based systems or algorithms programmed into the LIS to automate processes such reflex 
testing and alerts.  While most modern LISs have rule-based capabilities sufficient for results 
autoverification, the capacity necessary to program a rule-based system for CDSS and the clinical 
and pharmacy data necessary to support these systems (e.g., QC and QA data, results of other 
laboratory tests, and historical test performance data) are not always available.52  Even once a 
rule-based system has been programmed; it requires regular updating to ensure that the 
knowledge base is current.   
Point-of-Care Testing 
Innovative sensor technologies, microprocessor-based analyzers, and disposable test cartridges 
have enabled the creation of small and portable testing devices that support minimally-invasive 
collection techniques, followed by rapid analysis and results presentation.1  Examples of the many 
tests that can be conducted at the point of care include measurements of blood gases, blood count, 
glucose, drugs of abuse, and fecal occult blood.65  More recently, technologies are enabling new 
and less-invasive POCT, such as minimally-invasive, laser-based skin perforators that collect 
interstitial fluid for measurements of glucose levels, and infrared sensors that measure glucose 
and other analytes through the skin.66  Data captured in these devices can be downloaded via a 
docking station to a database that is linked to the laboratory or hospital information system, 
billing, and generation of summary data reports.67 
POCT devices in day-to-day patient care are expected to increase substantially in the near term, 
perhaps more so than any other laboratory-related technology.67  However, one of the key 
unresolved issues in clinical settings is the lack of interoperability between POCT devices and the 
LIS.65  The Connectivity Industry Consortium was formed in 1999 to develop a base-level 
interoperability standard for data exchange between POCT devices and EHRs and LISs.67, 68  The 
standard was transferred to CLSI and approved as POCT1-A2: Point-of-Care Connectivity (Second 
edition, 2006).j, 69, 70  It provides the framework for engineers to create medical devices, 
workstations, and interfaces that allow different types and brands of POCT systems to 
communicate with each other and LISs.71  CLSI developed additional guidelines for POCT device 
interoperability.k  In particular, POCT4-A2: Point-of-Care In Vitro Diagnostic Testing (2006) provides 
general definitions, procedures, and recommendations for POCT, including guidance on quality 
assurance, alternative QC, and specimen collection and identification.72  Two other guidelines 
target specific testing devices.l   
                                                     
j POCT4-A2 replaced its predecessor, AST2-A, published in 1995.  
k CLSI developed guidelines to provide users of POCT devices, including nonlaboratory personnel, with information 
and suggestions for good clinical testing practice and for producing reliable results regardless of where or by 
whom the test is performed. 
l C30-A2: Point-of-Care Glucose Testing in Acute and Chronic Care Facilities (2002) provides instructions and 
recommendations on the administration of a POCT blood glucose monitoring program, persons who perform the 
tests, selection of methods, reporting of results, and quality assurance.73  Guideline H49-A: Point-of-Care Monitoring 
of Anticoagulation Therapy. (2004) provides information on how to proceed in the evaluation, implementation, and 
monitoring of heparin and warfarin therapy.74 
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Technical issues (i.e., analytic performance, interconnectivity) are being addressed through 
international standards development initiatives; however, they have not yet been fully resolved.  
Many discrepancies between results from POCT devices and central laboratory values have been 
reported.  For example, in a 2006 study comparing seven POCT glucose meters from four 
manufacturers to a central laboratory analyzer, differences greater than 10% were found 61% of 
the time for POCT hyperglycemic values, and differences of 20% or greater were found 57% of the 
time in the hypoglycemic range.75  Some of these disagreements have been attributed to differences 
in testing methodologies between POCT and central laboratory testing.76  Among these, POCT 
typically involves multiple instruments, each of which is operated by several people, as opposed 
to central laboratory testing, which generally involves one instrument that is operated by only a 
few people.77   
The lack of standardized hardware and software continues to challenge the integration of POCT 
devices with health information systems and applications.  Until recently, vendors manufactured 
their respective devices with different data management features, data manager systems, and 
interface standards, resulting in high levels of redundancy in laboratory testing as well as significant 
additional costs.67  As POCT becomes more common in inpatient and outpatient settings, the 
devices must be designed for interoperability with LISs and EHRs to support electronic storage, 
retrieval, and comparability of patient data for current care and future reference.  
Electronic Medical and Health Records 
Although often used interchangeably, electronic medical records (EMRs) and electronic health 
records (EHRs) are different.  An EMR is a local (single provider) system installed in an 
organization to support secure, comprehensive, and electronic patient medical record information.  
An EHR is a shared information system that aggregates patient information from various systems 
and sites, including multiple patient EMRs, on a scale that is regional or broader.  Because EHRs 
include EMR data, yet offer more extensive linkages outside the provider organization, U.S.-based 
initiatives have focused on building the health information infrastructure for the EHR.         
Estimates of EMR and EHR adoption rates vary widely, often due to ambiguities in the definitions 
of EMRs and EHRs.  The 2007 AHA survey on hospital use of IT reported that 11% of U.S. hospitals 
had fully implemented EHRs (mostly larger, urban, and teaching institutions).10  The Healthcare 
Information and Management Systems Society (HIMSS) has developed a database that maintains 
assessments of EMR implementation in approximately 4,000 hospitals using a scale of stage 0 
(information systems for laboratory, pharmacy, and radiology not implemented) to stage 7 (the 
hospital has a paperless EMR environment).78  December 2007 data indicate that nearly 39% of 
hospitals were in stage 2 and 28% had reached stage 3 or higher (see Table 6.2).  However, the 
HIMSS definition of an EMR appears to fit the AHA definition of an EHR noted above. 
EMRs and EHRs also are being implemented outside of hospital settings.  A 2006 report and 
meta-analysis of quality-ranked studies sponsored by the Robert Wood Johnson Foundation 
estimated that 17-25%of physician offices, 13-16% of solo practitioners, and 9-57% of large 
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physician officesm had implemented EHRs.79  Despite relatively widespread support, three main 
barriers continue to inhibit widespread implementation:  
(1) Lack of adoption of common data standards for EHRs 
(2) Quick turnover of HIT companies 
(3) Cost of installing and converting to EHR systems80   
Table 6.2:  EMR Adoption Model Trend Q3 2007 
Stage of 
Adoption Description of EMR Capabilities 
Percent of 
U.S. Hospitals 
(N=4,381) 
7 
 Medical record fully electronic 
 CDO able to contribute to EHR as byproduct of EMR 0.0% 
6 
 Physician documentation (structured templates) 
 Full CDSS (variance and compliance) 
 Full Picture Archiving and Communications System (PACS) 
0.6% 
5  Closed loop medication administration 1.4% 
4 
 CPOE 
 CDSS (clinical protocols) 2.2% 
3 
 Clinical documentation (flow sheets) 
 CDSS (error checking) 
 PACS available outside radiology 
24.1% 
2 
 Clinical data repository 
 Controlled medical vocabulary 
 CDSS inference engine 
 May have document imaging 
39.1% 
1  Ancillaries- laboratory, radiology, pharmacy 15.0% 
0  All three ancillaries not installed 17.6% 
Adapted from: HIMSS Analytics Databases (derived from the Dorenfest IHDS+ Database™). ©2007 HIMSS Analytics™ 
Because laboratory results are a major component of patient records (electronic or paper), 
interoperability between LISs and EHRs can reduce medical errors, increase appropriate and 
reduce unnecessary testing, and improve quality and efficiency of health care.  Interoperability 
allows authorized clinicians (i.e., ordering and non-ordering) to electronically access laboratory 
results, view historical results, receive automatic alerts for critical values and abnormal results, 
and integrate laboratory data with other EHR-linked functions (e.g., CPOE, CDSS, disease 
management).81, 82   
Interoperability of EHRs and LISs is still in early stages of development, and most laboratory 
results cannot be directly integrated into an EHR.83  Data transfer between systems has been 
hindered by incompatible programming platforms, components that prevent successful 
authentication and authorization of patients and providers, and security protocols.  Existing LISs 
                                                     
m Large physician office was defined as greater than 20 physicians by one study and as greater than 50 physicians in 
another study. 
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are devoted primarily to optimizing performance across internal system modules; data exchange 
with external systems is not a priority.84  As part of a 2005 survey conducted by CAP, LIS vendors 
were asked about their products and the types of settings in which they were installed.85  A 
majority of respondents indicated that a portion of their LIS installations were stand-alone and 
had not been integrated with other clinical applications (e.g., EHR).     
The main barriers to EHR-LIS interoperability include technical complexity of developing data 
standards and costs.  To date, initiatives to develop national standards for EHR-LIS 
interoperability have targeted results reporting for patient care and disease management.  Several 
public and private sector initiativesn are underway to address these constraints, including 
activities to develop data standards for EHR-LIS interoperability, including the following:   
 The Health Information Technology Standards Panel (HITSP) is a multi-stakeholder 
coordinating body established in 2005 by the American National Standards Institute 
(ANSI).  The EHR Interoperability Specifications are based on the DHHS Office of the 
National Coordinator for Health Information Technology Use Case for EHRs 
initiative.o  Designed as national standards, the specifications were developed using 
the data standards approved for the national HIT infrastructure.  
 The EHR-Lab Interoperability and Connectivity Standards project (ELINCS), created 
by the California HealthCare Foundation (CHCF),p developed a standard and detailed 
specifications for coding and formatting laboratory results messages delivered in real-
time from the LIS to an EHR.88  The standard can be used by commercial and hospital 
laboratories to send test results electronically and by developers/vendors in technical 
design of EHR systems.  In 2006, CHCF funded pilot testing of ELINCS at five clinical 
sites, including three hospital-based laboratories and two national commercial 
laboratories.89  Four of the five sites are currently operational,q two of which have 
begun to extend ELINCS-based connectivity requirements to their data exchange 
partners (e.g., independent laboratories, other local hospital laboratories).  Ownership 
of ELINCS is currently being transferred to HL7.    
Digital Pathology  
Recent advances in tissue labeling/processing techniques, imaging sensors, digital image 
processing, image analysis, and personal computers are transforming anatomic pathology and 
traditional microscopy.  Digital microscopy is a form of digital pathology that integrates digital 
imaging and light microscopy to capture pathological images at the gross and microscopic levels.90  
                                                     
n In October 2006, the federal government finalized new HIT safe harbor regulations for the Stark and anti-kickback 
regulations that allow for the provision of HIT below cost by a medical organization as long as the HIT increases 
patient safety and is interoperable with other information systems.86 
o The Interoperability Specifications were developed from an assessment of the current practices in electronic 
laboratory results reporting, as well as from the EHR Use Case, which was created to describe interoperability 
between EHRs and laboratory systems from patient and provider perspectives.84  The recommended standards 
put forth by HITSP were chosen to meet the requirements identified in the Use Case and to reflect current 
practice and future HIT needs and were chosen with the assumption that the standards will become more broadly 
used over the next several years. 
p CHCF has also led the development of CALINX, a standard to retrospectively communicate batch reporting of 
laboratory test results to data warehouses and disease registries to support population-level quality-improvement 
programs.87  CALINX has been created to meet the specific needs of California. 
q The fifth site withdrew from the ELINCS pilot project after switching laboratory vendors. 
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The current rapid transition to digital media affords many advantages to pathologists, laboratory 
staff, and patients.  The images may be electronically stored, replicated, cataloged, employed for 
educational purposes, transmitted for further interpretation (i.e., telepathology), analyzed for salient 
features (e.g., medical vision/image analysis), or used to support a wider digital pathology strategy.  
Digital images of pathologic slides also can support quality assurance by eliminating the need to cut 
and disseminate multiple sections for analysis.  Following the substantial initial investment, digital 
technology costs less to operate than photographic prints.  Memory cards, CD-ROMs, and other 
storage media that capture the images are inexpensive and can be reused.  In addition, digital 
pathology shortens image production times.   
The combination of automation technology with digital pathology has facilitated the development 
of automated cytology screening.91, 92  Cytology automation reduces the false-negative detection rate 
of manual, microscopic cytology examinations that rely solely on human evaluation.  Computer-
assisted systems can enhance human performance by identifying highly suspicious areas.   
Digital technology is playing an important role in telepathology.  The advent of telemedicine, i.e., 
the exchange of medical information electronically from one site to another to improve patients’ 
health, has significantly changed the way pathologists compare and share diagnoses between 
institutions.93  Traditionally, information shared includes stained and unstained slides, tissue 
blocks, wet tissue, and pathology reports.94  Telepathology supports electronic multimedia 
communication between pathologists (and other authorized, trained laboratory staff) concerning 
primary diagnoses and second opinion consultations as well as consultations with other 
clinicians.94  Information for telepathology consultations, including photographic and video 
images,r is shared in three different ways:  statically (information is stored and forwarded), 
dynamically (information is shared synchronously), and via a hybrid mode, which incorporates 
both static and dynamic sharing.  
Educational institutions are incorporating digital pathology into their curricula as a user-friendly, 
interactive teaching method.  Instructional databases include pathology slides scanned at high-
magnification along with three-dimensional simulations of organs and links to other relevant 
literature, information, and diagnostic tools.95  Some institutions also provide Web access to 
digital pathologic images.   
Prominent issues in digital pathology pertain to image quality (e.g., optics and calibration of 
system components), standardization of image sizes, and Web-based connectivity.90  High-power 
computation, large storage capacity, new image formats, and novel processing algorithms are 
needed to advance digital microscopy from multiple single-field images to whole-tissue-
processing.  High-content screening technology is necessary to meet genomic imaging 
requirements.  Most pathology systems are currently designed as department-based applications; 
however, efficient and timely expansion of capacity for interpretive consultations requires broad 
implementation of Web-enabled, interactive telepathology.96   
                                                     
r In primary diagnosis telepathology, specimens at a referring site are diagnosed remotely by pathologists, and the 
pathologist at the remote site is solely responsible for the diagnosis.  In second opinion telepathology, 
responsibility for the diagnosis belongs to the pathologist at the local site (known as the referring pathologist) and 
the remote pathologist (the consulting pathologist). 
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DATA STANDARDS FOR COMPREHENSIVE SYSTEMS 
Lack of harmonized data standards is the greatest barrier to laboratories’ ability to integrate data 
within the laboratory as well as to exchange data with external “trading” partners (e.g., hospital 
and ambulatory clinicians, other laboratories, pharmacy department, radiology department, 
public health entities, payers).  Harmonization of data standards is at varying stages of 
completion and adoption for each application.  However, further progress in building the health 
information infrastructure and integrating laboratory data with clinical practice applications 
cannot be realized unless the standards issues are resolved.  Main components of data 
standardization are identified in Box 6.1. 
Box 6.1:  Components of Data Standardization 
• Definition of data elements:  determination of the data content to be collected and exchanged  
• Data interchange formats:  standard formats for electronically encoding the data elements.  Interchange 
standards include sequencing and error handling, document architectures for structuring data elements, 
information models that define relationships among the data elements, user interface, and patient data links 
• Terminologies:  medical terms and concepts used to describe, classify, and code the data elements 
• Knowledge representation:  standard methods for electronically representing medical literature, clinical 
guidelines, and the like for decision support 
Source: Institute of Medicine. Patient safety: achieving a new standard for care. Washington DC: National Academy Press, 2004. 
 
The challenge of data standards for the broader health and laboratory information systems is not 
their absence, but their proliferation.  The lack of uniform, common data standards creates great 
difficulty in establishing interoperability to transfer data easily and economically from one system 
or application to another.  Although most standards are publicly available and developed by 
international standards organizations, some standards are proprietary and developed by private 
sector organizations.  Traditionally, use of a standard in the U.S. has been voluntary and left to the 
discretion of the vendor or institution.  As a result, an obstacle to achieving interoperability 
among information systems and applications has been the haphazard adoption of data standards 
across the board.97  Historically, most laboratory-related systems and applications were designed 
to operate independently.  Thus, lack of common data standards in laboratory medicine has 
inhibited information sharing between laboratories and health care providers.   
Standards development organizations (e.g., CLSI), professional societies (e.g., HIMSS), and state 
and federal government agencies are collaborating to harmonize data standards specifications.  
Laboratory-specific technology integration initiatives include the following:  
 The American Health Information Community (AHIC) was established in 2005 by the 
DHHS Office of the National Coordinator for Health Information Technology to 
provide the Secretary with recommendations for accelerating the development and 
adoption of HIT.  To begin, the program will target standards harmonization and 
technology adoption in four areas:  consumer empowerment, chronic care, 
biosurveillance, and electronic health records.  This federal advisory committee is 
being converted to a public-private sector partnership.  Several documents on 
laboratory-related integration can be found at:  
http://www.hhs.gov/healthit/community/background/ 
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 HITSP, discussed above, develops harmonized interoperability specifications, 
implementation guides, code sets, terminologies, integration profiles, and information 
policies.  This panel provides input to the AHIC initiative. A summary of the 
recommended standards for interoperability can be found at:  
http://www.hhs.gov/healthit/ahic/materials/02_07/ce/hitsp.doc 
 The Laboratory Exchange meeting of public and private sector experts was convened 
by AHRQ in 2006 as part of the AHIC initiative to address challenges to data exchange 
between the LIS and EHR for test orders and results reporting.  The meeting identified 
relevant business, financial, regulatory, data security, privacy and confidentiality, 
technical, and patient identification issues.98  See:  
http://healthit.ahrq.gov/portal/server.pt/gateway/PTARGS_0_217663_0_0_18/AHR
Q_Lab_Meeting_Summary.pdf 
 The HIMSS’ Integrating the Healthcare Enterprise initiative was extended to clinical 
laboratories in 2003.99  The international, private-sector initiative developed a technical 
framework that defines exchange partners, data exchange standards, and guidelines 
for integration of laboratory information and automation systems with the larger 
health care enterprise (i.e., hospital or IDS).  See:  
http://www.himss.org/ASP/topics_News_item.asp?cid=66712&tid=10 
Efforts to harmonize standards and connectivity requirements through these initiatives have 
focused on data interchange formats and terminologies.  Data interchange standards include 
encoding formats for data exchange as well as document architectures for structuring data 
elements, information models that define relationships among the data elements, user interface, 
and patient data links, all of which are needed to support high-performance interoperability.  
Because the HL7 standard for data interchange has been selected as the core standard for the 
health information infrastructure, the standard also is serving as the primary exchange and 
interface standard for LIS system-to-system, automation-to-LIS, and application-application 
connectivity.  HL7 clinical document architecture is used for claims attachments to administrative 
transactions that use the ANSI American Standards Committee X12 standard for transmission.  
Other interchange standards address specific attributes or applications, such as the Unified Code 
for Units of Measure and Digital Imaging and Communications in Medicine standard.   
Even though these standards are well integrated in stand-alone systems and first-phase data 
exchange, they are not sufficiently developed for next-level integration and interoperability for 
clinical practice applications.  New means must be developed to represent data sets that are 
exchanged directly among EHRs or other end-user systems, consistent with CLIA requirements 
(e.g., where test was performed and methods used), and to accommodate ongoing changes and 
updates to laboratory reports in the EHR.98  Also to be developed is the ability to associate 
laboratory test results with test orders, and patients with their providers in the EHR.  The ELINCS 
project may offer a viable vehicle for specifying message standards to the rigorous degree 
necessary and to facilitate certification of conformance.   
Important integration issues also include:  record linkage and patient identification, data quality, 
data synchronization, business rules management, and real-time access.100  Detailed descriptions 
and analyses of the informatics challenges of relating laboratory data to the EHR and other 
functions (e.g., biosurveillance) are provided in reports of HITSP, AHIC, and HIMSS cited above.  
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Controlled vocabularies facilitate data collection at the point of care, retrieval of relevant data, 
information, and knowledge, along with data reuse for multiple purposes such as automated 
surveillance and clinical decision support.  The two vocabularies used in data interchange are the 
Logical Observation Identifiers Names and Codes (LOINC) and the Systematized Nomenclature 
of Medicine- Clinical Terms (SNOMED-CT).  Unlike data interchange standards, many other code 
sets are used for different types of data.  Examples include the Current Procedural Terminology® 
Fourth Edition and Healthcare Common Procedure Coding System.   
Although LOINC is an appropriate terminology for laboratories and their coding, it is not readily 
applicable to health care providers.98  Also, there is not a standard vocabulary for providers that 
maps unambiguously to LOINC.  Wide variability in the way that common tests are named 
among the different terminologies and vendors (e.g., “serum sodium” versus “NA_S”), and codes 
for test batteries have not been fully developed for all local patterns that may be selected by 
providers.  Another obstacle to the adoption of a common vocabulary is that most clinical data is 
stored in a natural language (free text) context that must be converted into an electronic format 
(structured, predetermined phrases and codes) prior to transmission.100   
Near-term LIS priorities for the laboratory medicine sector include achieving and implementing: 
 Standardized ways of representing orders for laboratory tests 
 Standardized means for reporting laboratory information in terms of both messaging 
format and test names 
 Standardized approaches for correlating laboratory information with the correct patient 
 Systematic, acceptable methods for maintaining privacy and confidentiality of 
laboratory data for public health surveillance and quality improvement purposes98 
CONCLUSIONS 
LISs have evolved from systems to facilitate clinical laboratory workflow and generate results 
reports to complete systems capable of linking laboratory data through the entirety of the TTP, 
including clinician-related pre- and postanalytic activities.  The extent of LIS adoption and 
capability varies; while IDS and large laboratories rely on LISs for many aspects of laboratory 
testing (e.g., test ordering, results reporting, links to the inpatient pharmacy database), POLs and 
smaller laboratories primarily use the LIS to facilitate compliance with QC, PT, QA, and patient 
test management requirements.   
To improve quality and safety, manage the increasing volume of clinical and administrative 
information, and support emerging laboratory tests and clinical practice applications, LISs must 
increase computing power and conform to common data standards.  All laboratories must develop 
Wed-based connectivity to becoming fully integrated into the health information infrastructure. 
 Successful integration of enhanced data management features requires 
multidirectional, coordinated communication that links the LIS, preanalytic processing 
components, the specimen transportation system, analyzers, and the postanalytic 
archiving system. 
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 The volume and complexity of data generated from genetic, proteomic, and 
pharmacogenetic testing, especially from high-throughput analyses and increased 
reliance on automation, requires that LISs be capable of storing and retrieving large 
quantities of data. 
 Enabling CPOE, CDSS, and EHR applications with laboratory data in real-time 
requires continued development of rule-based algorithms capable of generating and 
integrating accurate alerts, reminders, order sets, results reports, and a list of 
differential diagnoses based on patient signs, symptoms, and characteristics. 
 Digital pathology systems requires further advances in high-power computation, data 
storage capacity, image formatting, and processing algorithms to facilitate the shift 
from single-field images to whole-tissue-processing.   
 Lack of harmonized data standards is the single greatest barrier to laboratories’ ability 
to integrate data within the laboratory as well as exchange data with external “trading” 
partners.  Further progress in building the health information infrastructure and the 
capabilities for integrating laboratory data more fully with clinical practice applications 
cannot be realized unless laboratories, health care organizations, vendors, and other 
stakeholders resolve data interchange and terminology standards issues.  
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CHAPTER VII 
FEDERAL REGULATORY OVERSIGHT OF LABORATORY MEDICINE  
In the U.S. health care system, the purposes of regulation include one or more of:  protect and 
promote personal and public health, advance personal and public health, and ensure that the 
public has access to sufficient, accurate information for using regulated products and services to 
improve their health.  Regulation is designed to protect consumers by assuring certain levels of 
quality, such as acceptable performance, safety, and effectiveness of products and services; and to 
establish market conditions that will generate validated innovations for improving health, such as 
controlling elements of monopoly power, and minimizing fraud and abuse.1, 2  The purpose of 
oversight by designated agencies and organizations is to enforce and otherwise achieve adherence 
to the rules and standards comprising regulation.   
Three main elements of oversight are:  information development and synthesis, standards setting, 
and compliance mechanisms.3  Information development and synthesis refers to the scientific 
studies, data collection, and reporting requirements for identifying and measuring potential 
benefits and harms of a product or service.  Standards setting is a process for identifying and 
describing the attributes that a product or service should have in order to offer an acceptable mix 
of benefits and risks.  Compliance mechanisms refer to the manner and extent to which standards 
are followed and enforced, varying from traditional “command and control” regulatory 
approaches to informal or voluntary approaches. 
 In its 2001 report, Crossing the Quality Chasm, the IOM characterized U.S. regulation of health care 
as a patchwork of laws, regulations, agencies, and accreditation processes through which each 
care delivery system must navigate at the federal, state, and local levels.4  The regulatory 
frameworks at the various levels are often inconsistent, contradictory, and duplicative, in part 
because of their often disparate origins, jurisdictions and evolution, as well as because their 
respective needs, priorities, and available resources are poorly articulated and inadequately 
coordinated.  Moreover, current regulatory frameworks often lag behind changes in the health 
system, including those related to advances in scientific and medical knowledge and 
technological innovation.  This chapter provides an overview of the federal regulatory oversight 
in laboratory medicine by CMS and FDA. 
REGULATORY OVERSIGHT SYSTEMS 
Regulatory oversight of the laboratory medicine sector is conducted at multiple levels by 
numerous governmental and non-governmental bodies.  These include federal and state 
legislatures, federal and state regulatory agencies, professional and private sector organizations, 
and federal and state courts. 
Legislative Oversight  
The U.S. Congress establishes provisions for oversight through the passage of legislation that 
governs various aspects of laboratory medicine, including the Federal Food, Drug, and Cosmetic 
Act (FDCA) and CLIA.  At the federal and state levels, legislatures can delegate authority to 
regulatory agencies to interpret, apply, and enforce the statutory standards.3  Federal and state 
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agencies providing oversight generally have clearly defined jurisdictions for which they may 
exercise regulatory powers and controls.   
Federal Oversight 
Several DHHS agencies share oversight responsibility for health care products and services at the 
federal level.  In particular, CMS, FDA, and CDC have prominent oversight roles for clinical 
laboratories that generally complement one another.   CMS is responsible for oversight of clinical 
laboratories and their testing services under CLIA.  This includes implementation of the CLIA 
program and provisions that govern PT, QC, personnel requirements and training; laboratory 
inspections; enforcement of CLIA regulations; and approval of PT providers, accrediting 
organizations, and CLIA-exempt states.5  CMS’ authority extends to oversight of tests developed 
”in-house” by a laboratory, i.e., laboratory-developed tests (LDTs), that may or may not have 
sought FDA approval.  FDA is responsible for test categorization and for regulating diagnostic 
tests and certain software used in laboratory information systems under the provisions of the 
FDCA for medical devices.  These tests are developed by manufacturers and regulated as 
products, e.g., test kits.  CDC’s responsibilities include conducting CLIA-related studies, convening 
CLIAC, and providing scientific and technical support and consultation to CMS.   
The DHHS OIG also has a role in oversight of clinical laboratories.  The OIG conducts audits, 
investigations, inspections, and other evaluations to protect the integrity of DHHS programs, 
including FDA and CMS oversight, as well as the health and welfare of consumers and 
beneficiaries.  OIG provides reports to the Secretary of DHHS and Congress on findings and 
recommendations for corrective action, as appropriate.  
Other federal agencies regulating specific types of clinical laboratories include the DoD and the 
VHA.  Laboratories in the DoD Military Health System are subject to CLIA requirements.  
However, a memorandum of understanding with DHHS permits MHS to operate independently 
following a successful review giving it “deemed status” for CLIA certification.  In lieu of CLIA, 
separate legislative requirements govern laboratories in the VHA. 
State Oversight  
States can take a prominent regulatory role in laboratory medicine, although not all states 
uniformly do so.  Currently, 26 states have some degree of statutory authority for oversight of 
clinical laboratories.3  A state may also apply to CMS for exempt status.  If CMS approves, the 
state is recognized to be the primary regulatory authority of clinical laboratories within that state, 
and is determined to be exempt under CLIA.  At this time, only two states, New York and 
Washington, are CLIA-exempt. 
Private Sector Oversight 
Other important sources of formal and informal regulatory oversight include professional and 
private sector organizations such as The Joint Commission and CAP.  In a formal capacity, a 
federal oversight body may delegate regulatory oversight to selected organizations.  Informally, 
many of these organizations set professional standards to which compliance is voluntary or a 
condition for accreditation. 
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Judicial Decisions 
Legal remedies sought through state and, to a lesser degree, federal courts influence regulatory 
oversight.  Tort actions brought to the courts can facilitate definition of standards, clarify 
interpretation of laws, and enforce compliance with regulations and standards of conduct among 
those that can be held accountable, including manufacturers, laboratories, health care providers, 
and other parties. 
CLIA PROGRAM 
Overview of Clinical Laboratory Improvement Amendments of 1988 
Efforts to decrease laboratory error rates and improve the quality of laboratory testing led to the 
passage of the Medicare, Medicaid, and Clinical Laboratories Improvement Act of 1967 
Programs (Public Law 90-174).a  To obtain a license under that law, laboratories were required 
to maintain records and equipment, perform QC, participate in PT, and set qualifications for 
laboratory directors and other supervisory personnel.  However, the legislation did not define 
quality or set protocols to enforce performance standards, such as QC limits or PT criteria.  
Furthermore, laboratories receiving fewer than 100 specimens per year (mostly POLs) were 
exempt.b  Thus, as many as 25% of all tests performed on patient specimens were not subject to 
minimum quality standards.6   
In the mid-1980s, the news media began to publicize the high incidence of laboratory errors in 
many of the nation’s clinical laboratories, particularly reports of inaccurate test results from Pap 
smears.7  These media reports generated public and congressional concerns about the quality of 
clinical laboratory services in the U.S., prompting Congress to expand regulatory oversight of 
clinical laboratories.8  The resulting action was passage of CLIA 1988 (Public Law 100-578), which 
amended the 1967 law and revised the authority for the regulation of clinical laboratories 
conducting testing on “human specimens for health assessment or for the diagnosis, prevention 
or treatment of disease.”9   
The CLIA regulations, published on February 28, 1992, established explicit minimum standards 
for QA, QC, PT, record maintenance, certification, inspection, and personnel qualifications for all 
laboratories,c including POLs.10  States and private organizations can have standards that are 
more expansive and/or more stringent than CLIA.  Since its implementation, CLIA has served as 
the primary regulatory program governing the U.S. laboratory system.  A revised final rule 
published on January 24, 2003, included a restructuring of QC and QA requirements in a quality 
systems framework. 
                                            
a The Medicare, Medicaid, and Clinical Laboratories Improvement Act of 1967 regulated laboratories engaged in 
interstate commerce by declaring that “no person may solicit or accept in interstate commerce, directly or 
indirectly, any specimen for laboratory examination or other laboratory procedures unless there is in effect a 
license for such laboratory issued by the Secretary under this section applicable to such procedures.”   
b The 1967 law did not apply to laboratories whose operations were so small or infrequent as not to constitute a 
significant threat to the public health. 
c The regulations exclude three types of testing:  forensic testing; research testing for which patient-specific results are 
not reported; and drug testing that is performed in laboratories certified and governed by the SAMHSA. 
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The requirements are organized according to test complexity and the level of risk associated with 
reporting erroneous results, rather than the type of laboratory in which testing is performed.  
Waived tests follow a different regulatory pathway than non-waived tests, e.g., moderate 
complexity tests, and high complexity tests.  The regulatory requirements  for each category are 
considered the minimum requirements necessary to ensure accuracy, reliability, and timeliness of 
laboratory test results.11  Appendix C of the final rule, Survey Procedures and Interpretive 
Guidelines for Laboratories and Laboratory Services, is used to determine compliance with the 
regulatory requirements of CLIA.12 
Administration of CLIA 
Chief authority for CLIA is delegated to the CMS, which conducts the program in conjunction 
with CDC and FDA under an interagency agreement.  CMS has responsibility for all financial 
management and administrative operations of the program, including certification and fee 
collection, inspections, enforcement, accreditation and state exemption approvals, PT program 
approvals, and rulemaking.  The CLIA program is funded entirely through user fees managed 
by CMS.   
CDC conducts assessment studies; provides scientific and technical support and consultation to 
CMS in developing and revising technical standards, evaluating accreditation/exemption 
applications, reviewing PT programs, and developing technical information and educational 
materials; and manages the work of CLIAC.   
FDA is responsible for laboratory test categorization, including test complexity and waiver 
determinations.  The transfer of responsibility for test categorization from CDC to FDA allowed 
manufacturers of in vitro diagnostics (IVDs) to work primarily with one agency in pursuing 
requests to market their devices.  Manufacturers now submit IVDs for premarket review (via the 
510(k) clearance process or the pre-market approval (PMA) process, as appropriate) and requests 
for complexity categorizations solely to FDA.  
In addition, professional and private sector organizations may apply to CMS for accreditation 
status and, if approved, are provided with the authority to accredit clinical laboratories, evaluate 
compliance with CLIA regulations, and educate laboratory staff to improve performance.  
Currently, six accreditation organizations have received such approval from CMS;d 
approximately 25% of all laboratories receive accreditation through one of these organizations.14   
                                            
d Accreditation organizations may be granted “deemed status” for up to six years.  Designees include: AOA, AABB, 
ASHI, CAP, COLA, and The Joint Commission.13 
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WAIVED TESTS 
The original CLIA statute required laboratories performing one or more of a given set of nine 
types of tests or examinations (e.g., certain dipstick or tablet reagent urinalyses, fecal occult blood 
tests, ovulation tests) to obtain a CW from CMSe and pay biennial fees.   In a proposed rule 
published in 1995, DHHS clarified the criteria and process for applying for waived status.15  
Under the proposed rule, waived status can be obtained if a test employs methods that are so 
simple and accurate as to render the likelihood of erroneous results by the user negligible or that 
are determined by the Secretary of DHHS to pose no unreasonable risk of harm to the patient if 
performed incorrectly.16, 17  The FDA Modernization Act of 1997 contained provisions further 
amending these CLIA requirements, stating that a test will automatically be considered waived if 
FDA has approved it for home use.17   
As a result of simplification of testing procedures and advances in instrumentation, the number of 
waived tests has increased dramatically.  Tests that were once considered moderate complexity 
are being redesigned, and when they meet certain criteria for being simple and accurate, FDA 
may grant them waived status.  These new waived tests are expected to make analysis easier, 
faster and more accessible to the public while maintaining reliability and accuracy.  
Since implementation of CLIA, the proportion of laboratories performing only waived testing has 
increased from 20% to 58% of the more than 200,000 laboratories.18  From 1995 to 2005, the number 
of laboratories performing waived tests increased by more than 70% in clinical laboratories affiliated 
with non-exempt states and in POLs (see Table 7.1).  Whereas there were approximately 200 waived 
tests associated with 9 analytes available in the U.S. in 1993, these numbers had increased 
dramatically by 2004 to more than 1,600 waived test systems that test for 76 analytes.18  
Table 7.1:  Number of Facilities that hold Certificates of Waiver  
1995 to 2005 
 
 
 
 
 
Source: CLIA update—June 2007. Centers for Medicare and Medicaid Services. CLIA 
database information, 2000. Centers for Medicare and Medicaid Services.  
                                            
e Still in the waived category, these tests include:  (1) dipstick or tablet reagent urinalysis (nonautomated) for 
bilirubin, glucose, hemoglobin, ketone, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen; (2) fecal 
occult blood; (3) ovulation tests (visual color comparison tests for human luteinizing hormone); (4) urine 
pregnancy tests (visual color comparison tests); (5) erythrocyte sedimentation rate (nonautomated); (6) 
hemoglobin (copper sulfate, nonautomated); (7) blood glucose by glucose monitoring devices cleared by FDA 
specifically for home use; (8) spun microhematocrit; and (9) hemoglobin by single analyte instruments providing 
direct measurement and readout. See: 42 Code of Federal Regulations 493.15(c). 
 1995 2000 2005 2007 
Labs in non-exempt states 65,031 85,944 113,445 
 
119,839 
POLs 28,951 40,990 52,632 54,467 
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OUTSTANDING ISSUES IN WAIVED TESTING 
Risk-benefit Tradeoffs 
One of the factors contributing to the growth in waived testing is the increasing number of 
laboratories that are certified to perform only waived testing (Table 7.1).19  However, broad access to 
some tests in this category poses evolving risk-benefit tradeoffs to patients and other stakeholders.   
An example that presents such tradeoffs is the OraQuick Rapid HIV-1 Antibody Test (OraQuick), a 
single-use qualitative immunoassay that detects antibodies to HIV-1 in a finger stick sample or whole 
blood.  An IVD, OraQuick was originally approved via the PMA route by FDA in November 2002 as a 
moderate complexity test under CLIA.  In January 2003, FDA granted CLIA waived status to 
OraQuick.20  This made the test potentially available through many more health care providers and 
about five times as many clinical laboratories.  In March 2004, FDA approved the test for detection of 
HIV-2 (a variant of HIV that is prevalent in parts of Africa but rarely found in the US) in whole blood, 
with continued waived status.  Some in the public health community lauded the easier access to HIV 
testing and greater opportunity to reduce the number of individuals unaware of their HIV status.  On 
the other hand, many in the laboratory community expressed strong reservations about the 
implications of waived status due to concerns about specimen adequacy, availability of counseling for 
HIV positive results when testing is conducted in a waived setting, and the reliability of the device.  
These concerns address whether specific waived tests really are so “accurate as to render the 
likelihood of erroneous results by the user negligible” and present “no unreasonable risk of harm.”21, 22 
Oversight for Certificate of Waiver Facilities  
Facilities that perform only waived testing are not subject to many of the CLIA regulations 
applied to those that perform non-waived testing, including QC, routine inspections, PT, and 
personnel qualifications and training.  Although there is no routine oversight of these facilities, 
they are required to follow manufacturer’s instructions when performing testing and they must 
permit inspections by designated authorities as part of random compliance evaluations and 
complaint investigations.23  Due to the large number of waived facilities and this corresponding 
lack of oversight, the government became concerned about conditions that have the potential to 
contribute to errors and patient harm.  Several studies were undertaken to determine the extent to 
which waived facilities were meeting their obligation to follow manufacturers’ instructions and 
complying with other federal regulations requiring safe work practices. 
During 1999-2001, CMS conducted preliminary on-site surveys of a representative sample of CW 
sites in 10 states.  The pilot surveys detected certain quality concerns that had the potential to 
result in medical errors.  In 2001, the OIG published a report following its investigation of CLIA 
certification and enrollment processes, identifying quality deficiencies in approximately 50% of 
CW sites.24  
In response to these findings, CMS reported results of nationwide on-site surveys of 4,214 
laboratory sites during 2002-2004.  (Such surveys are ongoing.)  POLs comprised the largest 
percentage (47%) of CW facilities surveyed, followed by skilled nursing facilities (14%).18  About 
90% of facilities performed no more than 5 different waived tests, and another 9% performed no 
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more than 10 different tests.f  The CMS surveys indicated that the majority of CW sites were aware 
of and followed manufacturer instructions; however, lapses in quality were identified at certain 
sites.  About 5% of sites were conducting tests with a degree of complexity that exceeded their CW 
CLIA certification, which may compromise the accuracy of these tests and patient safety.g  The most 
frequently performed non-waived tests (72%) were direct microscopic examinations (e.g., 
potassium hydroxide preparations, wet mounts, or urine sediment examinations), although several 
other types of non-waived tests also were reported.  In addition to conducting these non-waived 
tests, the sites were found to be non-compliant with CLIA requirements for laboratories performing 
non-waived testing. 
For those facilities who were conducting only waived testing, 12% were not using the most recent 
manufacturer’s instructions and 21% did not routinely check the product’s package insert or 
instructions for changes to the information.18  Relative to manufacturer’s instructions, 21% of CW 
sites did not perform QC testing and 18% did not use the correct terminology or units of measure 
when reporting results.  Table 7.2 summarizes the prevalence of quality-related deficiencies in 
waived facilities.  Data from the CMS surveys are similar to the findings of CDC-funded studies 
conducted from 1999 to 2003 by the Laboratory Medicine Sentinel Monitoring Network.h  These 
findings indicate a need for greater oversight of waived facilities, more stringent enforcement of 
manufacturer’s requirements, and training of testing personnel.  CMS has taken several measures 
to support more frequent site visits to CLIA-waived laboratories in order to monitor compliance 
of CW sites.   Follow-up studies that evaluate the effect of strengthened enforcement on quality 
and safety in testing have not yet been conducted.    
CMS has data from follow-up visits to CW laboratories indicating that the initial educational 
visits by CLIA surveyors contributed to improvements in these laboratories performance of at 
least 70%.  CMS plans to continue this program of annual educational visits to a sample of 
waived laboratories.25 
                                            
f The most common waived tests performed were glucose, dipstick urinalysis, fecal occult blood, urine human chorionic 
gonadotropin (visual color comparison), and group A streptococcal antigen (direct test from throat swabs). 
g Conducting non-waived testing can be potentially hazardous to public health since these facilities do not have the 
same QC measures as those certified for non-waived tests. 
h Laboratory Medicine Sentinel Monitoring Network is a CDC network established through CDC Cooperative 
Agreements with the state health departments of Arkansas, New York, and Washington. 
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Table 7.2:  Number and Percentage of Quality Deficiencies Related to 
Following Manufacturer’s Instructions and Documentation in 
Certificate of Waiver Sites from CMS Surveyed Sites* 
2002-2004 
Quality Deficiencies No. of sites % of sites 
Following manufacturer’s instructions £   
The site did not:   
Have current manufacturer’s instructions 485 12 
Routinely check new product insert for changes ¤ 701 21 
Based on manufacturer’s instructions, the site did not:   
Perform quality control testing 866 21 
Report test results with terminology or units described in package insert 744 18 
Adhere to proper expiration dates 267 6 
Perform required confirmatory tests 265 6 
Perform function checks or calibration 195 5 
Adhere to storage and handing instructions 135 3 
Perform instrument maintenance 125 3 
Use appropriate specimen for each test 81 2 
Add required reagents in the prescribed order 24 1 
Documentation¶   
The site did not:   
Document the name, lot number and expiration date for all tests performed¤ 1,493 45 
Maintain a quality-control log¤ 1,151 35 
Maintain a log of tests performed 1,318 31 
Require test requisition (or patient chart) before performing a test¤ 304 9 
Keep the test report in the patient’s chart¤ 56 2 
Check patient identification ¤ 31 1 
Source: Howerton D, Anderson N, Bosse D, et al. Good laboratory practices for waived testing sites: survey findings from testing 
sites holding a certification of waiver under the Clinical Laboratory Improvement Amendments of 1988 and recommendations for 
promoting quality testing. MMWR Recommendations and Reports 2005;54(RR-13):1-25. 
* N= 4,214 sites 
£ Required for waived testing under CLIA 
¤ 2003-2004 data only (n=3,317)  
¶ Not required for waived testing under CLIA.  
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NON-WAIVED TESTS 
Diagnostic tests categorized by FDA as moderate and/or high complexity are considered non-
waived.  Laboratories performing these tests must comply with the regulatory requirements 
specified in CLIA for non-waived testing.  Regulatory requirements include, but are not limited 
to, QC and QA, participating in periodic PT, and meeting qualification requirements for 
personnel.  FDA categorizies the level of test complexity using specific CLIA regulatory criteriai 
(see Box 7.1).  Together, these requirements facilitate a laboratory’s ability to ensure quality 
testing. 
Box 7.1:  Test Categorization 
To categorize a test system, assay or examination, a grade of 1, 2 or 3 is assigned for each of seven criteria, 
and scores are totaled.  A score of <12 indicates categorization of moderate complexity, and a score of >13 
indicates high complexity.  Criteria include:  (1) knowledge needed to perform test; (2) training and 
experience required; (3) reagents and materials preparation; (4) characteristics of operational steps; (5) 
calibration, quality control and proficiency testing materials; (6) test system troubleshooting and equipment 
maintenance; and (7) degree of interpretation and judgment required.26 
A subset of the moderate complexity category, PPM tests are specific microscopy procedures performed by a 
physician, mid-level practitioner or dentist during the course of a patient’s visit (e.g., direct wet mount 
preparations for presence or absence of bacteria).  Under CLIA, separate certification requirements were 
developed for PPM.j 
 
State Exceptions 
A few states and territories expressed interest in applying for exemption from CLIA, notably 
California, New York, Oregon, Puerto Rico, and Washington.  Washington was the first state to 
have its clinical laboratory licensure program judged equivalent to CLIA and therefore was 
granted an exemption from the federal regulation.k  New York State holds an exemption for all of 
its laboratories, except POLs.  Oregon received exemption status on June 13, 1996, but formally 
notified CMS of its decision not to renew its application.  Oregon’s exemption period ended 
December 31, 1999.27  Puerto Rico’s request for exemption was denied on October 28, 1996. 
When a state is granted an exemption from CLIA, CMS may no longer charge a fee to the 
laboratories in the exempt state.  However, CMS does assess the state for its share of costs associated 
with CLIA.  The regulation indicates that exempt states must pay for costs incurred through federal 
oversight investigations and surveys, their share of general overhead costs, and costs associated 
with follow-up complaints.28  The weight of this cost for California, estimated at $2.4 million 
annually, was the reason the state withdrew its initial application for exemption (after meeting all 
requirements to be granted an exemption).29   
                                            
i In accordance with CLIA, CDC categorized more than 25,000 test systems before the responsibility for categorization 
was transferred to FDA in 2000. 
j Tests in the PPM category include:  (1) all direct wet mount preparations for the presence or absence of bacteria, fungi, 
parasites and human cellular elements; (2) all potassium hydroxide preparations; (3) pinworm examinations; (4) fern 
tests; (5) post-coital direct, qualitative examinations of vaginal or cervical mucous; (6) urine sediment examinations; 
(7) nasal smears for granulocytes; (8) fecal leukocyte examinations; (9) qualitative semen analysis (limited to 
appearance of sperm and detection of motility).16 
k Washington State Department of Health. Office of Laboratory Quality Assurance. 
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CLIA Standards 
The CLIA technical requirements were designed to establish quality standards for clinical 
laboratory testing through the assurance of accuracy, reliability, and timeliness of patient test 
results, regardless of where the test was performed.30  As noted above, the 2003 final rule 
reorganized the technical standards for laboratories performing non-waived testing to reflect the 
flow of a patient specimen through the laboratory (i.e., from receipt of the specimen with the test 
request through test performance and test result reporting).  However, the core technical 
standards related to analytic phase QA and QC remain intact, including PT.l  Although CLIA 
always required monitoring of all phases of testing, the reorganization more clearly aligns the 
regulations toward a comprehensive QMS-based approach.  Laboratories must establish and 
follow written policies and procedures for an ongoing mechanism to monitor, assess and, when 
indicated, correct problems identified in the preanalytic and postanalytic phases.32   
Data are limited regarding the impact of preanalytic and postanalytic QA.  The next section 
provides a brief description of unresolved issues associated with QC and PT.  Challenges 
concerning personnel qualifications and provisions for surveys and sanctions also are covered.  
Issues in regulatory oversight of genetic testing are discussed in a separate section.  More extensive 
discussion on the new CLIA framework for systems-based approaches is provided in the Quality 
Systems and Performance Measurement chapter of this report.  In a forthcoming report, CDC will 
publish recommendations of an expert workgroup for enhancing the effectiveness of PT. 
OUTSTANDING ISSUES ASSOCIATED WITH CLIA STANDARDS 
Methods for Analyzing PT Data 
PT is an objective means of evaluating analytical test performance in a laboratory.  It assesses 
whether compliance with CLIA has improved intra-laboratory quality.33  All laboratories that 
perform non-waived testing are required to participate in PT.  For most regulated analytes, each 
participating laboratory receives specimens three times a year from external, CLIA-approved PT 
providers.m,34  The laboratory tests these samples in the same manner that other tests are 
performed and reports the test results to their PT provider.  The PT provider grades the results to 
determine their accuracy and compares them to peer groups or reference laboratory performance, 
i.e., inter-laboratory comparisons.  PT is required for each specialty, subspecialty, analyte, or test 
listed in the regulations for which the laboratory is certified.   
Failure to attain an overall testing event score of at least 80% is considered unsatisfactory 
performance for all specialties and subspecialties, except for gynecologic cytology (90%), ABO 
                                            
l QA refers to the internal and external planned and systematic activities to monitor all components or characteristics 
that affect quality and customer satisfaction, including policies and procedures to ensure compliance with 
regulatory requirements.  PT is an external QA mechanism.  QC refers to the internal procedures and statistical 
analyses for day-to-day monitoring of analytic instruments and work processes, detecting problems, and 
implementing corrections prior to the delivery of products or services.31 
m Approved PT provider programs for 2007 include:  Accutest, Inc., American Academy of Family Physicians, 
American Association of Bioanalysts, American Proficiency Institute, California Thoracic Society, COLA, CAP, 
Medical Laboratory Evaluation Program, New Jersey Department of Health and Senior Services, Commonwealth 
of Pennsylvania, Puerto Rico Proficiency Testing Service, Wisconsin State Laboratory of Hygiene, Maryland 
Department of Health and Mental Hygiene, ASCP, and New York State Department of Health.  
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group and D (Rho) typing (100%), and compatibility testing (100%).  Unsatisfactory performance 
on two consecutive or two out of three testing events constitutes unacceptable performance for 
the laboratory.35  A laboratory with an unacceptable performance rating must cease testing the 
failed analyte until it passes two consecutive “remedial” PT events.  PT results are transmitted by 
the PT providers to a CMS database.  According to the GAO, PT is the one available data source 
that can be used to uniformly compare laboratory quality across survey organizations.36   
Few studies have examined the long-term impact of PT on laboratory performance.  A report 
published in 2007 examined PT performance in physician office, clinic, and small hospital 
laboratories during the ten-year period 1994-2004, using data from a PT provider, the American 
Proficiency Institute.  The data showed failure rates for chemistry and hematology analytes 
declined significantly over the ten-year period.  For example, failure rates for cholesterol testing 
dropped from 18.7% in 1994 to 3.2% and failure rates for glucose testing declined from 15.6% to 
2.4%.  Although failure rates for microbiology analytes also declined, they still exceeded 5% for 
certain tests in 2004, including positive genital/gonorrhea cultures, positive urine cultures, and 
Gram stains.  Several limitations of the study were noted by investigators:  the data were not 
stratified by type of laboratory and thus do not reflect the performance of laboratories that are 
newly-regulated under CLIA; PT focuses on the analytical phase of testing and cannot detect 
errors in the pre- and postanalytical phases; and the data reflect trends in a changing population 
of laboratories but not individual laboratory trends, making it difficult to determine if most 
laboratories improved or if poor performing laboratories ceased testing.37  Studies by CDC and 
the State of California also have been instrumental in generating key assessments of PT success 
and failure rates in POL and non-POL settings.38, 39     
Similarly, the PT results do not necessarily indicate that a laboratory’s proficiency is sufficient to 
meet the needs of the clinician.33  CMS would increase transparency of PT if it were to consider 
new ways to code certain tests for PT purposes, including disaggregation of tests within specialty 
areas.  For example, as noted by the authors of the report referenced above on PT performance 
during 1994-2004, CMS aggregates all bacteriology tests (cultures, Gram stains, and susceptibility 
studies) under one code, which means that statistics depicting unsatisfactory performance in 
bacteriology (5.1% of laboratories) are somewhat misleading.37  This is particularly the case in 
bacteriology, since methods of analysis can differ substantially, as some of these tests do not have 
analytes while others do.  Instead, analyzing failure rates for individual tests would show more 
clearly those areas posing the greatest challenges in order to focus improvement activities.     
Laboratories can interpret and use their PT results to improve their practices, along with their QC 
and QA data, whether or not grades are satisfactory.37, 40, 41  A recent study of detection and 
correction of systematic laboratory problems found that, although accredited laboratories 
generally perform well in PT, having the PT provider identify clusters of PT failures assists the 
laboratory in correcting the problems.42  Additional studies on the use of feedback from PT could 
facilitate further improvements in performance. 
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Cytology PT 
CLIA mandates that all laboratorians involved in the testing of gynecologic cytology specimens 
participate annually in a CMS-approved PT program.n,o,43, 44  Cytology PT consists of 10 
gynecologic cytology slides, which test-takers must examine and diagnose within two hours.  Of 
the 12,831 individuals who took the initial test in 2005, 93% of cytotechnologists passed the exam, 
67% of pathologists working without cytotechnologist passed, and 90% working with 
cytotechnologists passed.p,46   
Concerns have been raised about the structure of cytology PT programs.  CLIA requires 
unanimous agreement among at least three anatomic pathologists in order for a slide to be 
included in a cytology PT program.47  However, the regulations do not require that the slides be 
subject to the rigorous review usually undertaken during field validation studies.  Some 
organizationsq have found that slides selected by expert pathologists as good examples of 
cytodiagnostic abnormalities ultimately fail field validation.  A 2005 study of the CAP’s 
Interlaboratory Comparison Program in Cervicovaginal Cytology reported that, of more than 
10,000 conventional smears and ThinPrep cases selected by an expert panel of 3 cytopathologists, 
19% of conventional smears and 15% of ThinPrep specimens failed field validation.48 
It is not apparent whether cytology PT programs lead to improvement in the quality of Pap 
testing.  A 1999 study compared accuracy of diagnosis of Pap smear slides from 40,245 women 
examined by 81 cytology screeners with the PT scores received by the same screeners.49  
Correlation between the accuracy of diagnosis of the Pap smear slides and PT results led the 
researchers to conclude that performance on a 10-slide test gives only some indication of the true 
performance of screeners.  A study published in 2000 found a low correlation between cytology 
PT and actual work performance.  Researchers concluded that cytology PT should be considered 
just one measure of performance and should be evaluated in conjunction with other quality 
assessment monitors, such as re-screening studies, discrepancy rates, and workload patterns.50  
Several efforts could alter the structure of cytology PT.  CLIAC convened a workgroup to 
consider changes to the regulations in several areas:  participation in educational programs, use 
of new technology (virtual media), testing frequency, number of challenges, categories of 
challenges, number of challenges per category, grading scheme, validation, test site, retesting, 
and confidentiality.51  CMS has been developing a Notice of Proposed Rulemaking based on the 
CLIAC’s recommendations.  In 2006, the Cytology Proficiency Improvement Act was 
introduced in the Senate and the House (H.R. 6133, S. 4056), which would have amended CLIA 
to require all individuals involved in screening and interpreting cytological preparations to 
participate in annual continuing medical education programs in gynecologic cytology, rather 
                                            
n Laboratories performing only nongynecologic cytology are not required to enroll in PT programs. 
o Three organizations are currently approved by CMS to conduct cytology PT:  CAP, the State of Maryland Cytology PT 
Program, and ASCP.  
p Individuals have up to four opportunities to receive a passing score.  After not passing on the fourth opportunity, they 
must cease examining Pap smears and must obtain at least 35 hours of continuing education in diagnostic cytology.45   
q Slides that are donated to CAP’s Interlaboratory Comparison Program in Cervicovaginal Cytology are reviewed by a 
panel of three expert cytopathologists; slides that are determined to be good examples of a single cytodiagnostic entity 
enter the PT program, after which they undergo a field validation process in order to designate each slide as “graded,” 
a designation that marks that slide as being regularly and reliably identified by CAP cytology PT participants.48  
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than in PT programs.52, 53  The bill, never enacted into law, was re-introduced in the House in 
2007 (H.R. 1237).54   
Guidance on QC protocols, particularly for innovative testing technologies 
QC is designed to ensure that instruments perform as expected by controlling factors that affect 
test quality during the analytic phase, including technical and methodological variables, 
environment, and personnel performance.r  Generally, laboratories are required to run at least 
two levels of control per day, but the CLIA final rule considered technological changes in altering 
the frequency of QC testing in certain specialty and subspecialty areas of testing.56  The CLIA 
interpretative guidelines provide laboratories with the flexibility to determine control procedures 
that are equivalents to the traditional QC frequency of two levels of control per day, i.e., 
“equivalent QC.”12  The decision whether to implement equivalent QC is the responsibility of 
laboratory directors, not manufacturers or regulators, but can occur only if all of the laboratory’s 
quality systems are functioning properly.   
Implementation of the CLIA requirements has resulted in significant decreases in the number of QC 
deficiencies (see Figure 7.1).  A study of the impact of QC implementation in enzyme immunoassay 
testing for HIV-1 antibodies found that laboratories not using QC were at increased risk of 
systematic error, but adhering to CLIA requirements for QC was more protective against error.57  
However, several factors indicate a need for greater guidance in the area of QC, including the 
emergence of increasingly complex, innovative testing technologies (e.g., genomics, proteomics, 
PGx) and the need for immediate detection of errors and monitoring of ongoing test performance 
through QC protocols.  Specifically, additional QC guidance is needed in light of the diversity of 
technology used to perform genetic and molecular-based tests, the rate at which this technology 
evolves, regional differences in the tests that are offered and the populations that are tested, and the 
lack of standardization of laboratory-developed genetic tests.58  Given these factors, CLIA could fall 
short in assuring quality in laboratory testing in the future.  CMS is working with the genetics 
community to develop specific guidance for laboratories to address these QC needs. 
                                            
r Under CLIA, laboratories also must implement and monitor quality systems for the pre- and postanalytic phases, 
thereby emphasizing the role of QA throughout the entire testing process.55 
s The interpretive guidelines allow a laboratory to analyze two external controls per day for 10, 30, or 60 consecutive 
days to evaluate equivalent QC.  If the comparison of internal and external controls is acceptable during this full 
testing period, the laboratory may adopt equivalent QC and increase the interval for analyzing external controls to 
every 7 or 30 days, depending on the equivalent QC option selected.   
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Figure 7.1:  Percent of Labs with Major Quality Control Deficiencies 
Source: Memorandum from Mark McClellan, CMS Administrator, to Leslie Aronovitz, 
GAO, May 17, 2006.  Baltimore, MD: Centers for Medicare and Medicaid Services, 2006. 
During the phase-in, FDA was to establish a process to review and clear manufacturers’ instructions 
for use in QC protocols.56  Once approved, laboratories would follow manufacturers’ instructions 
for QC rather than develop their own QC protocols.59  The expected date for phasing-in this QC 
requirement was extended four times (December 6, 1994, May 12, 1997, October 14, 1998, and 
December 29, 2000) to allow completion of the phase-in period.  In the final rule, laboratoriest 
retained responsibility for establishing and adhering to written QC procedures for monitoring and 
evaluating the quality of the analytical testing process for each method of testing.56 
Another concern is use of the interpretive guidelines in deciding whether to implement equivalent 
QC.  CLIA states that the laboratory director must consider the laboratory’s clinical and legal 
responsibility for providing accurate and reliable patient test results versus the potential cost 
savings of reducing the QC testing frequency.56  Laboratory directors are likely to be aware of such 
tradeoffs in fulfilling their responsibilities; however, the lack of a framework for implementing QC 
for the wide variety of test systems may create inconsistencies in implementing QC.23  Factors that 
contribute to these inconsistencies may include the lack of adequate risk management information 
from manufacturers, the different types and levels of QC required by each device and method, and 
the unique considerations of individual laboratories (e.g., personnel).60  
                                            
t Although not part of the QC requirements, laboratories with unmodified FDA-cleared systems must include 
accuracy, precision, reportable range, and reference intervals in their procedures.  For modified, non-FDA-cleared 
systems, analytical sensitivity, analytical specificity, and interference must be addressed.  Validation studies must 
be provided for new methods.23 
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To address these concerns, CLSI is working on the development of evaluation protocols that will 
outline principles for validation and provide laboratories with scientific guidance on the 
development of QC procedures for specific testing technologies and environments.61  In addition, 
CLIAC members have reinforced the importance of laboratory directors’ understanding of their 
responsibilities in implementing equivalent QC.60           
While flexibility in methods for QC (both general and equivalent) may be desirable, more 
comprehensive information is required than is currently produced by instruments.62  
Technological advances have led to test systems that contain internal monitoring systems, but 
these newer types of control often monitor only certain elements of the test system.63  For 
example, electronic controls may indicate the status of the test systems’ electrical components, but 
may not alert the laboratory to trouble with environmental interactions.  Similarly, systems may 
now include tests that cross specialty areas, making standardized QC impractical.     
In some instances, the need to revise QC requirements was accomplished through stakeholder 
collaboration.  For example, the American Society for Microbiology (ASM) conducted two 
surveys to determine the rates of QC failures for 24 microbiology reagents.  ASM shared the 
resulting data with DHHS and recommended that, for commercial reagents with a 98% or greater 
success rate, only new lots need to be tested.64  This resulted in a change to the CLIA QC 
requirements for microbiology reagents, as published in the 2003 final rule.  A CLSI workshop 
held in 2005 discussed potential approaches for future QC, convening representatives from the 
laboratory, industry and government.  As a result of the workshop, a proposal to revise the CLIA 
QC requirements for laboratories, using the CLSI consensus process, was developed by 
stakeholders and accepted by CMS.   
In the absence of amending CLIA, some ways in which the laboratory community can improve 
QC include the following:  
 Select QC procedures commensurate with the quality required for the test and the 
precision and accuracy observed for the method.65 
 Encourage manufacturers to include in their instruction explanations of the 
components of internal monitoring systems.  
 Encourage manufacturers that want to diverge from traditional QC practices to 
demonstrate performance characteristics (improved stability of methods, better QC 
technology, etc.) and include such data in their dossiers submitted to FDA.  
 Eliminate confusion on proper QC use.66  
 Collect and share among laboratories data on specific test system performance.   
Personnel Qualifications to Meet Technical Requirements of Advanced Testing 
Methods 
CLIA specifies personnel requirements for experience, education, and training, along with 
detailed corresponding responsibilities, that must be met by laboratories performing PPM, 
moderate complexity testing, high complexity testing, or any combination of these tests.  
Laboratories performing only waived testing do not have specific personnel qualifications.67  A 
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summary of the CLIA personnel requirements for high complexity testing is provided in Box 7.2.  
The categories and requirements for moderate complexity are different. 
Box 7.2:  Summary of CLIA Personnel Requirements for High Complexity Testing 
• Director.  A director in a laboratory performing high-complexity testing has essentially the same responsibilities 
as a moderate-complexity testing laboratory director, including the overall operation and administration of the 
laboratory.  A director must hold a doctoral degree in medicine, osteopathy, or one of the sciences and have 
appropriate board certification or one to two years of laboratory training or experience directing or supervising 
high complexity testing.  Directors are limited to overseeing five laboratories at one time. 
• Technical Supervisor.  A technical supervisor is responsible for the scientific and technical supervision of high-
complexity testing in specialties or subspecialties in which they are trained or have experience.  Other duties 
are similar to those indicated for the technical consultant in laboratories conducting moderate-complexity 
testing.  The requirements for a technical supervisor vary depending on the specialty or subspecialty in which 
the laboratory conducts high-complexity testing.  Doctoral-level degrees are required for some subspecialties, 
including cytology, histopathology, dermatopathology, ophthalmic pathology, oral pathology, 
histocompatibility, clinical cytogenetics, and immunohematology. 
• Clinical Consultant.  The clinical consultant provides consultations to the laboratory’s clients in matters 
related to reporting and interpreting test results.  The qualifications and duties are similar to those specified 
for laboratories performing moderate complexity testing.   
• General Supervisor.  Unlike moderate testing facilities, high-complexity laboratories also have at least one 
general supervisor who provides day-to-day supervision of testing personnel and reporting of test results at the 
discretion of the laboratory director and technical supervisor.  In order to qualify as a general supervisor, an 
individual must have a doctoral, master’s or bachelor’s degree in medicine, osteopathy or one of the sciences 
and one year of applicable laboratory training or experience, or have an associate’s degree and two years of 
training or experience in high complexity testing.  Subspecialties in histopathology require board-certified 
pathologists for the role of general supervisor. 
• Testing personnel.  Responsibilities of testing personnel include specimen handling and processing, test 
analyses, and reporting and maintaining records of patient test results.  In order to conduct testing without 
direct supervision, testing personnel in high complexity labs are expected to have at minimum the education 
and training equivalent to an associate degree in a laboratory science or medical laboratory technology.   
Note: Personnel qualifications may vary with test complexity as well as with date and year an individual was hired into a 
laboratory position.  
Source: Laboratory requirements. Code of Federal Regulations, Title 42, Section 493.  Subpart M--personnel for non-waived 
testing. 
 
 
Technologists/scientists and technicians 
The matter of determining personnel requirements for clinical laboratories preceded CLIA and 
remains controversial today.  Two prominent laboratory professional societies and their members, 
ASCLS and ASCP, are collaborating to resolve their differing views concerning appropriate 
personnel qualifications and nomenclature (e.g., medical technologist vs. clinical laboratory 
scientist, medical laboratory technician vs. clinical laboratory technician).  (Refer to the Workforce 
chapter of this report for a more discussion of the personnel qualifications advocated by these 
organizations.) 
CLIA prompted some convergence among the organizations on these issues.  The CLIA rule 
outlined minimum qualifications needed for individuals to work in a laboratory and offered 
pathways for an individual to perform high- and moderate-complexity testing.  Rather than 
recognizing the titles of medical technologist or clinical laboratory scientist as approved testing 
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personnel, CLIA relied instead on education and training experience of personnel.  Phase-ins 
permitted some individuals to continue their testing responsibilities until they could achieve 
additional education and training, and grandfather clauses allowed individuals with certain 
qualifications to continue testing without additional education, training, or experience.68  Testing 
personnel responsibilities were outlined based on the complexity level of the tests.69, 70   
One concern for the professions was how the regulation would affect the National Labor 
Relations Board (NLRB) decision that technologists/scientists are considered professional 
employees.  Nine amicus briefs were filed with the NLRB by laboratory professional 
organizations, including CAP, American Association for Clinical Chemistry, ASCP, and ASCLS, 
that highlighted the educational and training experience required for technologists/scientists.  
The briefs confirmed that, while automation allows technologists/scientists to work more 
efficiently, accurately, and productively, it does not replace the intellectual and analytical nature 
of their work.  The NLRB agreed and upheld the educational and training requirements.71  
Laboratory Directors 
The matter of qualifications for laboratory directors prompted a different debate among 
laboratory organizations.  Since laboratory directors are responsible for communicating 
laboratory data to physicians, including the interpretation for patient diagnosis and management, 
some believe that only a pathologist be qualified to fill this role, while others find it acceptable to 
permit doctoral scientists to oversee the laboratory.  In its 2003 final rule, CLIA required that, after 
February 28, 2003, individuals with a doctoral degree in the chemical, physical, biological or 
clinical laboratory sciences seeking employment as a director of a laboratory performing high 
complexity testing must be certified by a DHHS-approved board.72  Physicians that are board 
certified in clinical and/or anatomic pathology continue to serve predominantly as laboratory 
directors, although some directors are certified by other boards.   
Certification and Personnel Requirements 
CLIA has provided impetus for change in the laboratory community.  Laboratory organizations 
offering professional certification use CLIA as a minimum standard, which in some instances has 
meant increasing their personnel requirements.  Other certifying bodies have used CLIA to build 
new career ladder opportunities, noting concern for the placement and retention of skilled 
personnel.  For example, ASCLS is working toward development of advanced practice scientists, 
representing a doctoral degree in clinical laboratory science, to serve in consultant roles and 
manage patient laboratory data.73  CLIA and its personnel provisions have prompted 
considerations to unite the ASCP Board of Registry and the NCA.  In July 2006, the ASCLS Board 
of Directors, ASCP Board of Registry-Board of Governors, ASCP Board of Directors, NCA Board 
of Directors, and Association of Genetic Technologists Board of Directors reviewed and voted on 
a document outlining the rationale for such a union.74 
Personnel requirements for performing genetic testing are also at issue.  A 2003 study of hospital-
based, independent, and research-based biochemical genetic testing laboratories in the U.S. 
examined personnel qualifications using a mail survey of laboratory directors.  Using survey 
responses, investigators assigned QA scores, which served as the main outcome measure of the 
study and were based on the standards defined by the American College of Medical Genetics 
Laboratory Practice Committee.  The study found that, although all directors had doctoral 
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degrees, personnel qualifications varied.  The mean QA score was 77%, with a range of 28-100%.  
Higher scores were associated with:  laboratory director having a PhD degree versus MD degree; 
director board certification in biochemical genetics; research and hospital laboratory versus 
independent laboratory setting; and participation in a PT program.  The investigators concluded 
that personnel qualifications and laboratory practice standards may need improvement to ensure 
quality in clinical biochemical genetic testing laboratories and appropriate use of test results.75   
Oversight Mechanisms Employed Through Surveys and Sanctions 
Non-waived laboratories must permit biennial inspections to assess their compliance with the 
regulations as well as permit non-routine inspections to validate and investigate complaints.  
During the survey process, surveyors may require the laboratory to test samples and will observe 
testing, interview all levels of personnel, review copies of records, and tour all areas of the 
laboratory.76  As noted above, laboratories with CWs are not subject to biennial inspections, but 
may be examined at any time to evaluate a complaint or assure compliance with CLIA. 
CLIA provides CMS with the discretion to select the appropriate corrective action or sanction for 
identified laboratory deficiencies.77  Enforcement mechanisms range from severe monetary 
penalties or onsite monitoring to cancelling a laboratory’s approval for obtaining Medicare 
payments for its services or suspending or limiting a laboratory’s CLIA certificate.  Often, 
regulators take an educational approach and work collaboratively with laboratories to correct 
problems in lieu of imposing sanctions. 
CMS also has implemented the Alternate Quality Assessment Survey (AQAS).  The goal of this 
self-assessment survey tool was to streamline the CLIA inspection process and reward good 
performers.  The AQAS form is consistent with the onsite survey process with a focus on QA.  
Laboratories with no deficiencies and satisfactory PT performance may use AQAS instead of 
having an inspection on their next two-year cycle.  Approximately 5% of laboratories using the 
AQAS are inspected on-site to validate their self-assessment process.78   
The initial CLIA on-site surveys of laboratories in 1992 revealed quality problems in as many as 
35% of laboratories; however, by 2004, fewer than 7% of 12,000 laboratories surveyed were 
considered to have quality problems.  In 2004, CMS reported that it had proposed enforcement 
action in 6,084 cases since 1999, and implemented such action in 487 of them.79  However, despite 
oversight mechanisms provided through CLIA requirements, laboratory quality problems in 
several states have raised questions about the adequacy of laboratory oversight.36  For example, in 
2003, the laboratory at Maryland General Hospital was among those identified with serious 
quality and management problems.  Accredited by CAP, the laboratory was the subject of several 
inspections, arising from State inspections and complaints.  A complaint by a laboratory 
employee alleged that the equipment used for HIV and hepatitis testing was not adequately 
maintained and that erroneous test results were possible.  Oversight, management, and 
communication concerns in this case triggered congressional interest and a GAO investigative 
report on the status of CMS and survey organization oversight of clinical laboratories.79, 80    
In 2003, CMS regional offices followed suit and initiated a program to review and monitor state 
agency surveyors against 13 performance standards, including the training and qualifications of 
surveyors.  However, the extent of serious quality problems at laboratories remained unclear 
because of incomplete data on condition-level deficiencies identified by state survey agencies 
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prior to 2004 and the lack of direct linkage between CLIA requirements and CLIA-equivalent 
requirements of some survey organizations.36  
The GAO’s 2006 report to Congress concluded that oversight of clinical laboratory quality is 
inadequate to ensure that laboratories are meeting CLIA requirements, noting weaknesses in survey 
methods, complaint processes, and enforcement.36  GAO stated that, aside from PT scores, there is 
lack of standardized means for measuring and reporting laboratory quality.  Among its concerns, 
GAO suggested that the announcement of forthcoming inspections up to 12 weeks in advance may 
result in an unrealistic assessment of laboratory performance.  The report observed that variability 
in reported survey deficiencies suggests that laboratories are not surveyed consistently.  GAO also 
observed that CMS and survey organizations appear to stress education over regulation in the 
implementation of the 2003 QC requirements and PT for gynecologic cytology.  Gaps in complaint 
processes compromise whistle-blower protection to those filing complaints about quality problems.  
GAO perceived that sanctions are not being used effectively as an enforcement tool to promote 
compliance even in laboratories with serious, consecutive, condition-level deficiencies.  CLIA 
regulations require PT three times per year on analytes listed in Subpart I rather than the statutorily 
originally defined rate of four times per year.  The report found that the length of time (2-4 years) 
allowed for implementation of new requirements is unnecessarily excessive and compromises 
quality.  GAO noted that CMS was late in ensuring CLIA equivalence of exempt states’ and 
accrediting organization inspection requirements, and that many of CMS’ validation reviews lack 
independence and reviews skip some state survey agencies. 
To address these issues, the GAO report provided 13 recommendations (see Box 7.3).  CMS, CAP, 
COLA, and the Joint Commission were provided with an opportunity to comment on the report.  
CMS agreed with 11 of the 13 recommendations, the exceptions being the frequency of PT 
assessments and the extent of simultaneous accrediting organization validation reviews.36  CMS 
also provided an alternative assessment of laboratory quality, disagreed with the GAO conclusion 
about the lengthy education phase-in for new CLIA requirements, and expressed concern about 
identifying and sanctioning laboratories with repeat condition-level deficiencies.  CMS restated its 
intention to retain an educational approach to CLIA compliance, commitment to cite deficiencies 
appropriately when found, and provide additional training to state agency surveyors.  CAP, 
COLA, and the Joint Commission agreed with some of the findings of the report, but disagreed 
with others.36  Since the report’s publication, CAP has implemented mandatory training for its 
surveyor team leaders, beginning on July 1, 2006.81  In response to GAO’s recommendations, CMS 
has undertaken and completed certain actions and efforts intended to augment the CLIA program 
and strengthen oversight. 
In 2006, CMS issued a guidance document, Partners in Laboratory Oversight, which identifies 
elements of an effective survey process that partner organizations are to incorporate into their 
respective survey protocols and suggests communication protocols for information sharing 
among partners.  The guidance applies to CLIA activities among the CMS central and regional 
offices, state agencies (including those with licensure requirements), accreditation organizations, 
and CLIA-exempt states.82   
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Box 7.3:  Summary of GAO Recommendations to 
Improve Regulatory Oversight of Clinical Laboratories 
Recommendation 1: To enable CMS to track the nature and extent of lab quality problems across survey 
organizations, the CMS Administrator should: 
• Work with exempt-state programs and accrediting organizations to standardize their categorization and 
reporting of survey findings in a way that tracks to CLIA inspection requirements and allows for meaningful 
comparisons across organizations, such as the analysis of trends in the citation of condition-level deficiencies.  
Recommendations 2-5: To ensure consistency in the oversight of labs by survey organizations, the CMS 
Administrator should:  
• Ensure that the advance notice of upcoming surveys provided to physician office labs is consistent with 
CMS's policy for advance notice provided by state survey agencies.  
• Ensure that regulation of labs is the primary goal of survey organizations and that education to improve lab 
quality does not preclude the identification and reporting of deficiencies that affect lab testing quality.  
• Impose appropriate sanctions on labs with consecutive condition-level deficiencies in the same 
requirements.  
• Require all survey organizations to develop, and require labs to prominently display, posters instructing lab 
workers on how to file anonymous complaints.  
Recommendations 6-13: To improve oversight of labs and survey organizations, the CMS Administrator should:  
• Consistent with CLIA, require quarterly proficiency testing, except when technical and scientific 
considerations suggest that less frequent testing is appropriate for particular examinations or procedures.  
• Ensure that evaluations of exempt-state and accrediting organization inspection requirements take place 
prior to expiration of the period for which they are approved in order to ensure the continued equivalency 
of their requirements with CLIA's.  
• Ensure that changes to the inspection requirements of exempt states and accrediting organizations be 
reviewed prior to implementation, as required by regulation, to ensure that individual changes do not 
affect the overall CLIA equivalency of each organization.  
• Allow the CLIA program to utilize revenues generated by the program to hire sufficient staff to fulfill its 
statutory responsibilities.  
• Ensure that federal surveyors validate a sufficient number of inspections conducted by each state survey 
agency to allow a reasonable estimate of their performance, including a minimum of one independent 
validation review for each state survey agency surveyor.  
• Require that almost all validation reviews of each accrediting organization’s surveys be an independent 
assessment of performance.  
• Collect and routinely review standardized survey findings and other available information for all survey 
organizations to help ensure that CLIA requirements are being enforced and to monitor the performance of 
each organization.  
• Establish an enforcement database to monitor actions taken by state survey agencies and regional offices 
on labs that lose their accreditation.  
Source: Clinical Lab Quality: CMS and Survey Organization Oversight Should Be Strengthened. Government Accountability Office. 
June 2006. 
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GENETIC TESTING 
Genetic testing is becoming an increasingly important component of health care delivery.  In 
federal and state legislation, a genetic test is considered a DNA-based test, though the term is also 
used to refer to tests of gene products (proteins and metabolites), chromosomes, and acquired 
somatic cell mutations.83  However, no single definition of a genetic test is universally accepted by 
all stakeholders.   
Genetic tests can be used to “diagnose existing disease, to predict future risk of disease, to identify 
carriers of mutations that might cause disease in one’s offspring, or to identify particular traits in a 
fetus or embryo such as gender or human leukocyte antigen type.”84  At present, genetic tests for 
at least 1,430 diseases are available for clinical use, and the number and availability of new tests 
continues to rise.85  Given the life-altering influence that genetic test results can have, it is 
imperative that they be subject to adequate regulatory oversight.   
PGx testing is a relatively new form of genetic testing.  To date, only a few PGx tests are used to 
support decisions for selecting and dosing therapies.86  Some early applications of PGx include 
HER2/neu testing to guide use of trastuzumab (Herceptin) for metastatic breast cancer, and 
thiopurine methyltransferase genotyping to manage the use of thiopurine drugs to treat acute 
lymphoblastic leukemia in children.  Other PGx tests include CYP2C9 and VKORC1 testing to 
manage the use of warfarin for those at risk of harmful blood clots, the Roche Amplichip for 
CYP450 mutations, and the UGT1A1 test for irinotecan (Camptosar) sensitivity.   
Currently, there are few laws and regulations that specifically address the complexity of genetic 
testing.  At the federal level, oversight authority is provided through application of CLIA, FDA, and 
the Federal Policy for the Protection of Human Subjects.  Specifically, while FDA has the regulatory 
authority for all tests, genetic tests developed as in-house (i.e., LDTs) are currently subject only to 
CLIA requirements, while tests developed by manufactures are subject to FDA requirements.  In 
addition, some state legislatures have introduced laws and regulations pertaining specifically to 
genetic testing.  Reports by SACGHS and others have concluded that serious gaps in the regulatory 
framework for genetic testing could compromise patient and public health.83   
OUTSTANDING ISSUES IN GENETIC TESTING 
Regulatory Oversight of Laboratory-Developed Genetic Testing  
For the specialty of cytogenetics,u CLIA provides specific requirements to address QC, PT, QA, 
analytical validity, and personnel.83  However, the broader scope of genetic testing is subject only 
to CLIA’s general requirements for non-waived testing.  Public and private sector stakeholders 
are working together to address outstanding concerns about the oversight of laboratory-
developed genetic tests and personnel requirements of those performing genetic tests. 
The CLIA Quality Systems final rule, published in 2003, restructured and updated certain 
requirements that are relevant to genetic testing, such as facility requirements for unidirectional 
workflow for molecular amplification procedures (§493.1101), quality system requirements for 
                                            
u Cytogenetics is the examination of chromosomes and the conditions caused by numerical and structural 
chromosomal abnormalities. 
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confidentiality of patient information (§493.1231), and QC procedures for PCR (493.1256).87, 88  
These latest requirements do not include tailored QC, personnel, or PT requirements for 
molecular genetic, biochemical genetic, or PGx testing.  Notwithstanding that genetic tests are 
high complexity tests, most genetic testing laboratories are not required by CLIA to perform 
formal PT, unless they are offering any one of the 83 regulated analytes.  According to CLIA 
regulations, alternative performance assessment must be conducted for all other tests.   
Consistent with earlier support by a National Institutes of Health-Department of Energy task 
force and CLIAC in 2000, SACGHS recommended that CMS develop regulations for genetic 
testing and that FDA review all genetic tests.  In September 2006, CMS announced that it would 
not pursue a Notice of Proposed Rule Making for genetic testing.  In August 2007, in response to a 
petition from the Genetics and Public Policy Center, CMS stated that supportive evidence does 
not justify rulemaking to establish a new genetics specialty under CLIA.  Included in its rationale, 
CMS noted: 
“Various tests that we would all regard as ‘genetic tests’ are in actuality dispersed throughout 
different operational sections of the laboratory and many are found in different existing CLIA 
specialties.  Creation of a new genetic testing specialty would require not only greater precision 
in the current definitions, but would also require a teasing out of certain tests from some 
existing specialties, and cause some disruption to existing regulatory and payment structures.” 
Instead, CMS stated that it would implement an action plan for enhanced oversight of genetic tests 
under the existing CLIA authority.89  CMS is working with SACGHS, FDA, and other experts to 
address current gaps in oversight of laboratories that conduct genetic testing and to otherwise 
support or augment its action plan.90  CMS has begun to implement its action plan, which includes: 
 Training of surveyors in how to assess genetic testing laboratories’ compliance with 
regulatory obligations 
 Collaboration with CDC to publish educational materials for genetic testing 
laboratories (e.g., Morbidity and Mortality Weekly Report Recommendations and Reports) 
 Development of alternative PT mechanisms for genetic testing laboratories, such as 
inter-laboratory comparisons 
 Collaboration with CDC and FDA on ongoing oversight activities91, 92   
CLIAC acknowledged CMS’ decision not to proceed with the rulemaking, but cited the need to 
examine the regulatory framework further in order to achieve enhanced oversight of genetic 
testing.92   
Some accreditation organizations also are addressing genetic issues related to laboratory-
developed genetic tests.  In 2007, CAP began an Internet-based registry service intended to 
connect genetic testing laboratories that perform low-volume genetic tests.  When three 
laboratories are identified as testing for the same genetic disorder, CAP will facilitate an exchange 
of specimens for alternative assessment. 
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Enhancement of FDA’s role in regulating laboratory-developed genetic testing 
FDA has statutory authority to fully regulate all LDTs but has not done so because of resource 
constraints.3  With genetic tests of increasing complexity continuing to be marketed, often 
unaccompanied by direct evidence of clinical utility, there is a need to clarify or extend regulatory 
oversight of these tests.84 
In September 2006, FDA issued two draft guidance documents to address regulatory oversight of 
more complex laboratory-developed test devices that are used in genetic testing.  One guidance 
document pertains to the marketing of in vitro diagnostic multivariate index assays (IVDMIAs) 
and the other pertains to the marketing of analyte specific reagents (ASRs), which are the active 
ingredients used by clinical laboratories in developing LDTs.      
 In Vitro Diagnostic Multivariate Assays 
Certain complex genetic and proteomic tests are IVDMIA test systems―tests that employ data 
from one or more in vitro assays, in some cases demographic data, and an algorithm that usually, 
but not always, runs on software to generate results for diagnosis and treatment.  A great concern 
with these test systems is that the results cannot be independently derived and confirmed by 
another laboratory without access to proprietary information used in the development of the test. 
In addition, the results cannot be interpreted by well-trained health care practitioners without 
information from the developer of the test regarding its clinical performance and effectiveness. 
According to the 2006 draft guidance, FDA proposed to actively regulate these test systems as 
medical devices and classify them according to their intended use and level of control necessary 
to assure their safety and effectiveness, including requiring premarket review as class II or III 
devices, where applicable.94   
After receiving comments on the initial draft guidance for IVDMIAs, FDA issued revised draft 
guidance for public comment in July 2007.  The revisions clarified the definition of an IVDMIA 
and provided examples of tests that the agency does and does not recognize as IVDMIAs.  The 
agency noted that these clarifications did not alter the scope or intent of the definition of an 
IVDMIA that appeared in the initial draft guidance document.95 
FDA approved the first IVDMIA PGx test system, MammaPrint, in February 2007.  Marketed in The 
Netherlands since 2005, MammaPrint is a gene expression profiling test for predicting whether an 
existing cancer will metastasize in women with early stage breast cancer.96  As genetic testing and 
PGx, in particular, evolve, there will be ongoing need for guidance from CMS and FDA.   
Analyte Specific Reagents 
FDA regulates certain components of genetic tests that are developed and performed by 
laboratories, but that are not marketed as test kits.  ASRs include antibodies, receptor proteins, 
nucleic acid sequences, and other biological or chemical reagents which, through specific 
binding or chemical reactions with substances in a specimen, are used to identify or quantify an 
individual chemical substance or ligand in biological specimens.  Among other regulatory 
requirements, ASR manufacturers must list with FDA, follow quality system regulation, and 
restrict the sale of these reagents to high-complexity laboratories.  FDA does not regulate how 
ASRs are used to create a new test.  The great majority of genetic tests performed by 
laboratories are based on FDA-approved ASRs.  FDA issued draft guidance in September 2006, 
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made final in September 2007, which clarifies the definition of ASRs and related regulatory 
requirements.  Specifically, a single ASR that is (1) combined, or promoted for use, with another 
product such as other ASRs, general purpose reagents, controls, laboratory equipment, 
software, etc., or (2) promoted with specific analytical or clinical performance claims, 
instructions for use in a particular test, or instructions for validation of a particular test using 
the ASR, is considered by FDA to be a test system and, thus, is not exempt from premarket 
notification requirements.97  The guidance addresses industry efforts to market increasingly 
complex combinations of ASR-based products (which might be considered test kits subject to 
premarket FDA review, rather than analytes) under the less demanding requirements of single 
ASRs.  Indeed, there has been an increase in LDTs for simultaneous detection of multiple 
genetic variants.  A related concern involves claims of multiple functions for a single ASR when 
selling it to a laboratory.98, 99 
 
Regulatory Oversight of Direct Access Testing for Genetic Tests 
Some tests are being sold directly to consumers via Internet web sites and retail stores without the 
involvement of a health care provider in ordering the test or interpreting the results.  The 
popularity of direct access testing is likely to increase given the rapid pace of genetic research 
availability of services via the Internet, and the growing interest of consumers in self-care.100  
When genetic tests are advertised and sold over the Internet or directly to consumers, significant 
clinical information may be missing or misleading, such as the clinical validity and utility of the 
test.3  For example, advertisements may de-emphasize the uncertainty of genetic test results, 
exaggerate the influence of a particular genetic polymorphism on health (e.g., likelihood of 
acquiring diabetes, heart disease, breast cancer, obesity), and exaggerate the positive influence the 
test can have on an individual’s health.  Reports of misleading information related to direct access 
genetic testing were published in a July 2006 GAO report.101  In that same month, the Federal 
Trade Commission issued a consumer alert on at-home genetic tests.  
Consumers often lack the requisite knowledge to make informed decisions about whether to get 
genetic tests or how to interpret test results.  Without the aid of a health care provider who can 
explain the advantages and disadvantages of being tested and implications of the results, and 
make sound recommendations on next steps, there is considerable potential for physical and 
emotional harm.   
The wide variability in policies for direct access genetic testing among laboratories adds to the 
concerns.  Although some laboratories require patients to provide the name of a physician to 
whom they may send the test results, others provide test results directly to the consumer.  
Similarly, although some laboratories have readily accessible genetic counselors to provide 
information and answer any questions that consumers may have about testing or their results, 
some laboratories do not.   
Stakeholders have proposed ways to regulate advertising of and limit access to genetic testing.  
Careful regulation of advertisements could minimize misleading or exaggerated claims made by 
test manufacturers and providers, as well as limit the channels through which these 
advertisements are introduced.  Regulating access to such tests would make it more difficult for 
consumers to obtain tests or results without authorization from a health care provider.  This 
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measure would help prevent consumers from misinterpreting tests due to a lack of knowledge.  
Even so, efforts to impose more stringent restrictions on direct access for genetic testing may be 
challenged by consumers’ desire for greater autonomy over their health care, including direct 
access to services and control of personal health information.3   
Contrasting the FDA and CLIA Routes 
FDA requirements for the 510(k) notification and PMA review processes for tests as medical 
devices and CLIA requirements for LDTs serve different purposes and rely on different data.  In 
general, FDA emphasizes safety and efficacy of testing devices and CLIA emphasizes a quality 
testing process.   
FDA has an agency-level responsibility for oversight via the 510(k) or PMA processes.102, 103  This 
oversight involves considerations of analytical validity and clinical validity for tests to establish 
their safety and efficacy, particularly those subject to premarket review via the PMA route.  
However, resources are inadequate for review of analytical validity and clinical validity for many 
tests, and there is little or no agency oversight of clinical utility for nearly all tests.  As noted above, 
due to resource constraints, FDA has not exercised its statutory authority to regulate all LDTs.   
Among other aspects of quality described elsewhere in this report, laboratories must 
demonstrate analytical validity of tests through an initial inspection and subsequent biennial on 
site inspections.  However, as standards of evidence for these inspections are determined by the 
individual laboratories, not CLIA, the quality of assessments of analytical validity for given 
tests can vary across laboratories.  CLIA specifies (Subpart M—Personnel for Nonwaived 
Testing) that the laboratory director must “Ensure that … [t]he test methodologies selected have 
the capability of providing the quality of results required for patient care.”67  As such, CLIA 
vests considerable oversight responsibility in the individual laboratory directors.  When a 
testing service is offered by a laboratory, its director is responsible for having determined that 
the testing service, as ordered by clinicians, is capable of providing the quality of results 
required for patient care.  Further, the laboratory director is responsible for ensuring that the 
test is performed and reported properly and is subject to appropriate QC.  LDTs can only be 
performed by the laboratories that develop those tests.  In contrast to the national scope of FDA 
oversight, this is more decentralized, testing service-specific form of oversight.   
Tests that are cleared or approved for market by FDA are available for use by any laboratories, and, 
like LDTs, are subject to PT and other CLIA oversight provisions.  Most tests that are performed by 
laboratories are either cleared or approved by FDA or are LDTs.  Some LDTs are based on ASRs 
that are regulated as medical devices by FDA.  (As described above, recent FDA guidance has 
clarified that ASRs marketed in combination or alone, but with specific indications are, by 
definition, IVDs and subject to FDA regulatory oversight, accordingly.)97  For the remaining LDTs 
that are not derived from these FDA-regulated products, the laboratory directors are still 
responsible for ensuring capability of providing the quality of results required for patient care.  
Certainly, many common LDTs that were not subject to FDA oversight have become standards of 
care over decades and have demonstrated, in practice, clinical validity and clinical utility.   
Notwithstanding the means and extents of their respective oversight of analytical validity, 
clinical validity, and clinical utility, both the FDA and CLIA provisions are incomplete in their 
oversight of these attributes of tests.  Whether for FDA-cleared or approved tests or LDTs, the 
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national capacity for establishing clinical validity and clinical utility, in particular, in field 
testing remains limited.   
Market factors influence decisions to develop tests and can influence the regulatory route 
pursued for marketing a test or testing service.  The likelihood of a manufacturer developing a 
test and collecting data sufficient to gain FDA clearance or approval is influenced by the size of 
the potential commercial market for that test.  Pursuing an FDA pathway for a low-volume test 
may be economically prohibitive.  Manufacturers may not find it commercially viable to pursue 
development and FDA review of tests for certain rare inheritable conditions or other “orphan” 
conditions affecting very small populations.  Given the lower hurdles for reaching the market, 
laboratories may pursue such tests as LDTs and offer them as specialty or “niche” testing 
services.  Manufacturers that choose to devote the necessary resources to generate data for 
gaining FDA approval to market a test may encounter competition from laboratories that 
develop and perform their own in-house version of the test.   Compared to CLIA-regulated 
genetic testing, FDA-regulated tests generally are subject to greater scrutiny for clinical validity 
and, in some instances, clinical utility.   
The current regulatory framework poses incentives for offering genetic tests as LDTs rather than 
marketing them via the 510(k) or PMA routes associated with FDA-regulated tests.  While 
compliance with CLIA provides certain assurances of quality, launch of a genetic test (including, 
e.g., a PGx test) in the form of an LDT offers the advantage of more rapid access to market than 
launch of the test in the form of an IVD test kit or system that must be approved by FDA.  
Furthermore, even when a manufacturer has gained FDA approval for a genetic test, laboratories 
can develop their own version of the test and add it to their menu of CLIA-only regulated 
laboratory services.  As noted above, depending on the benefit-risk tradeoffs of particular genetic 
tests to patients and clinicians, these tests may be more or less suitable for premarket clearance or 
approval by FDA.     
TRANSFUSION-RELATED SERVICES  
Transfusion-related services are critically important to the health and survival of millions of patients 
each year.  More than 15 million units of blood were collected and more than 14 million units of 
blood were transfused in the U.S. in 2004, the most recent year for which data are available.104   
Since the early 1980s, the concept of blood banking has changed from being a laboratory 
discipline to the clinical and consultation specialty of transfusion medicine.105  Concerns about 
transfusion-transmitted diseases contributed to this change, along with recognition of the success 
of transfusion-related laboratory services in addressing problems such as antibody identification 
and record keeping.   
Protection of the blood supply is a multi-step process.  Following collection, donated blood is 
tested in a clinical laboratory to detect the presence of pathogens and contaminants such as 
hepatitis B and C viruses, HIV, human T-lymphotropic virus,v and syphilis.108  If no pathogens or 
                                            
v Human T-lymphotropic virus can cause infections that can lead to leukemia or to a variety of neurological 
diseases.107  
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contaminants are found and the specimen is approved, the blood undergoes further testing for 
ABO blood type, Rh factor, and unexpected red blood cell antibodies. 
Clinical laboratories of large blood banking organizations are devoted exclusively to testing 
donated blood.  The American Red Cross, which collects approximately 43% of all blood donated 
in the U.S., maintains five national testing laboratories and 32 blood manufacturing facilities.109,w  
The laboratories test all blood collected by the American Red Cross, as well as some collected by 
other organizations.  Laboratories providing transfusion-related services are subject to both CLIA 
and FDA oversight, and, as such must be certified by CMS and registered with FDA.   
CLIA Requirements 
CLIA regulations apply to the blood testing processes related to transfusion services.  These 
laboratories must be certified and in compliance with the requirements for personnel, QC, QA, 
recordkeeping, and PT associated with performing high complexity testing and, when applicable, 
the specialty of immunohematology.  For laboratories that are part of transfusion services but not 
involved in processing blood components, CLIA and FDA have a memorandum of 
understanding under which CMS assumes responsibility for regulatory oversight.110  
CMS or CMS-approved accrediting agencies can assess compliance with CLIA regulations as well 
as with their own standards.  Most transfusion service centers are accredited and surveyed by 
AABB.  AABB currently accredits 221 laboratories and almost 1,600 organizations.111  CAP inspects 
laboratories using its transfusion medicine checklist, providing on-site inspections on a biennial 
basis with facilities completing interim-self assessments during alternate years.112  The Foundation 
for the Accreditation of Cellular Therapy runs a voluntary standard setting, inspection, and 
accreditation program for facilities involved in cellular therapy and cord blood banking.113  The Joint 
Commission also assesses transfusion services and donor centers within hospitals.114    
AABB is not a CMS-approved PT provider, but administers PT for laboratories seeking 
accreditation as an immunohematology reference laboratory.111  CAP offers two PT programsx for 
blood testing laboratories, one for laboratories involved in transfusion medicine (J-survey) and 
one for automated transfusion medicine laboratories (JAT-survey), in which more than 4,500 
laboratories currently participate.116  CLIA’s PT requirements for laboratories performing 
transfusion related testing is more stringent than for most other specialties.  A score of 100% is 
required for a satisfactory performance for ABO grouping, Rh D typing, and cross matching and 
80% for antibody detection and antibody identification. (Eighty percent is a satisfactory PT score 
for most other specialties.)   
FDA Requirements  
FDA seeks to ensure that blood and blood products are safe for transfusion.  FDA regulations 
apply to the components of blood product processing, including blood collection and testing, and 
                                            
w The American Red Cross’ national testing laboratories are located in Charlotte, NC; Portland, OR; Detroit, MI; St. 
Louis, MO; and Philadelphia, PA.109 
x The J-survey is mailed to subscribing participants three times each year and tests participants on determination of 
ABO group, Rh D type, antibody detection and identification, and cross-matching.115   
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mandate that blood testing laboratories implement QA and QC functions.  Laboratories 
performing tests on donated blood must use only FDA-approved tests.117   
Blood is regulated as a drug, as defined in section 201(g) of the FDCA, and a biological product, as 
defined in section 351(a) of the Public Health Service Act.118  FDA’s Center for Biologics 
Evaluation and Research holds primary statutory authority to regulate and set standards for all 
aspects of blood banking, including collection procedures, blood components used for transfusion 
or manufacturing of pharmaceutical products (e.g., clotting factors), and products that ensure the 
safety of the blood supply (e.g., cell separation devices, blood collection containers, and HIV 
screening tests).119, 120  The Center for Biologics Evaluation and Research also has authority to 
conduct regular unannounced inspections of blood banking centers and investigate reports of 
blood-related errors, accidents, and adverse clinical events.  
Title 21 of the Code of Federal Regulations (CFR) outlines the specific provisions to which 
laboratories and manufacturing facilities must comply, e.g., licensing requirements, QA 
procedures, product standards, and current good manufacturing practices.  Each laboratory must 
designate an individual who is responsible for ensuring compliance with regulations by all 
personnel and who will serve as the facility’s representative to FDA.120  Each facility’s QA 
operational framework must provide designated individual(s) with the authority to report serious 
infractions directly to FDA and, if applicable, stop production immediately.121    
At a minimum, FDA conducts biennial inspections of blood testing laboratories and 
manufacturing facilities, usually unannounced, to assess compliance with the CFR.  More 
frequent inspections may be undertaken if compliance problems are identified.  Inspections are 
based on a multi-layered set of safeguards highlighted in Box 7.4.117  Advisory, administrative, 
and/or judicial enforcement mechanismsy are available to FDA in the event that inspection 
findings demonstrate operational deficiencies and/or management is unwilling or unable to 
implement corrective actions in a timely fashion.   
Box 7.4:  Safeguards for Inspection of Blood Banking Laboratories 
• Donor screening:  donors are informed about potential risks and are required to answer questions about 
factors that may influence the safety of their blood 
• Blood testing:  each unit of donated blood is tested for infectious diseases 
• Donor lists:  blood establishments must keep a current list of deferred donors and must ensure that blood 
is not collected from anyone on that list  
• Quarantine:  donated blood is quarantined until it is tested and proven to be free of infectious agents 
• Problems and deficiencies:  blood centers must investigate manufacturing problems and correct all 
deficiencies; they must also notify FDA when product deviations occur in any distributed products107   
Source: Keeping blood transfusions safe: FDA's multi-layered protections for donated blood. Rockville: Food and Drug 
Administration, 2002. 
   
Industry stakeholders perceive several regulatory constraints in the area of blood banking. Many 
of these issues are related to manufacturing (e.g., cellular therapies, plasma preparation) and 
tissue storage and are, therefore, outside the scope of this report.  Those issues related directly 
                                            
y Mechanisms include warning letters, license revocation or suspension, seizure of products, injunction and prosecution.    
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with laboratory testing (e.g., recruitment of donors, health history questionnaire and emerging 
threats to blood supply) are discussed below.  
OUTSTANDING ISSUES FOR TRANSFUSION-RELATED SERVICES 
Simplification of Donor History Questionnaire 
Physical assessment and a medical history interview are tools used to determine a donor’s 
eligibility to donate blood and blood components.122  Since the first formal uniform donor 
screening questionnaire was developed in 1953, the number of questions and the amount of 
information that it captures as a part of donor screening has increased, reflecting advances in  
identifying risks of disease transmission.   
In 2000, AABB organized a multi-organizational task force to address concerns related to the 
donor assessment process with the goal of reducing the complexity and improving 
comprehension of the questionnaire and supplementary education materials.  The task force 
produced the Uniform Donor History Questionnaire (DHQ), a new set of documents that 
includes a full-length questionnaire (of 17 specific questions), user brochure, medication deferral 
list, and blood donor educational materials.  While FDA does not mandate the use of a particular 
screening tool for donors to assess risk of communicable disease, it does recognize the DHQ as an 
effective donor screening tool through which licensed and unlicensed facilities can meet 
regulatory obligations.123  
An abbreviated DHQ (aDHQ) was developed as an alternative for a specific subset of repeat 
donors.124  The aDHQ originally proposed by the AABB task force consolidated the 17 questions 
about medications and medical events on the full-length DHQ into one medical history capture 
question that asked donors whether they had any new medical problems, diagnoses, or treatments, 
including vaccination, since their last donation.124  However, FDA expressed concern about the 
ability of one question to capture important information.  The aDHQ was revised to include two 
medical questions that ask whether donors have had any new medical problems or diagnoses and 
whether they have had any new medical treatments since their last donation.  However, unlike the 
full-length DHQ, FDA has not officially recognized the aDHQ.125,z  Additional work is needed to 
improve the ability of abbreviated forms to account for the medical history of donors. 
Mechanisms to Handle Emerging Threats to Blood Supply 
FDA’s ability to handle emerging threats to the blood supply, such as new HIV variants, new 
hepatitis agents, Creutzfeldt-Jakob Disease, bacterial contamination of blood products, and others, 
has significant impact on the public health.127   In many cases, blood collection organizations 
choose to implement specific screening tests prior to FDA issuing guidance.  For example, FDA 
does not currently require blood collection agencies to test for West Nile Virus or Chagas’ disease, 
two diseases that are increasingly prevalent in the U.S.  However, the American Red Cross 
currently tests all of its blood for contamination with both of these diseases.  This decision was 
based primarily on the recognition that blood collected by the organization in one part of the U.S 
may be shipped to another area for transfusion, rendering the geographic clustering of the 
                                            
z Licensed blood establishments that plan to implement a version of the DHQ materials that have not been officially 
FDA-recognized must submit a formal request to FDA for approval.126 
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diseases less meaningful.  According to some reports, approximately 70% of all blood centers in 
the U.S. are testing blood for Chagas’ disease.128   
A 2006 IOM report on the future of drug safety provided recommendations to FDA related to 
protecting and improving the safety of the blood supply.129  In response to IOM’s 
recommendation that FDA strengthen the scientific base that supports their medical product 
safety team, and as a result of FDA’s self assessments, FDA began working with CDC in 2006 to 
identify new threats to the blood supply and to develop, evaluate, and deploy modern 
technologies to address them.130   
CONCLUSIONS 
CLIA 1988 has served as the primary regulatory program governing the U.S. laboratory system 
since its implementation in 1992.  The final rule addressing quality systems and certain personnel 
qualifications was published in 2003.  The CLIA program is administered as a tri-agency effort 
that involves CMS, which has primary oversight of the program, CDC and FDA.   
The current CLIA regulatory framework for clinical laboratory testing, including its goal to ensure 
high standards of quality, promote access, and improve patient outcomes, is limited in certain 
important ways by its language and by the time frame required for development and amending 
relevant  regulation.  Rapid technological advances, demographic shifts, lower tolerance for error, 
and higher expectations for personal data security are challenging and, perhaps, outstripping 
certain aspects of the current regulatory framework for clinical laboratories.  Population and 
epidemiological trends are increasing the incidence and prevalence of chronic diseases; broader 
screening benefits and coverage of prescription drugs for Medicare beneficiaries are contributing 
to the demand for rapid and patient accessible laboratory testing for screening, diagnosis, and 
therapeutic monitoring.   
 CLIA’s interpretative guidelines that allow laboratories the flexibility to determine control 
procedures that are equivalent to the traditional frequency of two levels of control per day 
lack a framework for implementing QC across the wide variety of test systems.  While 
flexibility in implementing QC is desirable, additional information is required to 
implement the guidelines effectively.   
• Several factors may contribute to the inconsistencies in implementing 
equivalent QC.  These include the lack of adequate risk management 
information from manufacturers, the different types and levels of QC required 
by each device and method, and the unique considerations of individual 
laboratories.60  CMS, CLSI, and other stakeholders are developing evaluation 
protocols that will outline principles for validation and provide laboratories 
with scientific guidance on the development of QC procedures for specific 
testing technologies and environments.61  
 Available evidence on the long-term impact of PT on laboratory performance is limited, 
and findings of existing studies are confounded by limited comparable data from CMS 
and survey organizations and other methodological shortcomings.  Existing studies 
indicate generally improved performance in recent years.   
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• Laboratories with PT performance scores of 80% or higher for most specialties 
and subspecialties are considered successful.  As such, PT statistics suggesting 
satisfactory laboratory performance may fail to detect significant proficiency 
problems in particular areas.  Similarly, the PT results do not necessarily 
indicate that a laboratory’s proficiency is sufficient to meet the needs of the 
clinician.  CMS would increase transparency of PT if it were to consider new 
ways to code certain tests for PT purposes, including disaggregation of tests 
within specialty areas, such as microbiology.   
• Several efforts are underway to improve the quality of cytology PT programs.  
CLIAC and CMS are emphasizing the importance of rigorous review and field 
validations studies of cytology slides used by PT programs.   CLIAC 
recommended changes to the regulations in several areas, such as use of new 
technology (virtual media), testing frequency, number of challenges, and a 
grading scheme.51  Legislation (H.R. 1237) also has been reintroduced.    
 Consistent with GAO recommendations, CLIA oversight is being improved by 
standardizing reporting of survey deficiencies and strengthened enforcement of 
regulatory obligations.   
• Many laboratories have more stringent quality management programs than are 
required by CLIA.  These programs provide opportunities for laboratories to 
adapt and validate quality improvement interventions or aspects of these 
programs.  In the short term, these may be incorporated into improved voluntary 
guidelines and perhaps eventually into an improved regulatory framework.  
 Technological advances have made laboratory tests easier to use and less subject to user 
error, resulting in considerable growth in the number of waived tests since the advent of 
CLIA.  From the nine tests or examinations waived in 1993, approximately 1,600 waived 
test systems that measure 76 analytes are now waived under CLIA.   
• The large proportion of clinical laboratories that are certified have wide access to 
tests in this category.  Tradeoffs include easier access to recommended testing, 
with benefits for individual and population health, versus the potential for 
waived tests to fall short on specimen adequacy, test reliability and accuracy. 
 Traditional oversight of LDTs under CLIA for analytical validity may be insufficient for 
genetic tests for which clinicians and patients seek assurances of efficacy and protections 
against potential harms.  CLIA requirements for LDTs and FDA requirements for the 
510(k) and PMA review processes serve different purposes and rely on different data.  In 
general, CLIA emphasizes testing accuracy (i.e., analytical validity, not clinical validity) 
and FDA emphasizes safety and efficacy (clinical validity and, in some instances, clinical 
utility).  Most genetic tests are LDTs and therefore are subject solely to CLIA regulations.  
Only a small number of genetic tests are regulated as IVD test kits or systems subject to 
premarket review by FDA for safety and efficacy via the 510(k) or PMA processes.    
• The extent to which FDA has actively regulated certain LDTs is changing.  
Guidance documents issued by FDA in 2006 and 2007 pertaining to ASRs and 
IVDMIAs indicate a noteworthy shift of regulatory oversight for a small, yet 
growing number of complex tests.  The guidance is likely to expose these tests to 
increased scrutiny similar to premarket review via the 510(k) or PMA processes.   
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 Although they account for a small proportion of all tests performed by clinical laboratories, 
more than 1,000 genetic tests are available for clinical use, with hundreds of others used in 
research settings.  PGx testing is a relatively new form of genetic testing; to date, only a few 
such tests are used to support decisions for selecting and dosing therapies.   
• CMS announced in September 2006 that it would not pursue a Notice of 
Proposed Rule Making for genetic testing, but that it would implement an 
action plan for enhanced oversight of genetic testing under existing CLIA 
authority.  Elements of the action plan include expanded training of surveyors, 
collaboration with CDC to publish educational materials, development of 
alternative PT mechanisms, and coordination with CDC and FDA on oversight 
activities.  CMS also is working with SACGHS, FDA, and other experts to 
address current gaps in oversight of laboratories that conduct genetic testing 
and to otherwise support or augment its action plan.   
• As genetic testing and PGx, in particular, evolve, there is an ongoing need for 
guidance from CMS and FDA regarding respective scopes of regulatory 
oversight pertaining to these tests.  Manufacturers of tests and therapies whose 
safety and effectiveness are mediated by genetic factors will seek ongoing 
guidance from FDA for co-development of drugs and diagnostics and related 
regulatory matters pertaining to PGx.   
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CHAPTER VIII 
REIMBURSEMENT FOR LABORATORY MEDICINE 
Reimbursement for most health care in the U.S. is administered by government and private sector 
third parties using multiple systems of coverage, coding, and payment.  Third-party payment has 
enabled patients to access and benefit from health care products and services, including 
laboratory testing, and ensures broad markets for these.  However, difficulty in acquiring 
coverage, appropriate coding, and adequate payment can pose significant hurdles to laboratory 
testing.  The consequences can include reduced patient access to laboratory testing and decreased 
incentives for laboratories and test manufacturers to engage in further test development.   
As health care continues to usurp a larger proportion of national spending, it places greater 
burdens on employers, patients, and the health care system itself, with broader implications for 
industry, competitiveness, and other aspects of the economy.  These pressures are leading to 
proposals to modify and even broadly reform health care payment systems.1, 2, 3    
Many of the concerns pertaining to Medicare payment for laboratory services were identified in 
the 2000 IOM report, Medicare Laboratory Payment Policy: Now and in the Future.4  Yet, little has 
changed since publication of that report.  This chapter provides an overview of the current public 
and private sector payment systems for laboratory services and an analysis of payment issues that 
affect laboratory testing access, effectiveness, efficiency, and innovation.    
PUBLIC AND PRIVATE SECTOR PAYERS 
The U.S. health system has multiple public and private sector payers.  CMS is the largest 
purchaser of health care in the U.S.  CMS administers Medicare, a federal program, and the 
federal portion of the Medicaid program and the State Children’s Health Insurance Program, 
which are funded jointly with the states.  In fiscal year 2006, CMS net outlays were approximately 
$515.2 billion for these programs,a about 19.4% of total federal outlays.5 
Medicare provides benefits for 43.2 million beneficiaries, including 36.3 million elderly and 7 million 
disabled enrollees, comprising 14% of the population.  By 2031, the number of beneficiaries will be 
an estimated 77 million.6  This includes the baby-boom generation, the last of which will turn 65 in 
2029.  The Medicaid program covers 50.3 million beneficiaries, about 17% of the U.S. population.  
More than 75% of Medicaid enrollees are low-income children and their parents.6  
Other government payers, i.e., the Military Health System (MHS), VHA, and Indian Health 
Service, operate independent health care systems that provide services directly to their 
beneficiaries or through negotiated contracts with private sector providers.  In fiscal year 2006, the 
MHS and VHA programs were estimated to spend $70 billion on health care for approximately 16 
million enrolled veterans, active duty, and retired military personnel and their beneficiaries.7, 8  
                                                     
a The other federal outlays included Social Security $586 billion (22%), defense $499 billion (18.8%), treasury $464 
billion (17.5%), and other $590 billion (22.2%). 
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Private sector payers include insurance companies and commercial health plans such as Aetna, 
Blue Cross and Blue Shield plans, CIGNA, Kaiser Permanente, UnitedHealthcare, and WellPoint.  
Some of these plans also act as contractors to Medicare and Medicaid, processing claims and 
administering payments to laboratories.  In 2005, approximately 200 million Americans were 
enrolled in managed care plans, including 15 million enrolled in Medicaid programs, and 7 
million in Medicare programs.9, 10   
Based on 1999 data reported by the IOM, clinical laboratories derive their revenues from fee-for-
service payments (42%), followed by Medicare payments (29%), Medicaid payments (12%), 
consumers’ out-of pocket payments (10%), and health maintenance organization (HMO) 
capitation payments (7%).4   
Components of Reimbursement Systems 
Three main components of payment systems are coverage, payment, and coding:  
 Coverage decisions establish the conditions under which third-party payment is 
provided, including the range of benefits provided under particular plans or contracts, 
which items and services can be reimbursed under those benefits, clinical indications 
for which these items and services (e.g., laboratory tests) will be reimbursed, and the 
circumstances or settings in which the items and services will be reimbursed.  Medical 
necessity and appropriateness determinations affect payer coverage decisions.       
 Payment methodologies establish payment levels for tests and services provided and 
methods for calculating these amounts.  Payment levels typically are tied to the codes 
for these tests and services.  These levels may be provided in the form of prospective 
payment systems (PPSs), fee schedules, or negotiated contracts with payment rates for 
particular codes.  The type of payment methodology of choice may vary by insurer.  
 Coding systems involve the alphanumeric nomenclatures assigned to particular health 
conditions, services, or products and the processes for assigning and updating these.  
The coding systems that apply to laboratory medicine include Current Procedural 
Terminology® (CPT) codes and Healthcare Procedural Coding System (HCPCS) codes 
for laboratory tests and services and International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes for diagnoses.  
Coverage and coding policies shape the operation of payment systems.  Whether for laboratory 
testing or other types of health care, the design and implementation of payment systems can 
influence patient access, provider decision-making, and innovation.  
COVERAGE DECISIONS 
Public and private sector payers make coverage decisions independently, often with 
consideration of the financial impact resulting from specific determinations.  However, legislative 
actions may mandate coverage of specific tests by all payers.   
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Medicare Coverage Decisions 
Medicare’s authorizing legislation in 1965 established broad categories of coverage for hospital, 
physician, and laboratory services, but limited payment to expenses deemed reasonable and 
necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a 
malformed body member.11  Coverage decisions are left to Medicare officials who, in turn, have 
delegated most of their authority to local contractors, which are typically private sector insurance 
companies that administer the program in specific geographic jurisdictions, subject to national 
Medicare provisions and requirements.12   
The contractors that administer Part A of Medicare are known as fiscal intermediaries (FIs) and 
those that administer Part B are known as carriers.  About 90% of all Medicare coverage reviews 
and decisions still occur at the local level while 10% occur at the national level.  In 2007, there 
were 16 carriers and 20 FIs.  However, for laboratory services, there are 56 carriers for 
corresponding geographic areas (see payment section below).  Carriers handling other Part B 
services can serve as one of the 56 carriers handling laboratory services.  
Most Medicare coverage policies for new tests and services under Part B are established by local 
carrier advisory committees and are known as local coverage determinations (formerly referred to 
as local medical review policies).  In this decentralized system, there is substantial variation 
among coverage policies of different carriers.  Aside from the uncertainty and inconsistency that 
arise from this arrangement are long-standing concerns regarding the lack of openness, 
transparency, predictability, and length of time involved in these coverage processes.11  In 
addition, the Medicare statute restricts payment for preventive and screening services and 
technologies, unless otherwise specified by Congress.   
Several legislative initiatives, along with various policy reports, have been directed at some of these 
issues.  The Balanced Budget Act of 1997 provided the legislative vehicle to consolidate the number 
of CMS contractors making coverage decisions and processing laboratory claims from 56 to 5.13  
However, the consolidation has not been implemented to date.  In 1999, CMS established the 
Medicare Coverage Advisory Committee (now called the Medicare Evidence Development and 
Coverage Advisory Committee) and restructured the national coverage processes in order to 
facilitate more systematic and transparent national coverage determinations for Medicare.  The 
Medicare Evidence Development and Coverage Advisory Committee provides recommendations 
based on literature reviews, technology assessments, and expert advice, though CMS retains control 
over final decisions.11  National coverage determinations take precedence over local carrier 
decisions.  Although it continues to improve, CMS has failed frequently to meet its standard for 
prompt assessment of six to nine months, depending on the type of test or technology.  Review 
times for some decisions frequently exceed nine to twelve months.14  
In 2001, the Medicare Payment Advisory Committee (MedPAC) recommended the elimination of 
local coverage policies and payment schedules in order to reduce complexity, inconsistency, and 
uncertainty associated with Medicare reimbursement.15  (MedPAC is an independent federal 
body established by the Balanced Budget Act of 1997 to advise the U.S. Congress on issues 
affecting the Medicare program.)  However, this proposal was resisted by many stakeholders, 
including those affiliated with laboratory medicine.  In response to concerns from the laboratory 
community, CMS published a negotiated proposed rule making in 2001 to implement 23 national 
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coverage policies for 66 CPT codes that represent about 60% of all laboratory tests billed to the 
Medicare program (see Box 8.1).16  The national policies describe the medical conditions for which 
a laboratory test is covered and set frequency limits on coverage of the same test for a patient.  
The rule making also established opportunities for stakeholder involvement in the decision-
making process during annual reviews of coverage policies.  Even so, some stakeholders continue 
to call for further transparency in this process. 
Under provisions in the MMA 2003, CMS began reforming the carrier-based approach to 
administration of its programs.  This initiative is expected to have a direct impact on the number 
of carriers affiliated with coverage and processing of laboratory claims.  CMS is transitioning to 
the Medicare Administrative Contractor (MAC) system that will eventually replace all carriers 
and FIs.  The first MAC contract was awarded in July 2006 to Noridian Administrative Services 
(Fargo, ND) to implement consolidated claims processing for Medicare Part A and Part B in 
Jurisdiction 3 (Arizona, Montana, North and South Dakota, Utah, and Wyoming).17  However, at 
present, the use of MACs will not change the geographic-oriented payment rates or number of fee 
schedules for laboratory services.18 
In 2003, GAO issued a report that also recommended elimination of local coverage and expansion 
of the national coverage system.  However, as noted in the GAO report’s summation of public 
comments, DHHS and certain stakeholders, including some in industry, opposed doing so, 
stating that the elimination of local coverage would result in net increases in expenditures, mainly 
due to spending on additional resources to manage national coverage decisions for all services 
and products.19  MMA 2003 expanded Medicare coverage of certain screening tests, including for 
cardiovascular disease and diabetes.20  These tests and other preventive services are 
recommended for certain population groups by authoritative groups such as the USPSTF and the 
Advisory Committee on Immunization Practices.21    
Box 8.1:  23 National Coverage Determinations for Medicare, Effective 2001 
Alpha-fetoprotein (AFP)  
Blood counts     
Blood glucose testing  
Carcinoembryonic antigen (CEA)  
Collagen crosslinks, any method  
Digoxin therapeutic drug assay  
Fecal occult blood test (FOBT)  
Gamma glutamyl transferase (GGT)  
Glycated hemoglobin/glycated protein  
Hepatitis panel/acute hepatitis panel  
Human chorionic gonadotropin (hCG)  
Human immunodeficiency virus (HIV) testing 
(diagnosis) 
Human immunodeficiency virus (HIV) testing 
(prognosis including monitoring) 
Lipid testing  
Partial thromboplastin time (PTT) 
Prostate specific antigen (PSA) 
Prothrombin time (PT) 
Serum iron studies 
Thyroid testing 
Tumor antigen by immunoassay – CA 125 
Tumor antigen by immunoassay – CA 15-3/ 
CA 27.29 
Tumor antigen by immunoassay – CA 19-9 
Urine culture, bacterial 
Source: Lab NCDs. Baltimore, MD: Centers for Medicare and Medicaid Services, 2007. 
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Denials and Advanced Beneficiary Notice 
Medicare denies claims for laboratory tests when they fail to meet required criteria.b  According to 
MedPAC, the national claims denial rate for laboratory services in 2002 was 15%, with much 
higher rates in certain geographic areas.22  A 2006 analysis found that Medicare denial rates for 
laboratory testing peaked in 1998 (15%) and have been declining since then to 8.8% in 2004.23  
However, this analysis is confounded by the definition of claims denial, which includes both true 
denials (i.e., services for which payment was never made) and “paperwork” denials (i.e., denials 
that are ultimately resolved and paid).   
Documentation of reasons for claims denials associated with medical necessity determinations 
have been inconsistent among carriers.  To remedy this problem, CMS introduced additional 
documentation requirements for medical necessity in the late 1990s.  However, inconsistencies 
have persisted.  The IOM concluded that regional variations in denial rates for the top 20 
laboratory tests (by dollar value) by carrier were attributed to geographic patterns of fraud and 
abuse, varying interpretation of Medicare rules by local carriers, and low numbers of tests in a 
particular region that might skew the proportion of denied claims.  Thus, while denials associated 
with fraud and abuse are certainly appropriate, some proportion of denials are associated with 
unresolved inconsistencies among carriers.4 
In a fee-for-service reimbursement system, denied claims are the financial responsibility of the 
laboratories, rather than the physician ordering the test.4  While justifiable claims denials can save 
costs and improve efficiency, those that are subject only to inconsistent decisions or policies, or 
that are otherwise unjustified, can contribute to the total cost of providing laboratory services 
because they may increase administrative costs, decrease aggregate revenue for laboratories, and 
create bad debt expense.  Because the laboratory does not have direct contact with the patient in 
most situations, it must depend on the clinician to recognize that:  (1) the laboratory test ordered 
is subject to medical review, (2) the medical necessity of the test is indeterminate, and (3) the 
patient’s signature on an Advanced Beneficiary Noticec (ABN) is needed.4  In cases where a 
patient receives a laboratory test that is not covered by Medicare and for which an ABN was not 
signed, the laboratory must absorb the cost.25   
In 2002, CMS issued an ABN form specific to laboratory testing that allowed laboratories to list 
tests that could be denied as well as specify the possible reasons for denial.26  To simplify ABN 
further, in 2007, CMS proposed combining the general use ABN and the laboratory ABN.27  
However, many clinical laboratory professional societies stated their preference to retain the 
separate laboratory ABN form as it provides beneficiaries with a clear understanding of the 
reasons for the denial of coverage of specific laboratory tests.28, 29  As of December 2007, CMS 
maintained both forms; however, laboratory experts anticipate that the agency will introduce and 
require use of a new, combined form in 2008.30     
                                                     
b Medicare denies claims for laboratory tests when such claims are for tests that Medicare does not cover, do not meet 
medical necessity requirements, are for individuals who are not Medicare beneficiaries, are from laboratories that 
are not Medicare-providers or are not certified by CLIA to perform that particular test, are not documented 
sufficiently, and are for patients whose primary coverage is from another payer.4 
c Medicare requires that physicians notify beneficiaries of the possibility that Medicare might not deem a laboratory 
test medically appropriate.  Beneficiaries must sign an ABN acknowledging their understanding of this policy 
and personal responsibility for payment.24   
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Medicaid Coverage Decisions 
Medicaid beneficiaries receive a comprehensive set of medical benefits, with some services 
required by the federal government and others offered at the discretion of the state.31  Individual 
states have substantial decision making authority over which benefits their Medicaid programs 
will cover.  Within the broad national guidelines established by federal statutes, regulations and 
policies, each state: (1) establishes its own eligibility standards; (2) determines the type, amount, 
duration, and scope of services; (3) sets the payment rates for services; and (4) administers its own 
program.32  About 35% of spending in each state is for federally mandated benefits (e.g., 
laboratory services) while 65% is for optional services (e.g., prescription drugs).33   
Federal guidelines apply to coverage and payment for laboratory services under Medicaid.  
Medicaid programs are required to cover professional and technical laboratory services that are:  
 Ordered and provided by or under the direction of a physician or other licensed 
practitioner, or ordered by a physician and provided by a referral laboratory  
 Furnished by a laboratory meeting the requirements outlined in CLIA33 
This includes laboratory testing conducted in the spectrum of inpatient and ambulatory care 
settings in which services can be provided to Medicaid beneficiaries.33  Also, Medicaid must cover 
screening, diagnostic, and treatment services for beneficiaries under age 21. 
All states participating in the Medicaid program must designate one state agency that is 
responsible for administering and supervising the  state’s Medicaid program.34  However, federal 
rules do not dictate a specific administrative structure for state Medicaid programs or how 
coverage decisions must be made, including those for new laboratory testing technologies.  In 
New York State, for example, various offices within the Department of Health, Governor’s Office, 
the Legislature, and other agencies all play a role in determining what benefits the state’s 
Medicaid program will cover and what models of service delivery it will employ.    
TRICARE and Veterans Health Administration Coverage Decisions 
Both the TRICARE and VHA significantly expanded their benefit programs in the 1990s.  
Independently, the programs were reorganized to incorporate policies and procedures used by 
preferred provider and managed care organizations.  For TRICARE, coverage of health care 
services, including laboratory services, has remained constant and generous.  Because TRICARE 
provides care to family members of military personnel, a full spectrum of diagnostic services are 
available as part of the benefits package, including many genetic tests used to screen and 
diagnose newborns through adults.  
The VHA provides a standard health benefits plan to enrollees; however, unlike TRICARE, it does 
not provide benefits to family members.  The plan emphasizes preventive and primary care, and 
offers a full range of inpatient and ambulatory care services within the VA health care system, 
including laboratory tests for screening, diagnosis and treatment.  Funding of the program is 
discretionary and the system is expected to meet the needs of its beneficiaries within its budget, 
although Congress may authorize additional funds if needed.   
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Private Sector Coverage Decisions 
Most private payers maintain their own process for making decisions regarding coverage, 
although they often follow the coverage decisions made by Medicare and some of the larger 
private health plans.10, 35-37  Similar to government payers, coverage decisions are made at the local 
level; however, in contrast, private payers are not obligated to establish advisory committees or 
engage in publicly open processes.38  Private payers may choose to adjust policies following 
introduction of new technologies to the market, with the impetus for such changes coming from a 
variety of sources, such as state or federal mandates, consumer preference, or financial concerns.d  
In addition, payers may negotiate specific coverage plans with the groups or employers 
purchasing the plan.39 
Constraints on health care costs, demand for better outcomes and higher quality, and the 
unprecedented rate at which new technologies are being introduced to the market have driven 
many health care payers to use evidence-based decision-making to determine the most 
appropriate services and technologies to cover.35  Public and private sector payers increasingly 
draw upon health technology assessments (HTAs) to inform their coverage decisions.  HTAs 
typically involve using a systematic approach to assembling and interpreting available evidence 
to determine whether a test or medical service is safe, effective, and, sometimes, cost-effective, for 
particular patients and health care settings.  Several payers have conducted health technology 
assessments for screening, diagnostic, and monitoring laboratory tests. 
Some health insurance plans and purchasers have created thorough processes for conducting 
HTAs internally.  Those that do not conduct formal reviews of new technologies may purchase 
assessments from HTA vendors.  Examples of private health plans that conduct formal reviews of 
new technologies include Aetna, CIGNA, UnitedHealthcare, and WellPoint.10  Various HTA 
vendors in the U.S. generate proprietary assessments that are available to payers and other 
subscribers.  For example, the Technology Evaluation Center (TEC), established by the Blue Cross 
Blue Shield Association, produces evidence-based technology assessments of the clinical 
effectiveness and appropriateness of a specific medical procedure, device, or drug.40, 41  TEC is 
guided by its Medical Advisory Panel, which consists of 19 independent, nationally recognized 
experts in HTA, clinical research, and medical specialties.42  ECRIe and HAYES, Inc.f are two other 
examples of U.S.-based HTA vendors whose reviews are used by payers in support of their 
coverage decisions.43, 44 
                                                     
d Health insurance plans are required by law to provide information to plan members about what services are 
covered and how coverage decisions are made and can be appealed.  Denied claims must be accompanied by a 
reason for the denial, including citations of any policy or criteria on which the coverage decision is based.35 
e ECRI Institute is a nonprofit organization that provides consulting services related to, e.g., patient safety, quality, 
risk assessment and management, and technology assessment.  It is also an AHRQ-designated Evidence-based 
Practice Center. 
f HAYES, Inc., provides technology assessment reports for health plans, managed care companies, hospitals, and 
health networks and offers training programs to facilitate participants’ understanding of the HTA process. 
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Laboratory tests that have been assessed by the TEC include: 
 Serial endpoint testing for the diagnosis and treatment of allergic disorders 
 High-sensitivity C-reactive protein measurement for coronary heart disease risk 
stratification 
 iFOBT vs. gFOBT 
 Use of intermittent or continuous interstitial fluid glucose monitoring in patients with 
diabetes mellitus 
 Use of epithelial cell cytology in breast cancer risk assessment and high-risk patient 
management 
 Chemotherapy sensitivity and resistance assays40 
In addition to HTA findings, private payers also may consider clinical practice guidelines, cost, 
and the availability of an appropriate CPT code.35  Private payers are becoming more open to 
meeting with manufacturers to discuss what data they need to make coverage decisions for new 
technology.39  In general, there is consistency in coverage among private sector payers in routine 
laboratory testing associated with standard of care, although some remaining variations in 
coverage may inhibit an individual’s access to certain tests and services.10  The 2006 SACGHS 
report on coverage and payment for genetic tests and services found that, of those private payers 
whose coverage policies are publicly available, most cover genetic testing for chromosomal 
abnormalities, prenatal and neonatal diagnosis, and pre-implantation genetic diagnosis in some 
cases.35  These payers also generally cover genetic testing for certain rare diseases.           
Less information is available regarding denial rates for private payers.  One indication of denial 
rates comes from Athenahealth, Inc., a provider of web-based services and software to medical 
practices, whose “PayerView” program reviews health insurance performance from the 
perspective of physicians.45  In 2006, Athenahealth published its first “PayerView” for of Texas, 
which analyzed claim performance data for more than 330 providers and 59 medical practices.  
Medicare Part B in Texas denied 5.6% of claims submitted, which was below the rate for the 
state’s private insurers, which ranged from 6.5 to 10.4% among the top eight companies. 
Outstanding Issues in Coverage 
Limited Medicare Coverage of Screening Tests 
Medicare is limited by statute to providing coverage only for items or services that are “reasonable 
and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a 
malformed body member.”  In order for Medicare to cover screening or preventive interventions 
(i.e., in patients without signs, symptoms, complaints or personal history of disease or injury), 
Congress must pass new legislation mandating coverage of those specific interventions.  Examples 
of preventive tests approved by Congress to date include tests to screen for cardiovascular disease, 
cervical and vaginal cancer, colorectal cancer, breast cancer, prostate cancer , glaucoma, 
osteoporosis, abdominal aortic aneurysm, and diabetes.46  In addition, Congress has also approved 
Medicare coverage of smoking cessation counseling, medical nutrition therapy for beneficiaries 
with diabetes or renal disease, vaccinations to prevent influenza, pneumonia, and hepatitis B virus, 
and a one-time “Welcome to Medicare” physical examination for new enrollees.  In contrast, 
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coverage of preventive services and screening tests is quite extensive for private sector payers.  The 
Medicare Preventive Services Coverage Act of 2007 (S. 2115), introduced in Congress in September 
2007 by Senator Ben Cardin (D-MD), includes provisions for expand Medicare coverage for certain 
preventive tests and related services.  (See Box 8.2.)47   
Box 8.2:  Medicare Preventive Services Coverage Act of 2007 (S. 2115) 
The bill’s core provisions call for Congress to:  
• Extend the eligibility period of the “Welcome to Medicare” visit, a preventive physical examination, 
from 6 months to 1 year  
• Authorize the Secretary of DHHS to expand Medicare coverage to include services deemed reasonable 
and necessary for the prevention or early detection of illness or disability, taking into account 
evidence-based recommendations by the USPSTF and other appropriate organizations 
• Eliminate coinsurance rates for the “Welcome to Medicare” visit and other preventive services47, 48 
Source: S. 2115: The Medicare Preventive Services Coverage Act of 2007.  
 
Inconsistencies in Coverage of Genetic Tests among All Payers 
Some emerging tests (e.g., those used in PGx) may not fit neatly within Medicare’s coverage 
criteria.  Medicare considers most predictive and predispositional genetic tests to be screening 
tests, and as such, congressional authorization is necessary for coverage.  Most genetic tests are 
not covered by Medicare unless they are performed on symptomatic individuals or are used to 
identify treatment-responsive populations.49  Unresolved issues pertaining to coverage of 
genetic tests include:  (1) the extent to which genetic tests used in broader metabolic profiles, or 
for more limited profiles targeted to specific biomarkers meet current medical necessity criteria; 
and (2) the extent to which genetic tests can be tied to clinical decision making and patient 
health outcomes.50 
In 2006, SACGHS recommended that Medicare cover predictive and predispositional genetic tests 
and their accompanying services (e.g., genetic counseling) that meet appropriate evidence 
standards.35  SACGHS also recommended that CMS clarify that a “personal history” of disease 
can include having a family history of a disease, thereby making it possible for beneficiaries with 
a family history of a disease to meet Medicare’s standard of “reasonable and necessary.”   
With the exception of newborn genetic screening and follow up, which are federally mandated, 
states are responsible for Medicaid coverage decisions for genetic tests and services.35  Given 
individual state differences in policy, there is significant disparity in patient access to these tests 
and services.  States’ decisions regarding whether to cover specific genetic tests is determined in 
large part by financial and political factors.  Although Medicaid programs account for, on 
average, about 22% of state budget, states sometimes restrict Medicaid spending by limiting 
coverage and/or payment rates, particularly on those items and services outside the scope of 
federal requirements.51, 52  In 2006, SACGHS recommended that DHHS ensure that all states 
receive information about genetic tests and services in order to inform their Medicaid coverage 
decision making processes.35                   
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Coverage for newly developed tests, especially molecular, genetic, and PGx tests, varies widely 
among private sector payers.  Often, there are fewer research studiesg available on their clinical 
utility and costs.10, 35, 39, 53  In 2004, the Congressional Research Service reviewed the coverage 
decisions of 27 private payers and found that 16 had developed policies for genetic testing to 
detect hereditary colon cancer.53  However, coverage decisions for this testing varied widely 
across individual payers.h      
The variability in coverage has arisen in part because neither public nor private payers have 
developed uniform methods for obtaining information from laboratories about the new tests.54  
The lack of a uniform process for making coverage decisions can lead to inappropriate use (e.g., 
overuse and underuse) of new laboratory testing technologies that otherwise have the potential to 
improve the quality of health care.10  Recently, some public and private sector stakeholders have 
recognized the need to provide guidance to private payers in the areas of PGx and genetic testing.  
In 2006, SACGHS recommended the establishment of a task group that includes public and 
private sector representatives to create a set of guiding principles for coverage decisions, 
addressing issues such as economic evaluation/cost-effectiveness, prevention, rare disease tests, 
therapeutic benefit, and informational utility, and make available all scientific evidence needed to 
support private payer coverage decisions for individual patient populations served by the 
respective payer. 
PAYMENT METHODOLOGIES 
Although private sector insurance accounts for higher revenues, it is the Medicare program that 
exerts the strongest influence on laboratory services payment for all payers.  According to a 
microcosting study performed for an IOM report, 66.7% of private insurance plans evaluated for 
the study used the Medicare payment rates as the basis for their own.55  The Medicare payment 
rates also affect state Medicaid programs and other federal payer programs.  As such, various 
strengths and weaknesses of the Medicare payment system extend beyond Medicare to other 
payers, providers, and beneficiaries.  
Medicare Payment Methodologies 
The current payment structure of the Medicare program comprises multiple, often complex 
payment methodologies for Part A (inpatient care), Part B (hospital outpatient and ambulatory 
care), and Part C (private sector options), depending on site of care and services provided.  Part A 
pays for inpatient hospital, skilled nursing facility, home health, and hospice care.  (See Appendix 
C for additional information on the development of the Medicare payment system.)  In 2006, Part 
A accounted for 41% of Medicare spending, Part B accounted for 35%, Part C accounted for 16%, 
and the new Part D prescription drug benefit accounted for 8%.56      
                                                     
g Although demonstrating improved health outcomes is a primary factor in coverage determinations, the effect of 
molecular and genetic test results on a patient’s health may not be realized for many years, making it difficult to 
perceive and measure the immediate benefits and long term cost effectiveness of such tests.39   
h Four payers covered genetic testing without specifying the genes, five covered mutation analysis in three common 
genes, four covered microsatellite instability analysis in addition to the standard genetic tests, one covered genetic 
testing of only one gene, and two did not cover genetic testing at all. 
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Rising costs of care and pending retirement of the baby boom generation suggest accelerated 
growth in Medicare outlays in 2010 and beyond.  Over the past 40 years, costs per beneficiary 
under Medicare and Medicaid have increased about 2.5% faster per year than has per capita gross 
domestic product.57  Medicare spending is projected to grow at a rate of 7.3% over the next 
decade.58  Congress has directed federal agencies, particularly payers, to study possible 
alternatives to the current payment methodology (such as competitive bidding) as well as more 
aggressive strategies to cut costs.   
Prospective Payment Systems for Inpatient and Hospital Outpatient Care  
For inpatient care under Part A, payment is provided via lump sum based on the patient’s 
diagnosis.  Hospital diagnosis-related groups (DRGs) are designed to cover institutional costs, 
excluding physicians’ services that are paid for through the Part B fee schedules.  Included in the 
DRGs are any laboratory tests that are bundled with other services for a given hospital admission.  
Other inpatient facilities use prospectively set groupings that are similar to DRGs; some use per 
diem rates.i  Generally, a standardized base rate is determined according to the diagnosis 
grouping and associated relative value, which may be adjusted to accommodate case-mix (i.e., 
health condition, clinical characteristics) and geographic differences in wages.  (Relative value 
payment methodology is discussed below.)   For hospitals, additional adjustments can be made to 
sites treating a disproportionate share of low-income patients, sites in rural locations, or outlier 
cases of extraordinarily high cost.   
Both operating and capital payment rates are updated annually for all PPSs.  Operating costs are 
updated according to the projected increase in CMS’ market basket index (which measures price 
increases of goods and services hospitals buy to produce patient care).  Capital updates are 
determined by the Secretary of DHHS.  In addition, payments to hospitals that fail to provide data 
on specified quality indicators are reduced by 2%.59  (Reporting on quality indicators as a 
condition to maintain payment level is not required of other inpatient facilities at this time.) 
The change to PPSs for inpatient care had a significant effect on clinical laboratories.  Until 1984, 
hospital laboratories generally were recognized as profit centers.  However, the institution of 
prospective payment based on DRGs and similar capped payment rates transformed inpatient 
laboratory testing into a cost center, creating incentives to reduce the number of tests ordered as 
well as to shift inpatient care to the hospital outpatient and ambulatory care settings.4  When 
DRGs were introduced, CMS assumed that the mean cost attributable to the laboratory as a 
proportion of the revenue generated by DRGs would not exceed 9.5%.60  
The proportion of payment attributed to laboratory tests is mediated, in part, by the patient’s 
health condition.  A 2000 report of a study that examined 486 DRGs drawn from a large 
University HealthSystems Consortium database found that the proportion of payment associated 
with laboratory tests and services averaged 6% for surgical DRGs and 9% for other DRGs 
designating the management of medical conditions.61  The highest proportion of total costs 
attributable to the laboratory was 18.3% for acute leukemia, 13.6% for HIV with surgical 
procedure, and about 8 to 10% for various transplant procedures.  Tests for kidney and urinary 
signs and symptoms in children also were higher than average.  Median laboratory costs were 
                                                     
i Separate Medicare PPSs have been developed for other for health care facilities, including skilled nursing facilities, 
long-term care, hospice care, inpatient psychiatric care, home health and inpatient rehabilitation. 
Laboratory Medicine: A National Status Report Chapter VIII – Reimbursement for Laboratory Medicine 
 
May 2008 324 
<1.0% for only 15 DRGs.  Since the publication of this study in 2000, there has been little research 
on the contribution of laboratory costs to total costs or the effect of variations in laboratory costs 
on quality of care.   
In August 2000, CMS began using an outpatient prospective payment system (OPPS) for outpatient 
hospital care in order to restrain cost increases.  This system provides a fixed, prospectively 
determined, bundled payment for products and services provided by hospitals in outpatient 
settings, excluding those services provided by physicians and other health care providers.62  Similar 
to DRGs, the OPPS classified services into ambulatory payment classifications (APCs).  All services 
within a given APC are assumed to be clinically comparable and have comparable resource 
requirements, and therefore, have the same payment rate.  APCs pertain to laboratory tests, 
implantable devices, items used in diagnostic radiography, and durable medical equipment (DME) 
associated with hospital outpatient services.63  Physicians’ fees, including those for certain 
pathologist-related consultative services, are paid through the Part B fee schedule.  (Splitting of 
laboratory fees into physician fees and “technical components” paid differently is discussed in the 
next section.)  
Along with bundling, the move to OPPS significantly affected the ways that independent 
laboratories can bill for their services.  Independent laboratories that provide pathology services 
to registered hospital outpatients must bill the hospital directly for the technical component.  The 
hospital receives payment from Medicare under Part A and the independent laboratory receives 
payment from Medicare for pathologist fees.64  Laboratory professional organizations have 
opposed the OPPS, citing concerns about administrative and financial burdens on hospitals and 
clinical laboratories.65  Stakeholder actions prompted the inclusion of an exception in the Benefits 
Improvement and Protection Act of 2000.66  The legislation allows independent laboratories with 
contracts in place by the date of the proposed rule-making to continue to bill Medicare directly for 
technical component services.   
Health care facility costs associated with blood banking and transfusion medicine are paid via the 
inpatient and outpatient PPSs.  Fees for services associated with end stage renal disease are paid 
via the outpatient dialysis services payment system.67  This system uses a composite rate that is 
intended to cover the bundle of services, laboratory tests, certain drugs, and supplies that are 
routinely required for dialysis treatment.  Providers must bill Medicare separately for certain 
injectable medications and laboratory tests that are not included in the bundle.   
Other government payers, i.e., Medicaid, TRICARE, VHA, use the Medicare DRGs, with some 
modifications, for payment of inpatient and hospital outpatient services for their respective 
beneficiaries.68-70  However, Medicare Part C (in which CMS contracts with health plans to 
provide care to Medicare beneficiaries), TRICARE, and the Federal Employee Health Benefits 
have switched from PPSs to competitive bidding contracts.71   
The change to PPS by Medicare prompted a similar move by private sector.  Private payers 
typically use one of several PPS methodologies for inpatient and outpatient hospital settings, such 
as all-inclusive case rates, per diem rates, and DRGs.10  As is the case with the Medicare PPS, all-
inclusive rates used by private payers do not provide separate payment for each resource used.  
These PPSs rely on their ability to capture or accurately estimate how much each resource costs in 
order to account for it when determining payment rates.  Private payers usually use the Medicare 
DRG groupings, but will assign their own relative weights to the individual DRGs.  While the 
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payment amounts negotiated between the hospital and the payer have been proprietary 
information, at least one major private payer recently announced that it will make public the 
actual payment rates negotiated with physicians.72, 7372, 73   
Fee-for-Service Payment Systems for Ambulatory Care    
Public and private sector payers cover ambulatory care and other services such as laboratory tests 
according to predetermined, fixed fee schedules, negotiated contracts, or competitive bidding 
contracts.     
A fee schedule is a list of allowable fees representing the average or maximum amount that the 
payer will reimburse providers for the service.6969  HCPCS codes, including CPT codes, describe 
specific tests or services and link the service to the fee schedules.  Medicare uses three fee 
schedules under Part B to provide payment for a given service, procedure, or item.  Most private 
sector payers base their fee schedules on the Medicare schedules.  
(1) Medicare physician fee schedule (MPFS).  This fee schedule covers physician and other 
licensed health care practitioner services, including office visits, surgical procedures 
and certain laboratory services that require professional interpretation, such as 
anatomic pathology tests and certain gene-based, molecular or similarly complex tests.  
Physician services can occur in different settings.  Determinations of the payment rate 
are based on three aspects affecting physician services:  physician work, practice 
expense (all costs other than physician time required for the physician to provide the 
service), and malpractice expense. 
(2) Clinical laboratory fee schedule (CLFS).  Medically necessary diagnostic and monitoring 
laboratory tests and, with recent legislation, certain preventive and screening tests, are 
reimbursed according to fee schedules differentiated by geographic region and the 
national limitation amounts (NLAs).  Testing and services may be furnished by 
hospital, independent, or physician office laboratories, which bill Medicare directly for 
tests performed.  Technologies covered under the CLFS include diagnostic test kits and 
reagents, devices that analyze test results, and other laboratory equipment essential to 
testing.   
(3) Durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS).  Medicare pays 
for non-implantable DMEPOS through this fee schedule, although some types of 
equipment are paid on a reasonable cost basis, such as dialysis supplies and 
equipment.  While the DMEPOS fee schedule does not directly affect payment for 
laboratory services, cost containment strategies used for DMEPOS are being examined 
to cut costs associated with the CLFS.     
Using Fee Schedules for Laboratory Tests and Services 
Use of the MPFS, CLFS, and other payment methods varies according to test type.  Payment for 
anatomic pathology tests and certain clinical pathology and highly complex molecular or gene-
based tests have two components—a professional component and a technical component.  The 
professional component covers the costs of interpretive consultation when the pathologist 
discusses test results with the patient’s clinician.  The technical component covers specimen 
collection, transport, processing, preparation (e.g., centrifugation, tissue block cutting), analysis 
(e.g., automated, microscopic exam), and storage.   
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While all covered anatomic pathology tests are afforded payment for consultative services, only a 
few clinical pathology and molecular and genetic laboratory tests can be reimbursed for 
consultations.  For anatomic pathology tests, both the professional and technical components are 
paid according to codes on the MPFS.  For clinical pathology, including molecular and gene-based 
testing, both components are paid via codes on the CLFS.    
Medicare Physician Fee Schedule 
The MPFS is a set of physician services and payment rates tied to CPT codes.  A resource-based 
relative value scale is the methodology used to classify and calculate the physician payment rates.  
Physician payments in the fee schedule are calculated by ranking medical services (as defined by 
CPT and other HCPCS codes) according to the relative costs of resources required to provide 
them.  Physicians who treat Medicare patients are paid for their services through the MPFS, 
including those providing inpatient, hospital outpatient, and other ambulatory care.j  This 
includes pathologists associated with laboratory tests and services. 
Payment rate calculations involve several steps.  First, for each CPT code, CMS assigns a relative 
valuek that is weighted based on three factors:  (1) the amount of work required to provide the 
service (e.g., differences in time and intensity of work between a physician exam and surgical 
procedure), (2) expenses related to maintaining a practice (e.g., supplies, staff), and (3) malpractice 
liability insurance costs.  Each factor’s relative value is the national average determined through 
periodic national surveys sponsored by CMS.l  Second, the relative values given to each factor are 
adjusted for geographic differences in input prices.  Separate geographic practice cost indexes are 
used for this purpose.  Third, the sum of the relative values (of the three factors) is multiplied by 
the standard dollar amount (the fee schedule’s conversion factor) to arrive at the payment amount 
for a particular service.74   
Unlike the CLFS, the MPFS is updated regularly.  The relative values are updated every five years 
at a minimum.  The conversion factor updates payments for physician’s services annually 
according to a formula-based sustainable growth rate (SGR).74  The SGR sets a targetm for growth 
in Medicare spending on physician services (per volume growth) that is no greater then growth in 
the national economy, after accounting for percent changes in enrollment in the Medicare 
program.75  The annual update to the MPFS depends on comparison to the target.  If spending is 
below the target, the fee update for the next year is increased.  Conversely, if actual spending 
exceeded the target, the fee update is reduced.  If spending exceeds the target by a large enough 
amount, fees will be cut for one year, up to a maximum of 7% below the underlying rate of 
inflation.  Since 1995, fee increases have averaged 2.5-3.0%.  
                                                     
j For most physician services, Medicare pays 80% of the MPFS amount and the beneficiary is responsible for the 
remaining 20% as coinsurance.  Additional modifiers may be used to adjust the payment depending on the type of 
service provided, type of clinician providing the service, and whether or not a physician participates in the Medicare 
program or is working in an underserved area.     
k The relative value unit is a unit of measure designed to permit comparison of the amount of resources required to 
perform various provider services by assigning weights to such factors as personnel time, level of skill, and 
sophistication of equipment required to render service.69 
l Payments for physician assistants, nurse practitioners, and nurse midwives also are tied to relative value amounts. 
m Four factors define the target:  (1) long-term trend in U.S. real gross domestic produce per capita; (2) growth in the 
Medicare fee-for-service population; (3) increases in Medicare fees (payment rate, conversion factor); and (4) the 
impact of changes in law and regulation (e.g., additional costs due to expansion of benefits to include more 
screening services).23 
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In recent years, overall growth in Medicare spending on physician services has significantly 
exceeded the SGR target, although growth in spending on laboratory tests during 2000-2004 
(10.8%) was consistent with that of all SGR-covered services (11%).23  Steep physician fee cuts 
were planned for 2003.  However, after strong opposition by physician groups, Congress agreed 
to consecutive, conservative increases of 1.5% for 2004 and 2005.  More recently, the planned cuts 
of 4.4% for 2006 were replaced with a one-year price freeze.  Given the multitude of factors 
affecting Medicare’s sustainability, continued use of the SGR in its present form could result in 
physician fee cuts of 4-5% per year (the result of 2-3% inflation less the 7% penalty, according to 
one analysis.23  However fee cuts of this magnitude have only occurred once before in 2002.  The 
matter of revising the SGR formula remains a central issue pertaining to the MPFS. 
CMS’ last estimate of laboratory practice expenses was reported in 2003.76  The supplemental 
expense data for this estimate was obtained from a survey conducted by CAP of independent 
laboratories reporting physician hours and expenses associated with anatomic pathology.n  The 
survey found that the total practice expenses in anatomic pathology per physician hour at 
independent laboratories averaged $160.50.  Although this amount was substantially higher than 
the all-physician average practice expense per hour and was at the upper end of the distribution 
of practice expenses per hour across all specialties, an objective auditor found that the data 
submitted for the survey met formal CMS requirements for supplemental practice expense data.  
On the basis of its review, the auditor recommended that CMS use these values in its calculation 
of 2004 practice expense relative value units for the 2004 MPFS.  This implies that the costs to 
provide laboratory services are higher than for other medical disciplines.    
Clinical Laboratory Fee Schedule 
Independent laboratories, POLs, and hospital laboratories when functioning as reference 
laboratories (except hospital outpatient services) receive payment for their services through 
prospectively set payment rates.  Payment rates are tied to laboratory services listed in HCPCS.  
The main factors that influence payment include:  (1) prevailing charges; (2) national limitation 
amounts; (3) annual updates; and (4) entry of new technologies.  
Prevailing charges. Medicare pays laboratories directly for services performed in the ambulatory care 
setting through the use of the 56 fee schedules that coincide with geographic areas and designated 
carriers that process claims.  These fee schedule amounts differ from carrier to carrier.  The original 
fee schedules were established by Congress in 1984.  Although the original intent was to move 
toward a single, national fee schedule, efforts to do so have been repealed repeatedly over the years. 
Payments for each laboratory test were set separately for each carrier’s geographic market based 
on a percentage of the prevailing charges for 1983.  Specifically, the 75th percentile of the carrier 
customary charges defined the prevailing charge for a given area.  The payment rate for hospital 
laboratories was set at 62% of the prevailing charge (reduced to 60% in 1987), while the rate for 
independent laboratories and POLs was set at 60% of the prevailing charges.  Because some 
carriers’ charges were significantly lower, the rules also include a provision mandating that all 
laboratories be paid the lower of submitted charges or the fee schedule rate.   
                                                     
n The survey asked respondents to exclude physician hours and expenses related to clinical pathology services. 
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National limitation amounts. Beginning in 1986, Congress established upper limits on laboratory 
payment rates, known as NLAs, at 115% of the median of all carrier rates for each test.  Since their 
institution, NLAs have been reduced seven times, and have remained at 74% of the median for 
the past decade.12  The actual payment paid to laboratories is the lowest of the providers’ charge, 
carrier’s fee schedule amount, or NLA.  Most laboratories are paid at or close to the NLA.   
According to the 2000 IOM report, 85% of all pricing amounts across the 56 carriers and more 
than 1,100 test codes were subject to NLAs in 2000.  Further, these pricing amounts applied to a 
disproportionately greater number of Medicare beneficiaries.  As such, NLAs appeared to 
constrain more than 98% of Medicare’s laboratory spending, making carrier fee schedules and 
provider charges of minimal relevance to Medicare.  Therefore, as noted by the IOM, “in practical 
terms there is now a de facto single fee schedule.”4  This constrained fee schedule remains largely 
stagnant, falling behind price increases applying to other elements of health care in the U.S.   
An exception to the NLA determination was made in the Benefits Improvement and Protection 
Act of 2000.  Congress approved setting the NLA at 100% of the national median for tests for 
which the cap was set on or after January 1, 2001.6  To date, CMS has applied this provision to 12 
diagnostic and screening codes associated with Pap tests. 
Fee updates.  In 1984, the initial CLFS included a mechanism for annual inflation adjustments 
consistent with the Consumer Price Index (CPI) for all urban consumers, determined by OMB.  
However, after a few years, the updates were reduced to a rate less than the CPI or zero, then 
eventually eliminated altogether.4  Following an update in 1997, payment rates for laboratory tests 
were frozen from 1998 to 2002, and a modest 1.1% inflation update was provided in 2003.  The 
MMA of 2003 cancelled a scheduled 2.6% update for 2006 and enacted another five-year freezeo 
for 2004 through 2008.6  A longitudinal comparison of the fee updates for laboratory and other 
services are provided in Table 8.1.  This comparison indicates that the 1995-2007 cumulative and 
average increases for the CLFS were 6.4% and 0.48% as compared to significantly higher increases 
for all other updates indexes, including 39.4% (2.6%) for CPI-U, 66.3% (4.0%) for CPI-U Medicare, 
48.6% (3.1%) for the Medicare inpatient hospital basket, 28.5% (3.2%) for Medicare outpatient 
hospital care, and 42.3% (2.8%) for the MPFS.  
New technologies.  For newly developed tests considered to be similar to existing tests, CMS 
assigns a payment rate based on the rates of the similar existing tests, a process known as “cross-
walking.”12  If a test is considered to be a truly novel or breakthrough technology for which there 
is no existing similar test, CMS relies on carriers to independently set rates for the first year of use.  
Carriers assign a new code and use data from manufacturers, other carriers, or other information 
to determine appropriate payment levels for the test along the range of existing payments, a 
process known as “gap-filling.”  In turn, CMS sets the NLA for new technologies at 74% of the 
median rate of all carriers.  (This process and corresponding issues are discussed below in the 
section on coding.)  
                                                     
o The latest five-year freeze (2004-2008) was established under MMA of 2003 as an alternative to a 20% co-payment 
requirement for Medicare beneficiaries, whose likelihood of being collected was considered to be low by many 
laboratories.10 
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Negotiated Contracts and Competitive Bidding 
Increasingly, federal payers are contracting with private payers (local and regional plans) to offer 
coverage to their beneficiaries.  For example, the Medicare Part C plans (Medicare Advantage) are 
private sector health plans approved by Medicare to provide Part A and Part B benefits to 
enrollees who choose this option. 77, 78  Under Part C, Medicare negotiates contracts to make 
monthly payments to the private plans.78  Medicare pays private plans according to the categories 
under which they fall: local plans or regional plans.   
However, in 2006, CMS implemented a system of competitive bidding to set payments for new 
contracts with preferred provider organizations (PPOs) as required under MMA of 2003.  Bidsp 
made by private plans to offer Part A and Part B coverage to Medicare beneficiaries can directly 
influence Medicare payment rates.  That is, payment rates will be based on the relationship 
between the private plan’s bid rate and the benchmark (which is the county-level payment rates 
used to pay for Medicare Part C plans before 2006).q  For plans whose standard bid exceeds the 
benchmark, Medicare’s base payment rate is set equal to the benchmark and enrollees are 
required to pay an additional premium that equals the difference between the bid and the 
benchmark.  For plans whose standard bid is below the benchmark, Medicare’s base payment rate 
is set equal to the standard bid.r  Methodology to determine benchmarks for regional plans is very 
similar, although CMS uses a more complex formula to calculate the benchmark.  (See discussion 
of competitive bidding further along.)
                                                     
p The bid represents the cost to cover an average, or standard, beneficiary; it includes any plan administrative cost 
and profit. 
q County-level payment rates were at least as high as per capita fee-for-service Medicare spending in each county 
before 2006 and were often substantially higher. 
r Medicare also pays a rebate to plans that bid below the benchmark, which is defined by law as 75% of the difference 
between the plan’s bid and its case mix-adjusted benchmark.  The plan is required to return the rebate to 
enrollees through supplemental benefits or by charging lower premiums.  
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Table 8.1:  Medicare pricing updates for certain provider types: percentage changes 
1995-2006 
Sources: a For data from 1995 to 2000, Medicare laboratory payment policy: Now and in the future.  Washington, DC: Institute of Medicine, 2000. 
2006 annual update for clinical laboratory fee schedule and laboratory services subject to reasonable charge payment.  CMS manual system.  Pub. 100-04 Medicare claims processing.  
Baltimore, MD: Centers for Medicare and Medicaid Services, 2005.    
2007 annual update for clinical laboratory fee schedule and laboratory services subject to reasonable charge payment.  CMS manual system.  Pub. 100-04 Medicare claims processing.  
Baltimore, MD: Centers for Medicare and Medicaid Services, 2006.   
b Section 1834(h)(4)(A) of the United States Social Security Act.  Payment for durable medical equipment. 
c Medicare program; Changes to the hospital outpatient prospective payment system and calendar year 2006 payment rates; Final rule.  Federal Register 70, no. 217 (November 2005): 
69516.  Medicare program; Hospital outpatient prospective payment system and CY 2007 payment rates; CY 2007 update to the ambulatory surgical center covered procedures list; Medicare 
administrative contractors; and reporting hospital quality data for FY 2008 inpatient prospective payment system annual payment update program—HCAHPS survey, SCIP, and mortality.  42 
Code of Federal Regulations, parts 410, 416, 419, 421, 485, and 488.    
 d 2005 annual report of the Boards of Trustees of the Federal hospital Insurance and Federal Supplementary Medical Insurance trust funds.  Washington, DC: Boards of Trustees of the 
Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, 2005.  ; 2006 annual report of the Boards of Trustees of the Federal hospital Insurance and Federal 
Supplementary Medical Insurance trust funds.  Washington, DC: Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, 2006.     
2007 annual report of the Boards of Trustees of the Federal hospital Insurance and Federal Supplementary Medical Insurance trust funds.  Washington, DC: Boards of Trustees of the Federal 
Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, 2007.     
Consumer price index—All urban consumers.  Washington, DC: Bureau of Labor Statistics, 2007.   
e Medicare program; Hospital outpatient prospective payment system and CY 2007 payment rates; CY 2007 update to the ambulatory surgical center covered procedures list; Medicare 
administrative contractors; and reporting hospital quality data for FY 2008 inpatient prospective payment system annual payment update program—HCAHPS survey, SCIP, and mortality.  42 
Code of Federal Regulations, parts 410, 416, 419, 421, 485, and 488. Medicare program; Changes to the hospital outpatient prospective payment system and calendar year 2006 payment 
rates. Federal Register 70, no. 217 (November 2005): 68516.  
History of the Medicare clinical laboratory fee schedule.  Washington, DC: Prepared by Avalere Health for the American Clinical Laboratory Association, 2005. 
 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Cum. Avg. 
CPI-U (July)a 2.8% 3.0% 2.2% 1.7% 2.1% 3.7% 2.7% 1.5% 2.1% 3.0% 3.2% 3.2% 2.5% 39.4% 2.6% 
CPI-U Medical 
Care (July)±,b 4.4% 3.6% 2.7% 3.4% 3.5% 4.1% 4.5% 4.9% 3.8% 4.5% 4.2% 4.0% 4.3% 66.3% 4.0% 
Medicare 
Inpatient 
Hospital Mkt. 
Basketc 
3.1% 2.4% 2.0% 2.9% 2.5% 3.6% 4.1% 2.9% 2.95% 3.4% 3.3% 3.7% 3.4% 48.6% 3.1% 
Outpatient 
Hospitald Cost-based system – no defined updates 3.6% 4.1% 2.9% 2.95% 3.4% 3.3% 2.2% 3.0% 28.5% 3.2% 
Physician 
Updatee 7.5% 0.8% 0.6% 2.3% 2.3% 5.5% 4.8% -4.8% 1.7% 1.5% 1.5% 0.2% 0.0% 42.3% 2.8% 
Actual CLFS 
Updatef 0.0% 2.9% 2.3% 0.0% 0.0% 0.0% 0.0% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0% 6.4% 0.48% 
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Medicaid Payment Methodologies 
In general, Medicaid payment rates are determined by individual states; however, payment for 
laboratory services may not be set higher than the Medicare NLA.  According to the Kaiser 
Family Foundation’s online Medicaid benefits database, 49 states use a fee-for-service payment 
methodology to pay for laboratory services and one state (Alabama) uses a reasonable charge 
methodology.79  Specific data indicate that nine states use the NLA as the payment rate, two states 
use a percentage of the NLA as the payment rate, and other states use some combination of these 
calculations depending on whether the test is a high or low volume procedure.  Eleven states 
currently require a co-payment for laboratory testing and x-ray services received outside a 
hospital or clinic.  
TRICARE Payment Methodologies 
The MHS provides direct care to beneficiaries and allows them to choose an option to receive care 
from civilian providers.  TRICARE Prime is a managed care option, TRICARE Standard (formerly 
known as CHAMPUS) is a fee-for-service option, and TRICARE Extra is similar to TRICARE 
Standard but offers discounts when beneficiaries use network providers.80, 81  TRICARE has 
negotiated contracts with approved managed care providers that accept the negotiated rate as 
payment in full.  In 2002, TRICARE issued a request for proposals for new contracts through 
competitive bid.71   
For laboratory services, TRICARE pays either the rate on the Medicare CLFS or the contract rate 
negotiated by HMOs and PPOs, whichever is lower.s,82  Three regional fiscal intermediaries have 
been contracted to administer payments for services accrued by TRICARE beneficiaries at non-
military health care facilities.83   
Payment and contract-related information could not be obtained for the Veterans Health 
Administration. 
Private Sector Payment Methodologies 
Private payers often use Medicare’s MPFS and CLFS for setting their own payment rates.  For 
example, a payer may pay a multiple or percentage of the rate designated for a CPT or other 
HCPCS code on the Medicare fee schedule (e.g., multiple of 1.2=120% or 80% of the CLFS).  
Private insurance companies also may use other methods to determine payment rates, such as a 
percentage of the laboratory’s actual charges (e.g., an 80% payment for a laboratory charge of $100 
for a test) or predetermined rates for services negotiated via contracts with employers or 
laboratories participating in their network.  Private payers also may negotiate rates with 
employers or participating laboratories, that become contractually binding.39  Unlike Medicare’s 
fee schedule, which is publicly available, data on payment rates and methodologies used by 
private payers are generally not publicly available.   
In addition to Medicare business, private sector payers also negotiate contracts independently with 
clinical laboratories.  Two such contracts were awarded recently.  In October 2006, United 
                                                     
s TRICARE uses an adjustment factor equal to the ratio of the local average charge (standardized for the distribution 
of clinical laboratory services) to the national average charge for all laboratory services during the base period to 
establish laboratory service local maximum allowable charges.  
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Healthcare awarded an exclusive ten-year managed care contract to Laboratory Corporation of 
America (LabCorp) worth an estimated $3 billion.84  Along with providing laboratory services to 
United’s 28 million members, LabCorp is obligated to develop a series of laboratory networkst in 
selected regions of the country.6  The goal of the contract was to cut a minimum of 15% to 20% off 
United’s over $2 billion per year laboratory testing expenses (including clinical and anatomic 
pathology outpatient and outreach testing.)  Also at that time, Aetna awarded an exclusive contract 
to Quest Diagnostics.  While the financial details of the contracts are not available, a news article 
quoted laboratory industry professionals who speculated that these contracts provide the insurance 
companies with testing services at costs that are as much as 45%–55% less than what Medicare pays 
for the tests.85, 86 
Outstanding Issues with the Current Payment Systems 
The 2000 IOM report, the 2005 report prepared by The Lewin Group, and others have concluded 
that the Medicare payment policy for clinical laboratory services is outdated and inadequate, and 
could inhibit beneficiary access and stifle innovation in testing technology.4, 10, 87, 88  The IOM 
Committee on the Medicare’s Payment Methodology for Clinical Laboratory Services evaluated 
the current methodology against five desirable goals of a payment system: 
 Beneficiary access to services on a timely basis 
 Flexibility to promptly recognize and determine fair payment for new technologies 
 Transparency in processes for setting payment policies and amounts that are 
understandable and open to input from the public and providers 
 Value that reflects efficient and appropriate use of laboratory services to support 
positive health outcomes and quality of care, and eliminate fraud and abuse 
 Administrative simplicity and efficiency of the system for the provider, payer, and patient4 
The IOM committee found significant shortfalls toward all of these goals except beneficiary 
access.  However, other experts, including some in government, assert that access remains limited 
for screening purposes and nonexistent for predictive purposes.35, 47  The IOM committee 
developed 12 recommendations to begin redesigning the current methodology toward a more 
rational approach for attaining the five goals.  Only one of the recommendations has been 
implemented since publication of the IOM report in 2000—improved transparency in the 
participation of stakeholders in annual meetings of the CMS Council on Technology and 
Innovation to assess the relationship between current CPT codes on the fee schedule and new 
testing technologies.89  
Multiple Fee Schedules Add to Administrative Burden and Result in Payment 
Inconsistencies 
The complexity and inefficiency resulting from use of 56 different fee schedules was cited as a 
major problem in the 2000 IOM report.  The administrative value of the original fee schedule 
system has been greatly diminished since many of the individual test fees on the schedules are 
now close to the NLA.4  Except for national coverage determinations, the use of different fee 
                                                     
t LabCorp will reimburse United Healthcare $200 million for the first three years of the contract for transition costs 
related to developing the expanded network in certain local markets. 
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schedules and corresponding carrier processes for coverage determinations contributes to 
administrative burden and inefficiencies for all parties involved.   
Because the original allowable payments set in 1983 were not linked to laboratories’ relative costs 
associated with performing tests or adjusted for inflation, some fees are most likely low relative to 
costs while others may be high.10  Such payment variations are arbitrary, and payment disparities 
for new tests that are integrated into the existing system often are compounded by other pre-
existing variations.  For tests where there is not convergence with the NLA (an estimated 25-30% 
of payments), wide variations in rates among carriers add to the challenges of setting appropriate 
payment levels.90  Variations in 2007 fee schedule payments for the top 15 clinical laboratory 
procedures (by allowable charges) are listed in Table 8.2.  Payment variations are as high as 40% 
for complete blood count and white blood cell count tests and 54% for a urine culture.90   
Based on principles of inherent reasonableness, Congressu gave CMS the authority to modify 
payment levels for Part B services it considered grossly inappropriate (excessive or deficient) by 
as much as 15% annually without using public notice and comment procedures.10  To date, CMS 
has not employed this authority.  The authority notwithstanding, this method of payment 
adjustment may be impractical, especially as the number of laboratory tests on the market 
continues to increase.   
                                                     
u CMS was given this authority under the Balanced Budget Act of 1997. 
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Table 8.2:  Variations across the Medicare Carrier Fee Schedules for the 
Top 15 Laboratory Tests Ranked by Allowable Charges 
2006 
Ranked by 
Total 
Allowed 
Charges in 
2006 
 
HCPCS 
Code 
 
Short Description 
 
NLA 
 
2006 
Mid-
Point 
 
Minimum 
 
Maximum 
 
$ 
Difference 
 
% 
Difference 
1 85025 Complete CBC w/auto diff WBC $10.86 $14.68 $6.50 $10.86 $4.36 40% 
2 84443 
Assay thyroid 
stimulating 
hormone 
$23.47 $31.72 $21.98 $23.47 $1.49 6% 
3 80061 Lipid panel $0.00 $0.00 $13.69 $18.72 $5.03 27% 
4 80053 Comprehensive metabolic panel $14.77 $19.96 $11.74 $14.77 $3.03 21% 
5 36415 Routine venipuncture $0.00 $3.00 $3.00 $3.00 $0.00 0% 
6 83036 Glycosylated hemoglobin test $13.56 $18.33 $9.77 $13.56 $3.79 28% 
7 83970 Assay of parathormone $57.67 $77.93 $57.67 $57.67 $0.00 0% 
8 85610 Prothrombin time $5.49 $7.42 $4.44 $5.49 $1.05 19% 
9 80048 Basic metabolic panel $11.83 $15.98 $8.93 $11.83 $2.90 25% 
10 84153 Assay of PSA, total $25.70 $34.73 $20.28 $25.70 $5.42 21% 
11 82728 Assay of ferritin $19.03 $25.72 $12.22 $19.03 $6.81 36% 
12 G0103 PSA screening $25.70 $34.73 $20.28 $25.70 $5.42 21% 
13 87086 Urine culture/ colony count $11.28 $15.24 $5.24 $11.28 $6.04 54% 
14 82607 Vitamin B-12 $21.06 $28.46 $14.56 $21.06 $6.50 31% 
15 83550 Iron binding test $12.21 $16.50 $7.58 $12.21 $4.63 38% 
Source: List of top 100 lab procedures by carrier in descending order by allowed charges.  From the 2006 BESS procedure data 
completed year. Baltimore, MD: Centers for Medicare and Medicaid Services, 2007. 
Clinical diagnostic laboratory fee schedule, 2006. Baltimore, MD: Centers for Medicare and Medicaid Services, 2007.  History of the 
clinical laboratory fee schedule. Washington DC: Prepared by Avalere Health for American Clinical Laboratory Association, 2005.   
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Insufficient Research on Alternatives to the CLFS 
In 2000, the IOM committee recommended replacement of the CLFS with a single national fee 
schedule based on a methodology similar to that of the MPFS.  The building blocks for this system 
would be a relative value scale; adjustments for laboratory, beneficiary, or other characteristics, 
including geographic location; a dollar conversion factor; and periodic updates.  On an interim 
basis, relative value payments could be calculated using the current NLA.4  This would provide 
time for more rigorous cost-based analyses of alternative methods for gathering data to be used in 
the calculation of the relative values.  The committee identified four approaches worthy of further 
study by CMS: 
 Microcosting studies to determine costs of individual procedures in order to set both the 
relative value and the conversion factor 
 Competitive bidding demonstration project to set the relative value (but not the 
conversion factor) 
 Negotiated fee demonstration project to set both the relative value and the conversion 
factor 
 Analysis of charges to set the relative value (but not the conversion factor)91 
Among these approaches, negotiated rulemaking has proven to be a successful model for 
updating the physician and ambulance fee schedules.10  Each alternative offers certain advantages 
and disadvantages and may have varied implications for the laboratory medicine sector.   Since 
publication of the IOM report, one study of a charge-based relative value payment system has 
been completed and plans for the competitive bidding demonstration project are underway 
(following a three-year negotiation of terms with stakeholders).  Both of these studies are 
discussed in greater detail below. 
Even though some of the proposed studies have not been completed, many stakeholders contend 
that an entirely new methodology is needed rather than conversion of the current system to one 
based on relative value.  Among potential alternative approaches are payment based on evidence, 
test complexity, episodes of care, and cost-effectiveness.       
Study of charge-based relative value 
In 2002, CMS funded a preliminary study that examined the use of charge data to determine relative 
values of laboratory tests and compared payment levels across several hypothetical fee schedules in 
selected carrier markets.  All charge-based relative values (CBRV) also were compared to NLA-
based relative values.  Although it was not a systematic effort to evaluate relative values for 
laboratory tests, this analysis found that payments for many tests would change under a charge-
based approach, including some that would increase or decrease dramatically.  A large number of 
outliers resulted from the comparison of charge-based and NLA-based relative values.  Calculations 
of standard deviations indicated that payment for outlier procedures would either decrease by at 
least 44% or increase by at least 82% (assuming a constant conversion factor) when a CBRV 
approach was used compared to the NLA approach.91  Further analysis revealed that low-volume 
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procedures accounted for a disproportionate share of outliers.v  In addition, the study found that 
there would be relatively little redistribution across procedure classes.  However, at the level of the 
individual procedure, differences would be significant for certain tests.w,91   
Using a CBRV methodology offers advantages.  Since it is based on available claims data, it is 
relatively inexpensive and administratively straightforward.  Supporters of this approach contend 
that the correlation between charge data and costs is valid.  In addition, CBRVs provide an 
automatic and timely methodology for accommodating the need to set payments for new tests 
and for updating payments on a regular basis.   
The CBRV approach has a few weaknesses that would have to be resolved prior to adoption.  First, 
CBRVs would not help to set payment rates for automated test panels, which are currently bundled.  
In the current system, automated test panels are paid based on the number of tests performed, the 
rationale being that the marginal cost of performing an additional test is less than the average cost of 
the set of tests.  The methodology used in this study assumed that the charges associated with a test 
are independent of other tests.  If submitted charges also reflect bundling, then the CBRV 
methodology could be applied, in principle.  Second, because there are limited data on relative costs 
to compare CBRVs, it was not possible to determine whether the CBRVs provide a good measure of 
the relative costs.  The investigators suggested the use of microcosting studies for this purpose. 
Third, this study did not examine how to set payment rates for new technologies.  Further, use of a 
CBRV methodology would require adequate provisions to control overcharging.      
Competitive Bidding Demonstration Project 
Another CMS study to assess payment alternatives involves a competitive bidding 
demonstration.  Competitive bidding refers to cost containment mechanisms whereby providers 
of a service or product submit price bids to a purchaser (e.g., Medicare).  Based on predetermined 
criteria and the proposed bids, the purchaser selects a winner or group of winners that will 
provide the services or products at a set price for a set period of time.  The goal of competitive 
bidding is to secure a set of prices that reflect the cost of efficient production, including a normal 
profit.4  A core assumption of competitive bidding is that competitors will reveal the minimum 
price at which a sale is acceptable, obviating the need for extensive data collection.  The approach 
of competitive bidding has provoked significant controversy among stakeholders.  While 
government payers generally have advocated it, providers, patient groups, and other 
stakeholders have opposed it. 
Since the mid-1980s, the Medicare program has attempted to implement competitive bidding 
demonstrations for payment of clinical laboratory services, health plans (Part C), drugs and 
biologics (Part B, e.g., for end-stage renal disease), and DMEPOS (Part B).92  Only the latter two 
have been implemented thus far.  Laboratory industry and provider opposition to competitive 
bidding for outpatient clinical laboratory services helped to persuade Congress to halt 
implementation of any of these demonstrations.  Similarly, there were four attempts to conduct 
competitive bidding demonstrations for Part C services; Congress and the courts intervened and 
                                                     
v CBRVs for independent laboratories were significantly different than CBRVs calculated for POLs, and the CBRVs for 
five of the ten CMS regions included in the study differed considerably from the CBRVs calculated for the nation as 
a whole. 
w Charge-based payment would be at least 33% lower than the NLA-based payment for 15% of procedures, and it 
would be at least 33% higher than the NLA-based payment for 28% of procedures.91   
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the demonstrations were not initiated.93  However, as stated earlier, competitive bidding was 
implemented in 2006 to set payments rates for new regional PPOs under Part C.  In addition, 
competitive bidding is now used by the Federal Employee Health Benefits program and 
TRICARE.  
CMS is proceeding with the competitive bidding demonstration project for laboratory services.  The 
attractiveness of competitive bidding derives from its potential for substantial savings to the health 
system.  By limiting existing firms’ market power, competitive bidding could encourage efficiency, 
innovation, and lower costs.  The competitive bidding demonstration project (1999-2002) for 
DMEPOS reportedly reduced Medicare payments by $7.5 million and reduced beneficiary 
payments by $1.9 million without a reduction in access (aggregate savings of nearly 20%).94, 95  
Supporters expect substantially higher savings for laboratory services, estimated at $1.43 billion 
over the 2007 to 2011 period (if a national competitive bidding program was implemented).96  
Many experts believe that overpayment for laboratory services originated in the late 1980s, when 
the fee schedule was established using payment rates provided by clinicians that had marked up 
the real cost of the test and kept the difference.  Thus, current prices on the fee schedule have no 
substantial relationship to actual costs.86  The IOM recommended a demonstration project in 
competitive bidding to gather information about needs for administrative resources, management 
at the local level, and impact on beneficiaries and providers.4  Congress included a provision in 
MMA of 2003 authorizing a competitive bidding demonstration project for clinical laboratory 
services that would otherwise be paid under Medicare Part B fee schedule.97  Congress awarded a 
task order contract in 2004 to initiate the demonstration.  The demonstration project may provide 
a more realistic assessment that can be used to identify those tests that are relatively expensive to 
produce and those that are inexpensive.  In addition, the data could be used to establish an initial 
set of relative values for a new payment methodology.  Whether CMS will use the data to develop 
a relative value-based payment methodology or as the pricing mechanism outright is unclear.   
Along with these strengths, the IOM Committee examined previous assessments of competitive 
bidding methodology and expert opinion and identified certain weaknesses of this approach 
when initiated via exclusive contracts.  Specifically, competitive bidding initiatives that rely on 
exclusive or selective contracting allow only those firms submitting winning bids to participate; 
losing firms are barred from receiving any payment from these contracts during the time of the 
procurement.4  Such arrangements could have significant impact on the financial health of 
excluded laboratories and the structure of the industry as well as disproportionately disadvantage 
certain segments of the market.    
CMS will include the 358 HCPCS codes that represented approximately 99% of Medicare laboratory 
testing by volume and payment in the demonstration project.  However, in terms of other 
parameters, the CMS contractor developed a highly exclusive model as outlined in Box 8.3.   
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Box 8.3:  Design of the Competitive Bidding Demonstration Project for Clinical Laboratory Services 
• The demonstration project will use two metropolitan statistical areas (MSAs) to define demonstration sites, and 
cover all tests paid under Medicare except Pap tests, colorectal cancer screening tests, and new tests added to 
the CLFS during the demonstration.  
• Independent, hospital, and physician office laboratories with $100,000 or more in annual Medicare Part B 
payments for nonpatient services will be required to participate in the demonstration, though they do not need 
to bid on coverage of the entire MSA.* Those that do not submit a bid will be barred from receiving any 
Medicare Part B payments for the duration of the project. 
• A laboratory’s bids for individual tests will be weighted according to expected demonstration volume and 
summed to form a single composite bid. The composite bids will be organized from lowest to highest and, along 
with unspecified criteria, a “pivotal” composite bid will determine the winners and losers.   
• CMS will use the pivotal bids to set and freeze payment rates for the three years of the project. Laboratories 
with a composite bid equal to or lower than the pivotal bid will be winners. 
• Laboratories with a composite bid higher than the pivotal bid will be losers, and will be barred from receiving 
any Medicare Part B payments for laboratory services for three years.  
• To ensure quality, CMS will rely on winning laboratories’ compliance with CLIA regulations, PT data, and 
reporting of data on standardized measures of turnaround time, log-in error rates, and physician satisfaction. 
TAT measures include: (1) total TAT; (2) transport TAT; (3) processing turnaround time; (4) total turnaround 
time for statim (STAT) testing; (5) reporting TAT for critical values; (6) reporting TAT for public health disease 
notification.  CMS also will review complaints received through a toll-free hotline for the demonstration. 
* POLs and hospital outpatient testing are exempt, except where they function as an independent reference laboratory 
earning Medicare payments of $100,000 or more per year. 
Source: Report to Congress—Initial report on the Medicare Clinical Laboratory Competitive Bidding Demonstration. Baltimore, 
MD: Centers for Medicare and Medicaid Services, 2006.   
 
 
According to 1999 data, laboratories derive about 29% of their income from Medicare Part B 
payments.4  Laboratories that are not selected in the competitive bidding process likely would be 
subject to steep, immediate cuts in revenue for three years.  Industry stakeholders contend that, 
without the ability to offer laboratory services to Medicare beneficiaries, many local area 
laboratories may have to close their business.  Stakeholders have sought to revise the exclusivity 
provision, allowing all interested CLIA-certified laboratories to continue providing services for 
Medicare beneficiaries during the demonstration at the amount accepted as the winning bid.98-100 
As another alternative, stakeholders have suggested that CMS simply indicate the percentage of 
cost reductions needed for the Medicare program.  However, CMS has maintained the initial 
framework that bars losing laboratories from any Medicare payments. 
Several other prominent issues with the current framework have been voiced by stakeholders.  In 
particular, industry representatives have stated that the $100,000 threshold is insufficient to 
protect many laboratories that qualify as small businesses, such as those performing low volume, 
highly complex testing as a reference laboratory or those that grow their business beyond the 
threshold.98-100  For example, if a laboratory earns $100,000 or less at the time of the initiation of the 
competitive bid and elects not to participate, that laboratory will be penalized if, at any time 
during the demonstration, Medicare payments exceed the $100,000 threshold.101  The penalty is 
the forfeiture of any further Part B Medicare payments for the remainder of the demonstration.  
The demonstrations likely would force approximately 90% of laboratories in the designated areas 
to participate.  Many small laboratories that earn $1-2 million per year have expressed that they 
Laboratory Medicine: A National Status Report Chapter VIII – Reimbursement for Laboratory Medicine 
 
May 2008 339 
cannot afford to lose Medicare payments.102  With more hospital laboratories expanding outreach 
testing programs, hospitals also are concerned about how the demonstration would affect their 
financial status.  Laboratories that serve as subcontractors or reference laboratories to other 
laboratories that win the competitive bid also would be affected by the current design.    
Supporters of the competitive bidding proposal disagree as to the financial effect on local 
laboratories.  Several contractors (i.e., winners) will be selected in each of the metropolitan 
statistical areas, but being named a contractor does not guarantee business.  Physicians can choose 
among several laboratories; thus, even the winning laboratories must compete for business.  In 
theory, competition would increase overall quality of laboratory services.  Also, if physicians 
choose to obtain services from multiple laboratories, this may decrease the potential for loss of 
Medicare market share among the winners.103  However, it is not yet known whether these market 
effects will occur, and loss of market share may be sizable.   
The extent to which competitive bidding of laboratory services affects beneficiaries and providers 
also is unknown.  Because the project confines the provider network, beneficiaries may be required 
to travel long distances to obtain even basic testing, thereby reducing access to necessary services.  A 
small group of winning laboratories may not be able to accommodate all Medicare beneficiaries in 
every setting in which laboratory services are needed.  Such restrictions could have a detrimental 
impact on continuity of patient care and, perhaps, health outcomes.104, 105  Potential problems with 
the current framework could be accentuated in rural areas and for specialized patient populations.  
In addition, patient preferences and patient satisfaction also were not incorporated into the 
competitive bidding process or in its standardized measures for reporting on quality.   
A laboratory industry stakeholder group, the Clinical Laboratory Coalition, has been seeking 
legislative action to address the competitive bidding framework.  The House Committee on Small 
Business held a hearing on this matter in July 2007.  Shortly thereafter, Representative Nydia M. 
Velázquez (D-NY) introduced H.R. 3453 (110th Congress), The Community Clinical Laboratory 
Fairness in Competition Act of 2007.  The Senate version of the bill, S.2099, the Protecting Access 
to Clinical Laboratory Services Act of 2007, was introduced by Senators Ken Salazer (D-CO) and 
Pat Roberts (R-KS) in September 2007.       
 Additional Studies Needed 
The IOM proposed microcosting studies using standard accounting practices to collect data on 
direct costs and develop an appropriate basis for determining indirect costs.4  Microcosting (also 
called activity-based costing) attempts to allocate itemized costs by identifying the components of 
each individual cost.106  In the context of the clinical laboratory, microcosting determines the total 
direct labor and supply costs that are required to produce a laboratory test and can serve as the 
starting point to determine the total cost and ultimately the price of a test.107  Data acquisition 
through microcosting studies is critical to the development of a relative value-based payment 
system, and could contribute to periodic evaluations of payment appropriateness.   
For its report, the IOM committee used a very small resource-costing study to gain an 
understanding of service level costs.  However, the study surveyors obtained only general 
information.55  The lack of standard cost accounting systems for the laboratory’s costs separate 
from the hospital and physician’s office, and the general reluctance of laboratories to reveal 
sensitive, proprietary cost information may be challenges to conducting these studies.  New 
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software programs are making such analyses significantly and, as a result, an increasing number 
of health care organizations, including clinical laboratories, are incorporating microcosting into 
their overall management strategies. 
A major advantage of microcosting is that it avoids or minimizes distortions in product costing 
resulting from subjective allocations of indirect costs and thus generates useful data on how 
money is being spent and whether an organization or entity is operating cost-effectively.108  
Findings derived from microcosting studies could provide insight into whether public and 
private payers are paying appropriate prices for particular laboratory tests and could be used to 
educate clinicians on the true cost of ordering laboratory tests.4, 109  Because of their level of detail 
and specificity, microcosting studies also allow others to see how well an analysis matches their 
own situation, even where patterns of care may differ.110  The investment in carefully designed 
microcosting studies, along with a standardized accounting mechanism, could yield the type of 
high-quality data needed to redesign the payment methodology.   
Reducing Fraud and Abuse 
As in other sectors of health care, laboratory medicine is subject to fraud and abuse in areas 
ranging from defrauding of payers to billing methods that combine legitimate claim information 
with falsified information.111  Examples of common types of fraud in laboratory medicine include 
billing for services that were not performed, ordered or needed; up-coding;x unbundling;y 
duplicate billing; and falsifying diagnoses.   
Several laws and regulations have been applied to reduce fraud and abuse in clinical laboratories.  
Under the False Claims Act Amendments of 1986 (Public Law 99-562, 100 Statute 3153), any 
person who knowingly presents or causes to be presented false claims for payment of 
government funds is subject to a civil penalty between $5,000 and $10,000 plus three times the 
amount of damages sustained by the government because of the act of that person.z,113  This act 
has been the primary means by which the DHHS OIG and Federal Bureau of Investigation have 
investigated fraudulent clinical laboratory billing practices.6  The Health Care Fraud and Abuse 
Control Program, established by the Health Insurance Portability and Accountability Act of 1996, 
is intended to coordinate federal, state, and local law enforcement efforts to prevent and disclose 
health care fraud and abuse, including in laboratory services.114    
The DHHS OIG has been involved in many actions and projects intended to curb clinical laboratory 
fraud and abuse.  For example, Project LabScam was the first nationwide law enforcement project to 
occur in the medical field and applied to all major independent clinical diagnostic laboratories in the 
U.S.  It arose from information revealed during the investigation that led to the 1992 guilty plea of 
National Health Laboratory and its agreement to repay $111 million.111  The Hospital Outpatient 
Laboratory Project has documented hospital laboratory abuses related to test unbundling, double 
billing of tests, and improper billing of medically unnecessary tests.  With input from medical care 
industries, the OIG has developed model compliance guidelines for laboratories for assisting 
                                                     
x Up-coding, also referred to as up-charging, is the misuse of standardized codes (i.e., increasing the bill by 
exaggerating or falsely representing medical conditions and serves provided) to obtain higher payment than 
legally allowed.112 
y In laboratory medicine, unbundling occurs when a laboratory bills separately for some or all tests that were 
analyzed simultaneously by a single piece of equipment on a single patient specimen.111   
z The False Claims Act does not encompass tax fraud. 
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development of effective internal controls to detect and prevent fraud, abuse, and waste.115  Among 
other aspects, the compliance plan includes written standards of conduct, policies, and procedures 
that address potential fraud, designation of a chief compliance officer, and a hotline or other means 
by which complaints can be received anonymously. 
Government investigations related to clinical laboratory businesses conducted from 1992 to 2006 
are estimated to have resulted in penalties exceeding $1.727 billion.6  Monetary penalties imposed 
as a result of laboratory fraud and abuse represent a fraction of penalties imposed throughout all 
health care sectors.  In 2005, the federal government won or negotiated an estimated $1.47 billion 
in settlements and judgments pertaining to health care fraud cases and proceedings.116  In 2006, 
state Medicaid fraud control units recovered more than $1.1 billion in court-ordered restitution, 
fines, civil settlements, and penalties and obtained 1,226 convictions.117  These units recovered 
$709 million in 2005.118     
Pod or Condo Laboratories 
Another type of fraud-and-abuse pertaining to laboratory medicine is physician self-referral, which 
is addressed by the Stark laws.  Enacted under Section 1877 of the Social Security Act, the laws 
prohibit physicians from referring Medicare patients for certain designated health services to an 
entity with which the physician or a member of the physician's immediate family has a financial 
relationship, unless an exception applies.119  When first enacted in 1989, the law applied only to 
clinical laboratory services; however, in 1993 and 1994, Congress expanded application of the law to 
10 other designated health services and financial arrangements involving physicians.  In 2003, 
Congress authorized certain exceptions in which physicians receive non-monetary remuneration 
that is used solely to send and receive electronic prescription information.  Additional clarification 
and exceptions were defined in the phase III provisions of the law published on August 27, 2007.  
However, the final rule did not fully address pathology-related self referrals (discussed below).120  
The potential for clinical laboratory-related fraud and abuse arises from contractual joint ventures 
that enable non-pathologist physicians and other entities to profit from self-referrals of pathology 
services.121  These arrangements are often cited in connection with regulatory changes affecting 
billing of anatomic pathology services as well as a loophole in how Medicare assigns benefits, which 
allows an independent contractor physician or non-physician to reassign Medicare billing privileges 
to a health care entity.121, 122  CMS plans to address these issues in a separate rulemaking.   
Two types of these referral arrangements have arisen:  “pod” or “condo” laboratories and 
referring physician billing arrangements.123  Pod or condo laboratories are established by a 
“manager” in a single office space that subdivides each room or cubicle into a separate, fully 
equipped laboratory.  Each “laboratory” is subleased to a physician group practice. The manager 
hires technologists/scientists and technicians for each laboratory and one pathologist to supervise 
all laboratory staff.  In seeking to be technically in compliance with applicable exceptions to the 
federal self-referral law, the staff rotate from one laboratory to the next, reviewing each group 
practice’s slides.  Each physician practice group compensates the laboratory at a discounted rate 
for each slide reviewed, but bill payers for the entire pathology service.  In referring physician 
billing arrangements, a laboratory offers to perform anatomic pathology services for referring 
physicians and bills such services at a discount; the referring physician then marks up the bill 
from the laboratory and bills Medicare.   
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These arrangements can create incentives for physicians involved in these arrangements to order 
more laboratory tests or to perform biopsies and other anatomic pathology procedures that may not 
be necessary, leading to increased and inappropriate utilization.120  Medical decision-making and 
the quality of patient care may also be compromised.124  The potential profits to the test-ordering 
physician are far greater than for clinical laboratory services.  Pod or condo laboratories also may 
violate the anti-kickback statute.  Until the rulemaking on pathology services is completed, CMS has 
emphasized that parties involved in shared arrangements in the same building must comply with 
the in-office ancillary services exception in operation of their business, not just on paper.120     
The proposed 2007 Physician Fee Schedule released by CMS included a series of proposals to 
prevent pod or condo laboratories and other contractual joint ventures.125  CMS chose to wait to 
address the issue in its final fee schedule, stating that it needed more time to study the issues 
involved.  The proposed 2008 fee schedule, published in July 2007, included a series of proposals 
to prevent pod or condo laboratories; however, these proposals differ substantially from those 
outlined in the previous 2006 proposed rule.126  Specifically, the proposed 2007 billing reforms 
address self-referral and reassignment abuses by strengthening anti-markup restrictions on the 
technical component of diagnostic services and by creating new anti-markup restrictions on the 
professional component.  Stakeholders are advocating adoption of these proposed rules.124           
Limitations Based on Volume  
Section 1128(b)(6)(A) of the Social Security Act grants the Secretary of DHHS power to exclude 
from any federal health care program individuals or entities that have submitted bills or requests 
for payments containing charges for items or services substantially in excess of such individuals’ 
or entities’ usual charges for such items or services.127  As such, a supplier or provider submitting 
a claim to Medicare or to a state health care program that contains charges “substantially in 
excess” of its usual charges may be excluded from participating in these programs.128   
In 1990, 1997, and 2003, the OIGaa proposed regulations to provide guidance on the Medicare and 
Medicaid programs’ exclusion authority for submitting claims that contain excessive charges.129  
The 2003 proposed rule stated that individuals and entities (including clinical laboratories) could 
be excluded from participating in federal health care programs if their charges or costs are more 
than 120% of their usual charges or costs.bb   
Several laboratory medicine organizations opposed the rule proposed by OIG.  In June 2007, the 
OIG announced that it would not proceed with the 2003 proposed rule, basing its decision on 
public comments and lack of sufficient information required to establish a fixed benchmark for 
substantially excessive charges or costs that could be applied across the health care sector.130  
Despite its decision not to issue a final rule, OIG expressed concern about disparities in the 
amounts charged to Medicare and Medicaid relative to private payers.cc   
                                                     
aa The Secretary has delegated this authority to the OIG.127  
bb The proposed 2003 rule exempted physicians on the basis that their payment is based on actual costs and is 
updated annually.129  
cc In its decision not to promulgate the 2003 proposed rule, the OIG also stated its continued concern about disparities 
between the amounts charged to Medicare and Medicaid and private payers.130     
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CODING 
Standardized coding systems are used to categorize claims for payment for health care services 
and ensure that they are processed consistently and systematically.131  Coding systems use 
alphanumeric nomenclatures to identify particular health conditions, services, or products.  The 
code assigned to a health condition, service, or product is linked to a payment amount 
reimbursed to providers.  For example, under Medicare, codes are linked to fixed payment 
amounts via fee schedules.  The coding systems that apply to laboratory medicine include CPT 
codes and HCPCS codes for laboratory tests and services and ICD-9-CM codes for diagnoses.132   
The CPT-4, published by the AMA, describes the professional services performed by physicians and 
is widely used as the standard for outpatient and ambulatory care procedural coding and payment.  
CPT codes fall within the larger national HCPCS, which was designed initially to represent services 
provided by physicians and non-physicians to Social Security beneficiaries covered by Medicare, 
currently is used by physicians to report services provided to Medicare and Medicaid patients.10, 132  
In 2004, there were approximately 1,000 clinical laboratory and pathology codes listed in the 80000-
89399 CPT-4 code series.10  The process for updating these coding systems varies by organization.  
The ICD is a product of the World Health Organization; however, CDC’s National Center for 
Health Statistics in collaboration with other U.S. government agencies has developed a clinical 
modification (ICD-9-CM) for use in the American health system.  It is used to describe illnesses, 
conditions, and injuries of people seeking medical services in the inpatient departments of 
hospitals.35  Box 8.4 depicts the main characteristics of these coding systems. 
The CMS HCPCS Workgroup comprises representatives of CMS, the state Medicaid agencies, and 
the Statistical Analysis Durable Medical Equipment Regional Carrier.133  The workgroup is 
responsible for considering each request for a change to a HCPCS level II national code at 
regularly scheduled monthly meetings.dd   
The CPT Editorial Panel, which consists of 17 members, 11 of whom are physicians nominated by 
the National Medical Specialty Societies and approved by the AMA Board of Trustees, is 
responsible for revising, updating, and modifying the CPT codes.ee,134  The Editorial Panel is 
supported by the CPT Advisory Committee, primarily comprising physicians nominated by the 
national medical specialty societies represented in the AMA House of Delegates.  Applications for 
new CPT codes are reviewed quarterly by the Editorial Panel and must be submitted by a specific 
date each year.  Because CPT coding changes are made effective only once each year for Category 
I codes and twice per year for Category II and III codes, the review process for CPT coding 
applications requires at least 8-15 months.10  Additional delays of 6-28 months can occur if the 
medical specialty societies and other reviewers do not reach a consensus regarding coding 
decisions within the appointed timeframe.   
The AMA has recently made efforts to increase the transparency of the coding process.  In order 
to provide public stakeholders more time to comment on coding changes, the public release of 
proposed changes was moved up from the fall to the summer of each year.10  The AMA also 
                                                     
dd Prior to 2006, the National Panel was responsible for final coding decisions.133 
ee The seven other members of the CPT Editorial Panel consist of four physicians nominated from the Blue Cross Blue 
Shield Association, America’s Health Insurance Plans, AHA, and CMS; one performance measures representative, 
and two members of the CPT Health Care Professionals Advisory Committee (including one at-large member).134   
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established the Pathology Coding Caucus to allow non-physician stakeholders to play a larger 
role in the development of CPT laboratory and pathology codes and to review code revision 
proposals.ff,35  The group reviews proposed new codes, suggests revisions to existing codes, and 
develops consensus recommendations. 
Box 8.4:  Description of Payment Coding Systems 
HCPCS 
• Developed by HCFA (now CMS) 
• Originally designed to represent physician and non-physician services provided to Medicare beneficiaries 
• Federal government currently requires physicians to use HCPCS codes to report services provided to 
Medicare and Medicaid patients 
Level I 
• Comprises CPT codes 
• Used to report hospital visits, surgical procedures, radiological procedures, supervisory services, and 
other medical services  
Level II 
• Known as national codes 
• Developed by CMS to report medical services that are not covered in CPT 
CPT-4 
• Published and maintained by the AMA 
• System for describing and reporting physician services in an outpatient setting 
• Also used for planning outpatient services, benchmarking, assessing quality of patient services 
Category I 
• Codes for evaluation and management, anesthesia, surgery, radiology, pathology and laboratory, and 
medicine 
Category II 
• Supplementary tracking codes for use in performance assessment and QI 
Category III 
• Temporary codes representing emerging medical technologies, services, procedures not yet approved by 
FDA and not otherwise covered by CPT codes 
Modifiers 
• Supplementary codes that can be reported along with Category I codes to report additional information 
about unusual circumstances under which a procedure was performed  
• Meant to support the medical necessity of procedures that otherwise might not qualify for payment 
ICD-9-CM 
• Based on classification system developed and maintained by WHO 
• Clinical modification published by CDC’s National Center for Health Statistics 
• CMS, private payers require physicians and other medical providers to report ICD-9-CM diagnostic codes on 
almost all payment claims 
Diagnostic Codes 
• Represent the reason why a patient is receiving medical care 
Supplementary Codes 
• Additional information about the patient and/or circumstances surrounding the patient’s illness or injury 
Source: Smith GI.  Basic CPT/HCPCS coding.  2006 Edition.  Chicago, IL: American Health Information Management 
Association, 2006. 
 
                                                     
ff The Pathology Coding Caucus consists of representatives from the AMA, Advanced Medical Technology Association, 
American Association for Clinical Chemistry, American Clinical Laboratory Association, ASCP, American Society of 
Cytopathology, CAP, National Association of Medical Examiners, U.S. and Canadian Academy of Pathology, 
CLMA, ASM, and American Association of Bioanalysts.35 
Laboratory Medicine: A National Status Report Chapter VIII – Reimbursement for Laboratory Medicine 
 
May 2008 345 
Inadequate Mechanism for Adding New Tests 
As noted above, CMS incorporates new CPT codes for laboratory tests into the CLFS and 
establishes payment levels for them using two primary methods:  cross-walking and gap filling.135  
Cross walking is used when a new laboratory test is deemed similar to an existing test, multiple 
existing test codes, or a portion of a test code that already exists.  When a new laboratory test is 
cross-walked, it is assigned the related existing local fee schedule amounts and resulting NLA.  
Gap-filling is used when it is determined that a comparable laboratory test does not exist.  Under 
this method, each Medicare carrier is provided with instructions to determine a payment amount 
for its geographic area(s) to be used for the first year; these carrier-specific amounts are used to 
establish a NLA for subsequent years.  However, gap-filling is rarely used as a payment 
methodology.10  Figure 8.1 depicts the basic payment pathways for gap-filling and cross-walking. 
The process for updating codes applicable to the CLFS has undergone certain significant changes 
over the past several years, some of which have been prompted by concerns that the CLFS is not 
sufficiently subject to stakeholder feedback and that greater opportunity for clinical laboratories 
and diagnostic manufacturers to provide input would increase the accuracy and efficiency of 
complex coding determinations.10  A provision of the Medicare, Medicaid, and State Children’s 
Health Insurance Program Benefits Improvement and Protection Act of 2000 mandated that the 
public be given an opportunity to consult on payment determinations for new clinical laboratory 
tests in a manner similar to the procedures established for implementing coding modifications for 
ICD-9-CM.gg,135  As a result of this and the IOM’s 2001 recommendations, CMS has held a 
“Laboratory Public Meeting” each year since 2002.137  These public meetings, notification of which 
is given in the Federal Register, are intended to allow experts to provide input on the nature of the 
new test codes and for CMS to receive recommendations regarding cross-walking and gap-filling. 
Despite these changes and attempts at greater transparency, the coding system through which 
new laboratory technologies are added remains inadequate, particularly for new and emerging 
laboratory tests such as genetic testing.  CPT codes used for billing genetic tests identify the test 
procedure performed (e.g., reverse transcription), but are not specific to the condition being 
evaluated (unlike codes for most tests which is disease specific).35  Thus, a new genetic test 
performed with existing procedures receives payment under existing codes, rather than under a 
newly assigned CPT code and payment rate.  (Only novel genetic technologies and testing 
procedures are assigned a new Category III CPT code.)    One of the main criticisms in the use of 
CPT codes for genetic tests has been the lack of specificity in the codes that limits the ability of 
payers to make informed claim determinations.   
 
                                                     
gg The ICD-9-CM Coordination and Maintenance Committee, a federal interdepartmental committee co-chaired by CMS 
and the National Center for Health Statistics, is charged with maintaining and updating the ICD-9-CM system.136  
Public meetings for discussion or education and proposed coding changes are held by the committee, presenting an 
opportunity for organizations involved in the coding field, e.g., American Health Information Management 
Association and AHA, as well as physician specialty groups, to voice their opinions on coding matters.  The 
committee ultimately creates recommendations that must be approved by CMS and the National Center for Health 
Statistics.   
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Figure 8.1:  Gap-Filling and Cross-Walking Payment Determination Pathways 
 
Adapted from: The Lewin Group. Outlook for medical technology innovation: Will patients get the care they need?  Report 2: The 
Medicare payment process and patient access to technology. Washington, DC: AdvaMed, 2000. 
CPT code modifiers have been criticized for being too vague to allow health insurance companies 
to make well-informed coverage determinations, leading them to deny coverage or request 
additional information.  The Genetic Test Coding Workgroup, a consortium of genetics and 
laboratory organizations founded by CAP in 2003, proposed a “numeric-alpha” coding section to 
be added to existing 5-digit CPT laboratory codes used for genetic testing.hh,138  The AMA CPT 
Editorial Board adopted these modifiers, which were included in the 2005 CPT Coding Manual.  
This coding modification will not change the rates at which these codes are reimbursed.35     
Many providers who supply medical services to Medicare beneficiaries argue that payment rates do 
not correspond to the cost of a genetic test.35  Testimony provided to SACGHS in 2004 indicated that 
the cost to one academic laboratory in Virginia to perform a genetic test for Fragile X syndrome was 
$255, but was reimbursed only $68 for it.  According to this laboratory, major health plans, 
including both Medicare and Medicaid, reimbursed 60-90% of claims filed for genetic tests.   
In its 2006 report on coverage and payment of genetic tests and services, SACGHS recommended 
that, by 2009, when the freeze on laboratory test payment rates is lifted, DHHS should be ready to 
revise payment rates to reflect the actual cost of genetic testing.35  SACGHS also recommended 
                                                     
hh This coding system includes a numeral that indicates the disease category and a letter that denotes the gene type, 
thereby conveying information about the nature of the test being billed.35  
New Laboratory Tests 
Gap-Fill 
•New and innovative technology 
•1 or more years to obtain new/modified code 
Adjustment 
•CLFS-CPI Update (infrequent) 
Addition of New/Modified CPT Codes 
Payment 
Update 
New Payment Level Assigned 
•Varying state fee schedules 
•CLFS NLA 
Obtain Payment for Existing Code 
•May be associated with new payment 
 
Cross-Walk 
•2nd generation technology replacing older tests 
•Map to existing code(s) 
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that DHHS assess the adequacy of CPT E&M (Category I evaluation and management) codes and 
allow non-physician health providers deemed qualified to provide genetic counseling services 
who are currently billing incident to a physician to use the complete range of CPT E&M codes 
that apply to genetic counseling.       
Need for a Better Coding System 
Some organizations have advocated the replacement of HCPCS, CPT, and ICD-9-CM with the 
ICD 10th revision, Clinical Modification (ICD-10-CM) and ICD 10th revision, Procedure Coding System 
(ICD-10-PCS).ii,140, 141  In contrast to the ICD-9-CM, the ICD-10-PCS includes a unique code for 
each substantially different procedure, expandability to allow new procedures to be easily 
incorporated as unique codes, a multi-axial structure with each code character having the same 
meaning within a specific procedure section and across procedure sections, and a standardized 
terminology in which each term has a unique and specific meaning.  MMA 2003 includes 
language that encouraged the Secretary of DHHS to proceed with developing and promulgating 
rules to adopt ICD-10-CM and ICD-10-PCS.142 
The transition to ICD-10-CM and ICD-10-PCS has been supported by the federal government and 
prominent national health care organizations (e.g., AHA, Federation of American Hospitals, and 
American Health Information Management Association).143  A 2005 study by the RAND 
Corporation estimated that the conversion would cost $425 million to $1,150 million in one-time 
costs, in addition to between $5 million and $40 million per year in lost coder and physician 
productivity over 10 years following conversion.144  Nevertheless, RAND concluded that the 
potential benefits of conversion outweighed costs.  One of the major benefits of conversion to 
ICD-10 would be its ability to more finely differentiate between new and old procedures, 
allowing the value and applicability of new procedures to be more fully realized.  Concerns about 
the high cost of implementation, the magnitude of benefits, and other issues associated with 
implementation have slowed the transition from ICD-9-CM to ICD-10 CM and PCS in the U.S.139      
The current coding system also is inadequate for supporting and enabling implementation of HIT.  
A coding system that provides more accurate, detailed clinical information capable of supporting 
quality measurement and patient safety efforts will enable a smoother, more effective transition to 
EHRs and other electronic storage and transfer of health information.  Widespread adoption of 
EHRs and interoperable information networks depends on classification systems that can 
summarize and report data.142  The capacity to integrate standardized laboratory data into next-
generation clinical practice applications is critical to establishing a national health information 
network.  For example, according to some HIT experts, U.S. efforts to invest in and promote use 
of SNOMED-CT, a comprehensive, multilingual clinical health care terminology developed 
jointly by the National Health Service in England and CAP, will be undermined if the U.S. fails to 
adopt ICD-10-CM and ICD-10-PCS.142, 145  The Health Information Technology Promotion Act of 
2006 (H.R. 4157), passed by the House in July 2006 but not signed into law, called for the 
implementation of the ICD-10 coding system by October 2009.146      
                                                     
ii ICD-10 has been used for mortality classification in the U.S. since 1999 and by health systems in much of the world 
since the mid-1990s.139 
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CONCLUSIONS 
The design and updating of coverage, coding, and payment systems should strive to enable 
patient access to medically necessary care, support delivery of high-quality care, and sustains 
innovation of new technologies.  Further, they should discourage inefficiency, fraud and abuse, 
and non-competitive practices.  However, these systems can pose significant barriers to achieving 
these ends in laboratory testing.  Changing demographics and disease patterns in the population, 
corresponding increases in utilization and expenditures, and attributes of emerging technologies 
are intensifying the challenges to the current laboratory services payment system. 
Medicare is the single largest payer in the country, accounting for 29% of all revenues for 
laboratory services.  All public payers and approximately 67% of private payers use Medicare’s 
payment methodologies as the basis for their own and as a tool for negotiating discounts with 
providers.  As such, suboptimal practices and other shortcomings in the Medicare reimbursement 
system pertaining to laboratory testing affect other public and private sector payers in the U.S. 
health system.   
Key reimbursement challenges to laboratory medicine include the following:  
 Medicare’s statutory restriction of coverage for screening tests and related preventive 
services remains a shortcoming in the scope of benefits for Medicare beneficiaries.  
Adding preventive services to Medicare benefits on a case-by-case basis via the 
legislative route is cumbersome and impedes access to certain proven, beneficial tests.  
Legislation is needed that would expand Medicare benefits to include such preventive 
services that are evidence-based and determined to be reasonable and necessary for 
prevention and detection of illness or disability among Medicare beneficiaries. 
 Continued use of 56 different fee schedules is inefficient and unnecessarily complex.  For 
certain commonly ordered tests, the multiple schedules result in large regional 
variations, while for other tests, NLAs constrain Medicare payment rate variations.   
 There is a notable lack of reliable data on the relationships among historical costs on 
which the CLFS is based, current production costs, and the effects of economies of scale 
and other cost-reducing effects of technological changes. 
 Studies of data-derived methods for evaluating the appropriateness of payment rates 
and for designing of potential new payment systems, such as resource-based relative 
value, microcosting, and negotiated rulemaking, have not been completed.  
 CMS is proceeding with a competitive bidding demonstration project for laboratory 
services, with the expectation of substantial savings.  Supporters of the project believe 
that current prices on the fee schedule have no substantial relationship to actual costs; 
thus competitive bidding may provide information about resources and costs.  However, 
the project model is highly exclusive and could have significant, detrimental effect on 
clinical laboratories that loose in the bidding process since many depend on Medicare 
reimbursement for a sizable portion of their revenues. 
 Despite modest improvements in the transparency, processes for establishing payment 
levels for new laboratory tests, including assignment of new and existing CPT codes to 
tests and related methods of cross-walking and gap-filling, remain archaic and 
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inadequate.  The expansion of genetic testing, including new types of testing technology 
and the use of PGx that links tests to therapies, are placing greater strains on flaws in 
these payment processes.   
 From 1992 to 2006, federal government investigations of clinical laboratory-related fraud 
and abuse resulted in penalties exceeding $1.727 billion.  Current government efforts aim 
to control fraud and abuse arising from contractual joint ventures that enable non-
pathologist physicians and other entities to profit from self-referrals of pathology 
services.  CMS plans to address these issues in a separate rulemaking. 
 Redesign of the current Medicare payment system for laboratory services is needed in 
order to meet the growing scientific, technical, clinical, and economic challenges of the 
U.S. health care system.   
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APPENDIX A 
DESIRABLE CHARACTERISTICS FOR PERFORMANCE MEASURE SELECTION 
CONSIDERED BY IOM, AHRQ, AND OTHER SELECTED GROUPS 
To be selected, the measure should rate highly for: 
Importance: Is the measure important in a clinical sense, important to the general population, 
or important to improve the quality of health care delivery. 
 The health problem addressed by a measure should be a leading cause of death or 
disability or associated with high resource use.  
 A measure must have an impact on health, be tied to national goals, and be 
susceptible to being influenced by the health care delivery system.  
 A measure should be stratified by race, sex, and age. 
Scientifically Sound: This criterion concerns properties of the measure that give it credibility 
in terms of reliability, validity, and explicitness of the evidence base.  
 Reliability means a measure consistently produces the same result when repeated 
within the same population and setting.  
 Validity addresses the question of whether a measure reflects what it is intended to 
measure. 
 The evidence base from which a measure is derived must be explicit—for example, 
randomized controlled trials, case control studies, observational studies, or formal 
consensus processes. 
Usability:  The measure should have been effectively used in the past and have high 
potential for working well with other measures currently in use. This criterion assesses 
whether the measure provides a workable solution for the needs of the health care 
organization. 
Feasibility: This criterion refers to the feasibility of implementing the selected measures by 
examining the existence of measure prototypes, availability of required data across the 
system, cost or burden of measurement on providers, and capacity of data and measures to 
support subgroup analyses. 
 Existence of prototypes means that the measure has already been precisely defines, 
field tested, and applied in a variety of settings, such that it can be used by others in 
a national data set. 
 Data required for the measure should be available across the health system for the 
nation as a whole. The data can be readily collected in the scale and time frame 
required.  
 Cost of measurement should be justified and should not impose an excessive 
burden on the health system or national collection systems. 
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 The measure should support meaningful comparisons across subgroups based on 
population and by health condition.  
Alignment: Optimally, measures should be selected from existing leading measure sets that 
are calculated with the same technical specifications for both the numerator and 
denominator to reduce redundancy and the burden of reporting. 
Comprehensiveness: Measures selected should be part of a set to reflect quality in a 
particular area of care or bundled services of necessary care for a given condition.  
 Each measure in the set should meet the criterion of importance to warrant inclusion.  
 To demonstrate comprehensiveness, the set of measures must address the way the 
care is delivered and the nature of the quality problem involved—underuse, 
misuse, or overuse.1-5 
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APPENDIX B 
COLLEGE OF AMERICAN PATHOLOGISTS QUALITY INDICATORS FOR 
PERFORMANCE MEASUREMENT STUDIED IN THE Q-TRACKS PROGRAM 
AND POSSIBLE ADDITIONAL INDICATORS STUDIES IN THE Q-PROBES 
STUDIES AND OTHER LITERATURE 
Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Structural Measures 
Policies, Procedures, 
and Practices Not studied or developed. 
Laboratories with written guidelines for changing solution 
in tissue processors and water baths 
Use or nonuse of preprinted “check off” test order forms 
Laboratory policies on double checking test orders 
Implementation of strategies for reducing identification 
errors 
• Reorganization of phlebotomy 
• Introduction of electronic event reporting system 
• Activation of automated processing system 
Implementation of strategies for reducing errors in surgical 
pathology 
• Use of checklists 
• Information access 
• Use of computerized forms 
• Use of specific QC processes at each step  
• Use of standardized tasks and language in reports 
• Techniques to simplify processes and reduce handoffs 
• Use of secondary checks 
• Adjustments in  work schedule and environment 
• Adequacy of staff training 
• Correct staff for correct job. 
How often test directory is updated 
Percentage of tests performed on site (could be POCT) 
Percentage of tests that must be referred to another 
laboratory 
Staff Not studied or developed. 
Staffing benchmarks 
• Output (workload) per technical staff 
• Management span of control ratios 
 Measurement of benchmarks in 4 areas: anatomic 
pathology; chemistry/hematology/ immunology; 
microbiology; transfusion medicine 
Percentage of employees complying with universal 
precautions requirements 
Number or percentage of employee exposures to 
bloodborne pathogens 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Access Not studied or developed. 
Percentage of time laboratory hours of operation meet or 
exceed those of the managed care organization 
Percentage of time patient waits less than 10 minutes for 
specimen collection 
Technology Not studied or developed. 
Use of Web-based systems for reporting, analyzing, and 
storing errors 
Implementation of specifications and strategies to prevent 
errors in point-of-care testing and measurement of 
compliance rate 
• Operator certification and validation in POCT (%) 
• Implement security, validation, performance, and 
emergency systems existing and new devices 
• Require flexible user-defined error-prevention system 
options on instruments as prerequisite for federal 
licensing 
• Integrate connectivity standards for data exchange 
• Preserve fast TATs 
• Monitor invalid use, operator competence, quality 
compliance, and other indicators 
Percentage of laboratory reports reported by each of the 
following: 
Fax, phone, computer 
Process Measures 
Preanalytic Phase- Clinical and Anatomic Pathology 
Physician Test 
Knowledge Not studied or developed. 
Not studied or developed. 
Current substitution: Scope of care within knowledge base (%) 
Appropriateness of 
Test Selection 
Not studied or developed. 
Measures not developed to evaluate appropriateness of test 
orders. 
Current substitution: Testing rates from National 
Healthcare Quality Report and HEDIS measures, other 
condition-related measures. 
Physician Test 
Ordering  
 
Not studied or developed. 
 
• Requisition slip accuracy and completeness 
 Breakdown of deficiencies by type 
• Duplicate orders (%) 
Patient Preparation Not studied or developed. Not studied or developed. 
Patient 
Identification 
• Wristband error rate (%) 
• Breakdown of wristband error 
types (%) 
• Patient identification errors caught before reporting (%) 
• Patient identification errors caught after reporting (%) 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Specimen Labeling/ 
Identification 
Not studied or developed. 
Blood bank safety 
• Rate of ABO specimen labeling errors  
• Rate of ABO typing result discrepancies  
Specimen labeling  
• Specimens with a labeling error for one or more 
reasons (%)  
• Relabeled specimens due to label misalignment (%)  
• Breakdown of labeling errors by type (%) 
• Specimen/requisition identification mismatch (%) 
• Unlabeled specimen (%) 
• Mislabeled specimen (%) 
Specimen Collection 
Blood culture contamination rate 
• Total contamination rate (%)  
• Neonatal contamination 
rate (%)  
• Other contamination rate (%)  
General specimen acceptability 
• Specimen rejection rate (%) 
• Breakdown of rejection 
reasons (%)  
 
Chemistry specimen quality and acceptability 
• Median rates of acceptance 
• Median rates of rejection due to: 
 Clotted specimen 
 Container leaking 
 Specimen contamination 
 Hemolyzed specimen 
 Insufficient volume 
 Tube over/underfilled 
 Specimen lost/not received 
 Improper container 
Hematology specimen quality and acceptability 
• Percentage of submitted specimens rejected for 
testing 
• Rate of rejection due to: 
 Specimen damaged in transit 
 Hemolyzed specimen 
 Clotted specimen 
 Specimen delayed in delivery/too old 
 Insufficient specimen quantity 
 Specimen contaminated by intravenous solution 
Phlebotomy 
• Percentage of successful encounters 
• Percentage of unsuitable specimens 
• Reasons for unsuccessful encounters (%) 
Compliance rate (%) with phlebotomy safety practices: 
• Preventing recapping of needles 
• Discarding tourniquets when contaminated with blood 
• Glove replacement for each patients 
• Handwashing between patients 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Extraneous tissue in surgical pathology 
• Overall extraneous tissues contamination rate (%) 
• Location of contamination on slides (% of total) 
• Origin of contamination (% of total) 
Specimen adequacy for atypical epithelian cells 
• Median rate of unsatisfactory specimen (%) 
• Median rate of satisfactory specimen but limited use (%) 
• Median rate of 3 most common reasons for inadequacy 
or limited use (%) 
Specimen Delivery Not studied or developed. 
Not studied or developed. 
Current substitute: Delivery within specified time and 
under specified conditions according to specimen type 
Courier service 
• Percentage of time courier service picks up specimens 
on time 
Clinical Pathology 
Specimen Processing 
and Preparation 
 
Outpatient order entry 
• Outpatient order entry rate 
(%) 
• Order entry error rates by 
category (%) 
Transfusion blood product wastage 
• Overall wastage rate (%)  
• Other blood components 
wastage rates (%)  
• Breakdown of wastage 
reasons (%)  
Order entry/transcription error rate 
Not studied or developed. 
Anatomic Pathology 
Specimen 
Accessioning and 
Preparation  
(Gross Room) 
Not studied or developed. 
Cutting errors 
• Error rates at tissue, block, slide level (%) 
• Lack of or incomplete sampling (%) 
• Injuries to laboratorians (%) 
Clinical information for surgical pathology 
• Percentage of cases requiring additional information 
Type of additional information needed (%) 
Analytic Phase- Clinical Pathology 
Specimen Analysis Not studied or developed. 
PT specifications and indicators 
• Laboratory tests reported in or out of range (reported 
by analyte, diagnosis, age group) (%) 
• QC reported in or out of range (%) 
Percentage of PT results reported accurately 
Report Review or 
Verification Not studied or developed. 
Percentage of test repeats due to abnormal values or errors 
identified through autoverification  
• Internal consistency checks 
• Delta checks 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Analytic Phase- Anatomic Pathology 
Microscopic 
Specimen 
Examination 
Not studied or developed. 
Cognitive and interpretive skills 
• Visual pattern recognition of cells and structures 
• Development of hypotheses and differential diagnoses 
• Skill at clinical and histologic grading 
Results Review 
 
Gynecologic cytology outcomes-
biopsy correlation 
• Predictive value of a 
positive cytology (%)  
• Sensitivity (%)  
• Screening/interpretation 
sensitivity (%)  
• Sampling sensitivity (%)  
• Percent positive for atypical 
squamous cells of 
undetermined significance 
interpretations  
• Percent positive for atypical 
squamous cells – cannot 
exclude high grade 
squamous intraepithelial 
Lesions Interpretations  
• Percent positive for atypical 
glandular cells 
interpretations  
Mammographically directed biopsies 
• Correlation of mammographic abnormality with 
microscopic findings 
False-negative rate 
False-positive rate 
Gynecologic cytology specimen adequacy 
• Mean and median rates of specimen accessioning 
(e.g., percentage with at least 300 squamous cells and 
a cluster of endocervical or metaplastic cells) 
• Mean and median rates of specimen rejection 
• Mean and median rates of reasons for specimen 
rejection 
Postanalytic Phase- Clinical and Anatomic Pathology 
Turnaround Time 
and Notification of 
Critical Values 
Stat TAT (outliers) 
• Stat TAT outlier rate (%)  
• Breakdown of outliers by 
shift (%)  
• Breakdown of outliers by 
day of week (%)  
TAT for troponin 
• Median TAT of troponin 
from order to ED availability 
• Results reported by 
deadline (%) 
Physician notification of critical values 
• Calls with read-backs (%)  
• Occurrences where only one call was needed to notify 
a caregiver of the critical result (%)  
• Measures of TAT for the following: 
 From result verification to non-physician caregiver 
notification 
 From non-physician caregiver notification to 
physician notification  
 From result verification to physician notification  
TAT for surgical pathology reports 
• Median TATs for routine processing 
• Median TATs for complex cases 
• Median TATs for processing special-handling cases 
• Percentage of outliers 
• Percentage of reports completed within 2 working days 
• Comparison of surgeon satisfaction and outlier rate 
• Percentage of presurgical TAT met 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Report Accuracy and  
Completeness Test result correction rate 
Surgical pathology report accuracy 
• Accuracy/completeness of descriptor analysis for 
carcinomas that includes 
 Gross measurement of primary tumor 
 Gross tumor configuration 
 Histologic type 
 Histologic grade 
 Depth of invasion 
 Margin status 
 Total number of positive/negative lymph nodes 
• Documentation errors 
 Transcription error (%) 
 Documentation error (%) 
 Poor or incomplete descriptions 
Practices associated with surgical pathology report 
completeness 
• Use of standard report form or check list 
• Amended report rates (%) (clinical pathology) 
• Aggregate mean rate 
• Rates according to change in diagnosis, clinically 
significant information, or patient identification 
Discrepancies in anatomic pathology reports 
• Frequency of discrepancies by type (e.g., margin 
status, diagnosis) 
• Frequency of discrepancies by patient outcome (e.g., 
no harm, near miss, harm) 
Report Delivery 
 
Morning rounds results 
availability 
• Morning rounds reporting 
compliance rate (%) 
Errors in report delivery (%) 
• Report delivered to wrong physician 
• Report delivered to wrong location 
• Report delivered about wrong patient 
Physician Follow-up Not studied or developed. 
Percentage of abnormal reports not documented in patient 
medical record by test type 
Percentage of follow-up tests needed but not ordered 
Percentage of reports appropriately interpreted by clinician 
Laboratory tests that confirm, alter, or add nothing to 
patient care 
Interpretive 
Consultation Not studied or developed. 
Consultation rate 
• Aggregate consultation rate 
• Consultation rate by specimen type 
• Median TAT 
• Consultation satisfaction rates (%) 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Outcomes Measures 
Customer 
Satisfaction 
Patient satisfaction with 
outpatient specimen collection   
• Patient satisfaction score  
• Percentage of patients “more 
than satisfied” 
Customer satisfaction in anatomic pathology 
• Overall satisfaction score 
• Aggregate satisfaction score 
• Percentage of excellent/good ratings 
• Percentage of below average/poor ratings 
• Satisfaction scores for 10 aspects of laboratory 
servicea 
Percentage of physician complaints per managed care 
organization 
Hospital nursing satisfaction with laboratory services 
• Nursing overall satisfaction score 
• Aggregate satisfaction score 
• Percentage of very satisfied/usually satisfied ratings 
• Percentage of rarely/not satisfied ratings 
• Productivity ratios: 
 laboratory tests per full-time employee and 
number of telephone calls per full-time employee 
 Number of complaints per million laboratory tests 
• Satisfaction scores for 13 aspects of laboratory 
services (rated 1-5)b 
Calls 
• Percentage of laboratories having written guidelines 
for handling telephone inquiries and dealing with 
security (e.g., procedures for caller identification or 
access to results) 
• Median time to complete a call  
• Percentage of calls requiring transfer to another 
person or laboratory section 
• Percentage of phone calls answered within 2 minutes 
of ringing 
• Percentage of requests for information successfully 
completed in the original phone call 
Patient satisfaction 
• Percentage of patient complaints per managed car 
organization 
                                                 
a The 10 aspects of laboratory services include (1) quality of professional interaction; (2) pathologist responsiveness to 
problems; (3) diagnostic accuracy; (4) courtesy of secretarial and technical staff; (5) communication of relevant 
information; (6) notification of significant abnormal results; (7) pathologists’ accessibility for frozen sections; (8) 
tumor board presentations; (9) teaching conferences and courses; (10) timeliness of reporting. 
b The 13 aspects of laboratory services include: (1) accuracy of test results; (2) stat TAT; (3) accessibility of laboratory 
management; (4) promptly answered phone calls; (5) abnormal results notification; (6) routine test TAT; (7) ability to 
answer telephone questions; (8) laboratory management responsiveness; (9) telephone courtesy; (10) laboratory 
point of care testing support; (11) phlebotomy courtesy toward nursing; (12) phlebotomy courtesy toward patients; 
(13) phlebotomy responsiveness to service requests 
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Step of Total 
Testing Process 
Q-Tracks Performance 
Indicators 
Examples of Performance Indicators 
From Q-Probes and Other Studies 
Other Measures 
Cost-related 
outcomes  
• Cost per test 
• Cost per unit of health outcome 
• Cost per QALY 
Reimbursement-
related  
• Percentage of laboratory tests not reimbursed 
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APPENDIX C 
DEVELOPMENT OF THE MEDICARE PAYMENT SYSTEM 
The Medicare program was enacted in 1965 to ensure access to medically necessary care for the 
elderly and disabled so as to diminish their financial liability, especially with regard to 
catastrophic illness or disability.  While the program’s initial structure that provides coverage and 
payment for hospital care (Part A) and ambulatory care (Part B) remains intact,  recent 
developments include options allowing beneficiaries to purchase private insurance (Part C) and 
an outpatient prescription drug benefit (Part D).  Except for catastrophic coverage, there is no 
“stop-loss” provision limiting a person’s financial liability.  Therefore, about 90% of seniors also 
have supplementary coverage (in addition to Medicare) obtained from various sources, including 
employers, Medigap, Medicare Advantage (Part C), or via dual eligibility for Medicaid.1  
From its inception until the mid-1980s, Medicare paid for inpatient and ambulatory care, 
including laboratory tests and services in either setting, using a fee-for-service system based on 
what providers considered to be customary and reasonable charges.  Physicians billed Medicare 
for laboratory services that they performed in their office and for laboratory services that they 
purchased at a discount from hospital and independent laboratories.2  Many physicians routinely 
marked up the cost of their purchased laboratory services when billing Medicare and other 
insurers.  The rule was changed in 1980 to eliminate mark ups, but enforcement was difficult. 
Steep increases in health care spending prompted further attempts to contain costs.  The 
foundation of the current Medicare payment system was established in the Omnibus Deficit 
Reduction Act of 1984.  Methodologies for calculating costs were further modified through major 
legislative acts, including the Consolidated Omnibus Budget Reconciliation Acts of 1985 and 1986, 
Balanced Budget Act of 1997, and MMA in 2003.  Each of these acts directly affected payment for 
laboratory tests and services.   
 Omnibus Deficit Reduction Act of 1984  
• Eliminated reasonable charge as a basis for payment 
• Allowed physicians to bill only for laboratory tests performed in their offices 
• Established a PPS for inpatient care under Part A that provides specific lump 
sum payments corresponding to particular patient diagnoses (based on 
diagnosis-related groups)  
• Established regional fee schedules for physician services, laboratory services, 
and durable medical equipment under Part B 
• Designated 56 geographic regions for price determinations  
• Set fee schedule payments for clinical laboratory services at 60% of prevailing 
charges for ambulatory care and 62% for outpatient hospital services  
• Required annual adjustment for all fee schedules according to the CPI and 
wage rates for each geographic area3 
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 Consolidated Omnibus Budget Reconciliation Act of 1985 
• Established payment caps (deemed NLAs) at 115% of the median of all local 
fee schedule amounts for each service4 
Note: Congress eliminated payment rate increases in 1988, reduced hospital 
outpatient rates from 62% to 60%, restricted updates to 2% of CPI each year 
from 1991 to 1993, and eliminated updates for 1994 and 1995.    
 Balanced Budget Act of 1997 
• Established more extensive payment provisions for inpatient care 
• Established PPS for hospital outpatient care (e.g., outpatient surgery) 
• Reduced Medicare payment caps for Part B laboratory services to the lowest 
of the actual charge by the carrier, 74% of the NLA, or 100% for new test 
without NLA 
• Required reduction of the number of regional carriers processing laboratory 
claims from 56 to 5, with one carrier designated as a central statistical resource 
for such claims  
• Required use of negotiated rulemaking to establish national coverage and 
administrative policies for Part B laboratory services 
• Required independent laboratories to bill hospitals for their services when 
they serve as reference laboratories 
• Required DHHS to fund an IOM study on Medicare Part B payments for 
laboratory services 
• Eliminated coinsurance for Part B laboratory services 
• Established Medicare+Choice (Part C) for managed care 
• Expanded coverage of selected laboratory tests for screening and preventiona 
• Expanded anti-fraud and abuse provisions  
• Ordered competitive bidding demonstration projects for durable medical 
equipment 
• Eliminated payment rate increases from 1998 through 2003 for laboratory 
services5 
 Medicare Prescription Drug, Improvement, and Modernization Act of 2003 
• Established the Medicare prescription drug benefit program (Part D) 
• Provided process for recognition and payment of new medical technology 
under Part A and Part B 
                                                     
a Subtitle B of the Balanced Budget Act of 1997 cites coverage for certain screening and prevention tests including 
mammography, Pap smear and pelvic exams, colorectal screening, diabetes self management, bone mass 
measurements, and vaccines. 
Laboratory Medicine: A National Status Report Appendix C – Development of the Medicare Payment System 
May 2008 C-3 
• Improved payment for certain screening tests (e.g., for diabetes, 
cardiovascular disease, mammography) 
• Increased Part B deductible to $110 in 2005; with subsequent updates by the 
annual percentage increase in Medicare expenditures 
• Mandated use of competitive bidding process for durable medical equipment 
• Required competitive bidding demonstration projects for clinical laboratory 
services 
• Eliminated Part B laboratory services payment increases for 5 years (2004-2008)6 
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